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Abstract 
Background 
Historically considered a rare disorder, it is now appreciated that coeliac disease is a 
major health problem affecting 1% of the population. The ability to screen for coeliac 
disease non-invasively and on a large-scale with the development of highly sensitive 
and specific serological tests has helped crystallise the coeliac iceberg of 
contemporary disease. Clinically overt coeliac disease only makes up the tip of this 
iceberg and accounts for only the minority of cases of coeliac disease. The majority of 
coeliacs in comparison have few obvious symptoms despite the presence of the 
enteropathy, have atypical symptoms or have physiological derangements such as iron 
deficiency anaemia. 
Recent population-based studies have provided more robust estimates of risks 
traditionally associated with clinically overt coeliac disease such as mortality, 
malignancy and fracture. However other morbidity and perhaps potential benefits 
associated with the spectrum that is contemporary coeliac disease and the effect of 
treatment need clarification. The benefits and possible harm of detection and 
treatment of coeliac disease in otherwise asymptomatic, healthy people or those 
presenting with non-classic features or mild enteropathy disease is also not clear. 
The rate of diagnosis of coeliac disease in developed countries has increased 
dramatically since the introduction of serological tests without an obvious 
environmental precipitant. 
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The principal aspect of this thesis is to examine the vascular, hepatic and psychosocial 
profile in people with contemporary coeliac disease to clarify the morbidity and 
perhaps potential benefits associated with contemporary coeliac disease. The 
physiological derangements and morbidity of mild versus severe enteropathy coeliac 
disease; and coeliacs presenting with classic disease, silent disease or gastrointestinal 
symptoms will be compared. The benefits and possible harm of detecting 
contemporary coeliac disease will also be explored by examining the effect of 
treatment with a gluten-free diet. Reported possession of conventional breast cancer 
risk factors by female coeliacs will be examined and compared to those possessed by 
the general population to further explore potential explanations for the apparent 50% 
reduced risk of breast cancer in women with coeliac disease. The socio-economic 
distribution of people with incident coeliac disease will also be examined to improve 
our understanding of the aetiology of the disorder in a further part to the thesis. 
Objectives 
1. To describe the relationship between degree of enteropathy and physiological 
derangement, clinical features in incident coeliac disease 
2. To examine the incidence of clinically diagnosed coeliac disease by socio- 
economic status 
3. To quantify the impact of diagnosed coeliac disease on the risk of: 
" 
hypertransaminasaemia 
" 
hypercholesterolaemia 
4. To estimate the vascular risk profile at diagnosis of coeliac disease and 
quantify any change following treatment with a gluten-free diet 
6 
5. To estimate the quality of life at diagnosis of coeliac disease and observe any 
change following exposure to a gluten-free diet 
6. To describe the breast cancer risk profile in women with coeliac disease and 
compare to that of the general population 
Methods 
To examine objectives 1,2 and 3I generated a historical cohort of people who had 
been diagnosed with coeliac disease at Nottingham and Sheffield. Dietetic, 
histopathology, immunology, clinical coding and outpatient records were used to 
retrospectively identify incident cases of coeliac disease at Nottingham University 
Hospital and Royal Hallamshire Hospital, Sheffield. I identified 1008 adults with 
incident coeliac disease between 1" January 2000 and 31St December 2006 at these 
centres that made up this historical cohort. Demographic, clinical, histological and 
laboratory data were collected on these identified incident cases of coeliac disease 
through systematic collection. 
Using a longitudinal, observational cohort study design, objectives 3 and 4 were 
examined. Consecutive cases of incident coeliac disease were identified at Derby 
Nottingham, Sheffield study centres using clinical alerts and records; dietetic alerts 
and records; histopathology and immunology databases. Extensive efforts were made 
to identify all incident adults with coeliac disease at these three centres to help 
generate an unselected, large and contemporary cohort. Data was systematically 
collected on the vascular risk profile and health-related quality of life in adults newly 
diagnosed with coeliac disease and any change following treatment with a gluten-free 
diet determined. 
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Objective 5 was studied in a cross-sectional, questionnaire-based survey where the 
reported possession of conventional breast cancer risk factors by female coeliacs were 
systematically collected and compared to those possessed by the general population. 
Female coeliacs that were members of Coeliac UK (population-based cohort) and 
identified female coeliacs that have attended between 1s` January 2000 
- 
31St 
December 2006 Nottingham University Hospital, Nottingham; Royal Hallamshire 
Hospital, Sheffield; or Derby Hospitals NHS Foundation Trust for management of 
their coeliac disease (historical hospital-based cohort) formed the study population. 
Female coeliacs with either incident or prevalent coeliac disease were identified using 
clinical alerts and records; dietetic alerts and records; histopathology and immunology 
databases. Coeliac UK, the principal national society for people with coeliac disease, 
has over 70,000 registered members from which we selected a random sample of 
9000 women from those women identified as being over the age of 35 years who on 
their membership information had registered a current UK postal address and they had 
reported that they have coeliac disease. 
Findings 
Coeliacs with mild enteropathy have few biochemical deficiencies at diagnosis of 
coeliac disease and therefore show no important biochemical improvements following 
treatment with a gluten-free diet in comparison to those with severe enteropathy 
coeliac disease. Approximately one-third of coeliacs with mild enteropathy coeliac 
disease had negative EMA serology at diagnosis and had significantly lower tTG 
values in comparison to those with severe enteropathy coeliac disease. Diarrhoea was 
the most common symptom reported in adults being diagnosed with mild enteropathy 
coeliac disease and more common than that observed in severe enteropathy. Iron 
8 
deficiency anaemia was much less common in mild enteropathy compared to severe 
enteropathy. 
There was a strong, independent graded association between the incidence rate of new 
diagnoses of coeliac disease and socio-economic status with the rate twice as high in 
adults from affluent areas compared with that in adults living in poorer areas. 
Socioeconomic status was not associated with features of more severe coeliac disease. 
Hypertransaminasaemia was uncommon (<2%) in newly diagnosed adults with 
coeliac disease and in those patients with an abnormal test 86% normalised following 
a year of treatment with a gluten-free diet. The presence of elevated transaminases in 
incident coeliac disease was associated independently with clinical features of 
malabsorption and more severe histological features of intestinal inflammation on 
duodenal biopsy. 
At diagnosis coeliacs have much lower total cholesterol levels than the general 
population with the observed reduction greater in men (21%) than in women (9%) 
with no increase in total cholesterol observed on treatment with a gluten-free diet. 
Furthermore, HDL cholesterol showed a small but statistically significant increase 
following treatment. 
The observed vascular risk profile in our study suggests both protective and adverse 
associations of coeliac disease. The lower mean levels of total cholesterol, LDL 
cholesterol, fibrinogen; the higher likelihood of being from more affluent social class; 
and the small but significant rise in HDL cholesterol and reduction in blood pressure 
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amongst coeliacs presenting with gastrointestinal symptoms observed following 
treatment with a gluten-free diet suggests coeliacs have favourable vascular risk 
profile features in comparison to the general population. However, the higher 
likelihood of having abdominal truncal obesity amongst incident coeliacs that only 
worsens following treatment with a gluten-free diet together with the higher 
proportion of measured systolic hypertension amongst male coeliacs suggests that 
there are also potentially adverse vascular risk profile features associated with coeliac 
disease. 
Though incident coeliacs with silent disease reported no change in their quality of life 
prior to diagnosis of coeliac disease, silent coeliacs were as likely to have villous 
atrophy and physiological derangement to those coeliacs presenting with symptoms or 
with classic features of coeliac disease. The quality of life reported by coeliacs 
presenting with silent disease, classic disease and with gastrointestinal symptoms was 
worse than that observed in the general population. A year's treatment with a gluten- 
free diet resulted in coeliacs having similar or in some components better quality of 
life than that observed in the general population. The rate of change of quality of life 
was similar amongst those coeliacs with silent, classic or symptomatic disease. 
The breast cancer risk profile suggests both protective and adverse associations of 
coeliac disease. The higher proportion of women being parous, having their first full- 
term pregnancy before 30 years and breastfeeding in addition to the younger mean age 
at menopause suggests women with coeliac disease have favourable breast cancer risk 
profile features in comparison to the general population. However, the higher 
likelihood of being Caucasian and of affluent social class together with higher 
10 
proportion having early menarche and irregular menstrual cycles suggests there are 
also potentially adverse breast cancer risk profile features associated with coeliac 
disease. 
Conclusions 
Persons with mild enteropathy disease have few physiological derangements at 
diagnosis of coeliac disease and show no important biochemical change following 
treatment with a gluten-free diet in comparison to those with severe enteropathy 
coeliac disease. The prevalence of hypertransaminasaemia is lower than previously 
reported which may be reflective of differences in study design or contemporary 
coeliac disease involves a milder spectrum of disease. The observed vascular and 
breast cancer risk profile suggests both protective and adverse associations of coeliac 
disease and on treatment with a gluten-free diet results in an attenuation or indeed 
reversal of the vascular risk profile in some co-variates. Silent coeliac disease is 
associated with a reduction with quality in life which improves like in symptomatic 
and classic disease with treatment with a gluten-free diet. Incident coeliac disease is 
associated with more affluent social class. 
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Chapter one: What is coeliac disease? 
1.1. Overview 
Previously regarded as a rare disorder, we now appreciate coeliac disease is common 
affecting 1% of the general population though the morbidity and perhaps potential 
benefits associated with contemporary disease needs clarification. The benefits and 
possible harm of treatment of contemporary coeliac disease in otherwise 
asymptomatic, healthy people or those presenting with non-classic features is not 
clear. The rate of diagnosis of coeliac disease in developed countries has increased 
dramatically since the introduction of serological tests without an obvious 
environmental precipitant. 
One aim of this thesis is to further explore the morbidity of contemporary coeliac 
disease by examining the risk of liver disease, hypercholesterolaemia and 
physiological derangement in a historical cohort of adults with clinically diagnosed 
coeliac disease. The effect of treatment of coeliac disease on identified hepatic and 
vascular morbidity will be explored. Clinical and physiological derangements of mild 
versus severe enteropathy coeliac disease will be contrasted using this historical 
cohort. The socio-economic distribution of people with incident coeliac disease will 
also be examined in this historical cohort to improve our understanding of the 
aetiology of the disorder. The health-related quality of life in an unselected, 
representative and contemporary cohort of people with incident coeliac disease 
presenting with gastrointestinal symptoms, classic or silent disease will be compared 
and also the effect of treatment of the disease will be examined in a longitudinal 
study. This longitudinal study will also examine the possible vascular benefits of 
having coeliac disease and to estimate the effect of treatment upon the vascular risk 
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profile. In a cross-sectional, questionnaire-based survey, reported possession of 
conventional breast cancer risk factors by female coeliacs are examined and compared 
to those possessed by the general population to further explore potential explanations 
for the apparent 50% reduced risk of breast cancer in women with coeliac disease. 
To understand the rationale for these studies this introductory chapter `What is coeliac 
disease? ' describes how coeliac disease is defined and diagnosed, and the aetiology 
and clinical manifestations of the disease. The introduction will also describe what is 
already known and what is not known about the occurrence and the impact of both 
undetected and clinically diagnosed coeliac disease. The aetiology of breast cancer in 
the general population and how this may differ in women with coeliac disease is 
discussed. This section will end with objectives of the thesis. 
1.2. Definition 
Coeliac disease is regarded by most as an immune-mediated disease of the small 
intestinal mucosa that results from exposure to dietary gluten in genetically 
susceptible individuals [1]. It is characterised by a chronic inflammatory state of the 
small intestinal mucosa that heals when gluten-containing foods are excluded from the 
diet and returns when gluten-containing foods are reintroduced. 
1.3. Aetiology 
Coeliac disease is most likely to have a multi-factorial aetiology with interactions 
between dietary gluten, immune, genetic, and environmental factors conferring either 
increased or reduced disease risk [1]. Throughout life, possibly even during fetal life, 
an individual's genetic predisposition interacts with the environment by means of 
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continuous and varying exposures, and jointly shapes the immunological response to 
dietary gluten. In most individuals, oral tolerance develops to gluten and prevails 
throughout life. However if tolerance fails to develop or is later broken down, then the 
gluten may act as a `dangerous' foreign antigen with the resulting development of 
coeliac disease. Coeliac disease could then be viewed as a failure of oral tolerance to 
gluten. 
With particular emphasis on environmental exposures, a simplified and hypothetical 
model of the multifactorial aetiology of coeliac disease [2] is shown in this figure: 
Figure 1.1: Proposed causal model of multifactorial aetiology of coeliac disease 
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In this multifactorial model there are directly causal factors, defined depending on 
their role in disease development as either necessary or contributing factors [3]. There 
are also structural, component and associated causal factors. 
A genetic susceptibility and the presence of dietary gluten are considered to be 
necessary causal factors as without these factors coeliac disease will not develop [4]. 
However, component causal factors also contribute such as whether breastfeeding is 
still ongoing during the period in which gluten is introduced into the diet, the amount 
of gluten ingested during this period [5], and whether or not the infant has repeated 
infectious insults early in life [6,7]. However, the combination of these component 
causal factors may vary from individual to individual and additional component 
causal factors might exert their effect later on in life. With the necessary causal factors 
and one or more component causal factors combined, coeliac disease develops (Figure 
1.2) [3] 
Figure 1.2: Theoretical model of causality of coeliac disease 
eessary 
caj, 
s @ 0ponent 
caul 
yn 
Genetic 
0 
oýticient cat,, 
Large 
aniounts V Dietary of gluten gluten 
?I 
D4 
amounts 
o(glurten 
) 
Nor, Infectious 
breast- 
feedng episodes 
J(j ce lt ca (% 
dent caus 
suscepubilly susupt+bilrty 
Dietary Dietary 
gluten gluten 
Non- 
breast- ? Infectiax 
feediffnig episodes 
19 
This model implies that the coeliac disease onset can be avoided by excluding a 
necessary cause such as excluding dietary gluten or excluding one or more of the 
component causes such as the consumption of large amounts of gluten. 
1.3.1. Necessary causal factors 
1.3.1.1. Genetic susceptibility 
A genetic susceptibility is considered to be a necessary causal factor for developing 
coeliac disease [4]. First degree relatives of people with coeliac disease have a 10% 
risk of developing the condition [8-10] which is ten times higher than that of the 
general population. The concordance rate in monozygotic twins is 70% [9,10]. 
Involvement of the human leucocyte antigen (HLA) complex in coeliac disease was 
first suggested by serotype-based association studies; HLA-DQ2 (encoded by 
DQA1*05 and DQB1*02) is found in 95% of people with coeliac disease [11] with 
nearly all of the remainder possessing HLA-DQ8 (encoded by DQA1*03 and 
DQB1*0302) [11,12]. Our current understanding of genetic susceptibility to coeliac 
disease implies possession of HLA-DQ2 is necessary but not sufficient for the 
development of coeliac disease since it is also possessed by 30% of the general 
population, suggests that a combination of some of these factors and their interaction 
with environmental factors is what induces coeliac disease. Furthermore, studies in 
siblings and identical twins suggest that the contribution of HLA genes to the genetic 
component of coeliac disease is less than 50% [13]. Several non-HLA genes including 
six regions (CCR3, IL12A, IL18RAP, RGS1, SH2B3 (nsSNP rs3184504) and 
TAGAP) that control immune responses involved in coeliac disease pathogenesis 
have recently been identified [14]. 
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1.3.1.2. Gluten 
- 
Probably one of the most important steps in coeliac disease history occurred when the 
Dutch paediatrician, Willem Karel Dicke, demonstrated that the malabsorption in 
coeliac disease was `elicited or aggravated by certain types of flour, especially wheat 
and rye flours' [15]. Nowadays, it is well established that coeliac disease is strictly 
dependent on exposure to wheat gluten and related proteins in rye and barley. Dietary 
gluten (such as the 33-amino acid peptide sequence PFPQPQLPY PQPQLPYPQ 
PYPQPQLPY rich in proline and glutamine derived from (x-gliadin) is necessary both 
to initiate and to maintain the disease process [16]. This response to dietary gluten is 
mediated by both the adaptive and innate immune systems. 
Gliadin peptides, derived from partial digestion of dietary gluten, pass through the 
epithelium of the small intestinal mucosa where they become bound to the HLA-DQ2 
(or HLA-DQ8) receptor situated on the surface of antigen-presenting cells. Native 
gliadin has relatively poor affinity for the HLA-DQ2 (or HLA-DQ8) receptor so 
undergoes modification by means of deamidation to enhance its affinity [17]. This 
deamidation is catalysed by tissue transglutaminase [17,18]. Deamidation also results 
in a greatly enhanced T cell response [17,18]. The deamidated gliadin, with its 
enhanced affinity, becomes bound to the HLA-DQ2 (or HLA-DQ8) receptor on the 
antigen-presenting cell, and is then presented to sensitised mucosal CD4+ T cells 
resulting in both the production of proinflammatory cytokines [4,19] that cause 
characteristic tissue damage such as villous atrophy and the activation and expansion 
of B cells that produce antibodies to gliadin. 
Gliadin peptides also activate an innate immune response in the intestinal epithelium 
that is characterized by increased expression of interleukin-15 by enterocytes, 
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resulting in the activation of intraepithelial lymphocytes expressing the activating 
receptor NK-G2D, a natural-killer-cell marker [20]. These activated cells become 
cytotoxic and kill enterocytes with surface expression of major-histocompatibility- 
complex class I chain related A (MIC-A) which is a cell-surface antigen induced by 
stress, such as an infection [21,22]. 
1.3.2. Component causal factors 
1.3.2.1. Breastfeeding and infant feeding practices 
It was suggested as early as the 1950s that breast-feeding could delay the onset of 
coeliac disease, and possibly also reduce the overall risk [23]. In the 1970s there were 
reports from England, Ireland and Scotland that there appeared to be a decline in the 
incidence of childhood coeliac disease [24-26]. Changes in infant feeding practices 
(including breastfeeding for at least two weeks and preferably for four months, 
avoidance of solids before the age of four months, use of infant formulas, avoidance 
of cereals being added to the milk in a bottle feed) in Britain were suggested as a 
possible explanation for the decline [27]. However there was no change in incidence 
in Sweden with similar infant feeding recommendations [28]. In a series of 
population-based studies carried out in Sweden during the 1980s and 1990s (an era of 
high breastfeeding and late gluten introduction) examining national breastfeeding 
practices and infant feeding on incidence of childhood coeliac disease, Ivarsson et at 
observed a rise in incidence of coeliac disease that was preceded by an increase in the 
amount of gluten consumed [7]. Though the increased use of antigliadin antibodies 
during the 1980s to screen for coeliac disease probably contributed to the rise in 
incidence, the majority of the diagnosed cases were identified because of symptoms 
[29] 
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Figure 1.3: Incidence of childhood coeliac disease in Sweden 
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The risk for coeliac disease was reduced when gluten-containing foods were 
introduced into the diet while the infant was still breast-fed [adjusted odds ratio (OR) 
0.59; 95% CI: 0.42,0.83], an effect even more pronounced in infants who continued 
to be breast-fed even longer [OR 0.36; 95% CI 0.26,0.51] [5]. 
The dose of dietary gluten and hence antigen ingested may influence whether or not 
oral tolerance develops [30]; a larger consumption of wheat gluten was reported for 
healthy infants in Sweden and Italy as compared to Finland, Denmark and Estonia 
with higher incidence of coeliac disease reported in Sweden and Italy [31,32]. In an 
incident case-referent study introduction of gluten-containing foods in large amounts, 
as compared to small or medium amounts, was observed to be an independent risk 
factor for coeliac disease development [adjusted OR 1.5,95% CI 1.1-2.1] [5]. 
However, age of the infant at introduction of gluten-containing food was not an 
independent risk factor, nor was the type of food used as the source of gluten, i. e. 
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solid foods or follow-on formula. It is, however, not clear whether there is a direct 
dose-response effect or a threshold effect. Furthermore, it seems likely that the 
amount of gluten tolerated varies with the genetic predisposition of the individual and 
other environmental exposures. 
Two Italian case-control studies examined infant feeding practices in relation to the 
risk of developing childhood coeliac disease [33,34]. Feeding practices in 216 
children with coeliac disease with compared with those used for their siblings. 
Siblings eating gluten within the first two months of life had a slightly greater risk of 
developing coeliac disease than those who were started on gluten from age of 3 
months [34]. A two-fold increase in risk for developing coeliac disease was observed 
when gluten had been introduced before the end of the second month of life on 
examining feeding practices in 201 children with coeliac disease and comparing them 
with 1949 non-coeliac and unrelated children though reporting was based on parents' 
recall and possibly subject to reporting bias [33]. 
Infections could also potentially contribute to the aetiology of coeliac disease. This 
was proposed initially because sequence similarities were identified between proteins 
of gluten and proteins produced during adenovirus infections [35]. Observational data 
suggested that children who experienced three or more infectious episodes before six 
months of age had an increased risk for coeliac disease before two years of age 
(adjusted OR 1.4,95% CI 1.0-1.9) [6,7]. The risk for coeliac disease increased 
further, in addition to having many infections, the child was also introduced to gluten 
in large amounts, as compared to small and medium amounts [6,7]. This association 
held even when episodes of gastroenteritis were excluded, and after adjustments for 
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differences in infant feeding patterns and family socio-economic group had been 
made [6,7]. Changes in gut permeability caused by infection thereby facilitating the 
entry of toxic gluten may also have a role [36-38]. 
1.3.3. Associated factors 
1.3.3.1. Early life processes 
The intrauterine environment might influence the risk for later coeliac disease since 
low birth weight and a neonatal infection diagnosis were both associated with an 
increased risk for coeliac disease [39]. Seasonality in month of birth has been 
demonstrated for Swedish coeliac disease children [40]. 
Figure 1.4: Relative risk for coeliac disease in children below two years of age by 
month of birth from 1973 to 1997 
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A temporal relationship indicates that this might be due to a casual effect of infections 
during foetal life and/or an interaction between infections and introduction of gluten 
into the diet. This is in accord with findings in case-referent studies of an increased 
risk for coeliac disease associated both with a neonatal infection diagnosis [39] and 
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repeated infectious episodes early in life [6,7]. However, non-infectious exposures 
with a seasonal pattern need to be explored. 
1.3.3.2. Socio-economic status 
An almost linear gradient has been observed between the prevalence of a number of 
chronic diseases and socio-economic status; at each more affluent level of socio- 
economic status, prevalence of chronic diseases such as osteoarthritis, hypertension, 
ischaemic heart disease; and autoimmune diseases such as rheumatoid arthritis, lupus 
decreases [41-43]. In addition to morbidity and mortality, a gradient between risk 
factors for disease and socio-economic status also has been demonstrated. For 
example, rates of smoking, cholesterol titres and prevalence of sedentary lifestyle are 
lower the higher one goes on the socio-economic hierarchy and these also occur in a 
gradient relationship [43-46]. It is unclear the nature of the relationship between 
socio-economic status and disease. It could be that socio-economic status influences 
health status, labelled `social causation'[47]. Alternatively health status contributes to 
socio-economic status through a `social drift' [48]. Although there is some reciprocal 
influence of socio-economic status and health [49], data is more suggestive for a 
social causation rather than a social drift explanation for the association between 
socio-economic status and health [50-53]. Furthermore, although some childhood 
diseases are sufficiently debilitating that childhood health may determine educational 
attainment and later socio-economic status, these are sufficiently rare that they are 
unlikely to account for the significant socio-economic association later in life in 
general populations. 
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Maternal socio-economic status has been associated with subsequent development of 
coeliac disease in their infants [54] though the relationship between socio-economic 
status and incidence of adult coeliac disease is not known. In a population screening 
study, people with undetected coeliac disease showed a trend towards more affluent 
socio-economic status in comparison to general population controls although this was 
not significant at the 5% level (chi-squared test for trend p=0.09) [55]. Although 
some cases of coeliac disease may be sufficiently debilitating that health may 
determine socio-economic status i. e. social drift, perhaps the more plausible pathway 
to explain any possible association between socio-economic status and coeliac disease 
is through exposure to different environments and adaptations to these environments 
in a social causation model. One aspect of the environment with health consequences 
is the differential exposure to antigens such as gluten in the instance of coeliac 
disease. The association between low birth weight and increased risk for coeliac 
disease may be in part due to social factors such as impaired poverty-related maternal 
health status causing lower physiological reserves, quality and quantity of healthcare, 
housing, diet, increased exposure to toxic antigens and differential risk of infectious 
disease [56-60]. Socio-economic factors surrounding infant feeding such as 
breastfeeding practices [61] could be part of the causal model of the multifactorial 
aetiology of coeliac disease. The environment also shapes health behaviours. For 
example, it has been suggested that access, uptake and utilisation of health services is 
lower in people in deprived areas [62-64] that could affect rate of clinical diagnosis of 
coeliac disease. The combination of individual characteristics and the environmental 
demands and constraints will affect the likelihood of enacting health-related 
behaviours. For example, low income neighbourhoods have more alcohol outlets and 
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together with the socio-economic gradient with smoking may affect the risk of coeliac 
disease [65,66]. 
1.3.3.3. Cigarette smoking 
Like ulcerative colitis, coeliac disease appears to be associated with non-smoking 
though it is unclear as to whether this is a causal association [67-69] or a reflection of 
the socio-economic association of coeliac disease. Although these case-control studies 
have observed some inverse relationship between current smoking and diagnosed 
coeliac disease the strength of the association has varied, probably due to the 
inconsistent reporting of smoking status amongst the selected control populations in 
comparison with the coeliac cohorts where the current smoking proportion was 
approximately 40% and due to the small sample sizes. Undetected coeliac disease was 
associated with 60% reduced risk of current smoking (OR 0.34; 95% CI 0.14,0.85) in 
comparison to general population controls [55]. 
1.4. Pathogenesis of coeliac disease 
The mechanisms of the intestinal immune-mediated response is not completely clear 
but the pathogenesis of coeliac disease is thought to involve a complex interplay of 
immunological factors including tissue transglutaminase, intra-epithelial lymphocytes, 
cytotoxic T-cells, adaptive and innate immune responses and autoimmunity. 
1.4.1. Tissue transglutaminase as autoantigen 
Tissue transglutaminase (tTG) has emerged as an essential player in the pathogenesis 
of coeliac disease, generating the antigenic epitopes present in a-gliadin [16]. As 
alluded above in the aetiology of coeliac disease, tTG is the essential `pivot' in the 
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pathogenesis of coeliac disease because it catalyses the deamidation of native gliadin, 
thereby enhancing gliadin's affinity for the HLA-DQ2 receptor on the antigen 
presenting cell [17,18]. Deamidation of gliadin also results in a greatly enhanced 
cytotoxic T-cell response [17,18]. tTG is also the target or autoantigen of the humoral 
immune response, with autoantibodies against tTG pathognomonic of coeliac disease 
[70]. Normally stored intracellularly, tTG is released during cellular wounding such as 
that brought on by stress and cross-links several matrix proteins stabilizing the 
connective tissue scaffold on which the cells rest [71-73]. Activated when 
intracellular, tTG reacts with several structural and functional proteins setting the 
stage for apoptosis. tTG also acts as a regulator of CD8+ T cell migration and is a 
controller of the early non-adaptive innate phases of coeliac disease [73]. 
1.4.2. Intra-epithelial lymphocytes 
The importance of intra-epithelial lymphocytes in the pathogenesis of coeliac disease 
was first recognised by Ferguson et al [74]. In particular it has now been recognized 
that the proportion of y/S intraepithelial T lymphocytes are increased in people with 
coeliac disease and recognize bacterial non-peptide antigens and unprocessed stress- 
related proteins. Two important such stress-related proteins that are expressed on 
intestinal epithelial cells by interferon-y are MICA and MICB which resemble major 
histocompatibility class I genes [75]. MICA and MICB gene expression is regulated 
by promoter heat-shock elements similar to heat-shock protein 70 [75]. Once 
activated y/6 intraepithelial T lymphocytes secrete cytokines that attract and stimulate 
cells of the innate immune response but also modulate the adaptive immune response 
by secreting IL-4 which dampers Thl activity in favour of Th2 reactivity. Such 
actions suggest y/S intraepithelial T lymphocytes protect the intestinal mucosa from 
29 
chronic exposure to damaging agents such as dietary gluten in gluten-intolerant 
individuals [75,76]. 
1.4.3. Autoimmunity 
Clinically diagnosed coeliac disease is associated with a number of autoimmune 
diseases though it is possible that in many instances ascertainment bias may be 
contributing to the associations reported. Nonetheless, recent screening studies have 
shown an increased prevalence of coeliac disease in autoimmune disorders including 
type 1 diabetes [77], thyrotoxicosis [78,79], primary biliary cirrhosis [80] and 
Sjogren's syndrome [79]. 
The aetiology of autoimmune disease is multi-factorial where a complex interplay 
between intrinsic (genetic predisposition and epigenetic changes) and extrinsic 
(environmental factors) triggers contribute to disease pathogenesis and progression 
[sib 
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Figure 1.5: A model for the multifactorial aetiology of autoimmune disease 
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The intrinsic abnormalities are complicated, with diverse genetic polymorphisms 
described in different ethnic groups, suggestive of a mosaic of autoimmunity where 
the immunologic disarray might not be the same for each individual [81]. 
Comparative analysis of the position of allelic loci within the major histocompatibility 
complex for type 1 diabetes with candidate allelic loci from other autoimmune 
diseases such as coeliac disease show considerable overlap consistent with a 
hypothesis that like, the major histocompatibility complex, some of these loci involve 
common susceptibility genes or biochemical pathways that are central to normal 
immune function [81]. These genes or pathways may contribute to immune 
dysregulation shown to be present in different autoimmune diseases, possibly before 
the onset of overt clinical symptoms [82]. For example, IDDMI candidate allelic loci 
identified for type 1 diabetes located on chromosome 6g21 is found at the exact same 
position as loci for coeliac disease (marker HLA-DQ2) [83], multiple sclerosis [84], 
Crohn's disease [85] and lupus [86]. Whilst the end-stage phenotype of a specific 
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autoimmune disease may be clinically distinct and / or organ specific, the aetiology of 
many autoimmune diseases may involve shared processes of immune regulation [87]. 
It is likely that basic pathways affecting pro-inflammatory : anti-inflammatory 
cytokine ratios, apoptosis, complex antibody regulation, effector T-cell populations 
and hormonal control of the immune system are involved in these related diseases 
[87]. Evidence suggestive of viruses encoding molecular mimics that behave as a 
microbial trigger for autoimmune disease include adenovirus in coeliac disease [35] as 
described above, enteroviruses in type 1 diabetes [88] and campylobacter jejuni in 
Guillain-Barre syndrome [89,90] has also been raised. 
Though limited by ascertainment bias but on the other hand perhaps underdiagnosed 
if testing for coeliac disease using serological tests based on IgA antibody presence, a 
10-fold increase in risk of coeliac disease has been observed in people with IgA 
deficiency [91]. Released at luminal surfaces, IgA serves a variety of functions to 
protect the vast surface area occupied by the mucosal surfaces such as the 
gastrointestinal tract, representing the first line of defence against invading antigens 
through agglutination thereby preventing penetration of the mucosa. It is possible that 
IgA deficiency leads to insufficient exclusion of food antigens allowing gluten to 
penetrate the intestinal mucosa resulting in immune complex deposition and thereby 
facilitate coeliac disease development [91]. The absence of IgA on mucosal surfaces 
could facilitate the absorption of environmental antigens that may cross-react with 
self-antigens. Abnormalities in T-cell regulation observed in IgA deficiency could 
also be a responsible factor for both IgA deficiency and autoinimunity [92]. 
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It is not clear whether the duration of gluten exposure or withdrawal of gluten through 
treatment of coeliac disease protects against the development of other autoimmune 
diseases [93,94]. 
1.4.3.1. Autoimmunity and gender 
Gender bias is characteristic of autoimmune disease [95]. In some of the more 
common autoimmune disorders such as Sjogren's syndrome, lupus, Hashimoto's 
thyroiditis, Grave's disease, scleroderma, representing a spectrum of diseases, the 
patient population is reported to be >80% women [96]. The female predominance of 
adult coeliac disease is also relatively well described where in general twice as many 
women are diagnosed as men [97-99]. 
Such female preponderance for abnormal autoimmune function is largely 
unexplained. Immune reactivity is reported to be more enhanced in females than in 
males [100] with higher IgM (but not IgG) concentrations in women than in men 
[101]. Lower CD4+ counts and lower CD4/CD8 T-cell ratio in men relative to women 
has also been reported [102]. However, the preponderance of the lupus in young 
women of childbearing age (female to male ratio of 9: 1), the tendency for lupus flares 
during pregnancy with remissions after menopause suggest that female sex hormones 
are crucial regulators of lupus activity in this autoimmune disease [103]. This is 
further supported by observations that prolactin (through induction of follicular zone 
self-reactive B cells) and oestrogen (through survival and activation of marginal zone 
autoreactive B cells) are immunostimulators that affect maturation and selection of 
autoreactive B cells as well as autoantibody secretion in molecular studies on lupus 
[104]. The effect of prolactin and oestrogen may be based on their capacity to allow 
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autoreactive B cells to escape the normal mechanisms of tolerance and mature to fully 
functional antibody-secreting B cells that can cause clinically apparent lupus [104]. 
The role of sex hormones and the preponderance of women in coeliac disease have 
been far less evaluated in comparison to the studies in lupus. One could speculate that 
the challenges of menstruation and pregnancy may act to accentuate anaemia and 
exacerbate any effects of coeliac disease in women. The health-seeking behaviour of 
women relative to men with differential symptom reporting may contribute to the 
apparent gender difference in clinically diagnosed coeliac disease [98]. Further work 
on the impact of gender upon contemporary coeliac disease such as mode of 
presentation is required. 
1.5. Presentation of coeliac disease 
1.5.1. The coeliac iceberg 
The coeliac iceberg concept has often been used to demonstrate the clinical variability 
of coeliac disease and helps to understand its systemic nature [105-107]. 
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Figure 1.6: The coeliac iceberg 
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The whole iceberg represents people with a genetic susceptibility for coeliac disease; 
however the majority are still healthy. The highest stratum of the iceberg (above the 
waterline) describes patients with typical symptoms of coeliac disease such as weight 
loss and diarrhoea. These symptomatic patients are usually healthcare seeking and 
present to gastrointestinal services where the diagnosis may be made. These clinically 
overt cases make up the tip of the iceberg, accounting for the minority of cases of 
coeliac disease. In contrast, the majority of people with coeliac disease are 
undiagnosed and hidden below the waterline. Those not diagnosed with coeliac 
disease may have overt symptoms though not yet been diagnosed. People with `silent' 
coeliac disease have characteristic small bowel morphological changes though in the 
absence of typical symptoms of the disorder. Silent coeliacs may have atypical 
symptoms, no overt symptoms and due to the malabsorption caused by the 
enteropathy may have physiological derangements such as iron deficiency anaemia or 
osteoporosis. People with `latent' coeliac disease have a genetic susceptibility to 
developing the disease though have normal small bowel morphology. Timing and 
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quality of gluten load combined with environmental triggers may be factors in the 
onset of disease and age of presentation of coeliac disease in these individuals. 
1.5.2. What constitutes a diagnosis of coeliac disease? 
As demonstrated by the coeliac iceberg, the presence of typical symptoms of the 
disorder is not essential for a diagnosis of coeliac disease. Still regarded by most as 
the gold standard for diagnosis is the characteristic histological appearance of the 
small bowel mucosa [108] though the introduction of highly sensitive and specific 
serological tests has revolutionalised the diagnosis of celiac disease, allowing non- 
invasive large-scale screening of the general population to identify individuals with 
"silent" coeliac disease who account for the majority of coeliac disease beneath the 
waterline of the iceberg model. 
1.5.2.1. Enteropathy 
The small intestinal mucosa from a patient with untreated coeliac disease has a 
characteristic histological appearance, classified by Marsh in the early 1990s [108]. 
The coeliac histopathological picture is described as a continuum from normal villous 
architecture with intraepithelial lymphocytosis, through partial villous atrophy to total 
villous atrophy [108] with the mucosal lesion classed into five types: 
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Type O. preinfiltrative lesion 
Mucosa appears normal. 
Type 1: infiltrative lesion 
Mucosal architecture is normal but there is an increased number of intra-epithelial 
lymphocytes. 
Type 2: hyperplastic lesion 
In addition to the infiltration of the mucosa with intra-epithelial lymphocytes, there is 
an increase in crypt depth without any reduction in villous height. 
Type 3: destructive lesion 
The mucosa is flat with reduction in normal villous height to crypt depth ratio (villous 
atrophy which may be partial, subtotal or total) with crypt hyperplasia and 
intraepithelial lymphocytosis. 
Type 4: hypoplastic lesion 
There is deposition of collagen in the mucosa and submucosa which is unresponsive 
to gluten withdrawal and is associated with the development of malignant 
complications such as lymphomatous transformation. 
Small intestinal mucosal biopsies are usually taken at endoscopy (usually 4-6 
specimens) from the proximal small intestine, usually from the second part of the 
duodenum [109]. 
1.5.2.2. Serological tests 
Serological tests have assumed greater importance as a screening investigation since 
histology of small intestinal mucosa, though regarded by most as the gold standard, is 
inconvenient, expensive, unpleasant and not without risk [110] and has permitted non- 
invasive and large-scale screening of the general population to identify individuals 
with "silent" celiac disease. The first reliable screening test was the endomysial 
antibody (EMA) devised by Chorzelski et al in 1983 [111]. A systematic review of 
published studies in 2000 calculated the pooled EMA sensitivity and specificity to be 
94% and 98% respectively [112]. However there are problems with the EMA test 
despite its impressive performance 
- 
the interpretation of the indirect 
immunofluorescence assay is subjective, is labour intensive and one commonly used 
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substrate (monkey oesophagus) is from an endangered species. With the identification 
of tTG as the autoantigen recognised by EMA, tests for detecting antibodies to tTG 
was soon devised using a quantitative enzyme-linked immunosorbent assay which is 
objective and lends itself to automation. A systematic review of published studies I 
performed (published peer-reviewed manuscript can be found in section 9.1) in 2006 
calculated the tTG performance to be comparable to that of EMA [113]. Follöwing 
the appreciation of the importance of gliadin deamidation catalysed by tTG in the 
immunopathogenesis of coeliac disease, diagnostic tests based on antibodies to 
deamidated gliadin peptides have been developed. The performance of the deamidated 
gliadin peptides antibody test was compared with tTG in a meta-analysis of published 
studies which I performed (published peer-review manuscript can be found in section 
9.2) [114]. Though both tests performed well, tTG with its greater sensitivity and 
specificity suggests that it should remain the preferred serological test for diagnosing 
and or excluding coeliac disease [114]. 
Assessment of serology performance in coeliac disease from published studies 
however is fraught with difficulty and much of the information required is often 
missing from reports. The biggest problem in assessing sensitivity of the serological 
tests is ascertainment bias since most patients now are selected for biopsy because 
they have positive serology and the resultant sensitivity is likely to be falsely high. 
Specificity can also be affected by ascertainment bias if a prerequisite for inclusion is 
negative serology (specificity will be falsely high), or if the controls are taken from 
patients who are thought to have coeliac disease (partly on the basis of positive 
serology) but turn out to have normal biopsies (specificity will be falsely low). There 
are several other factors which are important in assessing the validity of published 
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studies. Small bowel histology should be used as the gold standard and it is important 
that the result of histology is given in the published studies because serology depends 
on the severity of the small bowel mucosal abnormality [115-117]. Criteria for 
histological normality must be given in the published studies since some authors 
include Marsh 1 lesions (just an increase in intraepithelial lymphocytes) among their 
controls whereas others consider this an indication that the patient has mild coeliac 
disease. Because there may be an age-related serology response the mean age and 
range should be given or, at the very least, it should be stated whether the patients are 
adults or children. Finally, the choice of controls may be important. It has been argued 
that the best control group is a group who are suspected of having the condition being 
studied but, after investigation, turn out not to have that condition [118]. However, 
some studies use healthy volunteers and others choose patients with other diseases 
which might be associated with autoimmunity. 
Taking into the difficulties with coeliac serology, small bowel histology should 
remain the gold standard to diagnose coeliac disease; it not only provides a baseline 
reference for response to treatment but also allows the detection of coeliacs who 
would not be detected with reliance on serology alone 
- 
perhaps one in ten coeliacs 
with villous atrophy. On balance, coeliac serology should be used to exclude coeliac 
disease if the pre-test probability (i. e. proportion of people with coeliac disease in the 
population being tested) is low. Conversely, small bowel biopsies should be 
performed in those patients in whom coeliac disease is still suspected even if coeliac 
serological tests are negative [119,120]. 
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1.5.3. Presentation of clinically diagnosed coeliac disease 
Previously, when the diagnosis of coeliac disease was based exclusively on clinical 
observations, almost all patients were reported to present with clinically overt 
"classic" malabsorptive symptoms of diarrhoea and weight loss [121-123]. Later, 
when small intestinal biopsies became readily available [124-127], it was apparent 
clinically diagnosed coeliacs presented with an array of both gastrointestinal and non- 
gastrointestinal symptoms. A number of different modes of presentation of clinically 
diagnosed coeliac disease have been reported though associations observed may be 
due to ascertainment (Table 1.1). 
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Table 1.1: The many faces of clinically diagnosed coeliac disease in published 
studies 
Classic presentation Diarrhoea [121,122] 
Weight loss [121,122] 
Gastrointestinal features Abdominal pain [128] 
Heartburn [128] 
Bloating [129] 
Aphthous ulcers [129] 
Glossitis and stomatitis [129] 
Anorexia and vomiting [130] 
Extraintestinal features Iron-deficiency anaemia [128] 
Folate-deficiency anaemia [128] 
Osteoporosis [131] 
Hypertransaminasaemia [132] 
Arthralgia [130] 
Myopathy [130] 
Neuropathy [133] 
Ataxia [133] 
Epilepsy [133] 
Infertility [134] 
Delayed puberty [134] 
Recurrent miscarriages [134] 
Depression [135] 
Alopecia [136] 
Teeth enamel defects [137] 
Associated conditions Type 1 diabetes mellitus [77] 
Dermatitis herpetiformis [138] 
Autoimmune thyroid disease [139] 
IgA deficiency [91] 
Sjogren's syndrome [140] 
Primary biliary cirrhosis [141] 
1.5.3.1. Temporal changes in mode of presentation 
Since coeliac disease was first described the manifestation of clinically diagnosed 
disease appears to be changing, with increasing numbers of coeliacs being diagnosed 
as a result of anaemia and or non-malabsorptive symptoms [97,128,142-144] with 
temporal trends in the presenting features, age at diagnosis and gender distribution 
have been observed in a number of retrospective and historical case series, cohorts 
and a patient support group survey (Table 1.2). 
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The Lothian cohort of people with coeliac disease was one such historical and 
retrospective cohort, originally set up in 1979 through an attempt to identify all cases 
of coeliac disease diagnosed in the Lothian region of Scotland [25,128]. Cases were 
identified by examination of records of gastrointestinal units of all the hospitals in the 
Lothian region including the Edinburgh Royal Infirmary, Western General Hospital 
and Royal Hospital for Sick Children up to December 1981; The Scottish Hospital 
Inpatient Statistics between 1961 
- 
1977; the existing regional histopathology records 
in the three adult and one paediatric pathology laboratories between 1958 and 1980; a 
postal survey of all the general practitioners in the Lothian region in 1979; and the 
local branch of the Coeliac Society [25,128]. Comparing features at presentation 
through the four quinquennia spanning 1960 
- 
1979, Logan et al observed 21% 
coeliacs presented with classic symptoms of malabsorption in 1975 
- 
1979 in 
comparison to 63% in the 1960s [25,128]. The only other cohort of sufficient sample 
size and of comparable design is that of West et al who observed similar patterns in 
adults diagnosed with coeliac disease in Southern Derbyshire where data was 
collected prospectively by a single investigator using a standard proforma. Probably 
due to differences in study design, study populations, symptom classification and data 
collection it is difficult to infer the relative proportions of classic, silent to 
symptomatic modes of presentation. 
There are several further limitations to the available data observing the mode of 
presentation of coeliac disease. Many of the retrospective case series relied on data 
being collected from medical case records which may be incomplete or the records 
lost and are therefore exposed to information bias in comparison to the systematic 
collection used in the prospective cohort by West et al. Identification of all cases of 
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coeliac disease may not be possible, particularly with earlier non-electronic sources 
used to trace people with coeliac disease in retrospective case series resulting in 
selection bias. Further selection bias probably occurred in the patient support group 
survey with only 134 of 1032 respondents completing the full survey and only 1032 
respondents participating in the survey despite recruitment to a nationwide support 
group over an eight year period. It is likely that the non-responders differ from those 
who respond. Ability of people to recall information regarding previous consultations 
and symptoms and test results leading to diagnosis is likely to be inaccurate resulting 
in recall bias. The sample sizes in many of the studies are low with differences in 
mode of presentation over temporal periods may not be due to chance but are 
inadequately powered to demonstrate an effect. 
One explanation for any changes in presentation could be that the natural history of 
coeliac disease is changing, perhaps in response to changes in environmental 
exposures such as infant feeding practices or smoking. A more likely explanation is 
that the ability to diagnose coeliac disease has improved in both quality and 
accessibility over the past twenty years with the development of both highly sensitive 
and specific non-invasive serological tests and increasing use of endoscopic biopsy 
techniques rather than the traditional and more unpleasant Crosby capsule biopsy. It is 
likely that a broader spectrum of people is being investigated for coeliac disease and 
consequently being diagnosed. There is no real data observing the contemporary 
mode of presentation of contemporary / 21St century coeliac disease which perhaps 
includes a different spectrum of individuals with the development of better diagnostic 
tests and greater test accessibility. 
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1.5.3.2. Age at clinical diagnosis of coeliac disease 
Age at clinical manifestation of coeliac disease has classically been reported as a 
bimodal distribution with the first peak in early childhood between 9 and 24 months 
and the second peak between the third and fourth decade [1]. However later studies 
suggest an adult predominance [1,99,148,149] with dramatic reductions in 
childhood incidence in some [24,151] but not all studies [152]. It has been suggested 
that environmental factors might affect the incidence of coeliac disease in specific 
birth cohorts such as differences in infant feeding practices or relatively high gluten 
content in the infant diet [5,7,153]. The implications of coeliac disease being 
diagnosed in childhood rather than in adulthood are only beginning to be unravelled 
[154]. In the Lothian coeliac disease cohort, all-cause mortality more than 5 years 
after diagnosis was increased threefold in children (SMR 3.32,95% CI 2.05-5.07) 
compared with only a 38% increase in adults (SMR 1.38,95% CI 1.16-1.63) [154]. 
This excess mortality in children was primarily attributed to an increased risk of death 
from accidents, suicide, and violence (seven deaths, SMR 3.22,95% CI 1.29-6.63), 
cancer (five deaths, SMR 3.72,95% CI 1.21-8.67), and cerebrovascular disease (two 
deaths, SMR 10.03,95% CI 1.21-36.00) [154]. Further work using large, longitudinal 
coeliac cohorts observing the implications of the timing of coeliac disease diagnosis 
over the course of the human lifecycle is required. 
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1.6. Occurrence of coeliac disease 
1.6.1. Prevalence of undetected coeliac disease 
Several serological screening studies from Europe, South America, Australasia and 
America have shown that approximately 0.5 
- 
1.0% of these developed country 
populations may have undetected coeliac disease (Table 1.3) [155-160]. There is 
variation in reported prevalence estimates of coeliac disease in screening studies 
which may be due to screening strategy used (such as choice of coeliac serological 
test) and population screened (such as adult blood donors versus general population). 
Apart from the American study, all of the adult blood donor studies confirmed the 
presence of coeliac disease following positive serological result with small bowel 
histology. Two of the general population-based screening studies used populations 
recruited for the World Health Organisation Monitoring of trends and determinants in 
cardiovascular disease (MONICA) project [155,156] but not all people with positive 
serology had coeliac disease confirmed on small bowel histology. In the MONICA 
project, samples of a country's general population were randomly selected from 
population registers stratified by age and by sex. The adult blood donor studies show 
in general lower prevalence of coeliac disease than that observed in the general 
population studies which may reflect exclusion of coeliacs with anaemia due to 
transfusion services only allowing safe donation of blood by donors having minimum 
haemoglobin levels [161]. 
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1.6.2. Prevalence of clinically diagnosed coeliac disease 
Estimates of the prevalence of clinically diagnosed coeliac disease range from 0.05% 
- 
0.27% [171-174] with variation likely to be differences in case ascertainment 
reflecting some local interest in coeliac disease. 
1.6.3. Incidence of adult coeliac disease 
The rate of diagnosis of adult coeliac disease has risen dramatically in most areas of 
the world where there is data available to monitor such trends [172,173,175,176]. 
Although the rate of diagnosis does not completely represent incidence with the 
method of case ascertainment changing with the advent of increasingly sensitive 
serological markers, coeliac disease is being more commonly recognised. The 
estimated incidence per 1000 population has increased from 0.061 in the years 1987 
- 
1991,0.088 in the years 1992 
- 
1996,0.195 in the years 1997 
- 
2001 and 0.169 in the 
years 2002 
- 
2006 in Derby [ 174]. Despite an active case-finding strategy adopted by 
some centres, the incidence and clinically diagnosed prevalence estimates of coeliac 
disease suggest that there is a substantial gap between the number of adults with 
clinically diagnosed and undetected coeliac disease. The ratio of undetected coeliacs 
disease to symptomatic disease is reported to be approximately 8: 1 at present [174]. 
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1.7. Impact of clinically diagnosed coeliac disease 
1.7.1. Metabolic bone disease 
1.7.1.1. Risk of osteoporosis and osteopenia in untreated coeliac disease 
Earlier reports on bone involvement in coeliac disease were principally based on 
clinical and biochemical findings and probably on a highly selected group of adult 
coeliacs with severe disease [177-179]. With the introduction of single and dual x-ray 
absorptiometry (DEXA) providing more precise quantitative bone data in the 1980s, 
reduced bone mineral density (BMD) in adults with untreated coeliac disease was 
observed in published studies (Table 1.4) which have been subject to a recent 
systematic review that I performed [180]. 
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There are limitations to these published studies. Many of the studies are small with 
only 1 of the 18 studies having a sample size above 100 patients with untreated 
coeliac disease. Most of the studies are based on observations from specialty coeliac 
disease clinics and may not reflect the true risk. Only 4 of the studies included a 
control group. However, these published studies suggest that there is a moderate 
reduction of BMD in untreated coeliac disease with weighted mean Z scores at the 
lumbar spine and hip of 
-1.3 (95% CI -1.4, -1.2) and -1.1 (95%CI -1.2, -1.0) [180]. It 
is also not clear whether coeliac patients have the same major risk factors for 
osteopenia or osteoporosis such as female gender [180] or if degree of intestinal 
inflammation contributes to reduced BMD. Classic or symptomatic disease was 
associated with reduced BMD in some but not all studies, raising implications about 
screening for coeliac disease should asymptomatic disease be associated with reduced 
BMD [170]. 
Osteoporosis is a major public health problem because of its potentially severe 
consequences for both the patient and the health care system if it leads to fracture 
[199]; osteoporotic fractures are associated with pain, disability and up to 30% 
mortality at 1 year in addition to an estimated monetary cost in the UK of £940 
million yearly [200-202]. Although osteoporosis is just one of many factors 
predisposing to fracture, with the appreciation that the risk of sustaining an 
osteoporotic fracture doubles with each standard deviation decrease in BMD [203], 
determining the true risk of reduced BMD in an unselected and contemporary cohort 
of people with coeliac disease and identifying which coeliacs are at particular risk of 
reduced BMD is important. Such risk identification would then be of benefit such as 
in the rationalising referrals for BMD assessment rather adopting the policy of BMD 
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assessment in all newly diagnosed coeliacs [204] particularly in the wake of recent 
studies suggesting the risk of fractures, is at most, only slightly increased in people 
with coeliac disease (risk ratio 1.42; 95%CI 1.17,1.65) [180]. 
1.7.1.2. Effects of gluten-free diet on bone mineral density 
Observational studies have suggested that a gluten-free diet improves bone density in 
people with symptomatic coeliac disease. Valdimarsson observed a median 3% 
(interquartile range 1- 7) increase in BMD at the lumbar spine in 62 coeliacs 
following 12 months treatment with a gluten-free diet [194] whereas McFarlane 
observed a 6.6% (95% confidence interval 3.1,10.1) absolute increase in the lumbar 
spine over an identical time period of treatment in 21 coeliacs [205]. Similar 
observations regarding improvement in BMD with treatment with a gluten-free diet 
were reported in other studies observing change over longer periods of follow-up 
[184,191,196,206-208]. Despite the improvement in bone mass with treatment with 
a gluten-free diet, bone mass still appears to be reduced in comparison to age- and 
sex-matched general population controls [194,205] at one year with no studies 
evaluating whether the observed reduced BMD in coeliac disease is completely 
reversible by evaluating BMD changes in coeliacs and age- and sex-matched controls 
over a longer follow-up period. A separate but related question is whether people with 
silent / asymptomatic coeliac disease gain any improvement in their bone mass if 
initiated on a gluten-free diet, again raising the issue of whether or not we should be 
actively screening otherwise healthy people for coeliac disease. 
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1.7.2. Liver disease 
A number of liver conditions have been reported to be associated with coeliac disease. 
For example, recent population-based data using the General Practice Research 
Database and Swedish In-Patient Registry observed a four-fold increased risk of 
having an autoimmune liver disease such as primary biliary cirrhosis in people with 
coeliac disease in comparison to general population controls [209,210]. However 
several case series report the most common hepatic injury to affect people with 
untreated coeliac disease is of an isolated hypertransaminasaemia, observed to affect 
over 40% of adults newly diagnosed with coeliac disease (Table 1.5). 
Table 1.5: Prevalence of elevated transaminases in untreated coeliac disease 
Study Number of Proportion with Complete 
incident adult abnormal ALT normalisation 
coeliacs at diagnosis of ALT with 
GFD 
Hagender et al 53 55% 
1977 [211] 
Jacobsen et al 132 47% 
1990[212] 
Dickey et al 129 15% 87% 
1995 [212] 
Bardella et al 158 42% 95% 
1995 [213] 
Novacek et al 178 40% 96% 
1999 [214] 
ALT alanine transterase; ClF D gluten-tree diet 
Coined "gluten" or "coeliac hepatitis" this hepatic injury is reputed to be characterised 
by absence of serum auto-antibodies (other than endomysial and tissue 
transglutaminase antibodies), elevated transaminases and the presence of mild lobular 
and portal tract inflammation that is reversible on treatment with a gluten-free diet 
[215]. Given the relatively high prevalence of coeliac hepatitis observed in the 
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reported case series and the potential of the coeliac hepatitis to progress to liver 
fibrosis, cirrhosis and end-stage liver failure, some groups have recommended a 
vigorous search for liver disease in people newly diagnosed with coeliac disease [216- 
218]. To help determine if the liver work-up is warranted in modem coeliac disease, 
the prevalence of hypertransaminasaemia in an unselected, large and contemporary 
population of people newly diagnosed with coeliac disease is required. 
1.7.3. Symptoms and quality of life 
Above the waterline of the coeliac iceberg are usually symptomatic patients whom are 
usually healthcare seeking because of the overt symptoms where the diagnosis is 
made and treatment introduced. In contrast, the majority of people with coeliac 
disease are undiagnosed and silent 
- 
either due to absence of symptoms; presence of 
atypical symptoms resulting in coeliac disease going unrecognized for many years 
[219,220]. Predicting who will benefit from being diagnosed with coeliac disease is a 
fundamental question. It appears from available albeit limited studies, people with 
symptomatic coeliac disease not only reap an improvement in their quality of life but 
suffering from gastrointestinal symptoms like diarrhoea are alleviated with a gluten- 
free diet [221]. We do not know whether there should be a case for population 
screening for coeliac disease in otherwise asymptomatic, healthy people as it is 
unclear from a quality of life perspective whether this gets better with a gluten-free 
diet. A further fear is whether detection of silent coeliac disease will force otherwise 
healthy people to change their eating habits, which in turn may worsen their quality of 
life and be less willing to adhere to a strict gluten-free diet. 
Only a few studies have explored health-related quality of life measures with a 
longitudinal design such as in 35 coeliacs using Zung self-rated depression scale [222] 
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and in 40 coeliacs using the Psychological Well-Being Questionnaire [223]. However 
both of these quality of life assessment tools are generic instruments that are complex 
to administer and to score, prone to missing important clinical change and are a source 
of bias due to coeliac disease itself through containing items evaluating 
gastroenterological symptoms of depression such as decreased appetite, weight loss, 
change in bowel habit [224]. 
Only two further longitudinal studies evaluating change in quality of life with 
exposure to a gluten-free diet in incident coeliac disease has been performed [225, 
226], both of which used the Short-Form (SF-36) questionnaire which is both 
validated and reproducible for use in both the general population and in disease states 
with data from representative population samples giving a general population 
comparison [227]. Both studies looked at quality of life measured by SF-36 in silent 
and symptomatic coeliacs and compared these with healthy controls [225,226]. 
Johnston et al observed that 14 silent coeliacs had not different quality of life in 
comparison to healthy controls [225] whereas Nachman et al observed 35 silent 
coeliacs had significantly worse off quality of life in comparison to their control group 
[226]. Both groups observed that symptomatic coeliacs had lower quality of life in 
comparison to controls [225,226]. On exposure to one year on a gluten-free diet, 
Johnston et al observed that symptomatic but not the silent coeliacs reaped a 
significant improvement in their quality of life [225] using EMA positivity to assess 
for dietary compliance. Due to large losses to follow-up (over three-quarters of the 
study population) no meaningful interpretation could be made of the silent coeliac 
patients change in quality of life with treatment though a gluten-free diet was of 
significant benefit in the symptomatic group [226]. The small sample size, the 
56 
selection bias associated with the choice of healthy controls, exclusion of cases were 
further limitations to the studies [225,226]. A number of historical cross-sectional 
studies have also been performed on the quality of life of clinically diagnosed 
prevalent coeliacs established on a gluten-free diet [228-235] suggesting that health 
and psychological well-being is poor in prevalent coeliac disease with a high 
frequency of depression and anxiety. 
A large prospective longitudinal study assessing change in quality of life using 
validated assessment tools in a contemporary cohort of unselected coeliac disease is 
clearly required. 
1.7.4. Body composition and anthropometrics 
Other than the observational data on bone mineral density in selected coeliacs, there 
are few studies that have observed the effect of coeliac disease upon body 
composition and anthropometrics. A historical study based on a small number of 
people with classic coeliac disease were observed to have lower weight, height, body 
mass index, fat mass and lean mass in comparison to controls which increased 
significantly with twelve months treatment with a gluten-free diet [236]. Height, bone 
mineral content, arm muscle area, triceps skin fold, fat area index were significantly 
lower in 23 children newly diagnosed with coeliac disease in comparison to age- and 
sex-matched controls [237]. Treatment with twelve months of a gluten-free diet 
resulted in a significant improvement in these measures though the improvement in 
height did not reach control levels [237]. 
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With the broader spectrum of people being investigated for coeliac disease and 
consequently being diagnosed, prospective longitudinal studies are required to 
determine the impact of coeliac disease upon body composition and anthropometrics 
as well as quality of life and the effect of treating diagnosed coeliac disease in a 
contemporary cohort. 
1.7.5. Cardiovascular disease 
1.7.5.1. Impact and aetiology of cardiovascular disease in the general population 
Worldwide, ischaemic heart disease is the leading cause of death and loss of 
disability-adjusted life years and is expected to remain the leading cause of mortality 
and morbidity in the western world well into the 21St century [238,239]. The lifetime 
risk of having a cardiovascular event at 40 years of age is 49% in men (95% CI 45.8 
- 
51.3) and 32% in women (95% Cl 29.2 
- 
34.2) [240]. 
Established high-risk demographic factors for vascular disease are advancing age 
(relative risk 8 for 60 versus 40 year olds), male sex (relative risk 2-5 men versus 
women), lower socioeconomic status (relative risk 3 for social class V versus social 
class I) and immigrants born in the Indian subcontinent (standardised mortality ratio 
146 (95% CI 136,156) relative to England and Wales standard rate) [241-244]. 
There are a number of modifiable aetiological factors associated with vascular 
disease. Cigarette smoking is associated with a nearly two-fold increased risk of 
vascular disease with the risk increasing with the number of cigarettes smoked [245]. 
Smoking accounted for 28% of male and 26% of female all-cause vascular deaths 
aged 35 to 69 [246]. Smoking cessation results in reduced risk of vascular disease 
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(relative risk reduction 0.64; 95%CI 0.58,0.71 for those smokers that quit versus 
those who continued smoking) [247]. 
Increasing systolic and diastolic blood pressure is associated with increasing risk of 
vascular disease (relative risk 2 for developing vascular disease in 8 years with 
systolic blood pressure >/ 160 mmHg) [241]. A sustained reduction of 5 mmHg 
blood pressure over a 5-year period reduced coronary artery events by 25% and 
strokes by 30% in patients with ischaemic heart disease in five years [248]. 
Obesity is associated with increase in death from vascular disease (standardised 
mortality ratio 136 of BMI >/27 kg/m2 versus <22.4 kg/m2) [249]. People with central 
obesity are at increased risk of vascular disease in comparison to those of similar BMI 
but with peripheral adiposity [250]. Waist: hip circumference of >/ 0.91 was 
associated with nearly a threefold (relative risk 2.69 [95%CI 1.36,5.31) compared to 
<0.91) increased risk of coronary artery disease events whilst a waist circumference > 
95 centimetres was associated with a twofold increased risk (relative risk 2.02 [95%CI 
1.17,3.48] compared to <83.5 cm) in men during mean 10 year follow-up [251]. 
Overweight men as defined by BMI 25 
- 
30 kg/m2 were also observed to have a 
twofold (relative risk 2.09 [95%CI 1.24,3.53) to BMI < 24 kg/rn2) increased risk of 
coronary artery disease in this study [251]. 
There is a strong, independent and graded relationship between total cholesterol and 
risk of ischaemic heart disease with a reduction in total cholesterol of 0.6 mmol/L 
associated with 25 
- 
30% reduction in the risk of mortality from ischaemic heart 
disease in people aged 55 
- 
64 years [252]. The higher the LDL cholesterol level, the 
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higher the risk of vascular disease [253]. Reduction in LDL cholesterol by 1.3 
mmol/L resulted in reduction in risk of non-fatal acute coronary syndrome or death 
from vascular disease by a third (risk reduction 31%; 95%CI 17,43) in middle-aged 
men with hypercholesterolemia (non-fasting cholesterol 6.5 mmol/L or more) and no 
history of myocardial infarction [254]. HDL cholesterol is independently and 
inversely associated with the development of vascular disease where a rise in HDL 
cholesterol by 0.02 mmol/L results in a 3% reduced risk [255,256]. Elevated levels of 
triglycerides are associated with increased risk of coronary artery disease events 
though it is not clear whether it is the triglyceride levels or the associated changes in 
the lipoprotein metabolism as well as with other vascular disease risk factors such as 
insulin resistance, obesity and lowered levels of HDL cholesterol that are responsible 
[257,2581. 
Fibrinogen is independently associated with vascular disease risk (risk ratio 1.8 
[95%CI 1.6,2.0] of 0.35 g/L versus 0.25 g/L] [259] though it is not clear whether the 
increased risk observed in elevated levels of CRP are causal (odds ratio 2.13 [95%CI 
1.38,3.28] for 2.4 v 0.9 mg/L) [260]. 
Diabetes mellitus is associated with an excessive risk of vascular disease events with 
risks higher in women than in men (relative risk 3.5; 95%CI 2.7,4.5 in female 
diabetics to those without diabetes) [261]. 
1.7.5.2. Impact of cardiovascular disease in coeliac disease 
Like in the general population, vascular disease is the most important single cause of 
mortality in coeliac disease, accounting for 40% of all deaths [262]. However, the 
possibility that coeliac disease might afford some protection from vascular disease 
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was first raised by Whorwell et al in 1976 who observed a 40% reduction in 
ischaemic heart disease mortality in people with diagnosed coeliac disease [263] and 
further supported by studies in Italy and Scotland [264,265]. Any reduction in 
vascular-related mortality in coeliac disease needs consideration particularly as it 
might outweigh larger increases in mortality from less common conditions and any 
benefit might be reduced by treatment with a gluten-free diet. 
Recent studies have found some evidence of decreased cardiovascular morbidity 
suggesting that people with coeliac disease appear to have a favourable vascular risk 
profile. Coeliac disease appears to be associated with non-smoking although it is 
unclear whether this is a causal association [266-268]. In a cross-sectional population 
screening study people with positive endomysial antibodies had an 8% (0.5 mmol/L; p 
< 0.01) reduction in mean serum cholesterol and a 2.4 mmHg (p < 0.05) lower 
diastolic blood pressure in comparison to negative controls [170]. People with treated 
coeliac disease are reported to be less likely to have a diagnosis of 
hypercholesterolaemia (odds ratio 0.58 (95% Cl 0.47 
- 
0.72)) or hypertension (odds 
ratio 0.68 (95% CI 0.60 
- 
0.76) and a lower reported antihypertensive medication use 
in comparison to age- and sex-matched general population controls [269]. 
Despite this apparent favourable cardiovascular risk profile and reduced risk of 
vascular-related mortality in comparison to the general population, not all studies 
have observed coeliac disease having a protective effect upon cardiovascular disease 
events. A Swedish hospital-based cohort study of 13,358 people with coeliac disease 
observed people with coeliac disease were at increased risk of myocardial infarction 
(hazard ratio 1.27 (95% CI 1.09 
- 
1.48)) and angina pectoris (hazard ration 1.46 (95% 
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CI 1.25 
- 
1.70)) [270]. In contrast, no differences were observed in the risk of neither 
myocardial infarction (hazard ratio 0.85 (95% CI 0.63 
- 
1.13)) nor stroke (hazard 
ratio 1.29 (95% CI 0.98 
- 
1.70)) in people with treated coeliac disease in comparison 
to general population controls in a population-based cohort study [269]. Furthermore, 
367 coeliac patients identified by presence of positive coeliac serology and or 
characteristic change on small bowel histology had no increased risk of cardiovascular 
disease events such as myocardial infarction (unadjusted hazard ratio 1.10; 95%CI 
0.62,1.92) in comparison to 5537 seronegative controls [271]. Reasons for the 
observed lack of protection against cardiovascular disease events in diagnosed coeliac 
disease are unclear but possible explanations include an altering, attenuating effect on 
the vascular risk profile by treatment with a gluten-free diet or that other [272] 
processes particular to people with coeliac disease mediate the increased risk. For 
example, a low grade systemic inflammation causing accelerated atherosclerosis, 
adverse HDL-cholesterol and LDL-cholesterol profiles; anaemia; folate deficiency; 
homocysteine; weight changes; or some other reason [273-281]. The relationship 
between coeliac disease and vascular risk profile is clearly complex and requires 
unravelling. The effects of treatment with a gluten-free diet should also be determined 
before any screening programme for coeliac disease instituted. 
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1.7.6. Malignancy 
Diagnosed coeliac disease has been traditionally linked with greatly increased risks of 
lymphoproliferative malignancies [262,264,265,282-287]. Early studies have been 
limited in their ability to provide precise estimates of the risks of cancer experienced 
by people with coeliac disease in comparison with the general population by their 
small sample size, selected nature from specialist coeliac centres and ability to adjust 
for potential confounders. In addition, when people are first investigated for coeliac 
disease the likelihood of detecting an occult or overt malignancy may be increased or 
conversely coeliac disease may be more likely to be detected during the investigation 
for cancer. The excess risk of gastrointestinal malignancy is likely, in part, to be 
contributed by the more detailed investigation of gastrointestinal symptoms 
particularly at presentation of coeliac disease. Furthermore findings from these studies 
probably do not reflect the risks in contemporary coeliac disease. More recent data 
from Sweden based on cases of coeliac disease obtained from their hospital in-patient 
register have suggested more modest though still increased risks of malignancy in 
people with coeliac disease [262,283]. Although these studies were based on large 
numbers of people with coeliac disease, these studies are dependent on hospital 
admission of the index case for ascertainment and it is therefore possible that this may 
have led to an overestimate of the risks. Other recent data from a large population- 
based cohort study using the General Practice Research Database in the United 
Kingdom observed similar modest increases in the risks but still found that people 
with coeliac disease were at excess risk of certain malignancies [282]. Strengths of 
this study included validation of coeliac disease diagnosis and restriction analyses 
including assessment for ascertainment bias performed. However, with visit rate to 
general practitioners more frequent than in the general population, there is also the 
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possibility of differences in ascertainment of some malignancies as a result of 
opportunistic or systematic screening [282]. 
1.7.6.1. Impact and aetiology of breast cancer in the general population 
Breast cancer is the commonest malignancy in women, comprises 18% of all female 
cancers and is the commonest cause of cancer death among women worldwide [288]. 
Incidence rates are high in more developed countries; in the United Kingdom where 
the age standardised incidence and mortality is the highest in the world, the 
cumulative incidence among women aged 55 years is 2.7% [289]. The incidence of 
breast cancer increases rapidly with age (relative risk > 10), doubling every 10 years 
during the reproductive years until the menopause, when the rate of increase slows 
dramatically (Figure 1.7) [289]. 
Figure 1.7: Age-specific incidence and mortality of breast cancer in the UK [2901 
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It is a disease mostly, though not exclusively, of women. Established high-risk 
demographic factors for breast cancer are advancing age (relative risk > 10), 
Caucasian race (relative risk >5 to Asians) and women of higher socioeconomic status 
(relative risk 2 for social classes I and II to other classes) [289,291,292]. Many of 
the other established aetiological factors of breast cancer are linked to oestrogens with 
hormonal factors playing a key role. Oestrogen stimulates the mitosis of breast 
epithelial cells, and this mitogenic effect may be augmented by progesterone [293]. 
, 'actors extending the relative exposure of the breasts to high concentrations of 
oestrogen (and perhaps progesterone) are associated with an increased risk of breast 
cancer such as early onset of menarche and later onset of menopause [293]. Such 
exposures, in addition to being relatively unmodifiable, are highly prevalent amongst 
women of the developed world [294]. Women who start menstruating early in life 
(relative risk 3 for age at menarche before age 11 years) or who have a late 
11 
menopause (relative risk 2 for menopause after age 54 years) have an increased risk of 
developing breast cancer. The magnitude of this effect is similar whether menopause 
occurs naturally or as a result of bilateral oopherectomy [289]. Late age at first birth 
increases the lifetime incidence of breast cancer (two-fold increased risk in women 
who have their first child after the age of 30 years to those who have their first child 
before the age of 20) [295]. Compared with nulliparous women, women who have had 
at least one full-term pregnancy have on average 25% reduction in breast cancer risk 
[296]. Proliferative breast lesions with (at least four-fold) or without atypia (at least 
two-fold) confer an increased risk of breast cancer [297]. Familial aggregation of 
breast cancer is likely to be a reflection of both shared genes and to shared physical 
environments and lifestyles. A woman's risk of breast cancer is two or more times 
greater if she has a first degree relative who developed the disease before the age of 
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50 years with the younger the relative when she developed breast cancer the greater 
the risk [298]. Breastfeeding (pooled odds ratio 0.84; 95%CI 0.78,0.91) [299], 
regular menstrual cycles (relative risk 0.76; 95%CI 0.62,0.94 for <1 year to onset of 
regular menstrual cycles) [300] and severe caloric restriction caused by anorexia 
nervosa [301] have observed to have a protective effect upon breast cancer risk. 
Current use of oral contraceptives (relative risk 1.24) and use of hormone replacement 
therapy for more than 10 years (relative risk 1.34) are also aetiological factors [289, 
302]. Post-menopausal obesity, increasing adult height, high alcohol intake, high 
intake of saturated fat and folate are also associated with increased breast cancer risk 
(relative risk 1.3 
- 
1.5) [303-309]. Severe caloric restriction caused by anorexia 
nervosa prior to age 40 years was observed to be associated with 50% lower incidence 
of breast cancer [301]. 
Population attributable risk (PAR) estimates suggest that age at first birth at >29 
years, nulliparity, menarche before the age of 14 years, family history of breast cancer 
in 1st degree relative and history of benign breast disease account for the largest 
fraction of breast cancer cases in published studies (e. g. PAR 29.5% for age at first 
birth > 29 years and nulliparity in white women in United States ; 95%CI 5.6,53.3) 
[292,310]. 
The early life aetiological model for breast cancer emphasises early life events and 
conditions as determinants of breast cancer risk and summarises the distinct 
epidemiological characteristics of the disease on the basis of three major components 
[311-316]. The first major component of this model is that the likelihood of breast 
cancer occurrence depends on the number of mammary tissue-specific stem cells, 
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which is determined in early life processes. In early and later life, grow-enhancing 
mammotrophic hormones affects the replication rate of mammary tissue specific stem 
cells, the likelihood of retention of cells with spontaneous somatic mutations as well 
as the rate of expansion of initiated clones in the second component of the model. In 
the third component, pregnancy conveys long-term protection through differentiation 
of a large fraction of the mammary tissue-specific stem cells. The established breast 
cancer risk factors may be categorized into the different components of this model 
(Table 1.6)[317]: 
Table 1.6: Grouping of breast cancer risk factors according to the general 
principles of carcinogenesis and the postulated pathogenic process 
General 
principles of 
carcinogenesis 
Number of 
mammary tissue 
specific stem cells 
Growth enhancing 
mammotrophic 
hormones 
Terminal 
differentiation 
Age Gland mass Gender Age at 1st term 
Ionising radiation Atypical hyperplasia Age at menarche pregnancy 
Family history Gender Age at menopause Parity 
Specific genes Birth weight Type of menopause Lactation 
Growth in early life Oral contraceptives 
Height Hormone 
Ethnic group replacement 
Pregnancy timing 
Postmenopausal 
obesity 
Ethanol intake 
Physical activity 
Adult life diet 
Understanding the determinants underlying recognized risk factors and study of other 
factors that may confer risk or protection may help to advance our understanding of 
breast cancer aetiology and to aid in devising strategies for prevention. 
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1.7.6.2. Impact and aetiology of breast cancer in coeliac disease 
Several studies have suggested coeliac disease is associated with a reduced risk of 
breast cancer (Table 1.7). 
Table 1.7: Reduced risk of breast cancer in coeliac disease 
Authors Coeliac disease study Reduced risk of breast 
population cancer in comparison to 
eneral population 
Logan et al [265] Population-based cohort in SMR 0/1.52 
Edinburgh 
Askling et al [283] Swedish in-patient registry SIR 0.3 (0.1 
- 
0.5) 
West et al [282] Population-based cohort in Hazard ratio 0.24 (0.10 
- 
0.60) 
UK 
Card et al [287] Population-based cohort in SIR 0.59 (0.12 
- 
1.73) 
Derby 
Silano et al [318] Hospital-based cohort in SIR 0.2 (0.04 
- 
0.62) 
Italy 
Solaymani-Dodaran Population-based cohort in SMR 0/3.10 
et al [319] Edinburgh 
SMR standardised mortality ratio; SIR standardised incidence ratio 
Figures in brackets refer to 95% confidence interval 
Reasons for the apparent reduced risk of breast cancer in coeliac disease are unclear. 
Later age at menarche and earlier onset of menopause has been observed in women 
with coeliac disease in studies using small, selected populations [320-323] though a 
more recent and population-based study observed female coeliacs had similar fertility 
to that of the female general population though female coeliacs tended to have their 
babies at an older age [324]. Short stature, low body mass, caloric restriction, fat and 
folate deficiencies associated with coeliac disease [170,221,325] may also be 
implicated in the apparent reduced risk of breast cancer in women with coeliac 
disease. It may be the caloric reduction as a consequence of the intestinal 
inflammation and subsequent malabsorption that has an effect on breast cell growth 
and development; alternatively the reduced expression of oncogenes, levels of 
epidermal growth factor and insulin-like growth factor observed in caloric restriction 
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may be implicated [326-328]. The timing of the energy restriction may also be 
relevant. Energy restriction may be critical during early life and prior to first 
pregnancy when mammary tissue is particularly susceptible to carcinogenic processes 
[329,330]. This hypothesis is supported by the observation that greater height, which 
although is genetically influenced is reflective of nutritional status and hence caloric 
intake during growth, is associated with an increased risk of breast cancer [331]. 
With breast cancer in the general population associated with reproductive, hormonal 
and anthropometric exposures, comparing the possession of these risk factors in 
women with coeliac disease to women without coeliac disease may clarify as to 
whether reproductive, hormonal and or anthropometric exposures contribute to the 
reduced risk of breast cancer in coeliac disease. 
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1.7.7. Mortality 
Various studies have observed that diagnosed coeliac disease still confers a 1.3 
- 
2- 
fold increased risk in all-cause mortality compared with the general population [262, 
265,282,332-334]. It is unclear how much of this excess risk is related to coeliac 
disease itself and how much the increase might be only indirectly related through 
associated conditions. There has also been speculation that the duration of gluten 
exposure prior to diagnosis has long-term adverse effects and therefore contributes to 
mortality [334] though a recent study observed children diagnosed with coeliac 
disease had a three-fold increased risk of long-term mortality in marked contrast to the 
experience of adulthood diagnosed coeliac disease where there was a modest increase 
in mortality [319] refuting this speculation. 
Dermatitis herpetiformis, which forms part of the same spectrum of gluten-sensitive 
disorders as coeliac disease [335], has recently been observed to be not associated 
with an excess risk of mortality in comparison to the general population [336]. 
Differences in intestinal inflammation, reputed to be milder in dermatitis 
herpetiformis [337], or some other reason may be responsible for the difference in risk 
in comparison to that observed with coeliac disease. 
Data using the Swedish In-Patient Registry observed people (n = 3719) with latent 
coeliac disease, defined in the study as having positive coeliac serology up to 180 
days before duodenal biopsy was performed demonstrating normal mucosa, had 
excess mortality in comparison to those people without latent coeliac disease (1.7 per 
1000 person years; hazard ratio 1.35,95%CI 1.14,1.58) [338]. People with positive 
coeliac serology drawn as part of a population-based screening study in Finland had 
no excess mortality in comparison to serology-negative controls [339] in contrast to 
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the 4-fold increased mortality risk in 14 serology-positive military recruits compared 
to seronegative controls (hazard ratio 3.9; 95%CI 2.0,7.5) [340]. 
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1.8. Summary 
The prevalence of coeliac disease in the general population is 1% though only the 
minority of cases and a broader spectrum of people are clinically diagnosed with the 
disorder. Fracture risk, malignancy and mortality associated with clinically diagnosed 
coeliac disease have recently been described in large and contemporary population- 
based studies though other morbidity associated with clinically diagnosed coeliac 
disease and effect of treatment needs clarification. The benefits and possible harm of 
early detection and treatment of coeliac disease in otherwise asymptomatic, healthy 
people or those presenting with non-classic features is not clear. Understanding the 
determinants underlying recognized morbidity associated with coeliac disease and 
other factors that may confer risk or protection may help to advance our 
understanding of disease aetiology such as vascular disease, breast cancer and to aid 
in devising strategies for prevention. The rate of diagnosis of coeliac disease in 
developed countries has increased dramatically since the introduction of serological 
tests without an obvious environmental precipitant with further work needed to 
improve our understanding of the aetiology of the disorder. 
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1.9. Objectives of thesis 
The aim of the thesis is to achieve the following objectives: 
1. To describe the relationship between degree of enteropathy and physiological 
derangement, clinical features in incident coeliac disease 
2. To examine the incidence of clinically diagnosed coeliac disease by socio- 
economic status 
3. To quantify the impact of diagnosed coeliac disease on the risk of. 
" 
hypertransaminasaemia 
" hypercholesterolaemia 
4. To estimate the vascular risk profile at diagnosis of coeliac disease and 
quantify any change following treatment with a gluten-free diet 
5. To estimate the quality of life at diagnosis of coeliac disease and observe any 
change following exposure to a gluten-free diet 
6. To describe the breast cancer risk profile in women with coeliac disease and 
compare to that of the general population 
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1.10. Outline of thesis 
The outline of the thesis with aims and contents of each chapter is given below: 
Chapter 2: Study design 
9 Introduce historical, prospective and cross-sectional study cohorts used in the 
studies of the thesis 
Chapter 3: Historical cohort studies in incident adult coeliac disease 
" Describe relationship between degree of enteropathy and physiological 
derangement, clinical features 
" 
Examine the risk of hypertransaminasaemia and effect of treatment 
" Examine incidence of diagnosed coeliac disease and socio-economic status 
" 
Estimate cholesterol profile and effect of treatment 
Chapter 4: Prospective, longitudinal studies in incident adult coeliac disease 
" Quantify impact of coeliac disease on health-related quality of life and 
vascular risk profile and change with treatment 
Chapter 5: Cross-sectional survey of women with coeliac disease 
9 Estimate breast cancer risk profile in women with coeliac disease and compare 
with general population 
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Chapter two: Description of cohorts used in thesis 
2.1. Introduction 
There are three different populations of adults with coeliac disease used in this thesis: 
1. Historical, contemporary incident cohort (chapter 3) 
2. Prospective, longitudinal incident cohort (chapter 4) 
3. Cross-sectional survey of incident and prevalent female coeliacs (chapter 5) 
This chapter will describe how the cohorts used in this thesis were generated. The 
chapter also describes the demographic, clinical, histological and laboratory features 
of the historical cohort used in the thesis. 
2.1.1. Study design 
For the series of studies described in chapters 3,4 and 5I needed to identify adults 
with coeliac disease. The cohorts would need to be a representative sample of the 
coeliac disease population so that my results would be applicable to the coeliac 
population as a whole. People acquire a diagnosis of coeliac disease based on the 
results of a small bowel biopsy (requiring histopathologists) and or positive coeliac 
serology (performed by immunologists); and should have contact with healthcare 
teams (usually gastroenterologists, dietitians) for explanation of the diagnosis made 
and treatment recommended. Confirmation of these pathways and any others taken by 
a person with coeliac disease would be needed, thereby identifying the likely coeliac 
disease population from which recruitment to the study (and an assessment of how 
representative study sample is) could take place. Furthermore, the likely numbers of 
people being diagnosed with coeliac disease by a centre each year would help guide 
the number of centres needed and that could be practically involved to run the study 
within time constraints (such as that dictated by study funding). It would be useful to 
know when coeliacs had contact with health services (such as attending outpatient 
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clinic appointment, endoscopy investigation) to help coincide routine clinical care 
with collection of data for studies, thereby minimising hassle to the study participant 
with the view of maximising recruitment and continued compliance with the study. 
Though involving a number of centres to help achieve sample size aim, the different 
centres were likely to approach clinical care of people with coeliac disease differently 
such as the frequency and timing of outpatient clinics with gastroenterologists and or 
dietitians which would need to be explored and incorporated into study design. 
2.1.2. Possible choice of centres to involve in study 
Being based at the University of Nottingham for my PhD student training, it was 
logical to have Nottingham University Hospital that serves a population of about 640 
000 people as a study centre. Derbyshire Hospitals NHS Foundation Trust also forms 
part of the mid-Trent hospital network serving a population of approximately 600 000 
people and had repeatedly been a source of collaboration on previous coeliac disease 
projects with my PhD supervisors and was therefore chosen as another centre for the 
study. A research collaboration was developed between Joe West and David Sanders 
between the Nottingham and Sheffield centres. Serving a local population of around 
550 000 people, the Royal Hallamshire Hospital thereby became the third centre for 
the study. 
2.1.3. Evolution of historical coeliac cohorts 
With Nottingham, Derby and Sheffield hospitals confirmed as centres for the studies, 
I had to work out how to identify people being newly diagnosed with coeliac disease 
and how to get to meet these incident coeliac cases at each centre so that I could invite 
them to participate in the longitudinal studies of chapter 4. If I determined how 
incident coeliacs currently journeyed through each centre, I believed I could develop 
76 
systems in which to identify who was being diagnosed with coeliac disease and where 
I could meet them. For this I would need to firstly establish who had recently been 
diagnosed with coeliac disease and then determine what interactions (such as contact 
with an outpatient clinic) these people had had in the centre concerned. My plan was 
to identify all the people who were diagnosed with coeliac disease in the three centres 
between 2000 
- 
2006. How I worked out the journeys taken by people being newly 
diagnosed with coeliac disease at each centre is described in section 2.2. 
From performing extensive searches of who had been diagnosed with coeliac disease 
at each centre, I generated historical cohorts for Nottingham and Sheffield centres 
which included systematic collection of demographic, clinical, histological and 
laboratory data. These historical cohorts not only helped me develop systems of how 
to recruit incident coeliacs for the prospective studies of chapter 4 but the historical 
cohorts formed the study populations for exploring mild enteropathy disease; 
socioeconomic status; and liver and vascular morbidity associated with coeliac 
disease (chapter 3). Women with coeliac disease identified in these searches also 
formed the study population for the cross-sectional survey on breast cancer risk 
profile (chapter 5). 
2.2. Journeys taken by people newly diagnosed with coeliac 
disease 
This section will describe how I identified who was being diagnosed with coeliac 
disease at each of the study centres and what interactions (such as outpatient clinics) 
these coeliacs had with the centre in question. A summary flow diagram summarising 
how the historical cohort was constructed and how I identified adults newly diagnosed 
with coeliac disease at the Nottingham and Sheffield centres is first given. 
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2.2.1. Nottingham University Hospital, Nottingham 
2.2.1.1. Coeliac disease cohort at Nottingham University Hospital creating the 
Nottingham historical cohort: a summary 
Combining histological data on coeliacs identified from histopathology, clinical 
coding and immunology searches with clinical information (such as symptoms at 
presentation) obtained from general practitioner and hospital letters, endoscopy 
reports; coeliac serology results; and laboratory data the Nottingham historical cohort 
was constructed: 
Figure 2.8: Creation of historical coeliac disease cohort at Nottingham University 
Hospital 
Search histopathology database for people with coeliac disease using standardised 
coeliac disease histopathological diagnosis code 
Search clinical coding database for people assigned the clinical code for coeliac 
disease 
Search immunology database for people with positive coeliac serolo 
Add in coeliacs that have not 
been identified through 
histopathology, clinical coding, 
immunology searches 
but have been found through 
referrals from gastroenterologists 
and dietitians 
Create an Access database of people with coeliac disease with one entry to the 
database per person 
Nottingham historical 
coeliac disease cohort 
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2.2.1.2. Incident coeliac disease cohort at Nottingham University Hospital: a 
summary 
Monthly updates from histopathology, clinical coding and immunology databases 
were used to generate a list of people with coeliac disease. This list was cross- 
referenced with clinical information obtained from general practitioner and hospital 
letters to determine those that had been newly diagnosed with coeliac disease. The 
subsequent hospital attendances of these people newly diagnosed with coeliac disease 
was determined in order for me to go and discuss participation in the prospective 
studies. 
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Figure 2.9: Flow diagram of method of identifying people with newly diagnosed 
coeliac disease at Nottingham University Hospital to recruit for prospective 
vascular risk profile study 
Search histopathology database each month of study for people with coeliac disease 
using standardised coeliac disease histopathological diagnosis code 
Search clinical coding database each month of study for people assigned the clinical 
code for coeliac disease 
Search immunology database each month of study for people with positive coeliac 
Add in coeliacs that have not 
been identified through 
histopathology, clinical coding, 
immunology searches but have been 
found through referrals from 
gastroenterologists and dietitians 
Create an Access database of all people newly diagnosed with coeliac disease during 
the study period 
Use the patient administration system, 
secretaries, dietitians to determine date, 
time and place when these incident 
coeliacs are attending the hospital for 
appointments 
Attend hospital appointments of people newly diagnosed with coeliac disease and 
invite them to participate in prospective study 
Obtain informed consent 
Newly diagnosed coeliacs become study participants for 
prospective study 
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2.2.1.3. Histopathology records 
I assumed the majority of people would acquire a diagnosis of coeliac disease on the 
basis of small bowel histological appearances regardless of the events leading up to 
having the small bowel biopsy being taken. There is a single histopathology 
computerised database on which all tissue samples taken at the hospital that are 
submitted for histological examination are logged under an unique laboratory number. 
The referring consultant is included in the information logged with the tissue 
specimens which may be a gastroenterologist (indicated by their initials) but not 
necessarily so with people presenting to other specialists (such as to the Haematology 
or Respiratory Consultant). The range of specialties of referring consultants 
highlighted the variety of routes through which people could come through to get 
diagnosed with coeliac disease by means of a small bowel biopsy. Standardised 
SNOMED (Systemized Nomenclature of Medicine) codes are assigned to the 
histopathological diagnosis of the tissue specimens. The computerised 
histopathological database can be searched for specific diagnoses by entering the 
standardised code of interest such as `T6430D62180' which uniquely specifies coeliac 
disease. Following liaison with Dr Philip Kaye, a consultant histopathologist with 
subspecialty interest in gastrointestinal disease, a list of all people having tissue 
specimens assigned the code for coeliac disease between 1St January 2000 and 31st 
December 2006 was generated from the histopathology database. An excerpt of the 
list generated is shown below: 
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Figure 2.10: Excerpt of list of people possessing code for coeliac disease from 
histopathology database 
Lab 
number 
Consultant Surname* Forename* Date of 
birth 
SNOMED 
code 
03109205 KT Xx Xx 11/12/1952 T6430D62180 
03109605 PAJ Xx Xx 11/04/1966 T6430D62180 
03110054 WPG Xx Xx 10/04/1955 T6430D62180 
03110822 ROM Xx Xx 04/12/1929 T6430D62180 
03111028 RGL Xx Xx 16/04/1937 T6430D62180 
03111328 KT Xx Xx 13/04/1960 T6430D62180 
03111828 JTM Xx Xx 21/09/1963 T6430D62180 
*Excerpt anonymous but the real list generated that I used isn't anonymous 
The list of all people having tissue specimens assigned the code for coeliac disease 
between 1st January 2000 and 31st December 2006 generated from the histopathology 
database generated 983 unique laboratory numbers though some people appeared on 
the list on more than one occasion i. e. had further small bowel biopsies taken on a 
subsequent date where again coeliac disease was demonstrated. Some people on the 
histopathology list were children i. e. aged under 18 years and so not relevant to my 
studies. 
Using this list I entered each unique laboratory number into the histopathology 
computerised database to bring up the linked histopathology report and read through 
each person's small bowel histology result. I used a number of ways to determine 
whether the small bowel biopsy was taken to diagnose coeliac disease or whether the 
small bowel biopsy was taken in someone who had already been diagnosed with 
coeliac disease. 
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Features suggestive of the small bowel biopsy being taken to newly diagnose a person 
with coeliac disease included: 
" clinical information submitted with the small bowel specimen (such as 
`diarrhoea 
- 
rule out coeliac disease', `anaemia and positive endomysial 
antibody 
- 
confirm diagnosis of coeliac disease) 
" clinical information obtained around the time the small bowel specimen was 
taken from general practitioner referral letters to the hospital (such as `please 
see this person who has developed diarrhoea') 
9 clinical information obtained around the time the small bowel specimen was 
taken from hospital outpatient clinic and in-patient discharge letters to the 
general practitioner (such as `this person was diagnosed with coeliac disease 
following presentation with anaemia which was further investigated with 
endoscopy where duodenal biopsies showed coeliac disease') 
" no previous small bowel specimens demonstrating coeliac disease 
On the basis of these features, the following definition was used to define incident 
coeliac disease: 
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Definition 1: Incident coeliac disease and date of coeliac disease diagnosis 
A Consultant Gastroenterologist using the information available at the time made a 
diagnosis of coeliac disease. This decision was presumed to have been arrived at by a 
combination of suggestive clinical symptoms, characteristic small bowel pathology or 
abnormal coeliac serology around the time the diagnosis was made. The date at which 
they made the diagnosis as recorded in the medical notes or the date of the abnormal 
small bowel biopsy, whichever was earliest, was the diagnosis date. 
Definition 2: Time period of inclusion of incident coeliacs within historical cohort 
Adults newly diagnosed with coeliac disease on a date falling within 1st January 2000 
-3 1St December 2006. 
Features suggestive of the small bowel specimen being taken in people with 
previously diagnosed coeliac disease was derived from clinical information such as 
`coeliac 
- 
monitor response to treatment' or `coeliac with persistent symptoms query 
cause' either submitted with the specimen or contained on hospital letters. An attempt 
was made to establish the original date of diagnosis of incident coeliac disease in 
these people with previously diagnosed disease through looking through the 
histopathology database and hospital records. If the date of diagnosis of incident 
coeliac disease was between 1St January 2000 
-3 1st December 2006 then these people 
were included within the incident cohort. 
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Definition 3: People with prevalent coeliac disease within historical cohort 
A Consultant Gastroenterologist using the information available at the time made a 
diagnosis of coeliac disease. This decision was presumed to have been arrived at by a 
combination of suggestive clinical symptoms, characteristic small bowel pathology or 
abnormal coeliac serology around the time the diagnosis was made. The date at which 
they made the diagnosis as recorded in the medical notes or the date of the abnormal 
small bowel biopsy, whichever was earliest, was the diagnosis date with the diagnosis 
date prior to 1s` January 2000. 
It soon became evident that the histopathology database was of considerable help in 
identifying who had been diagnosed with coeliac disease on the grounds of the 
appearances of the small bowel specimens at Nottingham University Hospital over the 
defined time period. Each month I received a list of all people that had small bowel 
specimens taken that demonstrated coeliac disease. Using the techniques described 
above to determine whether these specimens were taken to newly diagnose a person 
with coeliac disease I was able to establish who was being newly diagnosed with 
coeliac disease. I would then work out using the hospital patient administration 
system when and where these people newly diagnosed with coeliac disease were 
attending outpatient clinics (such as to discuss the newly made diagnosis of coeliac 
disease) and or meeting the dietitian (such as to discuss how to switch to a gluten-free 
diet). This mapping out of hospital attendances was fundamental to the prospective 
studies of chapter 4-I needed to attend these key events to meet newly diagnosed 
coeliacs and use the opportunity to invite them to participate in the longitudinal 
studies on vascular risk profile and quality of life. 
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2.2.1.4. Immunology records 
Like with the histopathology department, there is a single immunology database on 
which all serum samples taken whether at the hospital or in the community that are 
submitted for coeliac serology testing are logged under an unique laboratory number. 
Like with the histopathology specimens, the referring consultant is included in the 
information logged with the serum sample which may be a gastroenterologist or from 
another specialty, again highlighting the variety of specialties potentially diagnosing 
coeliac disease. 
Definition 4: Coeliac serology status 
Coeliac serology is reported as `positive', `weak positive' or `negative' for the EMA 
test and a quantitative titre given for the tTG test with values above 4.0 U/L for the 
assay used considered as a positive test result. The tTG test is also banded by 300 U/L 
as maximum value reported. 
If a small bowel biopsy was not taken despite extensive efforts to do so (such as due 
to patient refusal, patient unable to tolerate endoscopy) and the person had clinical 
features suggestive of coeliac disease and had positive coeliac serology with 
symptoms and serology improving with a gluten-free diet then they would also 
acquire a diagnosis of coeliac disease by the reviewing gastroenterologist. 
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Definition 5: Histology unproven but serology positive coeliac disease 
If a small bowel biopsy was not taken but there were clinical features suggestive of 
coeliac disease and coeliac serology was positive which both improved with treatment 
with a gluten-free diet then the person was assumed to have histology unproven but 
serology positive coeliac disease. The date of diagnosis of histology unproven but 
serology positive coeliac disease was the date when the coeliac serology was 
performed. 
Each week a paper printout of all coeliac serology tests performed with their results is 
generated and stored by the Immunology department. Following liaison with Dr Liz 
McDermott, a consultant immunologist, I was allowed access to these weekly paper 
results. Searching for people with positive coeliac serology over a six year period 
(between 0 January 2000 and 31St December 2006 like with the small bowel 
specimen histopathology search) using this paper printout was fairly laborious and 
prone to error, scanning through the results of hundreds of tests performed each week 
attempting to identify those with positive coeliac serology. However, consulting the 
coeliac serology printouts was an useful adjunct to the histopathology search for 
identifying people newly diagnosed with coeliac disease for the prospective studies. 
Like with the histopathology search, I used a number of ways to determine whether 
the coeliac serology was being performed to diagnose coeliac disease or whether it 
was being used to monitor prevalent coeliac disease. Using the same approach as with 
the histopathology search, features differentiating positive coeliac serology due to a 
new diagnosis of coeliac disease from prevalent coeliac disease included clinical 
information supplied with the serum request or from hospital and general practitioner 
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letters at around the time the serology testing was performed such as `diarrhoea 
- 
rule 
out coeliac disease'. 
The date of coeliac disease diagnosis assigned on histopathological grounds of when 
coeliac disease was first detected on small bowel specimens was cross-referenced to 
the date when (if serological testing was performed) a person had positive coeliac 
disease serology. If the date of positive serology preceded the date where small bowel 
biopsies were performed showing characteristic histological changes, the date of 
diagnosis remained as the date on which small bowel biopsies were performed as per 
definition I have used of incident coeliac disease. Looking through coeliac serology 
test results proved to be an useful addition to the histopathology search. 
2.2.1.5. Clinical coding records 
Clinical coding refers to the "translation of medical terminology as written by the 
medical professional to describe a patient's symptoms, diagnosis, treatment or reason 
for seeking medical attention into a coded format" which is nationally and 
internationally recognised [341]. There are two coding systems used by NHS 
hospitals: ICD 10 (International Classification of Diseases 10th Revision) and OPCS4 
(The Office of Population Censuses and Surveys 4th Revision) [341]. ICD10 has been 
devised by the World Health Organisation and its codes are widely used 
internationally. ICD10 codes cover all reasons for patients admissions to hospital 
[341]. OPSC4 in comparison covers all operative procedures and interventions that 
patients have undergone during their hospital stay and codes are only used in the UK 
[341]. Clinical codes are used to support many functions within a hospital trust both 
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clinically (such as clinical governance) and numerically (such as commissioning, 
health trends) [341 ]. 
Following liaison with Brenda Brown, Clinical Coding Manager, I obtained a list of 
all people, identified by name, age and hospital number that had a clinical code for 
coeliac disease between 1St January 2000 and 3 1s` December 2006. An excerpt of the 
clinical coding list electronically generated is shown below: 
Figure 2.11: Excerpt of list of people possessing clinical code for coeliac disease 
REPORT: PATIENT DETAIL LISTING 
- 
ACTIVITY BASED 
GROUPED BY: Age Groups (10 Year Bands) 
- 
current 
FILTERED BY: From 01 January 2000 to 31 December 2006 inclusive 
Problem 1: COELIAC DISEASE 
OR 
Problem 2: COELIAC DISEASE 
SORTED BY AGE GROUPS (10 YEAR BANDS) 
- 
CURRENT 
. 
AGE GROUPS (10 YEAR BANDS) 
- 
CURRENT: 000 010 
1.1. 
X1* Hospital number Sxxxxxx** 
1.2. 
X%* Hospital number Sxxxxxx** 
1.3. 
XX* Hospital number Sxxxxxx** 
*Name and **hospital number made anonymous in this excerpt but the real list 
generated isn't anonymous 
The list of all people assigned the code for coeliac disease between I" January 2000 
and 31st December 2006 generated from the clinical coding database generated 780 
unique names and hospital numbers. The data was presented in 10 year age brackets 
so included children with coeliac disease aged 10 years or younger and a couple of 
centenarians! 
In 1998, an in-house electronic system of all gastroenterology consultations, 
endoscopies and nurse specialist services was introduced at Nottingham City Hospital 
with "live" data collection of all referrals and interventions involving people with 
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coeliac disease performed by Dr Kathy Teahon, Consultant Gastroenterologist, based 
on the clinical coding described above. I was allowed access to this database which 
listed 458 adults with a code for coeliac disease, identified by name and hospital 
number. An excerpt of the Nottingham City Hospital in-house electronic database of 
adults with a code for coeliac disease is shown below: 
Figure 2.12: Excerpt of list of people possessing clinical code for coeliac disease 
in Nottingham City Hospital in-house electronic system 
Surname Forename Patient number Dia osis1 
XX* XX* XX* * K900 
XX* XX* XX* * K900 
XX* XX* XX** K900 
Like with the histopathology and coeliac serology searches I needed to determine 
whether the clinical code assigned to the person was a newly acquired code i. e. the 
person had been newly diagnosed with coeliac disease or whether the person was 
known to have coeliac disease but acquired a further clinical code for coeliac disease 
such as through attending a follow-up dietetic appointment or having a repeat small 
bowel biopsy to monitor response to treatment. Using the histopathology, coeliac 
serology data and information contained on endoscopy reports, general practitioner 
and hospital letters as described above I was able to assign date of diagnosis of coeliac 
disease to each individual contained on the list. 
Clinical coding enabled identification of those who had been diagnosed with coeliac 
disease on the grounds of hospital attendances, procedures and interventions where 
coeliac disease code was acquired at Nottingham University Hospital over the defined 
time period. However, there was the possibility that some people newly diagnosed 
with coeliac disease may not appear on the clinical coding list during the period of 
90 
recruitment for the prospective studies. Each month I received a list of all people that 
had acquired a clinical code for coeliac disease. Using the techniques described above 
to determine whether the code was given to someone newly diagnosed with coeliac 
disease or someone with prevalent disease, I was able to establish who was being 
newly diagnosed with coeliac disease. I would then work out using the hospital 
patient administration system when and where these people newly diagnosed with 
coeliac disease were attending outpatient clinics (such as to discuss the newly made 
diagnosis of coeliac disease) and or meeting the dietitian (such as to discuss how to 
switch to a gluten-free diet). This mapping out of hospital attendances was 
fundamental to the prospective studies of chapter 4-I needed to attend these key 
events to meet newly diagnosed coeliacs and use the opportunity to invite them to 
participate in my study. 
2.2.1.6. Outpatient clinic set-up 
Nottingham University Hospital has a single gastroenterology and endoscopy 
department, encompassing subspecialty interests such as luminal gastroenterology, 
hepatology and nutrition. However there was no specific coeliac disease 
gastroenterology clinic. People were being diagnosed with coeliac disease by a 
number of different gastroenterologists as well as surgeons and other non- 
gastroenterological medical physicians. Using histopathological, serological and 
clinical coding searches described above, I was able to flag up who was being newly 
diagnosed with coeliac disease and what hospital appointments (such as dietetic) these 
people were due to attend so that I could exploit these opportunities to meet these 
incident coeliacs and invite them to participate in my prospective studies. 
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In addition, I emailed all gastroenterology consultants to invite them to forward me 
any referrals they received or contact they had with people with coeliac disease. The 
minority of gastroenterologists wished to continue reviewing people with coeliac 
disease so I attended their outpatient clinics. Any referrals I arranged to see in 
Professor Logan's outpatient clinic on Tuesday mornings which coincided with when 
Karen Columbell, senior dietitian with a special interest in coeliac disease, who held 
her dietetic appointments to see people with coeliac disease (newly diagnosed as well 
as monitoring those with established disease) referred by any consultant, whether 
physician or surgeon, within the hospital. Karen and I developed a system whereby 
people newly diagnosed with coeliac disease would be seen at an `one-stop' coeliac 
clinic 
-I would explain the diagnosis and implications of having coeliac disease and 
then once clinical care had been delivered, invite the person to participate in my 
prospective studies. If the person agreed to participate then following informed 
consent I would collect the necessary study data before passing over to Karen who 
would explain how to take a gluten-free diet. We would then arrange to review the 
person at the `one-stop' clinic together for monitoring response to treatment as well as 
to repeat study data collection. 
The majority of people taking part in my prospective studies were followed up in this 
one-stop coeliac clinic. For the patient there was continued contact with a doctor if 
needed as well as a dietitian (many gastroenterologists discharged patients to dietetic 
care) using the opportunity to ask clinically-based questions about their condition as 
well as have blood tests to monitor (and highlight need for treatment such as for 
anaemia) coeliac disease. Karen felt there was readily available medical advice when 
and if needed as well as accountability for reviewing normal and abnormal blood test 
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results. This simplified the process of meeting or following up patients who were 
recruits for the prospective study. 
2.2.2. Royal Hallamshire Hospital, Sheffield 
Like Nottingham University Hospital, the Royal Hallamshire Hospital has a single 
gastroenterology and endoscopy department though in comparison it has a 
. 
gastroenterology consultant with a special interest in coeliac disease, Dr David 
Sanders. Dr Sanders has held a dedicated outpatient clinic for people with coeliac 
disease on Thursday afternoon since 2002. Adults suspected as having coeliac disease 
were referred to this clinic by general practitioners, gastroenterologists and other 
specialists from within the Royal Hallamshire Hospital and from the other hospital of 
the same trust, the Northern General Hospital. The clinic was also attended by adults 
that were having a review of their coeliac disease. People attending this clinic could 
therefore be in different stages of their coeliac disease journey 
- 
some people were 
waiting for the diagnosis of coeliac disease to be confirmed and at this clinic 
confirmatory tests such as small bowel biopsies would be arranged; some had coeliac 
disease diagnosed though were attending clinic to be informed of this and counselled 
on the need for treatment; some had coeliac disease diagnosed an earlier point in time 
either at the Hallamshire or some other hospital and were being monitored at this 
clinic. 
A summary flow diagram summarising how the historical cohort was constructed and 
how I identified adults newly diagnosed with coeliac disease at the Sheffield centre is 
first given. 
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2.2.2.1. Coeliac disease at the Royal Hallamshire Hospital creating the Sheffield 
historical cohort: a summary 
Combining histological data on coeliacs identified from histopathology, dietetic, wire 
basket searches with clinical information (such as symptoms at presentation) obtained 
from general practitioner and hospital letters, endoscopy reports; coeliac serology 
results; and laboratory data the Sheffield historical cohort was constructed: 
Figure 2.13: Creation of historical coeliac disease cohort at Royal Hallamshire 
Hospital 
Search histopathology database for people with coeliac disease using standardised 
coeliac disease histopathological diagnosis code 
Search wire baskets in Dr Sanders office for people assigned coeliac disease diagnosis 
Search dietetic database for people with coeliac disease referred for dietary 
assessment 
Add in coeliacs that have not 
been identified through 
histopathology, wirebasket, 
dietetic searches but have been 
found through referrals via 
secretaries 
Create an Access database of people with coeliac disease with one entry to the 
database per person 
Sheffield historical 
coeliac disease cohort 
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2.2.2.2. Incident coeliac disease at Royal Hallamshire Hospital: a summary 
Monthly updates from histopathology database, wirebasket searches, and secretarial 
alerts were used to generate a list of people with coeliac disease. This list was cross- 
referenced with clinical information obtained from general practitioner and hospital 
letters to determine those that had been newly diagnosed with coeliac disease. The 
subsequent coeliac disease clinic appointments of these people newly diagnosed with 
coeliac disease was determined in order for me to go and discuss participation in the 
prospective studies. 
Figure 2.14: Identification of people with newly diagnosed coeliac disease at 
Royal Hallamshire Hospital to recruit for prospective studies 
Search histopathology database each month of study for people with coeliac disease 
using standardised coeliac disease histopathological diagnosis code 
Search wire baskets each month of study for people labelled as having coeliac disease 
Liase with secretary of letters she had typed or referrals she had received of people 
with suspected or confirmed coeliac disease 
Create an Access database of all people newly diagnosed with coeliac disease during 
the study period 
Use the patient administration system, 
secretaries, to determine date, 
time and place when these incident 
coeliacs are attending the hospital for 
appointments 
Attend hospital appointments of people newly diagnosed with coeliac disease and 
invite them to participate in prospective study 
Obtain informed consent 
Newly diagnosed coeliacs become study participants for 
prospective study 
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2.2.2.3. Histopathology records 
From experiences at Nottingham University Hospital in identifying who had coeliac 
disease, I first set about obtaining a list of people who had small bowel biopsies 
demonstrating coeliac disease via the histopathology department. Like at Nottingham 
University Hospital, there were consultant histopathologists with a special interest in 
gastrointestinal diseases. Dr Simon Cross was a consultant histopathologist at the 
Hallamshire who has a special interest in coeliac disease. Following discussion with 
Dr Cross and the Histopathology Manager, Louise Dunk, it was clear that small bowel 
histology would be routinely reported by Dr Cross but in his absence by other 
histopathologists also. However all small bowel specimens suggestive of or 
demonstrating coeliac disease would be ultimately reviewed by Dr Cross who would 
then grade the degree of intestinal inflammation according to modified Marsh criteria 
[342] if coeliac disease related enteropathy was present. I acquired the list of all 
people having a small bowel biopsy demonstrating coeliac disease from Vt January 
1997 
-3 1st December 2006. An excerpt of this list is shown below: 
Figure 2.15: Excerpt of list of people possessing code for coeliac disease from 
histopathology database 
Date of 
biopsy 
Pathology 
specimen 
number 
Code of 
specimen 
site 
Specimen 
site 
Histopathology 
diagnosis code 
Name Date 
of 
birth 
Hospital 
number 
Source 
of 
referral 
25/10/2004 PH011365V/04 T-58400 Jejunum D5-47100 Xx Xx Xx MOPD 
26/10/2004 LH025113T/04 T-58200 Duodenum D5-47100 Xx Xx Xx MOPD 
27/10/2004 LH025265K/04 T-58200 Duodenum D5-47100 Xx Xx Xx ENDO 
27/10/2004 LH025289K/04 T-58200 Duodenum D5-47100 Xx Xx Xx ENDO 
02/11/2004 LH02565OT/04 T-58200 Duodenum D5-47100 Xx Xx Xx ENDO 
03/11/2004 LH025782E/04 T-58200 Duodenum D5-47100 Xx Xx Xx MTH 
Just as at Nottingham University Hospital, each tissue samples taken at the 
Hallamshire that is submitted for histological examination are logged under an unique 
pathology specimen number. The source of referral is included in the information 
96 
logged with the tissue specimens such as endoscopy ('ENDO'), outpatients ('MOPD') 
despite the small bowel specimen presumably being taken in the endoscopy suite and 
pr operating theatres ('MTH') perhaps for a person requiring a general anaesthetic 
rather than local anaesthetic and sedation for the endoscopy. Despite the wide variety 
of routes to get to the stage of having small bowel specimens being taken, they all 
were analysed by the histopathology department. 
The list of all people having tissue specimens assigned the code for coeliac disease 
between 1st January 2000 and 31St December 2006 generated from the histopathology 
database generated 663 unique laboratory numbers though some people appeared on 
the list on more than one occasion i. e. had further small bowel biopsies taken on a 
subsequent date where again coeliac disease was demonstrated. Some people on the 
histopathology list were children i. e. aged under 18 years. 
Using this list I entered each unique laboratory number into the histopathology 
computerised database to bring up the linked histopathology report, reading through 
each person's small bowel histology result. I used identical techniques to those I used 
at Nottingham University Hospital described above to identify whether the small 
bowel histology was taken to diagnose someone with coeliac disease or whether the 
small bowel biopsy was taken in someone who had already been diagnosed with 
coeliac disease and then work backwards in time to determine the date of diagnosis. 
Combining this histological data with clinical information (such as symptoms at 
presentation) obtained from general practitioner and hospital letters, endoscopy 
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reports; coeliac serology results; and laboratory data the Sheffield historical cohort 
was constructed. 
During the period of recruitment for the prospective studies of chapter 4, I regularly 
received a list of all people that had small bowel specimens taken that demonstrated 
coeliac disease. Using the techniques described above to determine whether these 
specimens were taken to newly diagnose a person with coeliac disease I was able to 
establish who was being newly diagnosed with coeliac disease. 
2.2.2.4. Outpatient clinic set-up 
Adults with coeliac disease and attending the dedicated coeliac clinic at the Royal 
Hallamshire Hospital were systematically collected by Dr Sanders through copying 
each of the clinical letters written on each person to himself. An example of a letter 
sent from Dr Sanders to the general practitioner or other healthcare professional is 
demonstrated below: 
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Figure 2.16: Example of letter sent from coeliac disease clinic 
GASTROENTEROLOGY & LIVER UNIT 
Gastroenterology: Hepatology: 
or AJ Lobo MD FRCP DrDC GI.. wn MO Sac FRCP Tw: o114 =113)13/ 2713431 Ts 01112710162 Royal Hallamshlre Hospital 
or ME MtAlindon Anted Sri DM FRCP Dr MA Karajoh MRCP Glossop Road 
1.1 0114 usnsa Tb: 1o1 /4J 2260746 Sheffield 
DrD$S2, r, Mr. MOFRCP FACO SiC 2JF 
T. 4 0114 2201179 
Dr DP Mu, 1M... MD 10.1 MRCP Tel: 0114 271 1900 
7a 0114 2265706 Fax: 01 14 271 1901 
Fa 011417126.1 
DSS/MH/111111111111111 
Clinic 30 July 08 
Typed 14 July 08 
Or PA Bradbury 
Jordanthorpe Health Centre 
1 Dyche Close 
Sheffield 
S8 8DJ 
Dear Or Bradbury 
Re: 
Problem: 1 Coeliac disease? 
1 EMA positive. IgA and IgG gliadin positive 
- 
checked in primary care 
3 Bilateral hernia 2006/7 
4 Mother died of stomach cancer at the age of 69 
5 Fulfils ROME II criteria for IBS (symptoms ongoing for at least 10 years)/also has anaemia 
intermittently since childhood. 
Thanks for referring this 43 year old gentleman who may well have coeliac disease I have discussed these 
issues with him but currently he is not on a gluten free diet and we have not confirmed the diagnosis with 
duodenal biopsy. 
Plan Is as follows: 
1. I have checked FBC, ESR, U&Es, LFTs, glucose, CRP, calcium. TFTs, immunoglobulins, antigliadin 
antibodies, EMA, TTG, vitamin 812, folate, ferritin, HOL cholesterol ratio, thyroid autoantibodies and 
HLA typing- 
2I will review these then arrange for a gastroscopy with duodenal biopsy. 
3. At the time of his endoscopy we can arrange follow up 
Current medication: Nil 
Best wishes 
Yours sincerely 
Or 0S Sanders 
Consultant Physician & Gastroenterologist 
Honorary Reader in Gastroenterology, University of Sheffield 
Cc Or Marios Hadjivassiliou. Consultant Neurologist, L Floor, RHH 
For your interest, anti-GAD Ria/Elisa 
These letters would be stored in wire baskets on the shelves in Dr Sanders' office and 
filed under specifically named wire baskets. For example, people with refractory 
coeliac disease would be filed under `refractory coeliac disease'; people with irritable 
bowel symptoms and coeliac disease would be filed under `IBS coeliacs' and so on. 
Here is a photograph of what the filing system is like: 
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Figure 2.17: Wire baskets filing away coeliacs attending the Hallamshire coeliac 
clinic 
........................... 
rýi 
`sue?: eý- 
ý, ý; ý _ ;o 
With dictated clinic letters being typed up by Dr Sanders secretary, Deborah French, 
and then printed out to be put in the patient's case notes and in a particular wire 
basket, a system was set up where Deborah would copy me into letters of patients 
with newly diagnosed coeliac disease that Dr Sanders or a member of his team had 
seen. 
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2.2.2.5. Dietetic case notes 
Following referral to the dietitian from the Hallamshire coeliac clinic, the patient 
would be seen by a dietitian at the Northern General Hospital. There was no specific 
dietitian or dietetic team that would review referred coeliac patients nor was there a 
dedicated time or clinic. The Hallamshire referral letter and replying Northern 
General dietetic letter were stored in the department of dietetics based at the 
Hallamshire hospital. It was here in the notes stores of the dietetic department where 
these observations are kept. 
Figure 2.18: Entrance to the notes stores of the dietetic department at the Royal 
Hallamshire Hospital 
ýý ý.,. - 
Unfortunately, the dietetic notes were paper-based and had to be searched through 
manually by hand. All people regardless of diagnosis who had contact with the 
dietitian had notes stored in this basement. 
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Figure 2.19: Boxes containing case notes of all patients regardless of diagnosis 
having contact with a dietitian 
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The filing system was alphabetically by surname and then according to the date when 
they last had contact with a dietitian as shown in this close-up: 
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Figure 2.20: Alphabetical filing system of dietetic records 
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So if a patient was diagnosed with coeliac disease on the basis of characteristic small 
bowel histology say in September 2004 and then seen reviewed in the outpatient clinic 
in October 2004 by the gastroenterologist to discuss the diagnosis and the need for 
treatment with a gluten-free diet, this person would then be referred to the dietitian. 
Trying to find this particular patient's dietetic case notes would involve looking in the 
year 2004 boxes by alphabetical name as well as in the 2005 boxes as the patient may 
not get seen by the dietitian until 2005 due to dietetic clinic time pressures. If this 
patient was then reviewed again by the dietitian, provided this appointment took place 
in 2005 then the same place where the index appointment occurred would be fine. 
However if the patient was given a 12 month review then their dietetic case notes 
would be moved out of the 2005 box and transferred to the year 2006 box despite 
being diagnosed with coeliac disease in 2004. If the patient seen by the dietetic died 
then their dietetic case notes would be removed from the `alive patient' year boxes 
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and put into a box of all people seen by the dietitians in that particular year that had 
died that year. For example, the `2005 R. I. P. ' box contained patients that had contact 
with the dietitians in 2005 but subsequently died in 2005. The deceased patient boxes 
were not alphabetically filed. 
I had to manually trawl through each box of case notes to determine which patients 
contained in each box were coeliacs. I primarily used the `reason for referral' 
information contained on the dietetic referral card that was pinned to the front of each 
set of case notes as a screen to prompt detailed reading of those case notes. For 
example, if the reason for referral information given on a set of case notes was 
`nutritional assessment 
- 
dysphagia post-stroke' then I would reject this set of case 
notes due to no compelling features to suggest coeliac disease and move on to the next 
set. However if coeliac disease was suggested in the reason for referral information 
such as `coeliac 
- 
for GFD (gluten-free diet)' or even `GFD' I would then review the 
entire set of dietetic case notes to confirm or refute whether this person had coeliac 
disease. This is because not all people referred to dietitians for treatment with a 
gluten-free diet had coeliac disease 
-I picked up a handful of patients with no 
evidence of coeliac disease that had irritable bowel syndrome that were referred for a 
gluten-free diet to try and help their symptoms. 
From observations based on manually going through each set of dietetic case notes 
and reviewing the journey each person with coeliac disease had through the system, it 
became apparent that most patients had one appointment with the dietitian which 
occurred at diagnosis of coeliac disease where details of how to take a gluten-free diet 
were given. The patient was then discharged from further dietetic review unless 
specifically requested by Dr Sanders involving a further formal referral to dietetics to 
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re-review the patient. Linking this information in with the pattern of coeliac outpatient 
clinic attendances and hospital letters generated from the clinic attendance, it was Dr 
Sanders that provided follow-up and monitoring of the condition. The pattern and 
frequency of coeliac outpatient clinic attendances was typically around the time of 
diagnosis of coeliac disease, then three months later, then every twelve months 
thereafter. 
2.2.3. Derbyshire Royal Infirmary 
Compared to the processes described above at Nottingham University Hospital and at 
the Hallamshire, identifying how people were diagnosed with coeliac disease and 
passed through the hospital system at Derby Royal Infirmary was much more straight 
forward. 
Derbyshire Royal Infirmary and Derby General City Hospital form the Derbyshire 
Foundation NHS Trust. This trust has a single gastroenterology department with Dr 
Geoff Holmes, one of the consultant gastroenterologists, having a clinical and 
research interest in coeliac disease. Dr Holmes had developed a system over several 
decades where people with coeliac disease within the trust would be seen in his Friday 
afternoon coeliac disease clinic. This clinic Dr Holmes held with Fiona Moor, chief 
dietitian with a special interest in coeliac disease. As much as it was possible, people 
with suspected or confirmed coeliac disease were streamlined to Dr Holmes and his 
coeliac disease clinic. For example, if general practitioners suspected someone had 
coeliac disease, it would be Dr Holmes that the referral was addressed to. If the 
suspected or prevalent coeliac disease referral was addressed to `dear 
gastroenterologist' then the patient would be directed to the attention of Dr Holmes. If 
one of the other gastroenterologists diagnosed coeliac disease in their outpatient clinic 
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or on the hospital ward, then referral letters (or at least the clinic letters or discharge 
notes would be copied to Dr Holmes) would be addressed to Dr Holmes for Dr 
Holmes to continue the care of this patient with coeliac disease. 
In addition to the clinical activity alerts, Dr Holmes would receive printouts each 
month from Dr Peter Hill, consultant biochemist, of all the people having positive 
coeliac serology results. Dr Holmes would also be informed on a monthly basis of any 
people with small bowel specimens demonstrating coeliac disease by Dr David 
Semerero, consultant histopathologist. With each of these alerts, Dr Holmes would 
add `new' coeliacs to his list of people having coeliac disease managed and or 
diagnosed at Derby. Dr Holmes kept this list in two different modes. He would add 
each new person to the list in a dedicated notebook locked away in his office. He 
would note their demographic details, date of diagnostic small bowel biopsy and its 
laboratory reference number as well as the result of the coeliac serology test in this 
book. Each coeliac would be given an unique reference called a `coeliac number'. An 
excerpt of what the notebook looked like is shown below: 
Figure 2.21: Excerpt of Dr Holmes notebook list of people with coeliac disease at 
Derby 
Coeliac 
number 
Name* Hospital 
number* 
Date of 
birth 
Biopsy 
date 
Biopsy 
reference 
EMA 
result 
1214 XX xx-xx-xx 02/07/1957 27/10/2004 19322/04 ++ 
1215 XX xx-xx-xx 03/05/1966 15/02/2005 2752/05 + 
1217 XX xx-xx-xx 22/06/1951 26/06/2001 10886/01 + 
1218 XX xx-xx-xx 29/05/1966 22/10/2004 19080/04 + 
*Anonymous for the purpose of this thesis but names were used in the notebook 
The same information as well as a variety of clinical and laboratory data would be 
entered into an Access database for each coeliac again using the coeliac number as the 
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unique reference identity. This cohort of Derby coeliacs has been used as the study 
population for many studies on coeliac disease by Dr Holmes [287,343]. 
Through Dr Holmes, I was able to determine the number of people being newly 
diagnosed with coeliac disease in Derby. I was also able to meet these people being 
newly diagnosed with coeliac disease by attending the coeliac disease outpatient clinic 
and invite them to participate in my prospective studies. 
2.2.4. Study population for breast cancer risk profile study 
To estimate the breast cancer risk profile in women with coeliac disease and compare 
it to that of the general population, we elected to systematically collect data on 
reported conventional breast cancer risk factors in women with coeliac disease using a 
questionnaire-based survey in a cross-sectional study design. The study population 
had to be women that had coeliac disease and were alive in order to be able to 
participate in the study such as completing the questionnaire. There were two 
principal groups of women with coeliac disease that comprised the study population 
for the breast cancer risk profile study: 
1. Women with incident and prevalent coeliac disease of the Nottingham, 
Sheffield and Derby historical cohorts 
2. Women with coeliac disease who were members of the Coeliac UK patient 
charity organisation 
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2.2.4.1. Women with incident and prevalent coeliac disease of the Nottingham, 
Sheffield and Derby historical cohorts 
From performing extensive searches of who had been diagnosed with coeliac disease 
at each centre between 1st January 2000 
- 
3I't December 2006 as described in sections 
2.2.1. and 2.2.2., I generated historical cohorts for Nottingham and Sheffield centres 
of people with incident and prevalent coeliac disease, adding in demographic, clinical, 
histological and laboratory data through systematic collection. Women with incident 
and prevalent coeliac disease in these historical cohorts and in the prospectively 
collected Derbyshire coeliac cohort were invited to participate in the breast cancer 
risk profile study and form the study population in association with the Coeliac UK 
members. The methods of invitation and recruitment to the study are described further 
in Chapter 5. 
2.2.4.1. Women with coeliac disease who were members of the Coeliac UK 
patient charity organisation 
Coeliac UK is the principal national society for people with coeliac disease offering 
invaluable dietary guidelines and represents the largest population-based cohort of 
people with coeliac disease in the United Kingdom. It has over 70,000 registered 
members of which 26,238 are women aged between 45 and 75 years [Lawrence 
Munday, Coeliac UK, October 2006]. As a patient support group, it is likely that there 
are members of Coeliac UK that have coeliac disease. However, family of affected 
coeliacs (such as mothers of affected children, wives of affected husbands) that do not 
have coeliac disease are also members of Coeliac UK. People with functional bowel 
disturbances whose symptoms are helped with dietary exclusion such as wheat though 
do not have coeliac disease could also be members of Coeliac UK to utilise the dietary 
support offered by the organisation. The use of the Coeliac UK database to identify 
potential study participants for the breast cancer risk profile study would have to 
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involve screening questions to ensure the member is female and has coeliac disease as 
described further in Chapter 5. The methods for random selection of female Coeliac 
UK members, invitation and recruitment to the study are also described in Chapter 5. 
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2.3. Summary of different cohorts used in the studies 
There are three different populations of adults with coeliac disease used in this thesis: 
1. Historical, contemporary incident cohort (chapter 3) 
2. Prospective, longitudinal incident cohort (chapter 4) 
3. Cross-sectional survey of incident and prevalent female coeliacs (chapter 5) 
Chapter 3: Historical cohort studies in incident coeliac disease 
" Describe relationship between degree of enteropathy and physiological 
derangement, clinical features 
9 Examine the risk of hypertransaminasaemia and effect of treatment 
" Examine incidence of diagnosed coeliac disease and socio-economic status 
9 Estimate cholesterol profile and effect of treatment 
Using Nottingham and Sheffield historical cohorts 
Chapter 4: Prospective, longitudinal studies in incident coeliac disease 
" Quantify impact of coeliac disease on health-related quality of life and 
vascular risk profile and change with treatment 
Recruiting people with newly diagnosed coeliac disease at Nottingham, Sheffield and 
Derby 
Chapter 5: Cross-sectional survey of women with coeliac disease 
9 Estimate breast cancer risk profile in women with coeliac disease and compare 
with general population 
Using Nottingham, Sheffield and Derby historical cohort; female members of Coeliac 
UK with coeliac disease 
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2.4. Definitions of presenting features used within cohorts 
As described in section 2.2., histopathology, immunology, clinical coding, dietetic 
and other databases were searched to identify people with coeliac disease. Features 
that led to the person being investigated and diagnosed with coeliac disease were 
systematically collected using information contained in: 
" general practitioner's or referring doctor's referral letter 
" replying gastroenterologist letter 
9 dietetic case notes 
" clinical information supplied with the small bowel biopsy or coeliac serology 
request 
" 
laboratory data such as the presence of iron deficiency anaemia 
Below are descriptions of how I have defined the presenting features of coeliacs used 
within the studies of this thesis. 
2.4.1. Mode of presentation 
Definition 6: Iron deficiency anaemia 
Presence of serum ferritin, haemoglobin and mean cell volume below the lowest limit 
of normal range for the hospital laboratory concerned. Further corroborated by report 
of "iron deficiency anaemia" in referring letter of the general practitioner or referring 
doctor; and or in the replying letter from the gastroenterologist. In the absence of 
available laboratory data, report of "iron deficiency anaemia" in referring or replying 
letter, clinical information supplied with small bowel biopsy and or coeliac serology 
request. 
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Definition 7: B12 deficiency 
Presence of serum B12 below the lowest limit of normal range for the hospital 
laboratory concerned. Further corroborated by report of "B 12 deficiency" in referring 
letter of the general practitioner or referring doctor; and or in the replying letter from 
the gastroenterologist. In the absence of available laboratory data, report of "1312 
deficiency" in referring or replying letter, clinical information supplied with small 
bowel biopsy and or coeliac serology request. 
Definition 8: Folate deficiency 
Presence of serum or red cell folate below the lowest limit of normal range for the 
hospital laboratory concerned. Further corroborated by report of "folate deficiency" in 
referring letter of the general practitioner or referring doctor; and or in the replying 
letter from the gastroenterologist. In the absence of available laboratory data, report of 
"folate deficiency" in referring or replying letter, clinical information supplied with 
small bowel biopsy and or coeliac serology request. 
Definition 9: Diarrhoea 
Presence of loose, mushy or watery stools and or increase in frequency of bowel 
movements in comparison to normal stool frequency. In the absence of documentation 
of stool consistency and or frequency in the referring letter of the general practitioner 
or referring doctor; and or in the replying letter from the gastroenterologist, report of 
"diarrhoea" in referring or replying letter, clinical information supplied with small 
bowel biopsy and or coeliac serology request. 
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Definition 10: Weight loss 
Reduction in weight in comparison to normal or baseline weight as evidenced by 
decrease in measured weight, reduction in clothes size. In the absence of 
documentation of weight change (e. g. "5 kilogram weight loss") in the referring letter 
of the general practitioner or referring doctor; and or in the replying letter from the 
gastroenterologist, report of "weight loss" in referring or replying letter, clinical 
information supplied with small bowel biopsy and or coeliac serology request. 
Definition 11: Malabsorption 
Presence of weight loss; diarrhoea; and B12, folate and or iron deficiency anaemia. 
Definition 12: Constipation 
Presence of hard and or dry stools; and or infrequent bowel movements; and or 
straining to pass stool. In the absence of documentation of stool consistency and or 
frequency in the referring letter of the general practitioner or referring doctor; and or 
in the replying letter from the gastroenterologist, report of "constipation" in referring 
or replying letter, clinical information supplied with small bowel biopsy and or 
coeliac serology request. 
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Definition 13: Irritable bowel syndrome (IBS) symptoms 
Episodes of recurrent abdominal pain (which may be described as abdominal cramps, 
bloating, discomfort, flatulence) with change in bowel habit (which may be diarrhoea, 
constipation or alternating between diarrhoea and constipation). Onset of abdominal 
pain is related to a change in bowel frequency and consistency of stool and the pain is 
relieved by bowel movement. In the absence of documentation of abdominal pain, 
stool consistency and or frequency in the referring letter of the general practitioner or 
referring doctor; and or in the replying letter from the gastroenterologist, report of ý 
"IBS symptoms", "functional bowel disturbance" in referring or replying letter, 
clinical information supplied with small bowel biopsy and or coeliac serology request. 
Definition 14: Hypertransaminasaemia 
Presence of serum transaminases (ALT and or AST) above the highest limit of normal 
range for the hospital laboratory concerned. Further corroborated by report of 
"abnormal or deranged liver chemistries" in referring letter of the general practitioner 
or referring doctor; and or in the replying letter from the gastroenterologist. In the 
absence of available laboratory data, report of "deranged or abnormal liver 
chemistries" in referring or replying letter, clinical information supplied with small 
bowel biopsy and or coeliac serology request. 
Definition 15: Osteoporosis 
Presence of reduced bone mineral density with T score : 5-2.5 [344]. 
114 
2.4.2. Marsh grading of duodenal biopsy 
Definition 16: Marsh 0 
Normal histological appearance of small bowel mucosa. 
Definition 17: Marsh 1 
Mucosal architecture is normal but there is an increased number of intra-epithelial 
lymphocytes (more than 40 intra-epithelial lymphocytes per 100 enterocytes). 
Definition 18: Marsh 2 
In addition to the infiltration of the mucosa with intra-epithelial lymphocytes, there is 
an increase in crypt depth without any reduction in villous height. 
Definition 19: Marsh 3a 
The mucosa is flat with partial reduction in normal villous height to crypt depth ratio 
with crypt hyperplasia and intraepithelial lymphocytosis. Also referred to as partial 
villous atrophy. 
Definition 20: Marsh 3b 
The mucosa is flat with subtotal reduction in normal villous height to crypt depth ratio 
with crypt hyperplasia and intraepithelial lymphocytosis. Also referred to as subtotal 
villous atrophy. 
Definition 21: Marsh 3c 
The mucosa is flat with total reduction in normal villous height to crypt depth ratio 
with crypt hyperplasia and intraepithelial lymphocytosis. Also referred to as total 
villous atrophy. 
Definition 22: Unspecified degree of villous atrophy 
The mucosa is flat with unspecified degree of reduction in normal villous height to 
crypt depth ratio with crypt hyperplasia and intraepithelial lymphocytosis. Also 
referred to as villous atrophy. 
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2.4.4. Coeliac serology status 
This is defined in definition 4 in section 2.2.1.2. 
2.4.5. Co-morbidity present at diagnosis of coeliac disease 
Co-morbid conditions present at diagnosis at coeliac disease were also systematically 
collected including those considered as inactive such as appendicectomy. 
Definition 23: Graves disease 
Presence of thyroid-associated ophthalmopathy (such as exophthalmos) and 
hyperthyroidism (overproduction of thyroid hormones T3 and T4 which can be 
measured in the serum). Detection of thyroid-stimulating autoantibodies serologically 
are supportive of the presence of Graves disease. In the absence of available 
laboratory data, report of "Graves disease" in referring or replying letter. 
Definition 24: Hypothyroidism 
Underproduction of thyroid hormones T3 and T4 as measured in the serum as 
suggested by higher levels than normal of thyroid-stimulating hormone (TSH). In the 
absence of available laboratory data, report of "hypothyroidism" in referring or 
replying letter. 
Definition 25: Type 1 diabetes 
Lack of endogenous insulin production by pancreas resulting in fasting venous blood 
glucose more than 6.1 mmol/L or more than 10.0 mmol/L at 2 hours post glucose 
load. Presence of anti-islet autoantibodies, lack of insulin resistance as determined by 
a glucose tolerance test and absence of C-peptide in serum are supportive of presence 
of type 1 diabetes. In the absence of available laboratory data, report of "IDDM" or 
"type 1 diabetes mellitus" in referring or replying letter. 
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Definition 26: Hypertension 
Blood pressure consistently above 140 / 90 mmHg (130 / 80 mmHg in people with 
diabetes mellitus). In the absence of available clinical data, report of "hypertension" 
in referring or replying letter. 
Definition 27: Hypercholesterolaemia 
Fasting serum LDL (low density lipoprotein) above 4.5 mmol/L; the patient receiving 
regular statin therapy may further support the diagnosis. In the absence of available 
laboratory data, report of "hypercholesterolaemia" in referring or replying letter. 
Definition 28: Ischaemic heart disease (IHD) 
IHD includes the clinical syndromes of myocardial infarction and angina pectoris. 
The diagnosis of myocardial infarction is based on conventional grounds of cardiac 
symptoms, elevated cardiac enzymes with or without electrocardiograph (ECG) 
changes. Angina pectoris diagnosis may be presumed on the basis of typical 
exertional chest pain relieved by drugs such as glyceryl trinitrate and further 
supported by confirmatory results of an exercise tolerance test or coronary 
angiography. 
Definition 29: Stroke disease 
Clinical syndrome characterised by sudden onset of focal neurological deficit with 
diagnosis may be further supported with radiological such as computed tomography 
imaging 
117 
2.5. Description of historical cohorts 
Collecting the Nottingham and Sheffield historical cohorts not only helped me 
understand how to develop systems of recruiting a representative population of 
incident coeliacs for the prospective studies but they formed contemporary cohorts in 
which there was systematic collection of data that could be used for: 
" exploring morbidity associated with coeliac disease 
e. g. prevalence of hypertransaminasaemia in incident coeliac disease 
9 reference study population (from the same geographical area, contemporary in 
time) with which to compare the prospective cohort to 
e. g. proportion of coeliacs presenting with iron deficiency anaemia and marsh 
3b histological changes similar in historical and prospective cohorts? 
This section 2.5. describes the demographic, clinical, histological and laboratory 
features of the Nottingham and Sheffield historical cohorts. 
2.5.1. Methods 
2.5.1.1. Study design 
Historical cohort study. 
2.5.1.2. Study cohort 
Adults with incident coeliac disease diagnosed at Nottingham University Hospital 
(Nottingham historical cohort) and Royal Hallamshire Hospital (Sheffield historical 
cohort) between 1s` January 2000 
- 
31s` December 2006 and identified as described in 
sections 2.2.1. and 2.2.2. respectively. 
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2.5.1.3. Outcome measures 
" Number of adults per year with incident coeliac disease identified at 
Nottingham and at Sheffield 
" Demographic features of adults with incident coeliac disease (age, sex, 
ethnicity) 
" Proportion of adults newly diagnosed with coeliac disease presenting with 
diarrhoea, anaemia, weight loss, constipation, abdominal pain, IBS symptoms 
" Distribution of Marsh grading and coeliac serology status in adults newly 
diagnosed with coeliac disease 
" Prevalence of previously diagnosed autoimmune and vascular disease in adults 
newly diagnosed with coeliac disease 
2.5.1.4. Outcome ascertainment 
Systematic data collection of demographic, clinical, histological and laboratory data 
present at diagnosis of coeliac disease was performed as described in sections 2.2.1. 
and 2.2.2. respectively. Modes of presentation were defined as described in section 
2.4. Comparisons to the population structures of Nottingham and Sheffield general 
populations such as ethnicity were made using data from the Office of National 
Statistics [341,342]. 
2.5.1.5. Statistical analysis 
Descriptive analyses with calculation of mean and median were performed. 
Comparisons between binary variables were performed using Chi-squared tests and 
between continuous data using unpaired t-tests. 
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We considered a p-value of 0.05 to represent statistical significant in all tests. All 
analyses were performed using Stata 9.2 [TexCorp]. 
2.5.1.6. Ethical approval 
Advice was sought from local ethics committees (Nottingham 1 and South Sheffield) 
with Nottingham University Hospital (reference ID 290) and Royal Hallamshire 
Hospital (reference 04/63) giving audit approval under service evaluation guidelines. 
2.5.2. Results: Nottingham historical cohort 
2.5.2.1. Number of identified adults newly diagnosed with coeliac disease 
588 adults with incident coeliac disease between 1st January 2000 and 31st December 
2006 were identified. The number of adults newly diagnosed each year is shown in 
the following table. 
Table 2.8: Number of adults newly diagnosed with coeliac disease at Nottingham 
University Hospital 
Year Number of new diagnoses of coeliac disease in adults 
2000 57 
2001 60 
2002 79 
2003 91 
2004 102 
2005 101 
2006 98 
Of the 588 coeliacs identified during the study period, 501 were identified through 
searches of histopathological records. These 501 coeliacs identified through 
histopathological searches were also found to have entries within the clinical coding 
databases for coeliac disease. A further 87 coeliacs not identified through 
histopathological searches were found through searching of clinical coding databases. 
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Serology results of 65 of 588 coeliacs identified in histopathological and clinical 
coding databases could not be found through searches of immunological databases. 
2.5.2.2. Demography of cohort 
There were approximately twice as many women (n = 399) as men (192) in the 
cohort. The age at diagnosis appeared to be broadly normally distributed. 
Figure 2.22: Histogram of age at diagnosis of coeliac disease in Nottingham 
historical cohort 
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The mean age at diagnosis was 48.4 (SD 15.9) years; the median age at diagnosis was 
48.3 (IQR 36.9 
- 
59.9) years. Women were diagnosed with coeliac disease at an 
earlier age (46.9 (SD 16.2) years) than men (48.4 (SD 14.8) years; p=0.002). 
Whilst a lesser proportion of the cohort were Caucasian (n = 559,94.6%) in 
comparison to the Nottinghamshire general population (97.2%; p=0.0001) [345], the 
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proportion of Asians within the coeliac cohort were greater than that of the 
Nottinghamshire general population (5.4% v 1.1%; p=0.00001). There were no 
coeliacs from black ethnic groups in comparison to the 0.5% prevalence in the 
Nottinghamshire general population. 
2.5.2.3. Presenting features of cohort 
Iron deficiency anaemia and diarrhoea were the most common presenting features 
affecting over one-third of the cohort (Table 2.9). 
Women more commonly presented with iron deficiency anaemia than men (54.1 %v 
43.8%; p=0.018). One-quarter of the cohort had presented with weight loss with 
weight loss more common in men than in women (34.4% v 24.6%; p=0.01). 39 
women (9.8%) and 27 (14.1%) men had features of malabsorption present at 
diagnosis of coeliac disease. Irritable bowel symptoms were commoner in women 
than in men (5.3% v 1.6%; p=0.03). 
27% of the cohort had partial villous atrophy present on small bowel histology at 
diagnosis of coeliac disease; 25% had subtotal villous atrophy and 28% had total 
villous atrophy. At diagnosis, 83% were EMA positive. Only 25 of the cohort had 
tTG measured at diagnosis of coeliac disease with introduction of the test late 2006. 
45.2% (n = 267) of the cohort had ferritin values below 22 µg/L, the lowest limit of 
the normal range. The median ferritin was significantly lower in females (8 (IQR 4.9 
-23) µg/L) than in males (12 (IQR 6.2 - 34) µg/L); p=0.01.13.1%(n=77) had B12 
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and 16.2% (n = 95) had folate values below the lowest limit of the normal ranges, 
respectively. 
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2.5.2.4. Co-morbidity of the cohort 
A selection of autoimmune and vascular co-morbid conditions are displayed in the 
following table. 
Table 2.10: Prevalence of previously diagnosed co-morbid conditions in the 
Nottingham historical cohort 
Co-morbidity Female 
n=288 
Male 
n=124 
p-value 
Autoimmune (%) 
Graves disease 5(1.3) 3(l. 6) 0.76 
Hypothyroidism 27 (6.8) 5 (2.6) 0.03 
Type 1 diabetes 7(l. 8) 4(2.1) 0.78 
Rheumatoid arthritis 2(0.5) 1(0.5) 0.98 
Vascular (%) 
Hypertension 31(7.8) 26 (13.5) 0.03 
Hypercholesterolaemia 3 (0.8) 7 (3.7) 0.01 
IHD 4(1.0) 13(6.8) 0.0001 
Type 2 diabetes 2(0.5) 4(2.1) 0.07 
Stroke disease 14(3.5) 9(4.7) 0.49 
Hypothyroidism was the most common autoimmune disease previously diagnosed in 
the incident cohort of people with coeliac disease, affecting 5% of the cohort. 
Autoimmune diseases appeared to have a female gender predominance in the coeliac 
cohort similar to ratios observed in the general population [346]. Diagnosed vascular 
disease appeared to have male gender predominance such as that observed in the 
general population [347]. 
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2.5.3. Results: Sheffield historical cohort 
2.5.3.1. Number of identified adults newly diagnosed with coeliac disease 
I identified 412 people with incident coeliac disease between I" January 2000 and 31s` 
December 2006 with the number of adults diagnosed each year shown in the 
following table. 
Table 2.11: Number of identified adults newly diagnosed with coeliac disease at 
Royal Hallamshire Hospital 
Year Number of new diagnoses of coeliac disease in adults 
2000 44 
2001 42 
2002 43 
2003 45 
2004 62 
2005 96 
2006 80 
Of the 412 coeliacs identified during the study period, 383 of the 412 coeliacs were 
identified through searches of histopathological records. A further 24 coeliacs not 
identified through histopathological searches were found through searching of wire 
baskets in Dr Sanders' office of letters. Another 5 coeliacs not identified through 
histopathological searches were found through searching of dietetic records. Serology 
results of 34 coeliacs could not be found through searches of immunological 
databases. These 34 coeliacs without serology results had entries in histopathology 
databases as well as being assigned a diagnosis of coeliac disease in letters in Dr 
Sanders' wire baskets as well as in dietetic records. 
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2.5.3.2. Demography of cohort 
There were approximately twice as many women (n = 288) as men (n = 124) newly 
diagnosed with coeliac disease in the cohort. The age at diagnosis appeared to be 
broadly normally distributed. The mean age at diagnosis was 48.9 (SD 16.4) years; 
the median age at diagnosis was 48.8 (IQR 38.2 
- 
61.1) years. Women were 
diagnosed with coeliac disease at an earlier age (47.8 (SD 15.8) years) than men (51.6 
(SD 17.5) years; p=0.03). 
Figure 2.23: Histogram of age at diagnosis of coeliac disease in Sheffield 
historical cohort 
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A greater proportion of the cohort were Caucasian (n = 391,94.5%) in comparison to 
the Sheffield general population (91.2%; p=0.02). The proportion of Asians within 
the coeliac cohort were similar to that of the Sheffield general population (5.6% v 
4.6%; p=0.35). There were no coeliacs from black ethnic groups in comparison to 
the 1.8% prevalence in the Sheffield general population. 
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20 40 60 80 100 
Age at diagnosis of coeliac disease (years) 
2.5.3.4. Presenting features 
Iron deficiency anaemia and diarrhoea were the most common presenting features 
affecting over one-third of the cohort. 
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Table 2.12: Presenting features of the Sheffield historical cohort 
Female n= 288) Male (n = 124 All (n = 412) 
Presentation mode* (%) 
Iron deficiency anaemia 125 (43.4) 36 (29.0) 161 (39.1) 
1312 deficiency 15 (5.2) 6 (4.8) 21(5.1) 
Folate deficiency 16 (5.6) 10 (8.1) 26 (6.3) 
Diarrhoea 112 (38.9) 50 (40.3) 162 (39.3) 
Weight loss 55 (19.1) 17 (13.7) 72 (17.5) 
Constipation 8 (2.8) 2 (1.6) 10 (2.4) 
IBS symptoms 45 (15.6) 13 (10.5) 58 (14.1) 
Abdominal pain 47 16.3 14 11.3 61 14.8 
Marsh grading (%) 
0 1 3 (2.4) 4(1.0) 
1 8(2.8) 4(2.4) 12(2.9) 
2 6(2.1) 8(6.5) 14(3.4) 
3a 86 (29.9) 33 (26.6) 119 (28.9) 
3b 104 (36.1) 35 (28.2) 139 (33.7) 
3c 56 (19.4) 26 (20.9) 82 (19.9) 
Unspecified degree of VA 9 (3.1) 4 (2.4) 13 (3.2) 
Not done or missing data 18(6.3) 11(8.9) 29(7.0) 
Median tTG (IQR) iu 171 (36 
- 
300) 241.5 (41- 300) 197 (36 
- 
300) 
Not done (%) 10737.2 3024.2 13733.3 
EMA status (%) 
Positive 220 (76.4) 97 (78.2) 317 (76.9) 
Weak positive 8 (2.8) 3 (2.4) 11(2.7) 
Negative 30 (10.4) 16 (12.9) 46 (11.2) 
IgA deficiency 1 3 (2.4) 4 (1.0) 
Not done or missing data 29(10.1) 1 5(4.0) 34(8.3) 
*Patients may have possessed one or more of these presentations 
Women more commonly presented with iron deficiency anaemia than men (43.4% v 
29.0%; p=0.008). Nearly one-fifth of the cohort had presented with weight loss. 16 
women (5.6%) and 4 (3.2%) men had features of malabsorption present at diagnosis 
of coeliac disease. Abdominal pain and irritable bowel symptoms were also common 
gastrointestinal symptoms possessed by the coeliac cohort at diagnosis. 
29% of the cohort had partial villous atrophy present on small bowel histology at 
diagnosis of coeliac disease; 34% had subtotal villous atrophy and 20% had total 
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villous atrophy. At diagnosis, the median tTG was 197 (IQR 36 
- 
300) iu and 80% 
were EMA positive. 
40.0% (n = 165) of the cohort had ferritin values below 22 µg/L, the lowest limit of 
the normal range. The median ferritin was significantly lower in females (14.5 (IQR 
5.9 
- 
45.5) µg/L) than in males (27.5 (IQR 8.5 
- 
89.5) µg/L); p=0.004.5.1% (n = 
21) had B12 and 6.3% (n = 26) had folate values below the lowest limit of the normal 
ranges, respectively. 
2.5.3.4. Co-morbid conditions diagnosed before coeliac disease 
A selection of autoimmune and vascular co-morbid conditions are displayed in the 
following table. 
Table 2.13: Prevalence of previously diagnosed co-morbid conditions in the 
Sheffield historical cohort 
Co-morbidity Female 
n=288 
Male 
n=124 
p-value 
Autoimmune (%) 
Graves disease 7 (2.4) 1 (0.8) 0.28 
Hypothyroidism 36 (12.5) 7(5.6) 0.04 
Type 1 diabetes 12 (4.2) 4 (3.2) 0.66 
Rheumatoid arthritis 5(l. 7) 1(0.8) 0.48 
Vascular (%) 
Hypertension 33 (11.5) 15 (12.1) 0.83 
Hypercholesterolaemia 11(3.8) 10 (8.1) 0.07 
IHD 14 (4.9) 13 (10.5) 0.03 
Type 2 diabetes 7 (2.4) 4 (3.2) 0.63 
Stroke disease 2(0.7) 5(4.0) 0.02 
Hypothyroidism was the most common autoimmune disease previously diagnosed in 
the incident cohort of people with coeliac disease, affecting 10% of the cohort. 
Autoimmune diseases appeared to have a female gender predominance in the coeliac 
cohort similar to ratios observed in the general population [346]. Diagnosed vascular 
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disease appeared to have male gender predominance such as that observed in the 
general population [347]. 
2.6. Discussion 
2.6.1. Principal findings 
Clinically diagnosed coeliac disease is more common in women than in men and 
mean age at diagnosis in women is younger in comparison to men. Iron deficiency 
anaemia and diarrhoea were the most common modes of presentation of clinically 
diagnosed coeliac disease affecting over one-third of the cohort. Approximately 5% 
clinically diagnosed coeliacs have no villous atrophy changes affecting their small 
bowel and approximately 80% of clinically diagnosed coeliacs have positive coeliac 
serology at diagnosis. 
2.6.2. Merits and limitations 
This is the largest study describing the systematic, routine collection of demographic, 
clinical, histological and laboratory data in a contemporary, unselected and 
population-based cohort of adults newly diagnosed with coeliac disease. While one 
cannot be certain that every patient with coeliac disease has been identified in both 
hospitals during the study period there have been extensive efforts made to do so. On 
balance it is unlikely that the omission of the few patients that will have inevitably 
been missed will have led to a substantial underestimate of the mode of presentation 
of clinically diagnosed coeliac disease. 
Presence of symptoms such as diarrhoea, constipation were usually obtained by 
review of medical notes such as those made by the reviewing gastroenterologist. The 
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clinical mode of presentation of coeliac disease is thus dependent on the recording of 
the presence or absence of these symptoms in the medical notes. If a symptom is not 
documented such as abdominal pain it may not mean that the person presenting with 
coeliac disease does not have it. More formal and standardized approaches such as the 
use of a structured questionnaire would limit such measurement bias. 
There are also limitations specific to the search strategies used to identify people with 
coeliac disease which are described further below. 
2.6.2.1. Histopathology searches 
The histopathology database was of considerable help in identifying who had been 
diagnosed with coeliac disease on the grounds of the appearances of the small bowel 
specimens. However, there were also a number of reasons why all people newly 
diagnosed with coeliac disease over the same defined time period did not appear on 
the histopathology database generated list. Some people may not have had a small 
bowel biopsy taken to diagnose coeliac disease 
- 
either due to refusal to have the 
procedure done, ill health preventing the procedure being formed with the diagnosis 
of coeliac disease made on the grounds of symptoms and positive coeliac serology 
alone, or that alternative specimens were taken such as immunofluorescence of skin 
biopsies in people with dermatitis herpetiformis and labelled to have coeliac disease 
without small bowel biopsy confirmation. People may have had small bowel biopsies 
taken at another hospital (whether NHS or private) but were receiving treatment for 
coeliac disease at either Nottingham University Hospital or the Royal Hallamshire 
Hospital. People may have had small bowel specimens that were interpretated as 
being normal (i. e. Marsh 0 lesion) either because the person was taking a gluten-free 
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diet at the time of sampling and the small bowel had recovered or that small bowel 
histology was normal because the person had Marsh 0 lesions with positive coeliac 
serology and symptoms interpreted by the reviewing clinician as being consistent with 
a diagnosis of active rather than latent coeliac disease. For these reasons I felt use of 
histopathology searches alone was not a foolproof system to capture all people newly 
diagnosed with coeliac disease for the prospective studies nor to generate the 
historical cohort and that additional searches had to be employed to capture all 
coeliacs. 
2.6.2.2. Immunology serology results 
Looking through coeliac serology test results proved to be an useful addition to the 
histopathology search. However, there were a number of limitations to using coeliac 
serology test results that would prevent this system being used in isolation. Small 
bowel histology is regarded as the gold standard to diagnose coeliac disease and 
national guidelines recommend that small bowel biopsies should be taken in people in 
whom coeliac disease is suspected [348,349]. Furthermore, small bowel histology 
identifies coeliacs that could not be detected with reliance on serology alone [350, 
351]. Indeed 20 coeliacs had negative coeliac serology per 100 tested in our historical 
cohort. This may be due to the performance of the serology test with previous studies 
suggesting that IgA-tTG tests are less sensitive with milder degrees of histological 
abnormality [352,353]. People with IgA deficiency have a ten-fold increased risk of 
having coeliac disease in comparison to people without IgA deficiency so would not 
have positive coeliac serology. 
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2.6.2.3. Clinical coding 
Despite being within the catchment area of either Nottingham University Hospital or 
the Royal Hallamshire Hospital, people may have had gastroenterology appointments 
and endoscopic procedures performed at another hospital. However, provided there 
was a referral for dietetic review, these people would end up acquiring a code for 
coeliac disease as they would receive treatment for coeliac disease at Nottingham 
University Hospital from NHS registered dietitians with no local dietitians holding a 
private license to practice (personal communication, Sandra Evison Head of Dietetics, 
Nottingham University Hospital). There also may be delays in coding hospital 
attendances, procedures and interventions due to delay in medical case notes being 
returned from gastroenterologists, endoscopists, dietitians to the clinical coders. 
2.6.2.4. Dietetic records 
There were a number of limitations to using the dietetic notes stores as a means of 
identifying people with coeliac disease. If people did not attend their dietetic 
appointment or were not referred to the dietitian for whatever reason then they would 
not have an `entry' in the note stores. If the dietetic notes were currently being used 
then they would be found in an outpatient clinic department or on a secretary's desk 
and not in the notes stores. Though the case notes were meant to be filed 
alphabetically, this was not strictly adhered to. However by manually going through 
each set of case notes in turn hopefully this issue would be overcome. 
2.6.3. Comparison with other studies 
Previous studies, largely based on less recent and smaller case series, have observed a 
much higher prevalence of weight loss and diarrhoea in incident coeliac disease 
(section 1.5.3.1. ). The marked differences between these older studies and our own 
are probably partly explained by the era in which they were carried out. These older 
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studies were carried out prior to the advent of serological tests for EMA and tTG and 
therefore do not represent contemporary practice of identification and diagnosis of 
coeliac disease in the same way that our studies do. A fall in proportion of coeliacs 
presenting with overt symptoms such as diarrhoea though a rise in those presenting 
with anaemia over successive quinquennia in the study by West et al in Derbyshire 
[343] is suggestive of a fall in the clinical severity of the disease; this may reflect a 
greater awareness of the disease with improved diagnostic methods with a greater part 
of the coeliac iceberg tip being exposed. Another explanation for the difference is the 
manner in which we identified our coeliac population. For example, the use of a 
patient support group to estimate the proportion of coeliacs that had presented with 
diarrhoea and anaemia is likely to be limited by recall and selection bias. 
Our observation that 80% of people newly diagnosed with coeliac disease have 
positive coeliac serology may be reflective of the broader histological spectrum in our 
cohort with over 10% of the study population having `mild' (marsh 0,1 or 2) coeliac 
disease changes. 
2.6.4. Summary 
Clinically diagnosed coeliac disease is more common in women than in men and 
mean age at diagnosis in women is younger in comparison to men though the possible 
explanations for these observations are unclear. The lower prevalence of clinically 
overt symptoms in comparison to previous studies may be due to differences in study 
design but may also reflect identification of people with disease below the waterline 
of the coeliac iceberg with the introduction of improved diagnostic methods. 
Approximately 5% clinically diagnosed coeliacs have no villous atrophy changes 
affecting their small bowel though the benefits and possible harm of early detection of 
mild enteropathy coeliac disease is not clear. 
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Chapter three: Historical cohort studies in 
incident coeliac disease 
Using the Nottingham and Sheffield historical coeliac disease cohorts the aim of this 
thesis chapter is to: 
" describe relationship between degree of enteropathy and physiological 
derangement, clinical features in incident coeliac disease 
" examine the risk of hypertransaminasaemia in incident coeliac disease and 
effect of treatment 
" examine incidence of clinically diagnosed coeliac disease by socio-economic 
status 
" estimate cholesterol profile in incident coeliac disease and effect of treatment 
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3.1. Mild enteropathy (Marsh 1 and 2) coeliac disease: a 
comparison with more severe disease using a population 
based cohort 
3.1.1. Introduction 
While a recent randomized trial reported some benefits from gluten withdrawal in 
adults found to have mild enteropathy (Marsh 1,2) coeliac disease [354], the benefits 
and possible harm of early detection of mild enteropathy coeliac disease is not clear 
and only limited data exist on the occurrence and clinical features at diagnosis of this 
group. The aim of this study is to compare the clinical and laboratory features of 
people presenting with mild (Marsh 1,2) versus severe (Marsh 3) enteropathy coeliac 
disease. 
3.1.2. Methods 
3.1.2.1. Study design 
Historical cohort study. 
3.1.2.2. Study population 
Adults with incident coeliac disease diagnosed at Nottingham University Hospital 
(Nottingham historical cohort) and Royal Hallamshire Hospital (Sheffield historical 
cohort) were studied. Dietetic, histopathology, immunology, clinical coding and 
outpatient records were used to retrospectively identify incident cases of coeliac 
disease as described in sections 2.2.1. and 2.2.2., respectively. 
Serum haemoglobin (g2), mean cell volume (fl), ferritin (µg/L), folgte (µg/L), B12 
(ng/L), ESR (mm/hr), CRP (mg/L), leucocyte count (1091L), albumin (g/L), platelet 
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count (109/L) were routinely measured on newly diagnosed adult cases of coeliac 
disease attending Nottingham University Hospital and Royal Hallamshire Hospital 
between 1St January 2000 and 3 1St December 2006 at both diagnosis of coeliac disease 
and in the majority following approximately 12 months treatment with a gluten-free 
diet. Demographic, clinical, histological and serological data in addition to these 
laboratory co-variates was systematically collected, as described in sections 2.2.1. and 
2.2.2., respectively. The modes of presentation of coeliac disease and coeliac 
serological status at diagnosis of coeliac disease was determined and defined as 
described in section 2.4. 
3.1.2.3. Outcome measures 
" Presenting: 
- 
demographic characteristics (proportion female, mean age at 
diagnosis); 
- 
clinical features (proportion presenting with classic, gastro-intestinal, 
extra-intestinal and associated conditions); 
- 
laboratory values (mean haemoglobin, ferritin, folate, B 12, albumin, 
alanine transferase, ESR, platelet count); 
- 
coeliac serological status (proportion EMA positive, median tTG titre) 
in adults newly diagnosed with mild enteropathy (Marsh 1,2) coeliac disease 
were compared to those adults with severe (Marsh 3) enteropathy coeliac 
disease. 
" Change in the mean value between diagnosis and following 12 months 
treatment with a gluten-free diet the laboratory values of haemoglobin, ferritin, 
folate, B 12, albumin, ESR, platelet count in coeliacs with mild (Marsh 1,2) 
versus severe (Marsh 3) enteropathy coeliac disease. 
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3.1.2.4. Statistical analysis 
Descriptive analyses with calculation of mean and median where appropriate were 
performed. Comparisons between mild versus severe enteropathy disease for binary 
variables were performed using Chi-squared tests and for continuous data using 
unpaired t-tests. Comparisons between mild and severe enteropathy disease for binary 
dependent variables were performed using logistic regression where odds ratios and 
their 95% confidence interval were computed in univariate and multivariate analyses 
where age and sex were adjusted for. Paired values such as the mean haemoglobin 
value at diagnosis and the mean haemoglobin following treatment were compared 
using paired t-tests. 
We considered a p-value of 0.05 to represent statistical significance in all tests, All 
analyses were performed using Stata SE 9.2 [TexCorp]. 
3.1.2.5. Ethical approval 
Advice was sought from local ethics committees (Nottingham 1 and South Sheffield) 
with Nottingham University Hospital (reference ID 290) and Royal Hallamshire 
Hospital (reference 04/63) giving audit approval under service evaluation guidelines. 
3.1.3. Results 
3.1.3.1. Demography of cohort 
We identified 775 adults newly diagnosed with coeliac disease during the study 
period of whom 51 (7%) had mild (Marsh 1,2) enteropathy. There was no difference 
in the gender proportion between mild (women n= 36; 70.6%) and severe (women n 
= 496; 68.5%). There was no difference in age at diagnosis of coeliac disease between 
mild and severe enteropathy groups (47.8 (SD 16.8) versus 49.7 (SD 16.0) years; p= 
0.41). 
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3.1.3.2. Presenting features 
Diarrhoea was the most common presenting feature in mild enteropathy coeliac 
disease affecting over half of this group (Table 3.14). Coeliacs with severe 
enteropathy had a 10-fold increased risk (OR 10.1; 95%CI 3.6,28.4) of presenting 
with iron deficiency anaemia in comparison to those with mild enteropathy 
(proportion affected 46.3% versus 7.8%, respectively). Though it did not reach 
statistical significance, people with mild enteropathy coeliac disease appeared to have 
less severe modes of presentation with lower proportions presenting with weight loss, 
malabsorption, B 12 and or folate deficiency in comparison to those coeliacs with 
severe enteropathy coeliac disease. There was no difference in odds of presenting with 
gastrointestinal symptoms (such as irritable bowel like symptoms, constipation) or 
associated conditions such as dermatitis herpetiformis between mild and severe 
enteropathy coeliac disease. 
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3.1.3.3. Coeliac serological status at diagnosis of coeliac disease 
2 of the 51 (4%) coeliacs with mild enteropathy and 12 of the 724 (2%) coeliacs with 
severe enteropathy did not have an EMA result at diagnosis of coeliac disease. The 
proportion of coeliacs that were EMA positive was lower in mild enteropathy (71.4% 
versus 92.4% in severe enteropathy; p=0.000 1) disease. 
Only 26 (51%) coeliacs with mild enteropathy disease and 200 (28%) coeliacs with 
severe enteropathy disease had tTG measured at diagnosis. However the median tTG 
(iu) was also statistically significantly lower in mild enteropathy (18.5 [IQR 6- 300] 
versus 210.5 [IQR 42.5 
- 
300] in severe enteropathy; p=0.0001). 
3.1.3.4. Laboratory profile at diagnosis of coeliac disease 
The mean values of serum haemoglobin, ferritin, folate, B 12, and albumin in people 
newly diagnosed with mild enteropathy coeliac disease were within normal laboratory 
range (Table 3.15). These values were also higher than in those patients with severe 
enteropathy coeliac disease. 
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Table 3.15: Haematological and biochemical profile in mild versus severe 
enteropathy incident coeliac disease 
Mean value N At diagnosis of coeliac Mean difference 
disease [SDI 95%CI 
Hb g/dL 
Mild enteropathy 44 13.9 [1.6] 
Severe entern ath 662 12.3 2.3 
-1.6 -2.3, -0.9 
MCV fl 
Mild enteropathy 44 90.4 [4.7] 
Severe entern ath 651 86.5 13.7 
-3.9 -7.9, -0.1 
Platelets 10'/L 
Mild enteropathy 44 286.7 [58.6] 
Severe entern ath 650 327.1 [110.0] 40.3 [7.5,73.2] 
ESR ml/hr 
Mild enteropathy 32 12.5 [13.6] 
Severe entern ath 394 15.3 [15.4] 2.8 [-2.8,8.3 
Ferritin pg/L 
Mild enteropathy 31 67.7 [53.2] 
Severe enteropathy 516 35.9 [70.5] -31.9 [-57.2, -6.5] 
B12 ng/L 
Mild enteropathy 32 415.9 [205.0] 
Severe entern ath 492 389.2 [581.8] 
-26.7 [-229.7,176.3 
Folate pg/L 
Mild enteropathy 32 10.7 [5.9] 
Severe entern ath 494 8.7 [6.1] -2.0 [-4.7,0.8] 
ALT u/L 
Mild enteropathy 19 29.6 [14.9] 
Severe entern ath 391 34.1 [22.8] 4.5 [-5.9,14.9] 
Albumin g/L 
Mild enteropathy 44 41.0 [3.1] 
Severe entern ath 645 38.8 [4.6] 
-2.2 [-3.6, -0.8 
3.1.3.4. Laboratory profile following 12 months gluten-free diet 
Follow-up values were obtained after a mean of 12.8 (SD 1.9) months on a gluten-free 
diet. The majority of these coeliacs were considered by gastroenterologist and 
dietitian to adhere strictly to a gluten-free diet. The proportion of coeliacs that 
remained EMA positive was 25.5% (compared to 71.4% at diagnosis) in mild 
enteropathy and 14.0% (compared to 92.4% at diagnosis) in severe enteropathy 
coeliac disease. 
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The haematological and biochemical laboratory measures did not change on exposure 
to treatment with a gluten-free diet in mild enteropathy disease while the expected 
beneficial improvements were observed in severe enteropathy disease (Table 3.16). 
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3.1.4. Discussion 
3.1.4.1. Principal findings 
Coeliacs with mild enteropathy have few biochemical deficiencies at diagnosis of 
coeliac disease and therefore show no important biochemical improvements following 
treatment with a gluten-free diet in comparison to those with severe enteropathy 
coeliac disease. Diarrhoea was the most common symptom reported in adults being 
diagnosed with mild enteropathy coeliac disease and more common than that 
observed in severe enteropathy. Iron deficiency anaemia was much less common in 
mild enteropathy compared to severe enteropathy. Approximately one-third of 
coeliacs with mild enteropathy coeliac disease had negative EMA serology at 
diagnosis and had significantly lower tTG values in comparison to those with severe 
enteropathy coeliac disease. 
3.1.4.2. Merits and limitations 
This is a large prospective study describing the systematic routine collection of 
enteropathy profile in an unselected and population-based cohort of adults newly 
diagnosed with coeliac disease. While we cannot be certain that we have identified 
every patient diagnosed with coeliac disease in both Nottingham and Sheffield 
hospitals during the study period we have made extensive efforts to do so and thus it 
is. unlikely that omission of the few patients inevitably missed will have led to a 
significant change of enteropathy spectrum observed. 
Small bowel histology has likely to have identified coeliacs that could not be detected 
with reliance on coeliac serology alone [350,351). Indeed 29 coeliacs in our study 
with mild enteropathy coeliac disease had negative coeliac serology per 100 tested. 
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Presence of overt symptoms such as diarrhoea probably led to the person seeking 
medical attention where investigation of the gastrointestinal tract resulted in the 
diagnosis of coeliac disease being made. In the absence of overt symptoms or in the 
presence of atypical symptoms in a person with negative coeliac serology, further 
investigations such as a small bowel biopsy may not have felt warranted. There is a 
possibility of further misclassification bias, where people were labelled with a 
diagnosis of coeliac disease that did not have the condition. For example, those people 
with negative coeliac serology and mild enteropathy changes may not have coeliac 
disease but some other cause for their histological changes and symptoms such as 
Helicobacter pylori infection or gallstones. Often however the reviewing 
gastroenterologist proposed other information in support of their diagnosis of coeliac 
disease in clinical notes such as HLA-DQ2 genotyping and or unequivocal 
improvement in symptoms to gluten withdrawal to minimise this misclassification 
bias. 
3.1.4.3. Comparison with other studies 
Case reports and small case series have suggested that people with mild enteropathy 
coeliac disease may suffer from abdominal pain [355,356], weight loss [355,356], 
diarrhoea [355,356], anaemia [355,357], fatigue [356] and osteopenia [358] though 
are limited in their small sample size and selected observations from coeliac disease 
specialty clinics rather than on unselected and population-based contemporary cohort 
of people with coeliac disease. 
In a population-based screening study, adults with undetected coeliac disease as 
defined by positive EMA serology were found to have an increased risk of mild 
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anaemia and osteoporosis though they did not regard themselves as being unwell in 
comparison to serological negative controls [170]. However neither the presumed 
cases of coeliac disease or the serological negative controls had small bowel histology 
so it is unclear what the proportion of cases of coeliac disease that had mild 
enteropathy histological changes present. 
Recent study in Finland based on 23 adults newly diagnosed with mild (Marsh 1 and 
2) enteropathy coeliac disease and 47 adults newly diagnosed with severe (Marsh 3) 
enteropathy coeliac disease similarly observed that there was no difference in gender 
proportion or age at diagnosis between mild and severe enteropathy groups [354]. 
Lower tTG titres were also present in mild enteropathy disease with 19 of the 23 
coeliacs having tTG titres less than 20 iu [354]. Mean values of haemoglobin, 
albumin, calcium, iron, folate and B12 were also noted to be normal at diagnosis of 
coeliac disease in coeliacs with mild enteropathy disease [354] with no significant 
change in those coeliacs randomised to receive treatment with a gluten-free diet or in 
those randomised to continue on a gluten-containing diet. Clinical symptoms in 
people with mild and severe enteropathy coeliac disease were reported to be 
"alleviated" on treatment with a gluten-free diet [354]. However approximately one- 
third (3/23 with mild enteropathy; 17147 with severe enteropathy changes) of the 
newly diagnosed coeliacs had no or only occasional symptoms present at diagnosis of 
coeliac disease with no change in level of symptoms observed in 3 of the 23 coeliacs 
with mild enteropathy disease on treatment [354]. On balance with the semi- 
quantitative, non-validated methods used to determine clinical symptoms any 
meaningful observations and or comparisons are limited and a larger study using 
validated and quantitative methods is required. 
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The prevalence of folate and B12 deficiency in our cohort overall appears lower than 
in previous studies. In coeliacs (n = 50) diagnosed in the early 1990s, 49% had low 
folate and 11 % were B 12 deficient [359]. B 12 deficiency has been reported to be as 
high as 41% in another historical case series [360]. The marked differences between 
these older studies and our own are probably explained by the era in which they were 
carried out: the previous studies were carried out prior to the advent of EMA and tTG 
serological testing and do not represent contemporary practice of identification and 
diagnosis of coeliac disease in the same way that our study does. The apparent lower 
proportions of iron, B12 and or folate deficiency, presence of malabsorptive 
symptoms in coeliacs with mild enteropathy disease in comparison to those with 
severe enteropathy disease may also reflect that earlier published studies were based 
on coeliacs with severe enteropathy disease. 
3.1.4.4. Possible benefits and risks of having mild enteropathy coeliac disease 
In the absence of biochemical derangement at diagnosis of coeliac disease together 
with no meaningful improvement upon treatment with a gluten-free diet observed in 
this study and that of Kurppa et al [354] one could propose there are few 
physiological risks with mild enteropathy coeliac disease. Though it is unclear if 
changes occur with treatment, a reduction in cholesterol concentration with each unit 
increase in tTG titre in people with undetected coeliac disease may suggest of further 
physiological benefit of coeliac disease [170]. Over half of the coeliacs with mild 
enteropathy disease had diarrhoea though our study is limited in that we are unable to 
quantify the severity of this and other symptoms or its change with treatment with a 
gluten-free diet. 
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3.1.4.5. Degree of intestinal inflammation and severity of malabsorption 
With the proximal duodenum being the site of maximal absorption of iron [361], it 
would follow that iron deficiency is more likely in individuals with duodenal villous 
atrophy than in those without villous atrophy, reflecting the malabsorption of iron. 
3.1.4.5. Summary 
Coeliacs with mild enteropathy have few biochemical deficiencies at diagnosis of 
coeliac disease and thus show no important biochemical improvements following 
treatment with a gluten-free diet. Severe enteropathy disease appeared to have less 
biochemical deficiencies in comparison to previously reported studies with almost all 
deficiencies correcting following 1 year's treatment with a gluten-free diet. Diarrhoea 
is more common and iron deficiency anaemia is less common in mild enteropathy 
compared to severe enteropathy. Approximately one-third of coeliacs with mild 
enteropathy coeliac disease had negative EMA serology at diagnosis and had 
significantly lower tTG values in comparison to those with severe enteropathy coeliac 
disease. 
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3.2. Prevalence and consequence of hypertransaminasaemia 
in a contemporary cohort of adults with incident coeliac 
disease: how common is it and does it matter? 
3.2.1. Introduction 
Coeliac disease is known to be associated with several autoimmune liver diseases 
[209,210]. The most common hepatic abnormality found in people with untreated 
coeliac disease is of an isolated hypertransaminasaemia, observed to affect over 40% 
of adults newly diagnosed with coeliac disease [211-214,362]. However, the majority 
of these studies were carried out prior to the widespread use of anti-endomysial 
antibody (EMA) or anti-tissue transglutaminase antibody (tTG) tests so represent 
coeliac diagnosed in a different era to current practice. In addition, these studies 
mostly involved small, hospital-based case series and were likely to have concerned 
patients with more serious disease or other medical conditions being investigated at 
the time. Therefore the estimates of the prevalence of hypertransaminasaemia may 
poorly reflect the prevalence in contemporary coeliac disease. 
The observed hypertransaminasaemia has been coined "gluten" or "coeliac hepatitis" 
[363]. The hepatic injury is reputed to be characterised by absence of serum auto- 
antibodies (other than endomysial and tissue transglutaminase antibodies), elevated 
transaminases and the presence of mild lobular and portal tract inflammation, steatosis 
that is reversible on treatment with a gluten-free diet. Given the relatively high 
prevalence of coeliac hepatitis observed in the reported case series and the potential of 
the coeliac hepatitis to progress to fibrosis, cirrhosis and end-stage liver failure [364, 
365], some groups have recommended a vigorous search for liver disease in people 
newly diagnosed with coeliac disease [363-365]. To help determine if the liver work- 
up is warranted in contemporary coeliac disease, we have assessed the prevalence of 
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hypertransaminasaemia in an unselected, large and contemporary population of 
people newly diagnosed with coeliac disease. 
3.2.2. Methods 
3.2.2.1. Study design 
Historical cohort study. 
3.2.2.2. Study population 
Adults with incident coeliac disease diagnosed at Nottingham University Hospital 
(Nottingham historical cohort) and Royal Hallamshire Hospital (Sheffield historical 
cohort) were studied. Dietetic, histopathology, immunology, clinical coding and 
outpatient records were used to retrospectively identify incident cases of coeliac 
disease as described in sections 2.2.1. and 2.2.2., respectively. 
3.2.2.3. Outcome measures 
" Proportion of adults with abnormally high ALT at diagnosis of coeliac disease 
" Change in the mean value between diagnosis and following 12 months 
treatment with a gluten-free diet the value of liver chemistries (alkaline 
phosphatase, alanine transferase, gamma-glutamyl transferase, albumin) in 
adults with coeliac disease 
3.2.2.4. Outcome ascertainment 
Serum alkaline phosphatase (U/L), liver transaminase (alanine transferase (U/L) and 
or aspirate transaminase (U/L), gamma-glutamyl transferase (U/L), bilirubin 
(µmol/L), ferritin (µg/L), folate (µg/L), ESR (mm/hr), CRP (mg/L), glucose 
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(mmol/L), leucocyte count (109/L), albumin (g/L), platelet count (109/L), 
haemoglobin (g/L) were routinely measured on newly diagnosed adult cases of 
coeliac disease attending Nottingham University Hospital and Royal Hallamshire 
Hospital between 1St January 2000 and 31St December 2006 at both diagnosis of 
coeliac disease and in the majority following approximately 12 months treatment with 
a gluten-free diet. Demographic, clinical, histological and serological data in addition 
to these laboratory co-variates was systematically collected, as described in sections 
2.2.1. and 2.2.2., respectively. The modes of presentation of coeliac disease and 
coeliac serological status at diagnosis of coeliac disease was determined and defined 
as described in section 2.4. 
Dietary compliance was subjectively assessed by the gastroenterologist and dietitian. 
In addition, changes in endomysial antibody positivity, and when later introduced by 
the laboratories levels of tissue transglutaminase titre, were noted as a surrogate for 
compliance whilst following a gluten-free diet. 
Diagnosis of vitamin D deficiency and osteomalacia was based on characteristic 
biochemical abnormalities (including elevated parathyroid hormone and low 25 (OH) 
Vitamin D levels which were only usually measured on patients with elevated alkaline 
phosphatase). 
3.2.2.5. Statistical analysis 
Prevalence of abnormal liver profile at diagnosis of coeliac disease was determined by 
calculating the proportion (%) of coeliacs with a liver test result above the upper limit 
of normal for the hospital laboratory concerned. With respect to albumin, an abnormal 
albumin result was defined as any value below the lower limit of normal for the 
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hospital laboratory concerned; thrombocytopaenia was defined as any platelet count 
below 150 x 10121L. 
Univariate logistic regression analysis was performed to determine the association 
between abnormal liver profile at diagnosis of coeliac disease and all potential 
explanatory independent covariates. Multivariate logistic regression analyses were 
performed to determine the odds ratios with 95% confidence intervals of abnormal 
liver profile at diagnosis of coeliac disease with respect to proxy markers of severity 
of coeliac disease after adjusting for age at diagnosis, gender and presence of 
autoimmune liver disease. Degree of intestinal inflammation as defined by Marsh 
grading (mild (Marsh 0,1,2); moderate (Marsh 3a); and severe (Marsh 3b, 3c)) and 
malabsorption mode of presentation (presence of weight loss and diarrhoea and 
anaemia) were used as proxy markers of severity of coeliac disease; titres of tTG were 
not used due to missing data. 
Paired t-tests were used to examine changes in serum liver profile from baseline to 12 
months following a gluten-free diet. 
We considered a p-value of 0.05 to represent statistical significance in all tests. All 
analyses were performed using Stata SE 9.2 [TexCorp]. 
3.2.2.6. Ethical approval 
Advice was sought from local ethics committees (Nottingham 1 and South Sheffield) 
with Nottingham University Hospital (reference ID 290) and Royal Hallamshire 
Hospital (reference 04/63) giving audit approval under service evaluation guidelines. 
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3.2.3. Results 
3.2.3.1. Demography of cohort 
We identified 1008 adults newly diagnosed with coeliac disease between 2000 
- 
2006 
of whom 905 had at least one measurement of liver transaminases: 877 had a 
measurement of alanine transferase, 28 had a measurement of aspartate transaminase 
at diagnosis. There were nearly twice as many female (n = 610) as male (n = 295) 
incident cases in the study cohort. The mean age at diagnosis was 50.2 (SD 16.2) 
years with women (49.1 (SD 15.9) years) being diagnosed at an earlier age than men 
(52.5 (SD 16.4) years; p=0.003). 
3.2.3.2. Presenting features 
Iron deficiency anaemia and diarrhoea were the most common presenting features, 
affecting over one-third of the cohort. 10% (n = 92) of the cohort presented with 
malabsorption. 32% had partial villous atrophy; 30% had subtotal villous atrophy and 
26% had total villous atrophy. At diagnosis, the median tTG was 203 (IQR 37 
- 
300; 
n= 263) and 92% were EMA positive. 449 (49%) of the study cohort had ferritin 
values below 22 µg/L, the lowest limit of the normal range, whereas 143 (16%) had 
B12 values below 211 ng/L. 68 (8%) of the study cohort had red cell folate or serum 
folate values below the lower limit of the normal range of values. 21 (2%) of the 
cohort had evidence of osteomalacia with vitamin D deficiency at diagnosis of coeliac 
disease. 
The presenting features of those coeliacs presenting with abnormal ALT (n = 82) and 
normal ALT (n = 775) is shown in the following table. 
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Table 3.17: Presenting features of incident coeliacs with elevated alanine 
transferase 
Presenting feature Coeliacs with normal Coeliacs with abnormal 
ALT (n = 795) ALT (n = 82) 
Sex (%) 
Male 255 (32) 34(41) 
Female 540(68) 48(59) 
Mean age (SD) years 50.8 (16.3) 46.4 (14.5) 
Marsh grading 
0 4(1) 0 
1 29(4) 1 (1) 
2 14(2) 2(2) 
3a 263 (33) 16(20) 
3b 240 (30) 28 (34) 
3c 194 (24) 33(40) 
VA* unspecified 32 (4) 2 (2) 
Not done 19(2) 0 
EMA status (%) 
Positive 694 (89) 77 (95) 
Weak positive 15 (2) 1 (1) 
Negative 64 (8) 3 (4) 
Not done 4(l) 0 
Mean Hb (SD) g/L 12.3 (2.3) 12.2 (2.5) 
Mean ferritin (SD) 36.1 (69.7) 38.1 (75.5) 
Mean weight (SD) kg 66.3 (18.0) 66.9 (15.4) 
*VA degree of villous atrophy unspecified 
3.2.3.3. Prevalence of diagnosed hepatobiliary conditions in incident coeliac 
disease 
5% (n = 44) of the cohort had some form of diagnosed hepatobiliary condition at 
diagnosis of coeliac disease. With respect to autoimmune liver disease, 6 (0.7%) 
coeliacs had been previously diagnosed with primary biliary cirrhosis, 5 with 
autoimmune hepatitis and 1 with primary sclerosing cholangitis. 19 coeliacs (2.1%) 
had been treated for gallstone disease prior to the diagnosis of coeliac disease whilst 8 
(0.6%) were known to have alcoholic liver disease. 
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3.2.3.4. Liver profile at diagnosis of coeliac disease 
The mean alanine transferase (ALT) at diagnosis of coeliac disease was 33.5 (SD 
49.7; median 26, IQR 20 
- 
38) U/L with no significant difference between men and 
women. The mean ALP was 87.5 (SD 53.2; median 76, IQR 60 
- 
98) U/L (n = 485) 
and 195.8 (SD 141.9; median 166.5, IQR 115 
- 
237) U/L (n = 402) in the two 
different assays used in the study period. 55 (6%) of the cohort had an abnormally low 
albumin and 12 coeliacs had thrombocytopaenia. 
3.2.3.5. Prevalence of abnormal liver profile at diagnosis of coeliac disease 
9.4% (n = 82) of our study population had an abnormal ALT value (Table 3.18). The 
majority with an abnormal ALT at diagnosis of coeliac disease had an ALT value 
within two times the upper limit of normal range (71 of 82) with only 1.2% (n = 11) 
having an abnormal ALT above two times the upper limit of the normal range. 12.3% 
(n = 109) of the cohort had an abnormal ALP. However the majority of incident 
coeliacs with an abnormal ALP result (94 of the 109) had an ALP value within two 
times the upper limit of normal range with only 15 (1.7% of cohort) having a 
abnormal ALP above two times the upper limit of the normal range. 
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Table 3.18: Prevalence of abnormal ALP and ALT at diagnosis of coeliac disease 
Number 
with valid 
test 
n =1008 
Number 
abnormal 
% abnormal 
[95% Cl] 
ALP 887 (88%) 109 12.29 [10.29,14.61] 
>1 but <2 x ULN 94 10.60 [8.74,12.80] 
Above 2x ULN 15 1.69 [1.03,2.77] 
ALT 877 (87%) 82 9.35 [7.60,11.46] 
>1 but <2 x ULN 71 8.10 [6.47,10.09] 
Above 2x ULN 11 1.25 [0.70,2.23] 
3.2.3.6. Associations of abnormal ALP and ALT at diagnosis of coeliac disease 
ALT 
Having an abnormal ALT was associated with male gender (OR 1.50 [95% CI 1.02, 
2.39]) but not with age at diagnosis nor BMI (Table 3.19). Unsurprisingly, abnormal 
ALT at diagnosis was associated with previously diagnosed autoimmune liver disease 
(OR 7.30 [95%CI 2.26,23.58]). A strong independent graded relationship was 
observed between the presence of abnormal ALT and the degree of intestinal 
inflammation. Abnormal ALT was associated with a 2-fold increased odds (OR 2.02 
[95%CI 1.10,3.69]) of having moderate intestinal inflammation (Marsh 3a) and 3- 
fold (OR 2.70 [95%CI 1.49,4.87]) increased odds of having severe intestinal 
inflammation (Marsh 3b, 3c) relative to the baseline category of mild intestinal 
inflammation (Marsh 0,1 or 2) after adjusting for age at diagnosis, gender and 
presence of autoimmune disease. Abnormal ALT was associated with clinically more 
severe coeliac disease with 7-fold increased risk of presenting with features of 
malabsorption being present. 
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Abnormal ALP was not associated with gender, age at diagnosis nor body mass index. 
However presence of previously diagnosed autoimmune liver disease (OR 5.30 
[95%CI 1.65,16.99]) and the presence of osteomalacia (OR 35.76 [95%CI 11.78, 
108.54]) were statistically significantly associated with abnormal ALP at diagnosis of 
coeliac disease. Those coeliacs with an abnormal ALP were four times as likely to 
present with features of malabsorption (OR 3.56 [95%CI 2.13,5.92]). Furthermore a 
graded relationship was observed between having abnormal ALP and odds of having 
mild, moderate or severe degrees of histological inflammation. After adjusting for age 
at diagnosis, gender, presence of autoimmune disease, abnormal ALP was associated 
with 29-fold increased odds of having a diagnosis of osteomalacia (OR 29.12 [9.32, 
91.46]). 
3.2.3.7. Change in liver profile following treatment with gluten-free diet 
Follow-up liver profile values were obtained after a mean of 12.8 (SD 1.9) months on 
a gluten-free diet in approximately 80% of individuals in our study (Table 3.20). 
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The vast majority of these patients were considered by the gastroenterologist and 
dietitian to adhere strictly to a gluten-free diet. At diagnosis 92% were EMA positive 
while after a year of treatment only 19% remained positive. There were no significant 
changes in GGT or bilirubin on treatment with a gluten-free diet. However there were 
statistically significant reductions in ALP (mean difference 
-33.46 [95%CI -39.58, - 
27.33] U/L) and ALT (mean difference 
-6.65 [95%CI -10.30, -2.99] U/L). Only 14 
(17.1%) of the 82 coeliacs with abnormal ALT at diagnosis of coeliac disease had 
persistently abnormal ALT following treatment with a gluten-free diet with the ALT 
values normalising in the remainder. Of these, 2 had dyslipidaemia, 1 had type 2 
diabetes, I had primary biliary cirrhosis, I had hypothyroidism, 1 was non-compliant 
with gluten-free diet. The remaining 8 coeliacs only had non-invasive tests for liver 
disease which were negative. 
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3.2.4. Discussion 
3.2.4.1. Principal findings 
We found that in newly diagnosed adults with coeliac disease, clinically important 
hypertransaminasaemia (i. e. greater than 2x ULN) was uncommon (<2%). In those 
patients with an abnormal test of any level 86% normalised following a year of 
treatment with a gluten-free diet. The presence of elevated transaminases in incident 
coeliac disease was associated independently with clinical features of malabsorption 
and more severe histological features of intestinal inflammation on duodenal biopsy. 
Although relatively uncommon, abnormally high ALP at diagnosis of coeliac disease 
was strongly associated with a diagnosis of osteomalacia. 
3.2.4.2. Merits and limitations 
This is the first prospective study describing the systematic, routine collection of 
biochemical liver profile in a large, unselected and population-based cohort of adults 
newly diagnosed with coeliac disease. While we cannot be certain that we have 
identified every patient diagnosed in both hospitals during the period we made 
extensive efforts to do so. We believe it unlikely that the omission of the few patients 
that will have inevitably missed will have led to a substantial underestimate of the 
prevalence of hypertransaminasaemia we have reported. The recent widespread 
availability of highly sensitive and specific serological tests for coeliac disease has 
allowed identification and diagnosis of rapidly rising numbers of people with coeliac 
disease [343,366,367]. These people with, relatively, less serious disease, now 
account for the majority of people diagnosed with coeliac disease [366-368]. The 
patients in our study were all diagnosed during this era and therefore represent 
contemporary practice in a manner that has not been reported previously. 
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3.2.4.3. Comparison with other studies 
Previous studies, based on historical and smaller case series, have observed a much 
higher (40 
- 
55%) prevalence of hypertransaminasaemia in incident coeliac disease 
[211,213,214,362]. The marked differences between these older studies and our 
own are probably partly explained by the era in which they were carried out. The 
previous studies were carried out uniformly prior to the advent of serological tests for 
EMA and tTG and therefore do not represent contemporary practice of identification 
and diagnosis of coeliac disease in the same way that ours does. Emerging evidence 
suggests that patients diagnosed with coeliac disease more recently have, to some 
extent, less severe disease [366]. Another explanation for the difference is the manner 
in which we identified our population. In Jacobsen's case series 17% had some form 
of malignancy [362] in contrast to our cohort where none of our coeliacs were known 
to have cancer. In addition, not all of the coeliacs had a liver profile measurement in 
some studies such as in Hagander et al case series [211] suggesting that there were 
likely to have been specific reasons for doing so. Our observation that only 9.4% 
people have hypertransaminasaemia at diagnosis of coeliac disease is similar to the 
prevalence one study that used serological tests to screen for coeliac disease [212, 
214] indicating perhaps that those diagnosed in our region in the year 2000 onwards 
are more similar to these groups of screen-detected individuals. 
Alkaline phosphatase is regarded as an useful initial biochemical test to screen for 
osteomalacia in the general population although high false positive rates are 
recognised [369,370]. The strong association observed between elevated alkaline 
phosphatase and presence of osteomalacia in our coeliac cohort is consistent with 
these findings in the general population [369,370]. Our observed prevalence of 
elevated alkaline phosphatase in incident coeliac disease is similar to previous studies 
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investigating metabolic bone disorders in coeliac disease [191,194,207] though the 
prevalence of osteomalacia (2%; n= 21) observed in our study is considerably lower 
than in these studies [191,194,2071 suggesting there were specific reasons for 
measuring different elements of bone profile. Such ascertainment bias is likely to be 
present in our study too with no routine measurement of parathyroid hormone nor 
vitamin D levels unless there was a clinical or biochemical suspicion of underlying 
metabolic bone disease. The observed reduction in alkaline phosphatase with 
treatment of coeliac disease is in keeping with previous studies [191,194,207] and 
supports the importance of gluten withdrawal in coeliac disease to also help treat any 
underlying osteomalacia [191,194,207]. Normalisation of an isolated elevated 
alkaline phosphatase with treatment of coeliac disease may also remove the need for 
further invasive investigations such as a bone biopsy. 
3.2.4.4. Possible explanations for hypertransaminasaemia in coeliac disease 
With 86% of cases of hypertransaminasaemia in newly diagnosed coeliac disease 
normalising with a gluten-free diet in keeping with previous studies [212-214], this 
suggests the mechanism(s) underlying the liver abnormality involves a relationship 
between gluten intake, intestinal damage and potential hepatic injury. Hypothesising 
that the liver insult in coeliac disease may be due to increased intestinal permeability 
resulting from the gluten-related intestinal damage (thereby allowing the entrance of 
toxins, antigens and pro-inflammatory mediators (such as interleukins and y- 
interferon) to the portal circulation with subsequent hepatocyte insult) [371-373] 
could be supported by our findings of a strong independent graded relationship 
between the presence of elevated ALT at diagnosis of coeliac disease and the degree 
of intestinal inflammation. A role for malabsorption-induced `starvation' state causing 
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steatosis may be reflected by our observation that elevated ALT is associated with 9- 
fold increased odds of presenting with features of malabsorption. Chronic intestinal 
mucosal inflammation may have a role such as that observed in ulcerative colitis 
[374]. Extracellular deposition of IgA tTG-2 in liver biopsies of people with active 
coeliac disease [375] may suggest a pathogenic role for the humoral-mediated 
immune responses in the liver injury observed in coeliac disease. 
3.2.4.5. Possible role of vitamin D and calcium malabsorption in bone 
derangement of coeliac disease 
With the observation that elevated alkaline phosphatase in incident coeliac disease 
was independently associated with clinical features of malabsorption, one could 
speculate that the vitamin D and calcium malabsorption with the consequent 
osteomalacia state originates in the same context of a widespread nutritional failure, 
forming an important pathogenic mechanism of bone derangement in these coeliacs. 
The resolution of elevated alkaline phosphatase and dramatic increase in serum 
vitamin D levels in those patients with osteomalacia on gluten withdrawal further 
supports this speculation and is in keeping with previous observations of a gluten-free 
diet leading to significant bone mass improvement [191,194,207]. 
3.2.4.6. Summary 
In summary, clinically important hypertransaminasaemia is uncommon (<2%) in 
people newly diagnosed with coeliac disease and any abnormality of ALT or ALP 
only occurred in around 10% of patients. The majority of these abnormalities 
normalised following treatment with a gluten-free diet. The lower prevalence 
observed in comparison to previous studies may be due to differences in study design 
but may also reflect identification of people with disease below the waterline of the 
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iceberg of coeliac disease with the introduction of highly sensitive and specific 
serological screening tests. Our findings suggest that investigations for liver disease 
should only be initiated in those patients with persistent hypertransaminasaemia or if 
otherwise indicated. 
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3.3. Is the diagnosis of coeliac disease associated with socio- 
economic status? A population-based study 
3.3.1. Introduction 
The rate of diagnosis of coeliac disease in developed countries has increased 
dramatically since the introduction of serological tests without an obvious 
environmental precipitant. Little is known about the socio-economic distribution of 
coeliac disease; there is some evidence that it is less common in more deprived social 
groups [170J. The aim of this study is to quantify the incidence of new diagnoses of 
coeliac disease by socio-economic status in a large, contemporary and population- 
based cohort. 
3.3.2. Methods 
3.3.2.1. Study design 
Historical cohort study. 
3.3.2.2. Study population 
Adults with incident coeliac disease diagnosed at Nottingham University Hospital 
(Nottingham historical cohort) and Royal Hallamshire Hospital (Sheffield historical 
cohort) between Ist January 2000 and 31St December 2006 were studied. Dietetic, 
histopathology, immunology, clinical coding and outpatient records were used to 
retrospectively identify incident cases of coeliac disease as described in sections 2.2.1. 
and 2.2.2., respectively. 
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3.3-2.3. Outcome measures 
" Incidence rate of coeliac disease (all; by sex; and by age) by quintile of rank of 
IMD07 score (most deprived, below average, average, above average, least 
deprived) per 1000 population. 
3.3.2.4. Outcome ascertainment 
The postcode of residence at diagnosis was routinely collected on newly diagnosed 
adult cases of coeliac disease attending Nottingham University Hospital and Royal 
Hallamshire Hospital. This postcode of residence at coeliac disease diagnosis was 
used to determine the Index of Multiple Deprivation 2007 (IMD07) score and rank. 
The IMD07 score and rank determined was then used as an indicator of socio-' 
economic status [376]. 
The IMD07 is a measure of multiple deprivation at the small area level, produced on a 
statistical geography known as a Lower Layer Super Output Area (LLSOA) that 
contains approximately 1500 people and 750 households. The IMD07 is a statistically 
generated output that combines data from a number of indicators, chosen to cover a 
range of economic, social and housing issues into a single deprivation score for each 
LLSOA in England [376]. Separate indices at the LLSOA level are provided for each 
of the seven domains / themes of deprivation: income (9 indicators including 
proportion on Income Support), employment (5 indicators including employment 
deprived such as those with forced exclusion from work due to sickness); health 
deprivation and disability (5 indicators including SMR <65 years, limiting long term 
illness, low Birthweight); education, skills and training (6 indicators including level of 
qualifications and education amongst adults); access to housing and services (3 
indicators including proportion living in unsatisfactory housing); crime (4 indicators 
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such as recorded burglary); and living environment (such as proportion of houses 
without central heating) [376]. The IMD07 deprivation score generated allows all 
LLSOA to be ranked according to how deprived they are relative to each other [376]. 
A rank of 1 indicates the most deprived LLSOA and 32,482 the least deprived. The 
ranks are categorised into quintiles with quintile 1 (rank 1- 6496) being the most 
deprived and quintile 5 (rank 25,987 
- 
32,482) least deprived [376]. 
The area and boundaries of Nottingham and Sheffield were geographically defined by 
their super output area [377]. Each LLSOA within the middle super output area of 
Sheffield is listed as an example in Appendix 7.1. 
Demographic, clinical, histological and serological data in addition to these laboratory 
co-variates was systematically collected, as described in sections 2.2.1. and 2.2.2., 
respectively. The modes of presentation of coeliac disease and coeliac serological 
status at diagnosis of coeliac disease was determined and defined as described in 
section 2.4. The study population was divided into the age bands (16 
- 
29 years; 30 
- 
44 years; 45 
- 
64 years; 65 years and older) as used by the Office of National 
Statistics [42,378]. 
3.3.2.5. Statistical analysis 
Incidence rates of coeliac disease by quintile of rank of IMD07 score were calculated 
using the total adult population for Sheffield and Nottingham derived from the UK 
2001 National Census [42,378]. Multivariate poisson regression analyses were 
performed to estimate the incidence rate ratio (IRR) of coeliac disease according to 
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quintile of rank of IMD07 score with respect to proxy markers of severity of coeliac 
disease after adjusting for age and for sex as a priori confounders. 
Degree of intestinal inflammation as defined by Marsh grading (severe (Marsh 3b, 3c) 
and mild (Marsh 1,2,3a) and malabsorption mode of presentation (presence of 
weight loss and diarrhoea and anaemia) were used as proxy markers of severity of 
coeliac disease. 
We considered a p-value of 0.05 to represent statistical significance in all tests. All 
analyses were performed using Stata SE 9.2 [TexCorp]. 
3.3.2.6. Ethical approval 
Advice was sought from local ethics committees (Nottingham 1 and South Sheffield) 
with Nottingham University Hospital (reference ID 290) and Royal Hallamshire 
Hospital (reference 04/63) giving audit approval under service evaluation guidelines. 
3.3.3. Results 
3.3.3.1. Demography of cohort 
We identified 877 adults newly diagnosed with coeliac disease between ls` January 
2000 
- 
31st December 2006 of whom 837 had postcode at residence at diagnosis 
available. There were approximately twice as many female (n = 570) as male (n = 
267) incident cases in the study cohort. The mean age at diagnosis was 49.6 (SD 16.0) 
years with women (48.4 (SD 15.9) years) being diagnosed at an earlier age than men 
(52.1 (SD 15.9) years); p=0.0016. 
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3.3.3.1. Presenting features 
Iron deficiency anaemia and diarrhoea were the most common presenting features, 
affecting over one-third of the cohort. 31% had partial villous atrophy; 28% had 
subtotal villous atrophy and 23% had total villous atrophy. At diagnosis, the median 
tTG was 163 (IQR 28 
- 
300; n= 241) and 87% were EMA positive. 
3.3.3.2. Incidence of coeliac disease by quintile of rank of IMD07 score 
The incidence rate of identified adults with coeliac disease at Nottingham and 
Sheffield was 0.11 per 1000 population. There was a strong, independent graded 
association between the incidence rate of coeliac disease and socio-economic status. 
The incidence rate of coeliac disease was twice as high in coeliacs in the least 
deprived and most affluent quintile (age- and sex-adjusted incidence rate ratio (IRR) 
1.93; 95%CI 1.61,2.44) as compared to those coeliacs in the most deprived and 
poorest quintile (Table 3.21). 
Table 3.21: Incidence of coeliac disease by quintile of rank of IMD07 score 
Quintiles of N N total adult Rate Crude Adjusted* 
rank of exposed /1000 Incidence Rate Incidence Rate 
IMD07 score population population Ratio Ratio 
195% CI 195% CI 
I 160 2173052 0.07 1.00 1.00 
Most deprived 
II 125 1361311 0.09 1.23 1.22 
Below average [0.99,1.58] [0.96,1.53] 
III 170 1397949 0.13 1.69 1.61 
Average [1.36,2.09] [1.30,2.00] 
IV 168 1175846 0.15 1.97 1.82 
Above average [1.59,2.44] [1.50,2.30] 
V 189 1193626 0.17 2.20 1.93 
Least deprived [1.79,2.71 ] [1.61,2.44] 
' adjusted for age and tor sex 
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Socio-economic status in incident coeliac disease was not associated with more severe 
coeliac disease (Table 3.22). 
Table 3.22: No association of severity of coeliac disease with quintile of rank of 
IMD07 score 
Quintiles of Proportion OR Proportion OR 
rank of with Marsh [95% CI] with [95% CI] 
IMD07 score 3c, 3b univariate malabsorption univariate 
I 54.7% 1.00 7.4% 1.00 
Most deprived 
II 67.0% 1.68 5.6% 0.74 
Below average [1.01,2.79] [0.28,1.94] 
III 59.0% 1.19 11.3% 1.60 
Average [0.76,1.87) [0.76,3.39] 
IV 59.4% 1.21 7.5% 1.02 
Above average [0.77,1.91] [0.45,2.30] 
V 52.1% 0.87 7.6% 1.04 
Least deprived [0.56,1.34] [0.47,2.28] 
3.3.3.4. Incidence of coeliac disease by sex 
The incidence rate of coeliac disease in women was 0.15 per 1000 population and 
0.07 per 1000 population in men. There was a strong, independent association 
between the incidence rate of coeliac disease and sex with higher rates of coeliac 
disease in women with respect to men with the effect most marked in the youngest 
age band (Table 3.23). The incidence rate of coeliac disease was nearly four times as 
high in female coeliacs in the youngest age band 16 
- 
29 years (unadjusted incidence 
rate ratio (IRR) 3.75; 95%CI 2.31,6.32) as compared to males coeliacs within the 
same age band (Table 3.10). In comparison the incidence rate of coeliac disease was 
twice as high in female coeliacs aged 30 
- 
44 years (unadjusted IRR 2.34; 95%CI 
1.78,3.11) as compared to males within the same age band. Over 65 years of age 
there was no difference in incidence rate of coeliac disease between sexes. 
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Incidence of coeliac disease was independently associated with presence of iron 
deficiency anaemia in female coeliacs within the younger age bands though there was 
no difference in proportions between male and female coeliacs presenting with 
malabsorption or more severe histological changes on small bowel biopsy (Table 
3.24) 
176 
PO 
93 
as 
"r PC 
"r 
r. r 
po 
ro 
co 
"r 
ii 
u 
u 
u 
b 
i. + 
ee 
F 
^ 
t 
r1 
N 
ýO iý 
N 
"O 
Oý 
Rn 
p 
. --ý N per 
p0 
M p 
v1 
N 
ý Ö u 
Ö 
u 
Ö 
u 
Ö 
u 
o. 
-= "" it 3O 
c c e 
C C 
14o Cý p `n 
w 0 
o E 
sue. ýy ý ý ö 
Ö4 M G1 N 
ä E 
ö RI, ö S 
Oý CVi pý CN: 
r 
fy 
Ö 
u 
Ö 
u 
Ö 
u 
. -ý 
u 
b 
O"3M 
ö ö ö l 
O C9 
1"0 
o M 
O '-l C "-: 
a 
'. n 
ao 
4. 
' 
a4 
ý" M 
c 
N 
ö 
M 
c 
O 
c 
M 
M 3 i a 
*a ö ö 
V 
V'j 1 v i 
ä 3 
^ 
. 
-4 
.., 
I 
W MC M pN p 
(V 
u 
(-l 
u 
Ö 
u 
Ö 
u 
Cy ý 
4.0 
'3d ö ö ö ä 
ÖA N 
w %A 
ao 
o ýd A öö 00 0 
4-9 &. 3 
as 
eia ýö aýi 
Ö 
ý-+ ih 
'cý + cad 
d 
.0 0-4 -. -M -I 
n 
3.3.4. Discussion 
3.3.4.1. Principal findings 
The estimated incidence of adult coeliac disease in Nottingham and Sheffield in the 
period 2000 
- 
2006 was 0.115 per 1000 population. There was a strong, independent 
graded association between the incidence rate of new diagnoses of coeliac disease and 
socio-economic status with the rate twice as high in adults from affluent areas 
compared with that in adults living in poorer areas. Socioeconomic status was not 
associated with features of more severe coeliac disease. The incident rate of new 
diagnoses of coeliac was also independently associated with female sex in comparison 
to men with the effect most marked in the younger adult years but this did not explain 
the relationship with socioeconomic status. 
3.3.4.2. Merits and limitations 
This is the first study where there has been systematic and routine collection of 
socioeconomic status in a large, unselected and population-based cohort of adults 
newly diagnosed with coeliac disease. While we cannot be certain that we have 
identified every coeliac diagnosed in all three hospitals during the study period we 
made extensive efforts to do so. We believe it unlikely that the omission of the few 
patients that will have inevitably been missed will have led to a substantial under- or 
overestimate of the relationship between socioeconomic status and coeliac disease we 
have reported. The recent widespread availability of highly sensitive and specific 
serological tests for coeliac disease allowing identification and diagnosis of rapidly 
rising numbers of people with coeliac disease [343,366,367] adds to the 
contemporary nature to our cohort and representing today's coeliac disease. 
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The IMD07 score is a nationally consistent measure of how deprived an area is by 
identifying the degree to which people are disadvantaged by factors such as low 
income, unemployment, lack of education, poor health and crime [376]. Such 
indicators of social status and material conditions have been demonstrated to be 
associated with increased risks for health impairment and mortality [379-381]. The 
IMD07 is formed by pulling together a total of 38 different individual indicators 
chosen to cover a range of economic, social and housing issues for each small area in 
England (LLSOA) providing an overall measure of socioeconomic deprivation [376]. 
Despite the IMD07 score covering aspects of income, education, housing and access 
to services including health care, these are not direct measures of the quality of health 
care delivery in the communities [376]. There is also an element of ecological fallacy 
with the IMD07 score as it indicates that an area has a particular level of deprivation 
but it is not necessarily the case that specific individuals living in that area are 
similarly deprived. Furthermore, unmeasured environmental, social, behavioural 
factors are also beyond these proxy markers of socioeconomic status. The 
socioeconomic status given by the IMD07 score in this study is based on area of 
residence at the time of diagnosis of coeliac disease but it may not necessarily 
represent every coeliac's current or historical socioeconomic group. However, 
generally people living in the same area have similar levels of deprivation and have 
found to be robust over time [382]. Another possible source of bias is in the 
ascertainment of denominator populations. The UK census was criticised for 
underestimating the size of populations living in inner city areas [383]. However, this 
under-ascertainment would only act to strength the associations between 
socioeconomic status and rate of new diagnoses of coeliac disease. Any 
misclassification bias involved in defining the area and boundaries of Nottingham and 
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Sheffield geographically by their super output area is likely to be non-differential. It is 
feasible that coeliacs living within Nottingham or Sheffield could attend hospitals 
other than those in Nottingham or Sheffield. However in the lack of a regional or 
national tertiary referral centres for coeliac disease and assuming with the referral 
access of primary care practitioners for hospitals local to place of residence for routine 
care of coeliac disease, such bias is minimal. 
3.3.4.3. Comparison with other studies 
Our estimated incidence of adult coeliac disease of 0.115 per 1000 population is lower 
but is somewhat in keeping with that estimated in Derby (0.169 per 1000 population) 
during the same time period of study [174]. The higher estimates observed in Derby 
may reflect the active case-finding strategy adopted by the author of this study who 
has prospectively followed identified coeliacs in a weekly-run, dedicated coeliac 
clinic since 1978 [174]. The higher estimates may also be due to further steps being 
taken by the author to identify coeliacs such as using membership records of the 
coeliac society, Coeliac UK, and dermatitis herpetiformis clinic in addition to the 
steps we also took to identify the numerator population. The denominator population 
was defined also using Office for National Statistics Census data though it is unclear 
whether super output areas were the geographical mode to delineate the areas and 
boundaries. 
Our observation that the incidence rate of new diagnoses of coeliac disease is 
associated with socioeconomic status is new though it was suggested by the non- 
significant trend observed by West et al where EMA positive adults in a population- 
based screening study were less likely to be from partly skilled and unskilled 
occupational positions (OR 0.51 partly skilled and unskilled to professional positions, 
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95%CI 0.18,1.43) [170]. Whether these findings are limited by selection bias with 
volunteers for the study likely to differ in their attitudes, behaviours and health status 
compared to non-volunteers is unclear. However maternal exposures in infancy 
suggest direct and indirect evidence for the association of social class with incidence 
of coeliac disease. With breastfeeding at the time of gluten introduction associated 
with protection against coeliac disease [384] and breastfeeding associated with less 
deprived social class [385], this suggests an increased risk of coeliac disease for 
children whose mothers are from more deprived social classes. Conversely increased 
risks of coeliac disease for children whose mothers were from manual social classes 
(assessed by spouse's occupational position) was observed in the Oxford Linkage 
study [386]. The association between low birth weight and increased risk for coeliac 
disease [387] may be in part due to social factors such as poverty-related maternal 
health status causing lower physiological reserves, quality and quantity of healthcare, 
housing, diet, increased exposure to toxic antigens and differential risk of infectious 
disease [388-391] and supporting the observations of the Oxford Linkage Study [386]. 
It is known that people from poorer social classes are less likely to attend for routine 
health checks at which blood tests are performed [392-394], access healthcare [395, 
396] and have different health seeking behaviours [397,398] in comparison to people 
from more affluent social classes. Indeed, the incidence of coeliac disease was not 
associated with more severe coeliac disease. Whether the observed association 
between incidence rate of coeliac disease and affluence is a reflection of the variation 
in environmental exposures to aetiological factors or could be accounted for by 
differences in uptake and utilisation of health services it is unclear but further work to 
unravel the contribution of social class to the aetiology and incidence of coeliac 
disease is required. 
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The female predominance of adult coeliac disease observed in our study is well 
described where in general twice as many women as men are diagnosed with coeliac 
disease [172,173,399]. This may be a reflection of female preponderance for 
abnormal autoimmune function with enhanced immune reactivity due to female sex 
hormones or some other factor [400-403]. With the incidence of coeliac disease 
independently associated with presence of iron deficiency anaemia in female coeliacs 
and particularly within the younger age bands, one could speculate challenges of 
menstruation and pregnancy may act to accentuate anaemia and exacerbate any effects 
of coeliac disease in women. Women are also more likely to access and attend health 
checks than men in these childbearing years such as for antenatal care and 
contraception-related routine health reviews where the opportunity for detecting 
anaemia is very much greater. The health-seeking behaviour of women relative to 
men with differential symptom reporting may also contribute to the apparent gender 
difference in clinically diagnosed coeliac disease [399]. 
3.3.4.4. Summary 
The estimated incidence of adult coeliac disease in Nottingham and Sheffield in the 
period 2000 
- 
2006 was 0.115 per 1000 population. The incident rate of coeliac 
disease is strongly associated with socio-economic status with the rate twice as high in 
adults from affluent areas compared with that in adults living in poorer areas. 
Socioeconomic status was not associated with features of more severe coeliac disease 
though could be a reflection of the variation in environmental exposures to 
aetiological factors or could be accounted for by differences in uptake and utilisation 
of health services. The associations of incident rates of coeliac disease with female 
sex and with iron deficiency anaemia with the effect most marked in the younger 
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adult years may be explained by the physiological challenges of menstruation and 
pregnancy acting to accentuate anaemia and exacerbate any effects of coeliac disease 
in women or due to gender differences in attending health checks, access to healthcare 
and health-seeking behaviour. 
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3.4. Cholesterol profile in people with newly diagnosed coeliac 
disease: a comparison with the general population and changes 
following treatment 
3.4.1. Introduction 
Recent studies have suggested that untreated coeliac disease is associated with a low 
serum cholesterol. Ciacci et al observed 0.7 mmol/L lower total cholesterol in 10 
adults with coeliac disease presenting with hypochromic anaemia in comparison to 
those with hypochromic anaemia due to other causes [272] while West et at found that 
total cholesterol in people with undetected coeliac disease as assessed by EMA 
positivity was 0.5 mmol/L lower in comparison to EMA negative general population 
controls [170]. While these reductions might seem modest it has been calculated that a 
reduction in total cholesterol of 0.6 mmol/L will result in 25 
- 
30% reduction in the 
risk of mortality from ischaemic heart disease in people aged 55 
- 
64 years [252]. 
Nevertheless, patients with coeliac disease do not appear to have a decreased risk of 
ischaernic heart disease or stroke, despite an apparently favourable vascular risk 
profile such as the low cholesterol, lower levels of hypertension [269] and lower 
prevalence of smoking [266,267] observed in people with coeliac disease. Indeed, 
the evidence on vascular outcomes appears to be conflicting with some studies [270, 
404] suggesting an increased risk of ischaemic stroke and heart disease while others 
no increase in risk [269]. Ludvigsson et al observed a 27% (HR 1.27; 95% CI 1.09 
- 
1.48) increased risk of myocardial infarction and 35% increased risk of ischaemic 
stroke (HR 1.35; 95% CI 1.14 
- 
1.60) in coeliacs using the Swedish in-patient registry 
whereas West et al observed an adjusted HR 1.90 (95% CI 1.00 
- 
3.60) in an 
184 
endomysial antibody positive cohort versus an antibody negative cohort [170,270]. In 
contrast he hazard ratio for myocardial infarction was 0.85 (95% CI 0.63 
- 
1.13) and 
for stroke 1.29 (95% Cl 0.98 
- 
1.70) in the study by West et al [269]. 
Concern has also been raised as to whether treatment of coeliac disease may have an 
adverse effect on serum cholesterol. For example, Brar et al worryingly observed a 
0.5 mmol/L increase in serum cholesterol following treatment of incident coeliac 
disease [405] though the study is based on a retrospective identification of patients 
that had happened to have cholesterol profile measured before coeliac disease was 
diagnosed so was limited by its non-systematic assessment of cholesterol profile. We 
have therefore prospectively examined cholesterol profiles at diagnosis and after one 
year of a gluten-free diet in a contemporary cohort of newly diagnosed coeliac disease 
patients. 
3.4.2. Methods 
3.4.2.1. Study design 
Historical cohort study. 
3.4.2.2. Study population 
Adults with incident coeliac disease diagnosed at Royal Hallamshire Hospital 
(Sheffield historical cohort) were studied. Dietetic, histopathology, immunology, 
clinical coding and outpatient records were used to retrospectively identify incident 
cases of coeliac disease as described in section 2.2.2. 
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3.4.2.3. Outcome measures 
" Proportion of adults with raised total cholesterol at diagnosis of coeliac disease 
" Change in the mean value between diagnosis and following 12 months 
treatment with a gluten-free diet the value of lipid profile (total cholesterol, 
HDL cholesterol, total : HDL cholesterol ratio, triglycerides) in adults with 
coeliac disease 
3.4.2.4. Outcome ascertainment 
Serum total cholesterol (mmol/L), HDL cholesterol (mmol/L), total cholesterol: HDL 
cholesterol ratio, triglyceride (mmol/L), ferritin (µg/L), folate (µg/L), ESR (mm/hr), 
CRP (mg/L), glucose (mmol/L), leucocyte count (109/L), albumin (g/L), platelet count 
(109/L), haemoglobin (g/L) were routinely measured on newly diagnosed adult cases 
of coeliac disease attending Royal Hallamshire Hospital between 1St January 2004 and 
31St December 2006 at both diagnosis of coeliac disease and in the majority following 
approximately 12 months treatment with a gluten-free diet. Demographic, clinical, 
histological and serological data in addition to these laboratory co-variates was 
systematically collected, as described in section 2.2.2. The modes of presentation of 
coeliac disease and coeliac serological status at diagnosis of coeliac disease was 
determined and defined as described in section 2.4. 
3.4.2.5. Statistical analysis 
We examined the association between baseline HDL cholesterol and other continuous 
baseline variables using Spearman's rank correlation coefficients. We examined the 
association between baseline HDL cholesterol with each of sex, age group and 
symptoms using student's unpaired t-tests. Paired t-tests were used to examine 
changes in blood variables from baseline to 12 months following a gluten-free diet. 
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We explored univariate associations between baseline characteristics and change in 
HDL cholesterol using correlation coefficients for continuous variables and student's 
t-tests for categorical variables. Finally, in order to examine the potential effect of a 
change in the severity of coeliac disease we modelled the change in tTG against 
change in HDL cholesterol using multiple linear regression. We included any factors 
that were found to be associated in the univariate model as well as adjusting for a 
priori confounders of age and sex and, to account for potential regression to the mean, 
for baseline HDL cholesterol measurements. 
Finally, we carried out a comparison of baseline cholesterol with the findings from the 
Health Survey for England 2006 (Cardiovascular disease and risk factors in adults) 
[347], which is representative of the whole population at both national and regional 
level. In this survey, non-fasting blood samples were collected from a representative 
sample of the general population (70% of sampled population provided valid blood 
samples) with total cholesterol measurements obtained on 3618 men and 3850 
women. For our comparisons we firstly age-adjusted the mean cholesterol values in 
our coeliac cohort compared with those in the survey. Secondly we calculated a ratio 
of observed number of people with total cholesterol greater than 5.0 mmol/L versus 
expected, standardised for age. We considered a p-value of 0.05 to represent statistical 
significance in all tests. All analyses were performed using Stata SE 9.2 [TexCorp]. 
3.4.2.6. Ethical approval 
North Staffordshire Local Research Ethics Committee gave ethical approval 
(reference 06/Q2604/91) to this study in October 2006. Royal Hallamshire Hospital 
gave research and development approval (reference STH14597) in March 2007. 
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3.4.3. Results 
3.4.3.1. Demography of cohort 
We identified 100 people with incident coeliac disease between 2004 
- 
2006. There 
were nearly twice as many female (n = 65) as male (n = 35) incident cases in the study 
cohort. The mean age at diagnosis was 50.6 (SD 15.8) and was similar in men and 
women (p = 0.45). The cohort was 96% Caucasian compared with 89% for Sheffield 
as a whole [378]). 
3.4.3.2. Presenting features 
Iron deficiency anaemia and diarrhoea were the most common presenting features, 
affecting 30% of the cohort respectively. 28 % had partial villous atrophy; 36% had 
subtotal villous atrophy and 23% had total villous atrophy. At diagnosis, the median 
tTG was 194 (range 2- 300) and 86% (n = 86) were EMA positive. The median 
weight at diagnosis of coeliac disease was 58 (IQR 50,67) kilograms in women (n = 
39) and 73 (IQR 64,79) kilograms in men (n = 17). The mean haemoglobin was 12.4 
(SD 2.0) g/L in women and 14.0 (SD 1.7) g/L in men at diagnosis of coeliac disease. 
49 (49%) of the study cohort had ferritin values below 22 µg/L, the lowest limit of the 
normal range, whereas 14 (14%) had B12 values below 211 ng/L. 17 (17%) of the 
study cohort had folate values below 3.4 µg/L, the lowest limit of the normal range of 
values. 
3.4.3.3. Lipid profile at diagnosis of coeliac disease 
The mean total cholesterol and mean triglyceride at diagnosis of coeliac disease was 
4.84 mmol/L (SD 1.2) and 1.24 (SD 0.8) mmol/L respectively (Table 3.25). Mean 
HDL cholesterol was 1.36 (SD 0.48) mmol/L; the ratio of total cholesterol to HDL 
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cholesterol was 4.00 (SD 2.4)). HDL cholesterol at diagnosis of coeliac disease was 
associated with weight and sex but no other variables. 
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Both men and women with incident coeliac disease had lower age-adjusted mean 
total cholesterol in comparison to the general population (difference in mean adjusted 
total cholesterol 
-1.09 [95% CI -0.97, -1.21] mmol/L; -0.46 [95% CI -0.24, -0.68] 
mmol/L, respectively). At diagnosis of coeliac disease, men had 21% lower and 
women had 9% lower mean total cholesterol in comparison to the general population. 
When we carried out age standardisation (Table 3.26), we found that men with 
incident coeliac disease were 60% less likely (ratio of observed versus expected 0.40 
[95% CI 0.12,0.68]) to have a total cholesterol of >=5.0 mmol/L when compared 
with the general population. In women the effect was smaller and not statistically 
significant (ratio of observed versus expected 0.91 [95% CI 0.61,1.20]). 
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3.4.3.4. Change in weight and haematinic profile with gluten-free diet 
The mean values of haemoglobin, mean cell volume and B12 significantly increased 
with exposure to a gluten-free diet (Table 3.25). There were no substantial changes in 
folate, ferritin, albumin, ESR, CRP, leucocyte count or platelet counts. There was a 
4.22 kilogram increase in mean weight [95% CI 2.90,5.54] from the baseline mean 
weight of 66.51 (SD 4.02) kilograms. 
3.4.3.5. Change in lipid profile following treatment with gluten-free diet 
Follow-up lipid values were obtained after a mean of 12.6 (SD 1.9) months on a 
gluten-free diet (Table 3.25). There was no change in mean cholesterol or triglyceride 
level with treatment of incident cases of coeliac disease. However, there was a small 
and statistically significant increase of 0.12 mmol/L [95% CI 0.05,0.18] in the mean 
value of HDL cholesterol with exposure to a gluten-free diet. Furthermore the total 
cholesterol: HDL cholesterol ratio was reduced by 0.28 [95% CI 
-0.09, -0.47]. 
On univariate analyses the changes in HDL cholesterol observed did not vary with 
demographic variables such as age at diagnosis nor gender. Features suggestive of 
malabsorption (such as by stratifying the cohort into those having diarrhoea and or 
weight loss; height, weight, albumin, haemoglobin), systemic inflammation (such as 
ferritin, ESR, white cell count, platelet count) or more severe coeliac disease (such as 
by stratifying the cohort into those with subtotal or total villous atrophy, those with 
higher tTG) were not associated with change in HDL cholesterol. 
However when we examined change in tTG, a proxy marker often used in clinical 
practice to reflect response to treatment in coeliac disease, this was weakly associated 
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with change in HDL cholesterol on univariate analysis (p = 0.06). After adjusting for 
age at diagnosis, gender, baseline HDL cholesterol and baseline tTG, change in tTG 
was independently associated with change in HDL cholesterol (p = 0.03) on treatment 
of incident coeliac disease with a gluten-free diet on multivariate analyses. Thus for 
each 50 unit decrease in tTG that occurred on treatment of coeliac disease there was a 
0.03 mmol/L increase in HDL cholesterol. 
3.4.4. Discussion 
3.4.4.1. Principal findings 
Our study shows that at diagnosis coeliacs have much lower total cholesterol levels 
than the general population with the observed reduction greater in men (21%) than in 
women (9%). In addition to the changes in weight and haemoglobin profile expected 
when diagnosing and treating people with coeliac disease, our study reassuringly 
observed no increase in total cholesterol on treatment with a gluten-free diet. 
Furthermore, HDL cholesterol showed a small but statistically significant increase 
following treatment. These findings indicate that any increase in risk of ischaemic 
heart disease or stroke in people with coeliac disease is not due to increases in total 
cholesterol induced by the diet. On the contrary the lower total cholesterol levels and 
increases in HDL cholesterol on treatment should afford people with coeliac disease 
relative protection against ischaemic heart disease and stroke. 
3.4.4.2. Merits and limitations 
This is the first prospective cohort study where there has been systematic collection of 
lipid profile in a large and unselected sample of cases of incident coeliac disease. 
Since serum total cholesterol and HDL cholesterol can both be measured accurately 
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on a random non-fasting sample [406-408], fasting status or timing of blood collection 
is unlikely to have had an effect on the values obtained. In the absence of 
malabsorptive processes and systemic inflammation one would not expect HDL 
cholesterol to increase as substantially as we have observed simply during a 12 month 
period. For example, exposure to four years of the Mediterranean dietary pattern did 
not cause any change in serum levels of total cholesterol nor HDL cholesterol 
suggesting that change in dietary patterns alone was not responsible for the change in 
HDL cholesterol observed in our study [409]. Clearly though, if the gluten free diet is 
markedly different with respect to its effect on cholesterol profile then this could be a 
potential explanation for our observations but there is no evidence that this is true. 
Neither the effects of body mass index nor exercise have been shown to alter 
cholesterol profile substantially over such a short time period [410]. 
3.4.4.3. Comparison with other studies 
Our observation that people with newly diagnosed coeliac disease have a lower total 
cholesterol compared with the general population is new though it was suggested in 
the only comparable study of 10 patients, presenting with hypochromic anaemia 
where no general population comparison was made [272]. The reductions in total 
cholesterol we have found in diagnosed coeliacs were somewhat greater than those 
reported by West et al who found total cholesterol levels were 10% lower in 
endomysial antibody positive people in comparison to endomysial antibody negative 
general population controls [170]. 
The finding of no increase in total cholesterol following treatment with a gluten-free 
diet is in contrast to the only other study to have examined cholesterol profile before 
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and after treatment. Brar et al observed a 0.5 mmol/L (11%) increase in total 
cholesterol [405] despite similar proportions of men and women in the cohort, and 
similar proportions of partial to total villous atrophy present on duodenal biopsy at 
diagnosis. This is probably a reflection of differences in the study populations. As 
only a small proportion of their study population (132 out of 700) had a cholesterol 
measurement there are likely to have been specific reasons for doing so. Conversely, 
our study was based on all newly diagnosed patients over a2 year period and is likely 
to be more representative of celiac disease in general. 
Intestinal malabsorption, reduced cholesterogenesis, increased biliary secretion, and 
or high faecal elimination of cholesterol have all been proposed as mechanisms which 
might lower total cholesterol in people newly diagnosed with coeliac disease in 
comparison to the general population [411-413]. However the lack of increase in total 
cholesterol with treatment of coeliac disease suggests that any mechanism based on 
intestinal malabsorption is less likely. Conversely there has been no reported increase 
in risk of cholesterol gallstones or cholecystectomy in people with coeliac disease to 
I support increased biliary secretion as the mechanism involved. 
An inverse association has been reported between proxy markers of vascular 
inflammation (such as CRP, ESR) and HDL cholesterol [39,274,414]. HDL 
cholesterol is regarded as a potent anti-atherogenic mediator having a wide range of 
anti-oxidative, anti-thrombotic and anti-inflammatory effects [275]. Indeed HDL 
cholesterol increasing compounds have been shown to attenuate systemic 
inflammation 
, 
vessel wall inflammation as well as reducing risk of ischaemic heart 
disease events [275]. Anti-inflammatory treatment of active rheumatoid arthritis, an 
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autoimmune and chronic inflammatory disorder like coeliac disease, has been 
observed with a reduction in median ESR levels by 36% (23 mm/hour) and an 
increase in median HDL cholesterol by 9% (0.10 mmol/L) over a 12 month period 
[414]. With this in mind, perhaps the increase in HDL cholesterol we have observed 
on treatment of active coeliac disease a proxy marker for reduction in intestinal and or 
systemic inflammation? We did not however observe any particularly strong 
associations between the inflammatory markers we measured and cholesterol profile. 
3.4.4.4. Summary 
People with coeliac disease have lower total cholesterol levels than the general 
population, with the reduction greater in men (21%) than in women (9%). While we 
observed no increase in total cholesterol following treatment with a gluten-free diet, 
there was a small but significant increase in HDL cholesterol. It is unclear why 
despite an apparently favourable cardiovascular risk profile including also the lower 
prevalence of smoking and hypertension in people with coeliac disease, coeliac 
disease has not consistently been shown to be associated with a reduced risk of 
ischaemic heart disease. This paradox remains unresolved. However, with the 
calculation that a reduction in total cholesterol of 0.6 mmol/L will result in 25 
- 
30% 
reduction in the risk of mortality from ischaemic heart disease, any increase in risk of 
ischaemic heart disease or stroke in people with coeliac disease is unlikely due to an 
adverse cholesterol profile either before diagnosis or after treatment with a gluten free 
diet. 
A copy of the published peer-reviewed manuscript may be found in section 9.3. 
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Chapter four: Longitudinal change in vascular risk 
profile and quality of life on treating incident coeliac 
disease with a gluten-free diet 
In an unselected and large sample of adults newly diagnosed with coeliac disease at 
Nottingham, Sheffield and Derby hospitals a longitudinal prospective study was 
performed with the aim to: 
" estimate the vascular risk profile at diagnosis of coeliac disease and quantify 
any change following treatment with a gluten-free diet 
" estimate the quality of life at diagnosis of coeliac disease and observe any 
change following exposure to a gluten-free diet 
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4.1. Vascular risk profile at diagnosis of coeliac disease and changes 
on exposure to a gluten-free diet 
4.1.1. Introduction 
Vascular disease is the commonest cause of mortality in the developed world, 
accounting for 40% of all deaths in the general population [415]. As alluded to in 
section 1.7.5.1., established high-risk demographic factors for vascular disease [241- 
244] are: 
9 advancing age (relative risk 8 for 60 versus 40 year olds) 
" male sex (relative risk 2-5 men versus women) 
" lower socioeconomic status (relative risk 3 for social class V versus social 
class I) 
" immigrants born in the Indian subcontinent (standardised mortality ratio 146 
(95% CI 136,156) relative to England and Wales standard rate) 
There are a number of modifiable aetiological factors associated with vascular disease 
as discussed in section 1.7.5.1. including: 
" Cigarette smoking (nearly two-fold increased risk of vascular disease with the 
risk increasing with the number of cigarettes smoked [245]) 
" Increasing systolic and diastolic blood pressure (sustained reduction of 5 
mmHg blood pressure over a 5-year period reduced coronary artery events by 
25% and strokes by 30% in patients with ischaemic heart disease in five years 
[248]) 
9 Obesity (standardised mortality ratio for death from vascular disease 136 of 
BMI >/27 kg/m2 versus <22.4 kg/m2 [249]) 
" Central obesity (increased risk of vascular disease in comparison to those of 
similar BMI but with peripheral adiposity [250]} 
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" Raised waist: hip circumference ratio (waist: hip ratio >/ 0.91 was associated 
with nearly a threefold increased risk of coronary artery disease events 
compared to <0.91 in men during 10 year follow-up [251]) 
" Raised waist circumference (> 95 centimetres associated with a twofold 
increased risk of coronary artery disease events compared to <83.5 cm in men 
during mean 10 year follow-up [2511) 
" Raised total cholesterol (reduction in total cholesterol of 0.6 mmol/L 
associated with 25 
- 
30% reduction in the risk of mortality from ischaemic 
heart disease in people aged 55 
- 
64 years [252]) 
" Raised LDL cholesterol (reduction in LDL cholesterol by 1.3 mmol/L resulted 
in reduction in risk of non-fatal acute coronary syndrome or death from 
vascular disease by a third in middle-aged men with hypercholesterolemia and 
no history of myocardial infarction [254]) 
" Low HDL cholesterol (rise in HDL cholesterol by 0.02 mmol/L results in a 
3% reduced risk of vascular disease [255,256]) 
0 Elevated triglycerides [257,258] 
" Raised fibrinogen (risk ratio for vascular disease 1.8 for 0.35 g/L levels versus 
0.25 g/L fibrinogen [259]) 
" Elevated CRP (odds ratio 2.13 for 2.4 v 0.9 mg/L CRP [260]) 
" Diabetes mellitus (relative risk in female diabetics to those without diabetes 
for vascular disease events [261]) 
Vascular disease is also the most common cause of mortality in coeliac disease [262]. 
However, recent studies have found some evidence of decreased cardiovascular 
morbidity suggesting that people with coeliac disease may have some favourable 
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features to their vascular risk profile. We have observed adults with incident coeliac 
disease have lower total cholesterol levels than the general population which did not 
change following treatment with a gluten-free diet (study 3.4. ). Potentially beneficial 
increases in HDL cholesterol however were observed following treatment (study 3.4. ). 
As alluded to in section 1.7.5.2. coeliac disease appears to be associated with non- 
smoking although it is unclear whether this is a causal association [266-268]. In a 
cross-sectional population screening study people with positive endomysial antibodies 
had 2.4 mmHg (p < 0.05) lower diastolic blood pressure in comparison to negative 
controls [170] and those with treated coeliac disease are reported to be less likely to 
have a diagnosis of hypertension (odds ratio 0.68 (95% CI 0.60 
- 
0.76) and a lower 
reported antihypertensive medication use in comparison to age- and sex-matched 
general population controls [269]. 
Despite this apparent favourable cardiovascular risk profile, population-based studies 
have not observed coeliac disease having a protective effect upon cardiovascular 
disease events [269) with even increased risks observed [270]. Reasons for the 
observed lack of protection against cardiovascular disease events in diagnosed coeliac 
disease are unclear but one could speculate (persistent) systemic inflammation driven 
by coeliac disease perpetuates the inflammatory atherosclerotic lesion. 
The aim of this longitudinal study is to describe the vascular risk profile in adults 
newly diagnosed with coeliac disease and to observe any change in the profile 
following treatment with a gluten-free diet. 
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4.1.2. Methods 
4.1.2.1. Study design 
Longitudinal observational study. 
4.1.2.2. Study population 
Data was collected on the vascular risk profile in adults with incident coeliac disease 
and following their treatment with a gluten-free diet that had attended Nottingham 
University Hospital, Nottingham; Royal Hallamshire Hospital, Sheffield; or Derby 
Hospitals NHS Foundation Trust for management of their coeliac disease. 
Consecutive cases of incident coeliac disease were identified at Nottingham using 
clinical alerts and records; dietetic alerts and records; and pathology databases as 
described in sections 2.2.1.4. and 2.2.1.6. At the Royal Hallamshire Hospital, 
consecutive incident cases of coeliac disease were identified using clinical and dietetic 
records as well as pathology and immunology databases as described in section 
2.2.2.5. Clinical and dietetic records were used to identify incident coeliacs in Derby 
as described in section 2.2.3. Extensive efforts were made to identify all incident 
adults with coeliac disease at these three centres in order that they could be invited to 
participate in this study. 
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4.1.2.2.1. Classification of coeliac disease within study population 
In view of comparisons being made with respect to the quality of life between 
different ` glaciers' of the coeliac iceberg in study 4.2., the vascular risk profile was 
also similarly compared between coeliacs presenting with classic disease, 
gastrointestinal symptoms and those with silent disease as defined below: 
Definition 30: Classic symptoms 
Those coeliacs presenting with weight loss and diarrhoea. 
Definition 31: Gastrointestinal symptoms 
Those coeliacs presenting with gastrointestinal symptoms including diarrhoea but in 
absence of weight loss (would be included as having `classic symptoms'), weight loss 
in the absence of diarrhoea (would be included as having `classic symptoms'), 
constipation, IBS syndrome, nausea, bloating, steatorrhoea, acid reflux, heartburn, 
vomiting, abdominal pain. 
Definition 32: Silent coeliac disease 
Those coeliacs presenting with no gastrointestinal symptoms; or physiological 
derangements such as anaemia, osteoporosis, deranged liver chemistries in the 
absence of gastrointestinal symptoms. 
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4.1.2.3. Inclusion criteria 
Adults with incident coeliac disease. 
4.1.2.4. Exclusion criteria 
Significant co-morbidity that would prevent the study participants being well enough 
to take part. 
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4.1.2.5. Outcome measures 
" Proportion of people at diagnosis of coeliac disease that smoke (current, ex- 
and never) and were ever diagnosed with hypertension, 
hypercholesterolaemia, hypertriglyceridaemia, diabetes mellitus, coronary 
artery disease, atrial fibrillation, peripheral vascular disease and or stroke 
compared to the general population. 
" Total cholesterol, HDL cholesterol, total cholesterol: HDL cholesterol ratio, 
triglycerides, fibrinogen, CRP, HbA1C, weight, systolic and diastolic blood 
pressure, body mass index, waist circumference, waist: hip circumference at 
diagnosis of coeliac disease (all coeliacs, coeliacs with classic symptoms, 
coeliacs with gastrointestinal symptoms, coeliacs with silent disease) and in 
comparison to the general population 
" 
Proportion of people at diagnosis of coeliac disease that are obese (BMI 30 
kg/m2 or more), raised waist circumference, raised waist: hip circumference 
ratio compared to the general population 
" Change in the mean value between diagnosis of coeliac disease and following 
12 months treatment with a gluten-free diet the value of weight, body mass 
index, pulse rate, blood pressure, waist circumference, waist: hip 
circumference ratio, total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, ESR, CRP, folate, ferritin, HbA1C, glucose, leucocyte count, 
albumin, platelet count, haemoglobin, haematocrit, fibrinogen, APTT, PT. 
Below are descriptions of how I have defined the outcome measures used within this 
study. 
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Definition 33: Body mass index (BMI) 
Refers to and calculated by determining the ratio of the weight in kilograms divided 
by the square of the height in metres. Study participants were classified into the 
following BMI groups according to the WHO and National Institute for Health and 
Clinical Excellence (NICE) BMI classification [416]: underweight (BMI less than 18.5 
kg/m2); normal (BMI 18.5 to less than 25 kg/m2); overweight (BMI 25 to less than 30 
kg/m); obese (BMI 30 kg/m2 or more); morbidly obese (BMI 40 kg/m2 or more). 
Definition 34: Raised waist circumference 
Waist circumference that is greater than 102 centimetres in men and greater than 88 
centimetres in women in accordance with the definition of abdominal obesity used by 
NICE [416]. 
Definition 35: Raised waist: hip circumference ratio 
Ratio of waist circumference to hip circumference more than 0.85 in women and more 
than 0.95 in men in accordance with the definition of abdominal obesity used by 
NICE [416]. 
Definition 36: Smoker 
Current smoker referred to a person who was currently smoking cigarettes or has 
stopped smoking in the 12 months preceding date of diagnosis of coeliac disease. An 
ex-smoker referred to someone who has smoked in the past and has last smoked more 
than 12 months preceding the date of diagnosis of coeliac disease. 
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Definition 37: Hypertension 
Presence of consistently elevated blood pressure above 140 / 90 mmHg (130 / 80 
mmHg in people with diabetes mellitus). Further corroborated by report of 
"hypertension" in referring letter of the general practitioner or referring doctor; and or 
in the replying letter from the gastroenterologist. Person receiving regular anti- 
hypertensive medication also further supported the diagnosis. 
Definition 38: Hypercholesterolaemia 
Presence of serum total cholesterol above the highest limit of normal range for the 
hospital laboratory concerned. Further corroborated by report 
"hypercholesterolaemia" in referring letter of the general practitioner or referring 
doctor; and or in the replying letter from the gastroenterologist. Person receiving 
regular statins also further supports the diagnosis. 
Definition 39: Hypertriglyceridaemia 
Presence of serum triglycerides above the highest limit of normal range for the 
hospital laboratory concerned. Further corroborated by report "hypertriglyceridaemia" 
in referring letter of the general practitioner or referring doctor; and or in the replying 
letter from the gastroenterologist. Person receiving regular fibrates also further 
supported the diagnosis. 
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Definition 40: Diabetes mellitus 
Presence of fasting venous blood glucose more than 6.1 mmol/L corroborated by report by 
study participants that they currently had diabetes and or whether the study participants had 
been told by a doctor that they had diabetes. Further corroborated by report "diabetes 
mellitus" in referring letter of the general practitioner or referring doctor; and or in the 
replying letter from the gastroenterologist. Person receiving regular anti-diabetic 
medication also further supported the diagnosis. For classification purposes, type 1 
diabetes was defined as those study participants on insulin therapy alone (no oral anti- 
diabetic medication) and further corroborated with report of "type 1 diabetes mellitus" 
or "insulin-dependent diabetes mellitus" in referring letter of the general practitioner 
or referring doctor; and or in the replying letter from the gastroenterologist. Type 2 
diabetes was defined as those study participants taking oral anti-diabetic medication 
and further corroborated with report of "type 2 diabetes mellitus" or "non-insulin- 
dependent diabetes mellitus" or "diet controlled diabetes mellitus" in referring letter 
of the general practitioner or referring doctor; and or in the replying letter from the 
gastroenterologist. 
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Definition 41: Coronary artery disease 
Refers to atherosclerotic disease of the coronary arteries resulting in clinical 
syndromes of myocardial infarction and angina. Supported by confirmatory cardiac 
investigations (such as cardiac angiography reports, exercise tolerance tests, serum 
cardiac enzymes results, stress echocardiography) and or interventions to help treat 
the condition (thrombolysis, angioplasty, coronary artery bypass grafting). Suggested 
by report of study participant suffering from angina and or heart attack and the study 
participants reporting diagnosis had been confirmed by a doctor. Corroborated by 
report "myocardial infarction" and or "angina pectoris" and or "ischaemic heart 
disease" and or "coronary artery disease" in referring letter of the general practitioner 
or referring doctor; and or in the replying letter from the gastroenterologist. Person 
receiving regular anti-anginal and anti-platelet medication also further supported the 
diagnosis. 
Definition 42: Atrial fibrillation 
Refers to the presence of irregularly irregular pulse confirmed 
electrocardiographically with absence of P waves. Suggested by report of study 
participant suffering from an irregular heart beat and the study participants reporting 
diagnosis had been confirmed by a doctor. Corroborated by report "atrial fibrillation" 
in referring letter of the general practitioner or referring doctor; and or in the replying 
letter from the gastroenterologist. Person receiving regular anti-arrhythmic and anti- 
thrombotic medication also further supported the diagnosis. 
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Definition 43: Peripheral vascular disease 
Refers to atherosclerotic disease of the arteries resulting in clinical syndromes of 
intermittent claudication, ischaemic arterial limb ulcers and aortic aneurysm, 
Supported by confirmatory investigations (such as angiography reports, radiological 
imaging demonstrating aneurysmal dilatation, Doppler flow studies) and or 
interventions to help treat the condition (such as angioplasty, vascular bypass). 
Suggested by report of study participant suffering from claudication, gangrene, 
arterial ulcers and or aortic aneurysm with the study participants reporting a doctor 
had confirmed the diagnosis. Corroborated by report "claudication" and or "aortic 
aneurysm" and or "peripheral vascular disease" and or "gangrene" and or "arterial 
ulcers" in referring letter of the general practitioner or referring doctor; and or in the 
replying letter from the gastroenterologist. Person receiving regular anti-platelet 
medication also further supported the diagnosis. 
Definition 44: Stroke 
Refers to atherosclerotic disease of the cerebral arteries resulting in clinical syndromes 
of acute stroke, chronic stroke disease and transient ischaemic attack. Supported by 
confirmatory cerebral investigations (such as computed tomography appearances of 
brain). Suggested by report of study participant suffering from mini-strokes, strokes 
and the study participants reporting diagnosis had been confirmed by a doctor. 
Corroborated by report "stroke" and or "transient ischaemic attack" and or 
"cerebrovascular disease" in referring letter of the general practitioner or referring 
doctor; and or in the replying letter from the gastroenterologist. Person receiving 
regular anti-anginal and anti-platelet medication also further supported the diagnosis. 
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Definition 45: Any cardiovascular condition 
Study participants were classified as having any cardiovascular condition if they 
reported ever having any of the following conditions (as defined above): angina 
pectoris, myocardial infarction, stroke, atrial fibrillation. 
4.1.2.6. Outcome ascertainment 
4.1.2.6.1. Anthropometry measurements 
All measurements were done while the study participants were without shoes, lightly 
clothed and had no restrictive underwear [417]. All measurements were done by the 
same study investigator (NRL). Measurements were taken at the end of respiration 
while the participant was standing erect, with the arms at the side and the feet together 
[417]. All hip and waist circumference measurements were taken using the same 
inelastic tape (SECA circumference measuring tape SE200ST) without compressing 
the skin and were recorded to the nearest 0.1 cm. 
Waist circumference was measured around the smallest circumference between the 
lowest rib and the iliac crest, or for obese subjects with no natural waist midway 
between the lowest rib and iliac crest. 
Hip circumference was measured horizontally at the level of the greatest lateral 
extension of the hips. 
Weight was measured to the nearest lOOg using the same set of digital scales (SECA 
electronic scale SE888/4). 
Height was measured to the nearest 0.1cm using the same free-standing stadiometer 
(SECA Leicester portable height measure SE001). 
212 
4.1.2.6.2. Vital sign measurements 
All measurements were done by the same study investigator (NRL). 
Blood pressure measurements were performed using an A&D UA-774 non-invasive 
oscillometric monitor (A&D Instruments, UK). Study participants were seated in a 
chair with their backs supported and their right arm bared at the level of the heart. 
After 5 minutes of rest, systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) were measured twice with at least a2 minute interval between measurements. 
The averages of the 2 readings for both SBP and DBP were used. 
Heart rate measurements were performed using an A&D UA-774 non-invasive 
oscillometric monitor (A&D Instruments, UK). Study participants were seated in a 
chair with their backs supported and their right arm bared at the level of the heart. 
After 5 minutes of rest, heart rate was measured twice with at least a2 minute interval 
between measurements. 
4.1.2.6.3. Serum and plasma measurements 
Plasma and serum samples were obtained from blood taken by venepuncture. A 
Coulter MD 18 haematology analyser was used for measurement of full blood counts. 
Serum ferritin, vitamin B12 and red cell folate were analysed using 
radioimmunoassay. CRP was measured using ELISA (Kalon Biological, Hants, UK). 
Serum albumin was determined using standard automated methods. Serum total 
cholesterol, high density lipoprotein cholesterol and triglyceride concentrations were 
be measured by colorimetry (RA 1000, Bayer Diagnostics, Basingstoke) and low 
density lipoprotein cholesterol concentrations calculated by the Friedewald formula. 
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Glycated haemoglobin assays (HbA1C) used a Biorad Diomat high pressure liquid 
chromatography analyser. 
4.1.2.6.4. Smoking history and vascular disease diagnoses 
Smoking history and previous diagnoses of vascular disease were obtained by review 
of the medical notes and medication history as well as interviewing the study 
participant by the same investigator (NRL) using a standard questionnaire. The 
questionnaire examined the previous diagnoses of vascular disease, current 
medication and smoking histories as well as collected data on proxy markers of 
socioeconomic status including occupational history, educational and vocational 
training. The questionnaire used may be found in Appendix 7.2. 
4.1.2.7. Assessment of compliance with gluten-free diet 
Compliance with the gluten-free diet was assessed clinically and immunologically. 
Study participants were asked to rate their compliance with the gluten-free diet using 
a visual analogue scale (see Appendix 7.3). The visual analogue scale is a 100 mm 
horizontal line with the two anchors of `no compliance to diet' and `strict compliance 
with diet' [418]. The study participants were asked to mark the scale with a single 
vertical mark through the 100 mm horizontal visual analogue scale to illustrate their 
compliance to the gluten-free diet. 
Study participants compliance with the gluten-free diet was also assessed by the 
reviewing dietician and described as `optimal' (no dietary transgressions), `fair' (one 
or two dietary transgressions since last dietary review) or `poor' (more than two 
dietary transgressions since last dietary review). 
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Antiendomysial antibody (EMA) and quantitative titres of human recombinant tissue 
transglutaminase (tTG) were used as laboratory measures to assess compliance to 
gluten-free diet [419,420]. 
4.1.2.8. Controls 
Data from the Health Survey for England 2006 (Cardiovascular disease and risk 
factors in adults) [347], which is representative of the whole population at both 
national and regional level, was used as a general population comparator for serum 
proxy markers of vascular disease (such as total cholesterol) and possession of 
vascular disease diagnoses. In this survey, a general population sample of 14,400 
addresses were randomly selected from the Postcode Address File using a multi-stage 
sample design to help ensure that households were sampled proportionately across the 
nine Government Office regions of England. 720 postcode sectors were selected, and 
20 addresses selected within each sector between January 2006 
- 
December 2006. 
Where an address was found to have multiple dwelling units, one was selected at 
random. Where there were multiple households at a dwelling unit, up to three 
households were included and if there were more than three then a random selection 
was made. Each individual within a selected household was eligible for inclusion; at 
each address, all households, and all persons in them, were eligible for inclusion in the 
survey. A nurse visit was arranged for all participants who consented. In this survey, 
interviews were held with 14,142 adults aged 16 and over in 8614 households from 
the general population. Response to the survey at a household level was 68% of 
sampled eligible households in the general population. At an individual level, 
interviews were obtained with 88% of adults within the general population sample. 
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Adults were asked modules of questions including general health, cardiovascular 
disease (including the Rose Angina Questionnaire), physical activity, alcohol 
consumption, smoking, and fruit and vegetable consumption. 
Approximately 70% of adults allowed for their height, weight, waist circumference 
and blood pressure to be measured for the study. Height was measured using a 
portable stadiometer with a sliding head plate, a base plate and three connecting rods 
marked with a metric measuring scale. Survey participants were asked to remove 
shoes. One measurement was taken, with the informant stretching to the maximum 
height and the head positioned in the Frankfort plane. The reading was recorded to the 
nearest millimetre. Weight was measured using Soehnle, Seca and Tanita electronic 
scales with a digital display. Study participants were asked to remove shoes and any 
bulky clothing. A single measurement was recorded to the nearest 100g. Those who 
were pregnant, chairbound, or unsteady on their feet were not weighed. The waist was 
defined as the midpoint between the lower rib and the upper margin of the iliac crest. 
It was measured using a tape with an insertion buckle at one end. The measurement 
was taken twice, using the same tape, and was recorded to the nearest even millimetre. 
Waist circumference was categorised according to NICE guidelines: for men, less 
than 94cm was low, 94-102cm was high, and more than 102cm was very high; and 
for women, less than 80cm was low, 80-88cm was high, and more than 88cm was 
very high. Three blood pressure readings were taken, at one-minute intervals, using an 
appropriately sized cuff on the right arm, with the informant in a seated position after 
five minutes' rest using oscillometric automated device, the Omron HEM 907. 
Systolic (SDP) and diastolic pressures (DBP) were displayed on the Omron from each 
measurement. The blood pressure variables used in the survey were the means of the 
second and third measurements obtained from the informants in whom three readings 
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were successfully obtained, excluding those who had eaten, drunk alcohol, exercised, 
or smoked in the 30 minutes before the measurement was taken. Survey participants 
were classified in one of four groups on the basis of their SBP and DBP readings and 
their current use of antihypertensive medication: 
" Normotensive untreated SBP<140 mmHg and DBP<90 mmHg, not currently 
taking medication specifically prescribed to treat high blood pressure 
" Hypertensive controlled SBP<140 mmHg and DBP<90 mmHg, currently 
taking medication specifically prescribed to treat their high blood pressure 
" Hypertensive uncontrolled SBP>140 mmHg or DBP>90 mmHg, currently 
taking medication specifically prescribed to treat their high blood pressure 
9 Hypertensive untreated SBP>140 mmHg or DBP>90 mmHg, not currently 
taking medication specifically prescribed to treat their high blood pressure 
The last three categories together were considered as `hypertensive' in the survey with 
the threshold of 140/90 mmHg used in accordance with available guidelines on 
hypertension management [421 ]. 
Non-fasting blood samples and spot urine samples were collected from a 
representative sample of the general population; 74% of men (n = 5076) and 71% (n = 
5418) of women of the sampled population provided valid blood samples. 
4.1.2.9. Potential confounders 
Age, sex, socio-economic class. 
Occupational social class and Index of Multiple Deprivation 2007 (IMD07) score 
were used as measures of socio-economic class with data collected using a standard 
questionnaire as described in section 4.1.2.6.4. Social class by current or last known 
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occupation of the incident coeliac was coded according to the Registrar General's 
classification [422] and grouped into categories: professional (social class I), 
managerial (social class II), non-manual skilled (social class IIIN), manual skilled 
(social class HIM), manual semi-skilled (social class IV), manual unskilled (social 
class V) [422]. The postcode of residence at enrolment to the study was used to 
determine the IMD07 score and rank [376] as described in section 3.3.2.2. Data was 
also collected on indicators of material condition including formal education attained 
at school, vocational training, and house ownership as other measures of 
socioeconomic status [423-425]. 
218 
4.1.2.10. Statistical analysis 
Descriptive analyses with calculation of mean and median where appropriate were 
performed. 
Prevalence of: 
9 previously diagnosed vascular disease (hypertension, angina, myocardial 
infarction, stroke, diabetes mellitus); 
" smoking (current, never, ex-); 
9 abnormal anthropometric vascular profile (overweight, obese, raised waist 
circumference, raised waist: hip circumference, hypertension, ); 
" abnormal serum vascular profile (raised total cholesterol, low HDL 
cholesterol, raised LDL cholesterol, raised triglycerides, raised CRP, raised 
blood glucose, raised glycated haemoglobin) 
were determined by calculating the proportion (%) of coeliacs that had been 
previously diagnosed with vascular disease, were smokers or had an anthropometric 
or serum value above the upper limit of normal as described in the definitions for the 
measurement or test concerned. 
The mean anthropometric and serum values in adults newly diagnosed with coeliac 
disease were then compared with the findings from the Health Survey for England 
2006. We firstly age-adjusted the mean anthropometric and serum values in our 
coeliac cohort compared with those in the Health Survey for England with men 
standardised to the male population and women to the female population. We then 
performed unpaired t-tests to examine for any difference in the mean anthropometric 
and serum values, standardised for age and sex, between the coeliac cohort and the 
Health Survey for England cohort. 
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Secondly we calculated, standardised for age and sex, the ratio of observed number of 
coeliacs with: 
" hypertension (>/ 140 systolic and or >/ 90 diastolic); 
" raised waist circumference (>/ 88 cm in women; >/102 cm in men); 
" raised waist: hip circumference ratio (>0.85 in women; >0.95 in men); 
" overweight or obese body mass index; 
9 raised total cholesterol (greater than 5.0 mmoUL) 
" low HDL cholesterol (\< 1.0 mmol/L); 
" raised LDL cholesterol (>/ 3.0 mmol/L); 
" raised triglycerides (>/ 1.0 mmol/L); 
" raised CRP (>/ 5.0 mg/L); 
" raised HbA 1C (greater than 7%); 
versus expected number of coeliacs. We calculated the number of outcomes of interest 
(such as number of coeliacs with hypertension) we would expect in the observed 
coeliac population if it experienced the same age- and sex-specific rates of the general 
population comparator, the Health Survey for England. The standard error was 
calculated by dividing observed: expected ratio by the square root of the observed 
proportion of coeliacs with the outcome of interest ((O/E)/IO) from which the 95% 
confidence interval could be calculated. 
Such standardisations were performed to adjust for the confounding effects of 
differences in the age and sex population structure between the coeliac and Health 
Survey for England cohorts, allowing the two populations with different demographic 
characteristics to be compared directly with each other. 
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Paired t-tests were used to examine changes in anthropometric, vital signs and blood 
variables from baseline in incident coeliacs to following 12 months treatment with a 
gluten-free diet. 
Logistic regression modelling was performed to examine the factors associated with 
selected outcome variables, after adjusting for a priori confounders such as age and 
sex. For example, regression analyses were performed to examine the association 
between change in total cholesterol (outcome variable) and predictor variables (such 
as change in tTG coeliac serology titre, presence of villous atrophy). Forward 
stepwise models were used with a wide range of possible predictor variables tested in 
each model with any that were significant included in the final multivariate model. 
The gradient of the increase or decrease of each outcome was modelled, adjusting for 
confounders, in the multivariate analyses. 
We considered a p-value of 0.05 to represent statistical significance in all tests. All 
analyses were performed using STATA SE 9.2 [TexCorp]. 
4.1.2.11. Sample size and power 
In study 3.4. we observed incident coeliacs (n = 100) had 15% lower mean total 
cholesterol in comparison to the general population and following 12 months 
treatment with a gluten-free diet there was a 9% increase in HDL-cholesterol. If we 
recruited at least 100 incident coeliacs in our study, we anticipated that we would 
have in excess of 90% power at the 95% level of significance to observe 10% lower 
mean total cholesterol at diagnosis of coeliac disease and or a 10% increase in HDL- 
cholesterol following a gluten-free diet. Our sample size aim was to recruit 150 
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incident coeliacs in order to have sufficient power to detect any change in the other 
vascular risk profile co-variates following treatment with a gluten-free diet. 
4.1.2.12. Ethical approval 
North Staffordshire Local Research Ethics Committee gave ethical approval 
(reference 06/Q2604/91) to this study in October 2006. Nottingham University 
Hospital gave research and development approval (reference 06GM012) to this study 
in January 2007. Derby Hospitals NHS Foundation Trust gave research and 
development approval (reference DHRD/2007/005) in April 2007. Royal Hallamshire 
Hospital gave research and development approval (reference STH14597) in March 
2007. 
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4.1.3. Results 
4.1.3.1. Study population 
Following securing ethical approval and then research approval at each of the centres 
the first study participant was recruited to the study in March 2007 at Nottingham, 
April 2007 in Sheffield and May 2007 in Derby. 151 adults newly diagnosed with 
coeliac disease were recruited to participate in the study following informed consent 
by July 2008 of whom 50 were from Nottingham, 62 from Derby and 39 were from 
Sheffield study centres (Figure 4.24). 
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During this time period, 78 incident adult coeliacs were diagnosed at Nottingham 
University Hospital: 56 at Queen's Medical Centre and 22 at Nottingham City 
Hospital. 50 of the 56 (89%) coeliacs diagnosed at Queen's Medical Centre, 
Nottingham University Hospital were approached and all agreed to participate in the 
study following informed consent. 76 adults were newly diagnosed with coeliac 
disease at Derbyshire Hospitals of whom 62 (82%) were approached and all agreed to 
participate in the study following informed consent. Only 39 of the 74 (53%) adults 
newly diagnosed with coeliac disease at the Royal Hallamshire Hospital during this 
time period were approached though all 39 agreed to participate in the study following 
informed consent. No coeliac approached refused to participate in the study. 
The proportion of incident coeliacs recruited to the study (n = 151) out of all incident 
coeliacs diagnosed during the study period at the study centres (n = 206) was 73%. 
Reasons for not capturing all incident coeliacs diagnosed during the study period 
included those where the diagnostic work-up and subsequent management for coeliac 
disease occurred along `non-conventional routes' with delay in either identifying them 
as potential recruits as I was unaware they had been diagnosed or that the person had 
been taking gluten-free diet for more than four weeks (n = 33); non-attendance at 
hospital clinic following referral for treatment (n =12). 
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4.1.3.2. Demography of cohort 
151 people newly diagnosed with coeliac disease were included in the study. There 
were nearly twice as many women (n =94; 62%) as men (n =57) in the study cohort. 
The mean age at diagnosis was 50.6 (SD 19.1) years. The mean age at diagnosis of 
coeliac disease was significantly younger (p = 0.0029) in women (46.9 (SD 19.7) 
years) than in men (56.4 (SD 16.6) years). 
4.1.3.3. Presenting features of incident coeliac disease 
Iron deficiency anaemia and diarrhoea were the most common presenting features, 
affecting half of the cohort (Table 4.27). 32% (n = 48) had partial villous atrophy; 
31% (n = 47) had subtotal villous atrophy and 23% (n = 34) had total villous atrophy. 
12 (8%) coeliacs had mild enteropathy changes on duodenal biopsy with no evidence 
of villous atrophy. 10 of the 151 incident coeliacs did not have a duodenal biopsy. At 
diagnosis, the median tTG was 56 (IQR 13 
- 
164; n= 151) and 94% (n = 142) were 
EMA positive. 
Table 4.27: Presenting features of incident coeliac cohort 
Presenting features Incident coeliac cohort 
n=151 
Classic 
Diarrhoea 74 (49%) 
Weight loss 38 (25%) 
Malabsorption 8(5%) 
Gastrointestinal 
Abdominal pain 42 (28%) 
Constipation 3 (2%) 
IBS symptoms 19(13%) 
Heartburn and or reflux 10 6% 
Extra-intestinal 
Iron deficiency anaemia 78 (52%) 
Folate deficiency 8 (5%) 
B12 deficiency (3%) 
Associated conditions 
Dermatitis herpetiformis 6 (4%) 
Type 1 diabetes 5(3%) 
The presenting features of those coeliacs presenting with gastrointestinal symptoms 
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(n = 85), with classic (n = 22) or silent disease (n = 44) are shown in the following 
table. 
Table 4.28: Presenting features of classic, symptomatic and silent coeliac disease 
Presenting feature Classic disease Symptomatic Silent disease 
(n = 22) disease (n = 85) (n = 44) 
Sex (%) 
Male 9(41) 31 (36) 17(39) 
Female 13 (59) 54(64) 27(61) 
Mean age (SD) years 56.9 (17.3) 47.8 (19.0) 52.4 (19.5) 
Marsh grading 
1 0 3 (4) 3(7) 
2 0 4(5) 2(5) 
3a 5 (23) 30 (35) 13 (30) 
3b 8 (35) 23 (27) 16 (36) 
3c 7(32) 19(22) 8(18) 
Not done 2(10) 6(7) 2(4) 
EMA status (%) 
Positive 17 (77) 70 (82) 39 (89) 
Weak positive 2 (9) 10 (12) 4 (9) 
Negative 3(14) 5 (6) 1(2) 
Median tTG [IQRJ 114.7 112.1 133.9 
iu 15-300 12-151 15-300 
Mean Hb (SD) g/L 12.6 (1.9) 12.8 (1.7) 11.4 (2.3) 
Mean weight (SD) kg 62.0 (13.9) 73.1 (16.5) 70.0 (18.2) 
There was no difference in proportion of females presenting with classic, 
symptomatic or silent coeliac disease. There was no difference in mean age at 
diagnosis in those coeliacs presenting with symptoms (classic or gastrointestinal) in 
comparison to those coeliacs presenting with silent coeliac disease. There was no 
difference in proportion of those coeliacs with villous atrophy or EMA positivity or 
median tTG in those coeliacs presenting with classic, symptc vatic or silent coeliac 
disease. Coeliacs with classic disease had the lowest presenting weight though this did 
not significantly differ from that observed in silent or symptomatic disease. 
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4.1.3.4. Prevalence of diagnosed vascular disease in incident coeliac disease 
92 (61%) of the incident coeliacs had never smoked. 29 (19%) were ex-smokers, 
smoking for a mean 24.1 (SD 12.9) pack years. 29 (19%) were current smokers with a 
mean 22.1 (SD 15.0) pack year history. 23% (n = 13) of men and 17% (n = 16) of 
women reported as being current smokers at the time coeliac disease was diagnosed. 
Prevalence of reported current smoking varied by socio-economic status. For both 
men and women, those in the most deprived and below average quintiles were more 
than twice as likely to smoke cigarettes as those in the above average and least 
deprived quintiles (p = 0.03). The proportion of coeliacs that were current smokers or 
had never smoked was not significantly different from the smoking behaviours 
reported in the general population (Table 4.29). 
Table 4.29: Prevalence of smoking in adults newly diagnosed with coeliac 
disease compared to the general population 
Smoking history Observed Prevalence Expected Observed: 
number in in general number in expected 
coeliac population coeliac [95% CI] 
cohort (%) cohort 
n =151 
Current smokers 
Men 13 24.5 14.0 0.93 [0.42,1.43] 
Women 16 22.2 20.9 0.77 [0.38,1.15] 
Never smoked 
Men 26 49 27.9 0.93 [0.57,1.28] 
Women 66 57 53.6 1.23 [0.93,1.53] 
21% (n = 12) of male coeliacs and 8% (n = 7) of female coeliacs reported having been 
diagnosed with a cardiovascular condition (Table 4.30). The prevalence of coronary 
artery disease was higher in male coeliacs (n = 8,14%) than in women (n = 4; 4%) 
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with coeliac disease. Stroke disease was more than twice as prevalent in male coeliacs 
(n = 5,9%) than in female coeliacs (n = 2,2%). 
The prevalence of coronary artery disease did not significantly change with socio- 
economic status though appeared to higher in more affluent socio-economic classes. 
For example, 11 of 19 coeliacs reported having been diagnosed with any 
cardiovascular disease were from the highest two quintiles (above average and least 
deprived) quintiles of IMD07 rank. 
Coeliacs were as likely to have reported to been diagnosed with stroke disease or 
ischaemic heart disease as to the general population (Table 4.30). Female coeliacs 
were over 50% less likely (observed: expected 0.47; 95%CI 0.19,0.75) to have been 
diagnosed with hypertension in comparison to the general population. 
229 
0 
L 
Q 
{70 
.: 
5 
15 
3 
cz 
a 0 
32 
b 
u 
eý 
.r 
rr 
G 
U 
r. + 
si u 
u C 
U 
40 
.r 
'fl 
tw 
ce 
mg 
u y 
U 
0 
bG 
90 
0 
U 
u 
U 
V 
it 
.a 
ec 
H 
- 
I Gý 00 
- Iýt M en tn 
' 
N O 
n Oý 00 0ý N 00 1- 1-4 . ~ ýt N M 
-0 "o .-0 
M rn N 
00 en 
000 
00 Öý ýG"--ý ý ýý kG00 N ý QÜ 
ÖÖ Ö9 99 OO ÖÖ O N 
N O Ö Ö C Ö 
y u uu u ui L... ý u 
i L "I i u uu 
OC 
--ý V1 M110 tryN Rt* N 000 N00 1O1O tf) ý ONN NN QOM 110 C*s N* oll m N %fli 
. --ý0 0 C-i "--. . -r . -" 66 MÖ 146 1ý6 
is 
h. 
410 
Ö 
.dO 
w 00 0 Q, T ,TO Ito O'n NN I'D V-) c r- . '00 "-ý mo N- M V) MO MM N 'Y ON 14, N [- 
W cd (14 M fV 
. --ý kr; . --ý fV ý--ý N ÖO NM MM 
$0 
40 
bA 
a 
. \o 
y +r 
C 
t= 
Lo O 00 M -N 00 00 '-N 
OO 
V'1 v1 
. -' 
N NO 
Ar 
"T M i- CV wi CV CV NN ÖÖ NM ýC et 
. PIK 
L 
s b 
Ö 
^C 
W2 Pz; 
. 
oü 00,1- In N 
'- 
- 
NM .. n N 00 'I 
i. 
b h 
- 
brio "Q 
ý ý ä v 
- 
s 
.o .0 .0 cl 
E o E E y 
b 
bD 0 
d0 
0 
3 
C0 
d 4) 3 
C 
g. 
C-n I3 x3 H3 H 3 
0 M 
N 
4.1.3.5. Vascular risk profile at diagnosis of coeliac disease 
4.1.3.5.1. Weight and body mass index 
The mean weight at diagnosis of coeliac disease was 64.7 (SD 14.3) kg in women and 
80.3 (SD 16.6) kg in men (Table 4.31). Mean BMI was lower in women (24.4 kg/m2, 
SD 4.85) than in men (26.2 kg/m2, SD 4.7) with incident coeliac disease (Table 4.31). 
56% (n = 32) of men and 36% (n = 34) of women were either overweight or obese at 
diagnosis of coeliac disease (Table 4.32). A greater proportion of men than women 
were overweight (42% v 23%; p=0.00001) though there was no significant 
difference in the proportion obese (14% v 13%) or underweight (5% v 4%). A greater 
proportion of women than men were of normal BMI (60%; n= 56 v 39%; n= 22) at 
diagnosis of coeliac disease (p = 0.01). One female (BMI 44.9 kg/m2) and one male 
(BMI 43.3 kg/m2) coeliac were morbidly obese at diagnosis of coeliac disease. Being 
overweight or obese at diagnosis of coeliac disease was weakly associated with higher 
affluence (proportion amongst above average and least deprived quintiles 52% (n = 
35) versus average, below average, most deprived quintiles 38% (n = 31); p=0.08). 
4.1.3.5.2. Waist circumference and waist: hip circumference 
The mean waist circumference was 93.9 (SD 13.4) cm in men and 81.6 (SD 10.8) cm 
in women at diagnosis of coeliac disease (Table 4.31). The proportion of coeliacs with 
a raised waist circumference (Table 4.32) was higher in women than in men (21 %v 
16%). Raised waist circumference was not associated with quintile of socio- 
economic rank. 
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The mean waist: hip circumference was 0.94 (SD 0.1) in men and 0.84 (SD 0.1) in 
women at diagnosis of coeliac disease. Over half of the incident coeliacs had an 
unfavourable waist: hip ratio with 52% (n = 78) of the cohort having a raised ratio. 
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The proportion of coeliacs with a raised waist: hip ratio was similar in men and 
women (47% v 54%, respectively); p=0.41 and did not vary with socio-economic 
status. 
4.1.3.5.3. Measured blood pressure and measured hypertension 
The mean systolic blood pressure measured at diagnosis of coeliac disease was 132.6 
(SD 20.0) mmHg in men and 120.4 (SD 16.7) mmHg in women. The mean diastolic 
blood pressure was 74.6 (SD 9.5) mmHg in incident male coeliacs and 71.5 (SD 10.1) 
mmHg in incident female coeliacs. The prevalence of measured hypertension (at least 
140 mmHg systolic and or at least 90 mmHg diastolic blood pressure) was 5% (n = 3) 
in men and 1% (n = 1) in women in the coeliac cohort (Table 4.32). 
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4.1.3.5.4. Cholesterol profile 
The mean levels of total cholesterol as shown in Table 4.33 was 4.2 (SD 1.0) mmol/L 
for men and 4.7 (SD 1.1) mmol/L for women (mean difference in total cholesterol 0.5 
[95%CI 0.1,0.8) mmol). A higher proportion of female coeliacs (38%; n= 34) had 
raised total cholesterol (5.0 mmol/L or above) in comparison to male coeliacs (20%; n 
= 11) at diagnosis of coeliac disease; p=0.009 (Table 4.34). Total cholesterol and 
raised total cholesterol was not related to age or socio-economic status. 
Table 4.33: Vascular serum risk profile in incident coeliac disease compared to 
the general population 
Vascular risk profile co- N Incident General Mean 
variate coeliac population difference 
disease [95% CI 
Mean cholesterol mmol/L 
(SD) 57 4.2 (1.3) 5.30 (1.2) 
-1.1 [-0.8, -1.4] 
Men 94 4.6 (2.3) 5.40 (1.2) 
-0.8 [-0.5, -1.1] 
Women 
Mean HDL cholesterol 
mmol/L (SD) 56 1.1 (0.5) 1.3 (0.6) -0.2 [-0.1, -0.4] 
Men 89 1.3 (0.8) 1.6 (0.6) 
-0.3 [-0.2, -0.4] 
Women 
Mean LDL cholesterol 
mmol/L(SD) 40 2.3 (0.9) 3.6 (0.9) -1.3 [-1.0, -1.6] 
Men 46 2.9 (0.9) 3.6 (0.9) 
-0.7 [-0.4, -1.0] 
Women 
Mean triglycerides mmol/L 
(SD) 47 1.4 (0.8) 1.8 (1.4) 
-0.4 [-0.8,0.1] 
Men 62 1.3 (0.7) 1.4 (0.8) 
-0.1 [-0.3,0.1] 
Women 
Mean fibrinogen g/L (SD) 
Men 46 2.5 (0.9) 2.8 (0.6) 
-0.3 [-0.1, -0.5] 
Women 64 3.1(2.3) 3.1(0.6) 0.0 [-0.2,0.21 
Mean CRP mg/L (SD) 
Men 54 3.5 (0.2) 3.1 (7.2) 0.4 [-1.5,2.3] 
Women 87 4.1(9.5) 3.6 (8.9 0.5 [-1.4,2.4] 
Mean HbA1C % (SD) 
Men 31 6.0 (0.2) 5.5 (1.2) 0.5 [0.1,0.9] 
Women 30 5.3(0.2) 5.5(0.6) 
-0.2 [-0.4,0.1 
236 
Women had higher HDL cholesterol at diagnosis of coeliac disease in comparison to 
men (1.4 (SD 0.4) versus 1.1 (SD 0.3) mmol/L; mean difference 0.3 mmol/L; 95%CI 
0.1,0.4). Men had significantly higher prevalence of low HDL cholesterol (below 1.0 
mmol/L) than women with coeliac disease (29% (n = 16) versus 6% (n = 5); p= 
0.0001). Low HDL cholesterol was not related to age or socio-economic status. HDL 
cholesterol at diagnosis of coeliac disease was related to weight, BMI, waist 
circumference, waist: hip circumference ratio but not to proxy markers of more severe 
coeliac disease (such as presence of villous atrophy, malabsorption). 
The total cholesterol: HDL cholesterol ratio was 4.0 (SD 1.3) in men and 3.6 (SD 0.9) 
in women at diagnosis of coeliac disease (mean difference 
-0.4; 95%CI -0.1, -0.8). 
Mean LDL cholesterol was lower in men (2.3 (SD 0.9) mmol/L) than in women (2.8 
(SD 0.9) mmol/L); mean difference 
-0.5 mmol/L; 95%CI -0.1, -0.9. Men had 
significantly lower prevalence of raised LDL cholesterol (3.0 mmol/L or more) than 
women with incident coeliac disease. 41 % of women and 22% men had raised LDL 
cholesterol (mean difference in proportion 19%; 95C% 2,37). LDL cholesterol at 
diagnosis of coeliac disease was not related to anthropometric measures such as 
weight, waist: hip circumference nor markers of more severe coeliac disease. Raised 
LDL cholesterol was not related to socio-economic status. 
Triglycerides were significantly higher in incident male coeliacs (1.5 (SD 0.8) 
mmol/L) than in females (1.2 (SD 0.7) mmol/L); p=0.02. Triglyceride titres were 
related to weight, waist circumference, waist: hip circumference, systolic blood 
pressure, tissue transglutaminase titre, and age but not to proxy markers of deprivation 
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or more severe coeliac disease. Prevalence of raised triglyceride (1.6 mmol/L or 
higher) was not significantly different between men (31%; n= 16) and women (22%; 
n= 19); p=0.29. Raised triglyceride levels did not vary significantly across quintiles 
of rank of IMD07 score. 
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4.1.3.5.5. Haemostasis and thrombosis profile 
The mean fibrinogen at diagnosis of coeliac disease was significantly higher in 
women (3.1 (SD 1.3) g/L) than in men (2.6 (SD 0.8) g/L); p=0.02 as shown in Table 
4.33. Fibrinogen was not related to age, anthropometric measures such as weight or 
waist circumference, blood pressure or cholesterol profile. Fibrinogen was associated 
with the presence of malabsorption (p = 0.0022) but not other features of severe 
coeliac disease such as level of tissue transglutaminase or the presence of villous 
atrophy. Level of fibrinogen was related to current smoking (p = 0.0185), CRP (p = 
0.00001) but not HDL cholesterol. Fibrinogen levels were significantly higher in 
those coeliacs who had been diagnosed previously with vascular disease (mean 
difference in fibrinogen 0.7 g/L; 95% CI 0.07,1.3). 
Platelet count at diagnosis of coeliac disease was significantly higher in women 
(325.0 (SD 89.4) x 109/L) than in men (279.3 (SD 80.3) 109/L and in those coeliacs 
presenting with iron deficiency anaemia (336.4 v 277.1 109/L); p=0.00001. Total 
cholesterol (p = 0.0014) and HDL cholesterol (p = 0.03) were the only co-variates 
associated with platelet count. 
The mean APTT at diagnosis of coeliac disease was 26.1 (SD 2.9) seconds. The 
presence of malabsorption was the only variable associated with APTT with 
significantly longer APTT when malabsorption was present (mean difference in 
APTT with the presence of malabsorption 2.0 seconds; 95%CI 0.3,4.2). The mean 
prothrombin time at diagnosis of coeliac disease was 10.5 (SD 1.9) seconds. 
Prothrombin time was associated with HDL cholesterol (p = 0.05) and previously 
diagnosed vascular disease where prothrombin time was significantly higher than in 
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coeliacs without diagnosed vascular disease (mean difference 1.2 seconds; 95%CI 0.2, 
2.1). 
4.1.3.5.6. Inflammatory markers 
Mean CRP levels in incident male and female coeliacs were 3.9 (SD 6.0) and 4.5 (SD 
5.2) mg/L, respectively (Table 4.33). Presence of diarrhoea and malabsorption was 
associated with significantly higher CRP levels at diagnosis of coeliac disease. For 
example, mean difference in CRP with the presence of malabsorption compared to the 
absence of malabsorption was 8.3 mg/L; 95%CI 3.9,12.6. The mean CRP was 
significantly higher in coeliacs of more deprived socio-economic status (mean CRP 
4.6 (SD 4.4) in most deprived quintile versus 2.9 (SD 1.5) mg/L in least deprived 
quintile; p=0.05) and in those coeliacs with previous diagnosis of stroke disease. 
Fibrinogen and triglycerides were the only other variables associated with CRP (r = 
0.44, p=0.0001; r=0.21, p=0.01 respectively). There was a non-significant higher 
proportion of women with raised CRP (more than 4.9 mg/L) than men (30% v 20%; p 
= 0.21). The proportion of coeliacs with raised CRP rose with increasing deprivation 
with 37% of coeliacs from the most deprived quintile having raised CRP compared to 
12% of those from the least deprived quintile (mean difference in proportion 24.8%; 
95%CI 6.1,43.6). 
The mean ESR was higher in women at diagnosis of coeliac disease than in men 
(19.6 (SD 19.8) versus 11.9 (SD 17.5) mm/hr, respectively); p=0.01. Mean ESR was 
also associated with age, weight (0.03), waist circumference (p = 0.05), HDL 
cholesterol (p = 0.05), LDL cholesterol (p = 0.04), presence of anaemia (p = 0.004), 
tissue transglutaminase (p = 0.008) and fibrinogen (p = 0.0001). 27% (n = 38) of the 
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incident coeliacs had ESR of 20 mm/hr or more with increasing age the only 
associated variable (p = 0.012). 
The mean ferritin in incident coeliac disease was significantly lower in women than in 
men (mean difference 
-35.4 ýtg/L; 95%CI -55.6, -15.2). 54% of women and 42% of 
men had ferritin values below 15 µg/L. Mean ferritin was associated with 
haemoglobin and presentation with iron deficiency anaemia (p = 0.00001); tissue 
transglutaminase (p = 0.001); triglycerides (p = 0.002); and waist circumference, 
waist: hip ratio, weight and BMI (p = 0.03). Mean ferritin was higher with increasing 
affluence. For example, mean ferritin in most deprived quintile 14.3 (SD 17.1) µg/L 
versus 40.8 (SD 60.6) pg/L; p=0.04). Only men (n = 6,11%) had raised ferritin (200 
µg/L or higher). Mean leucocyte count at diagnosis of coeliac disease was 6.6 (SD 
2.2) x 109/L with no difference between men and women. Mean leucocyte count was 
associated with waist circumference, waist: hip ratio, age at diagnosis of coeliac 
disease and presentation with weight loss. 
The mean white cell count was significantly higher in current smokers than in non- 
smokers (mean difference 1.5 109/L; 95%CI 0.7,2.4). The mean white cell count was 
significantly lower in more affluent male coeliacs than in more deprived (5.9 (SD 1.5) 
109/L versus 9.9 (SD 2.5) 109/L, respectively; p=0.0006) though there was no 
association with deprivation and leucocyte count amongst female coeliacs. 
4.1.3.5.7. Glycaemic profile 
The mean random glucose was significantly higher in men than in women and in 
those coeliacs who had been previously diagnosed with diabetes mellitus (mean 
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difference 
-1.4 mmol/L; 95%CI -2.0, -0.8). Mean random glucose was associated with 
waist circumference, waist: hip ratio and systolic blood pressure. Four coeliacs had 
raised random glucose (7 mmol/L or more) at diagnosis of coeliac disease. 
The mean HbAlc was 5.8 (SD 1.2) % and was associated with waist: hip ratio and 
age at diagnosis of coeliac disease. Raised HbAlc (7% or higher) was observed in 
those coeliacs with previous diagnosis of ischaemic heart disease and diabetes 
mellitus. 
4.1.3.5.8. Anaemia profile 
Mean haemoglobin was significantly lower in women (11.9 (SD 1.8) g/L) than in men 
(13.0 (SD 2.0) g/L). Mean haemoglobin was associated with weight, BMI, waist 
circumference, waist: hip ratio and ferritin. Current smokers had Ig/L (95%C1 of 
difference 0.2,1.7) higher haemoglobin than non-smokers. 44% (n = 66) of the 
incident coeliacs were anaemic (haemoglobin 12.0 g/L or less) with a higher 
proportion amongst women than men (mean difference in proportion 16.2%; 95%CI 
2.0,32.1). Only 3 of the 151 incident coeliacs had haemoglobin value of 16 g/L or 
more. 
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4.1.3.6. Vascular risk profile in incident coeliac disease compared to the general 
population 
4.1.3.6.1. Weight and body mass index 
The mean weight of both male and female coeliacs was significantly lighter than that 
of the general population (Table 4.31). However, there was no difference in the 
proportions between coeliacs and general populations of being underweight, of 
normal BMI and of being overweight (Table 4.32). Female coeliacs were less likely to 
be obese in comparison to the general population (observed: expected 0.51; 95%CI 
0.22,0.80) (Table 4.32). 
4.1.3.6.2. Waist circumference and waist: hip circumference 
The mean waist circumference of both male and female coeliacs was significantly 
lower than that of the general population (Table 4.31). For example, mean difference 
in waist circumference in male coeliacs v males 
-5.3 cm; 95% -0.9, -9.7. The 
proportion of coeliacs with a raised waist circumference was also lower than that of 
the general population (Table 4.32). Female coeliacs were 48% (observed: expected 
0.52; 95%CI 0.29,0.75) less likely and male coeliacs were 51% (observed: expected 
0.49; 95%CI 0.17,0.81) to have a raised waist circumference in comparison to the 
general population. 
Despite the apparent favourable waist circumference, coeliacs had no significantly 
lower nor different waist: hip circumference to the general population (Table 4.32). 
Furthermore, both male (observed: expected 1.59; 95%CI 1.02,2.16) and female 
(observed: expected 1.52; 95%CI 1.07,1.97) coeliacs were more likely to have raised 
waist: hip circumferences in comparison to the general population. 
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4.1.3.6.3. Blood pressure and hypertension 
The prevalence of hypertension was no different in female coeliacs in comparison to 
the general population (Table 4.32). However, there was almost two-fold increased 
prevalence of hypertension in male coeliacs in comparison to the general population 
(observed: expected 1.87; 95%CI 1.22,2.52). 
4.1.3.6.4. Cholesterol profile 
The mean levels of total cholesterol were significantly lower in coeliacs compared to 
that of the general population (Table 4.33). Male coeliacs had 
-1.1 (95%CI for 
difference 
-0.8, -1.4) mmol/L lower total cholesterol and female coeliacs had -0.8 
(95%CI for difference 
-0.5, -1.1) mmol/L lower total cholesterol in comparison to the 
general population. Male coeliacs were 66% less likely to have raised total cholesterol 
(observed: expected 0.34; 95%CI 0.14,0.54) than the general population (Table 4.34). 
Female coeliacs were 37% (observed: expected 0.63; 95%CI 0.42,0.84) less likely to 
have raised total cholesterol than the general population. 
Coeliacs had significantly lower HDL cholesterol than that observed in the general 
population (Table 4.33) with men three times as likely to have low HDL cholesterol 
(observed: expected 3.04; 95%CI 1.55,4.53). 
Coeliacs had significantly lower LDL cholesterol than that observed in the general 
population with the effect more marked in men than in women (Table 4.33). For 
example, male coeliacs had -1.3 (95%CI -1.0, -1.6) mmol/L lower LDL cholesterol 
than the general population. Male coeliacs had over 70% lower LDL cholesterol than 
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the general population (observed: expected 0.29; 95%CI 0.11,0.47). In female 
coeliacs, LDL cholesterol was 44% lower than in the general population (observed: 
expected 0.56; 95%CI 0.34,0.78). 
There was no difference in the mean triglyceride levels in coeliacs to the general 
population nor did the proportion of having raised triglycerides differ (Tables 4.33, 
4.34). 
4.1.3.6.5. Haemostasis and thrombosis profile 
Mean fibrinogen was significantly lower in male coeliacs (-0.3 mmol/L; 95%CI for 
difference 
-0.1, -0.5) than in the general population. Female coeliacs had similar 
fibrinogen levels to the general population. 
4.1.3.6.6. Inflammatory markers 
The mean CRP at diagnosis of coeliac disease was not significantly different from that 
of the general population (Table 4.33). Furthermore, the proportion of coeliacs with 
raised CRP did not differ from that of the general population (Table 4.34). 
4.1.3.6.7. Glycaemic profile 
The mean random glucose was significantly higher in men than in women and in 
those coeliacs who had been previously diagnosed with diabetes mellitus (mean 
difference 
-1.4 mmol/L; 95%CI -2.0, -0.8). Mean random glucose was associated with 
waist circumference, waist: hip ratio and systolic blood pressure. Four coeliacs had 
raised random glucose (7 mmol/L or more) at diagnosis of coeliac disease. 
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The mean HbAlc was 5.8 (SD 1.2)% and was associated with waist: hip ratio and age 
at diagnosis of coeliac disease. Raised HbAlc (7% or higher) was observed in those 
coeliacs with previous diagnosis of ischaemic heart disease and diabetes mellitus. 
Though the mean HbAlc did not differ between coeliacs and the general population, 
male coeliacs were nine times as likely to have raised HbAlc in comparison to the 
general population (observed: expected 8.97; 95%CI 2.32,15.62). 
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4.1.3.7. Vascular risk profile at diagnosis of classic, silent and symptomatic 
coeliac disease 
4.1.3.7.1. Weight and body mass index 
Coeliacs with classic disease had the lowest presenting weight 62.0 (SD 13.9) kg 
(Table 4.28) and lowest BMI 21.9 (SD 4.2) kg/m2 (Table 4.36) in comparison to those 
presenting with silent disease or with gastrointestinal symptoms. 54% (n = 44) of 
coeliacs presenting with gastrointestinal symptoms were either overweight or obese at 
diagnosis of coeliac disease which was three times the proportion of those coeliacs 
with classic disease being obese or overweight (18%); p=0.0002.41% (n = 18) of 
coeliacs presenting with silent disease were obese or overweight at diagnosis of 
coeliac disease. 
4.1.3.7.2. Waist circumference and waist: hip circumference 
The mean waist circumference (Table 4.36) was significantly lower in those coeliacs 
presenting with classic disease (78.7 (SD 9.3) cm) compared to those with silent (85.8 
(SD 12.7) cm) or with gastrointestinal symptoms (88.1 (SD 13.6) cm); p=0.002. In 
keeping with the highest mean waist circumference, the proportion of coeliacs 
presenting with gastrointestinal symptoms with a raised waist circumference (27%) 
was more than twice that observed with silent disease (11%) and more than five times 
that observed with classic disease (Table 4.36). 
The mean waist: hip circumference ratio did not significantly vary between silent, 
classic and symptomatic coeliac disease (Table 4.36). However those presenting with 
silent disease had the highest proportion with an unfavourable waist: hip ratio, 
affecting two-thirds of silent coeliacs (Table 4.36); p=0.04. 
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Table 4.36: Vascular anthropometric risk profile in classic, silent and 
symptomatic coeliac disease at diagnosis 
At diagnosis Classic disease Symptomatic Silent disease 
(n = 22) disease (n = 85) (n = 44) 
Mean BMI kg/m 21.9 (4.2) 26.0 (4.9) 24.8 (4.6) 
(SD) 
BMI group N (%) 
Underweight 4 (18) 1 (1) 2 (5) 
Normal 14 (64) 40 (47) 24 (55) 
Obese 3 (14) 28 (33) 15 (34) 
Overweight 1(5) 16(19) 3(7) 
Mean waist 78.8 (9.3) 88.1 (13.6) 85.8 (12.7) 
circumference cm 
(SD) 
Proportion (%) 4.5 27.1 11.4 
raised waist 
Mean waist : hip 0.88 (0.07) 0.89 (0.08) 0.87 (0.07) 
ratio (SD) 
Proportion (%) 50.0 47.1 61.4 
raised waist : hip 
ratio 
Mean systolic BP 126.0 (23.9) 125.4 (17.2) 123.8 (19.7) 
(SD) mmHg 
Mean diastolic BP 73.8 (12.5) 72.6 (10.2) 72.1 (8.3) 
SD mmHg 
Proportion (%) 4.6 3.5 0 
with hypertension 
4.1.3.7.3. Blood pressure and hypertension 
Both the mean systolic and diastolic blood pressure appeared to be the highest in 
those coeliacs presenting with classic disease (Table 4.36). 
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41.3.7.4. Cholesterol profile 
Coeliacs presenting with classic disease appeared to have a more favourable 
cholesterol profile than those coeliacs presenting with silent or symptomatic disease 
(Table 4.37). Coeliacs with classic disease had the lowest observed mean total 
cholesterol (4.39 (SD 1.22) mmol/L), highest mean HDL cholesterol (1.32 (SD 0.43) 
mmol/L), and lowest mean LDL cholesterol (2.46 (SD 0.90) mmol/L). In comparison, 
those coeliacs presenting with silent disease appeared to have the least favourable 
cholesterol profile. Silent coeliacs had the lowest HDL cholesterol (1.26 (SD 0.39) 
mmoUL), highest LDL cholesterol (2.71 (SD 1.08) mmol/L) and highest proportion 
with raised triglycerides (3 3%). 
4.1.3.7.5. Haemostasis and thrombosis profile 
The mean fibrinogen at diagnosis of coeliac disease was highest in classic disease 
(3.34 (SD 1.55) g/L) than in symptomatic or silent disease (Table 4.37). Those with 
silent coeliac disease had the highest mean platelet count at diagnosis (333 (SD 100) 
x 1091L). The mean APTT and prothrombin time did not significantly differ between 
classic, silent and symptomatic coeliac disease. 
4.1.3.7.6. Inflammatory markers 
Despite the apparent favourable cholesterol profile, coeliacs presenting with classic 
disease had the highest mean white cell counts and CRP (Table 4.37) with silent 
disease having the lowest values. 
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Table 4.37: Vascular serum risk profile in classic, symptomatic and silent disease 
At diagnosis Classic disease Symptomatic Silent disease 
(n = 22) disease (n = 85) (n = 44) 
Mean total 4.39 (1.22) 4.58 (1.09) 4.46 (1.10) 
cholesterol 
mmol/L (SD) 
Proportion (%) 33.3 32.5 27.3 
with raised total 
cholesterol 
Mean HDL 1.32 (0.43) 1.29 (0.38) 1.26 (0.39) 
cholesterol 
mmol/L (SD) 
Proportion (%) 14.3 11.1 22.7 
low HDL 
cholesterol 
Mean LDL 2.46 (0.90) 2.54 (0.88) 2.71 (1.08) 
cholesterol 
mmol/L (SD) 
Proportion (%) 41.2 25.0 43.3 
raised LDL 
cholesterol 
Mean 1.25 (0.54) 1.34 (0.81) 1.21 (0.63) 
triglycerides 
mmol/L (SD) 
Proportion (%) 19.0 23.1 32.5 
raised 
tri 1 cerides 
Mean fibrinogen 3.34 (1.55) 2.87 (1.13) 2.80 (0.89) 
g/L (SD) 
Mean CRP mg/L 6.13 (9.87) 4.46 (5.22) 2.98 (1.70) 
(SD) 
Proportion (%) 25.0 29.1 21.4 
with raised CRP 
Mean white cell 6.87 (2.42) 6.94 (2.39) 5.97 (1.46) 
count x 109/L (SD) 
Mean platelet 291.0 (79.5) 299.1 (82.9) 333.3 (99.6) 
count x 109/L (SD) 
Mean HbAlc % 6.09 (1.24) 5.56 (0.75) 6.07 (1.62) 
(SD) 
Proportion (%) 10.0 11.1 28.6 
with raised 
HbAlc 
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4.1.3.8. Continued participation in study and adherence to gluten-free diet 
118 of the initial 151 (78%) recruited study participants with incident coeliac disease 
completed the full 12 months of the study. Of the 33 study participants that did not 
complete the full 12 months of their study period: 
"5 were students attending universities away from the study centres with their 
ongoing coeliac care switched to hospitals local to their university 
"I study participant returned to her native Poland shortly after coeliac disease 
was diagnosed (had been resident in Derby for preceding 5 years) 
"1 study participant did not wish to take a GFD following extensive 
discussions with the gastroenterology team and elected not to return back to 
the reviewing hospital as he elected not to be treated or reviewed for his 
coeliac disease 
"1 study participant was an existing nursing home resident where the 
gastroenterologist elected for further care and monitoring to be performed by 
her local general practitioner rather than returning to the hospital 
91 study participant due to rapidly deteriorating cognitive functioning was 
transferred to a nursing home away from Nottingham near his daughter 
"9 other study participants attended for routine coeliac disease review at three 
months post-initiation of a GFD where their vascular risk profile was 
measured for the purpose of this study but did not attend later coeliac disease 
reviews despite repeated appointments sent by the reviewing centres to alert 
them of the appointment date 
"4 other study participants attended for routine coeliac review at six months 
post-initiation of a GFD where their vascular risk profile was measured for 
the purpose of this study but did not attend later coeliac disease reviews 
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despite repeated appointments sent by the reviewing centres to alert them of 
the appointment date 
The remaining 11 coeliacs were lost to follow-up after index appointment with the 
hospital where their baseline vascular risk profile was measured. Repeated 
appointments were sent to offer alternative follow-up appointment dates but to no 
avail. 
The mean score on the self-rated visual analogue scale of compliance to a GFD at 12 
months was 9.7 (SD 1.3) cm (maximum score 10 cm). 91% (n = 106) reported strict 
adherence to GFD with no dietary transgressions with self-rated visual analogue scale 
score of 10. Of the 11 coeliacs not complying with a strict GFD, 6 reported good 
(self-rated visual analogue scale score of >/ 8.0 and \<9.9 cm) adherence to a GFD. 
The remaining 5 coeliacs reported adherence to GFD less than 50% of the time (self- 
rated visual analogue scale score of <5.0 cm). 
Dietitians assessing the compliance of the study participants with a GFD as being 
optimal in 91% (n = 106), fair in 5% (n = 6) and poor in remaining 4% (n = 5). 
The mean tTG titre fell from 112.5 (SD 156.7) iu at diagnosis of coeliac disease to 
12.0 (SD 24.8) following treatment (mean difference 
-100.5; 95%CI -127.2, -73.7). 
94% of the 151 incident coeliacs were EMA positive at diagnosis of coeliac disease. 
18% of the 117 coeliacs remained EMA positive following treatment. 
254 
4.1.3.9. Change in vascular risk profile following 12 months treatment of coeliac 
disease with a gluten-free diet 
4.1.3.9.1. Weight and body mass index 
There was mean increase in weight of 2.7 (95%CI 1.9,3.6) kg following treatment 
with a GFD (Table 4.38). The gain in mean weight was twice as much in those 
coeliacs that had villous atrophy present at diagnosis (mean weight change 2.9 kg; 
95%CI 1.9,3.9) in comparison to those coeliacs with mild enteropathy changes (mean 
weight change 1.1 kg; 95%CI 
-0.1,2.3) though the difference in weight gain between 
the severe and mild enteropathy did not reach statistical significance. Change in 
weight was not related to presence of villous atrophy; presentation with weight loss, 
malabsorption; incident weight; incident tTG or change in tTG titre on regression 
analyses. 
65% (n = 49) of men (mean difference in proportion following treatment to at 
diagnosis 8.9%; 95%CI 
-10.7,28.4) were either overweight or obese following 12 
months treatment with a GFD. There was a similar but not significant increase in the 
proportion of obese and overweight female coeliacs following treatment (mean 
difference in proportion 11.3%; 95%CI 
-26.0,3.5). The two morbidly obese coeliacs 
at diagnosis of coeliac disease put on further weight following 12 months treatment 
(mean increase in weight 2.6 kg) causing an increase in their BMI. There was no 
significant change in the proportion underweight following treatment to that observed 
at diagnosis of coeliac disease. 
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The mean weight and BMI of both male and female coeliacs was no different to that 
of the general population following 12 months treatment with a GFD (Table 4.39). 
There was also no difference in the proportions between coeliacs and general 
populations of being underweight, having normal BMI, of being overweight or obese 
(Table 4.40). 
4.1.3.9.2. Waist circumference and waist: hip circumference 
There was a mean increase in waist circumference by 2.3 cm (95%CI 1.7,2.8) 
following 12 months treatment with a GFD (Table 4.38) with no difference in the gain 
between men and women. Change in waist circumference was not related to clinical 
or histological presenting features of coeliac disease; or incident or change in 
anthropometric profile on regression analyses. 
The mean waist circumference in male coeliacs following exposure to a GFD 
continued to be lower than that observed in the general population (mean difference in 
waist circumference 
-8.4 cm; 95%CI -13.7, -3.1) though there was no difference 
observed between female coeliacs and the general population. However the proportion 
of coeliacs with a raised waist circumference rose with treatment with coeliacs as 
likely as the general population to have a raised waist circumference (Table 4.40). 
The mean waist: hip ratio increased following treatment with a GFD with a greater 
change in women than in men (mean difference in waist: hip between men and 
women 0.12; 95%CI 0.09,0.14). The change in waist: hip ratio was significantly 
greater in those coeliacs with mild enteropathy (marsh 1 and 2 changes) present at 
diagnosis of coeliac disease in comparison to those with villous atrophy. The mean 
change in waist: hip ratio was 0.05; 95%CI 0.03,0.10 in those with mild enteropathy 
257 
00 
N 
.r 
Ctý 
0 
&. 
on O 
0 
b V 
L. 
tL 
8 
0 Co 
m 
u 
ec 
C 
V 
V 
V 
i7 
O 
0 
No 
V 
.r L 
r. + 
V 
8 O 
0 
w 
rr 
V 
V 
A 
04 
E-+ 
o ö N 
I'D ItT 
N 00 
-p 
I C; C; 
M 
vu M lZ 
OO 
. -ý N 
-4 . C> C> uu 
6L I 
L 
y°výj - OEM ýö 
kn 00 
O OH 
CN t,: N 99 00 
Ö m O i ýO ^^ I- N 
ÖÖ 
0o N 00 
0 Q\ ÖÖ NN 0 0 
ee 00 Ö 
1-1 ^ ON C> 
10 ÖN ý~ ýi V1 
aý w pÖ 
w ý= 0 -4 
co 
ONO It ýo 0 0 
so V 
00 00 ÖÖ 
NN 
4 ON 00 IS ON 00 mt- C5 00 ": rS M 
co 1.4 
40 
0 ý v d 
Ow I. Z a 
.W ICU A O-M 
a a 
A 
w G7 
bA 
0 
as 
10 
Q 
Ac 
0 0 C. 0
C 
PC 
c 
0 
t 
0 G. ; oi 
.o 
as 
F 
n 000 ÖÖ N oý M NM 
" N C% "O M MO M NM 
(V Ö -- -- "-ý NN 
0 M M Ö 
ai- 0 0 "0 kn 
N 
M 
N 
V 00 00 00 O üü 
ö 
6- L-J 6- 6-J 
ic l- - ON ADN N Oý Gý 
v' ýO "-+ Oý NN 00 NN 
o 
"--" 
C 
"--i Ö ÖÖ Ö "--ý 
O 
a 
e, m C 'zP o10 O 
.O 00 SO p, ý--ý O Oo N o, O 'n - oý oo Ö 
rV 
-4 z1 1 
N cý fý rV M 
Wu 
-N "-+ N Oý "--+ -M -N 
00 C) 00 00 00 00 00 
- M M 
r 6m 
M- 
-- 25; 't -- 
- 
-N 
- 
N rq 
oV -- N N 
.- 93 tc 
(D - 
° 
"o u 
^ 
iE OO O O OO OO 
Q 
. --4 00 rn N M kn N "--ý MO o MN M NN M MM 
u v 
L O 
-w 
y 
W 2 
. 
3 3 
^" cu = U 
aýi ea aoi 'd aoi 'fl aoi 
ý ýýo 3 u 3 m) 3 ý; xý3 oý3 oý xý xý 
0*8 
kn N 
changes. There was no association of change in waist: hip ratio with tTG titre or any 
other variates. 
Despite at diagnosis of coeliac disease coeliacs having no different waist: hip 
circumference to the general population, following 12 months treatment with a GFD, 
coeliacs had significantly higher waist: hip ratio than the general population (Table 
4.40). For example, the mean difference in waist: hip ratio in male coeliacs to the 
general population was 0.04; 95%CI 0.01,0.07. Furthermore, coeliacs were 80% 
more likely to have raised waist: hip circumferences in comparison to the general 
population (observed raised waist: hip in male coeliacs versus general population 
1.79; 95% 1.03,2.52). 
4.1.3.9.3. Blood pressure and hypertension 
Though there was no change in diastolic blood pressure with treatment, there was a 
fall in systolic blood pressure in male coeliacs (mean difference in systolic blood 
pressure 
-3.5 mmHg; 95%CI -5.7, -3.3) but not in female coeliacs (Table 4.38). 
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4.1.3.9.4. Cholesterol profile 
There was a mean increase in total cholesterol by 0.17 (95%CI 0.02,0.31) following 
treatment of women with coeliac disease though there was no significant change 
observed in male coeliacs (Table 4.41). This change in total cholesterol was 
associated with change in HDL cholesterol and LDL cholesterol but no other variates. 
For each 1 mmol/L increase in total cholesterol there was a rise in HDL cholesterol by 
0.9 mmol/L on regression analysis (p = 0.0001). 
The higher proportion of female coeliacs with raised total cholesterol (n = 35; 50%) in 
comparison to male coeliacs (n = 15; 34%) did not reach statistical significance. 
The mean levels of total cholesterol remained significantly lower in coeliacs 
compared to that of the general population following treatment with a gluten-free diet 
(Table 4.42). Male coeliacs had 
-1.3 (95%CI for difference -1.0, -1.7) mmol/L lower 
total cholesterol and female coeliacs had 
-0.6 (95%CI for difference -0.9, -0.3) 
mmol/L lower total cholesterol in comparison to the general population. 
Male coeliacs were 40% less likely to have raised total cholesterol (observed: 
expected 0.60; 95%CI 0.30.0.90) than the general population. Female coeliacs were 
as likely to have raised total cholesterol than the general population (Table 4.43). 
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Women continued to have a higher HDL cholesterol following treatment with a GFD 
(1.55 (SD 0.39) mmol/L versus 1.29 (SD 0.36) mmol/L). There was a mean change in 
HDL cholesterol following treatment by 0.16 (95%CI for difference 0.12,0.21) 
mmol/L. Though the change in HDL cholesterol appeared to be greater with the 
villous atrophy (mean change 0.18 mmol/L versus 0.05 mmol/L in mild enteropathy; 
p=0.27), it was only change in tTG (p = 0.019) and change in LDL cholesterol that 
were the co-variates independently associated with change in HDL cholesterol on 
regression analysis. For every 50 unit decrease in tTG that occurred on exposure to a 
GFD, there was a 0.02 mmol/L rise in HDL cholesterol. 
Male coeliacs continued to have significantly higher prevalence of low HDL 
cholesterol than women with coeliac disease following treatment with a GFD (9% (n 
= 4) versus no female coeliacs). 
Only male coeliacs had lower HDL cholesterol than the general population (mean 
difference in HDL cholesterol 
-0.21 mmol/L; 95%CI -0.39, -0.03) whereas there was 
no difference between female coeliacs and the general population following treatment 
with a GFD (Table 4.43). 
Coeliacs were as likely to have low HDL cholesterol in comparison to the general 
population following treatment with a GFD. 
The mean LDL cholesterol changed following treatment with a GFD in men but not in 
women. Mean LDL cholesterol change was 0.19 mmol (95%CI 0.01,0.37) in men 
with GFD. The proportion of female coeliacs with raised LDL did not change with 
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GFD treatment and remained higher than that observed in male coeliacs (n = 11; 
30%). 
Coeliacs continued to have significantly lower LDL cholesterol with GFD treatment 
than that observed in the general population with the effect more marked in men than 
in women. For example, male coeliacs had 
-1.1 (95%CI -1.4, -0.8) mmol/L lower 
LDL cholesterol than the general population. Male coeliacs continued to have 
significantly lower LDL cholesterol than the general population (observed: expected 
0.39; 9%CI 0.16,0.62) with LDL cholesterol was 55% lower than in the general 
population in female coeliacs following treatment. 
Triglycerides continued to be significantly higher in incident male coeliacs than in 
females though the mean value did not change on treatment with a GFD (Table 4.41). 
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4.1.3.9.5. Haemostasis and thrombosis profile 
The mean fibrinogen following treatment for coeliac disease continued to be 
significantly higher in women than in men but there was no significant change 
following treatment (Table 4.44). 
The mean change in platelet count following treatment with a GFD was 
-38.5 (95%CI 
-51.2, -25.8) x 109/L with no difference in the mean change between men and women. 
Change in platelet count was not associated with change in total cholesterol or HDL 
cholesterol. However for every 50 unit fall in tTG that occurred on treatment with a 
GFD there was a4x 109/L fall in platelet count observed on regression analysis (p = 
0.03). 
There was a significant change in the mean APTT following treatment for coeliac 
disease in men but not in women (mean change 0.9 (95%CI 0.3,1.4) seconds. Change 
in APTT was not associated with any variable. 
There was also a significant change in mean PT following treatment for coeliac 
disease in men but not in women. Change in PT was also not associated with any 
variable. 
4.1.3.9.6. Inflammatory markers 
The mean CRP in female coeliacs but not male coeliacs changed on exposure to a 
GFD (mean difference in CRP in female coeliacs following treatment to that at 
diagnosis of coeliac disease 
-1.5 g/L; 95%CI -2.6, -0.4). Change in CRP was 
associated with baseline fibrinogen (p = 0.019). 
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The mean CRP following treatment was no different to that observed in the general 
population. 
4.1.3.9.7. Glycaemic profile 
There was no significant change in the mean random glucose nor the mean HbAl c 
following treatment with a GFD (Table 4.44). Furthermore there was no significant 
change in the HbAlc following treatment of coeliacs who were also diabetics with a 
GFD. 
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4.1.3.9. Change in vascular disease risk profile following treatment of classic, 
symptomatic and silent coeliac disease 
4.1.3.9.1. Weight and body mass index 
The gain in weight observed with a gluten-free diet (Table 4.45) was greatest on 
treating classic disease and least on treating silent disease (mean difference in weight 
change 1.1 kg; 95%CI 0.1,2.3). The increase in mean BMI was however similar 
between classic, symptomatic and silent disease (Table 4.45). 60% of coeliacs 
presenting with gastrointestinal symptoms were either overweight or obese following 
12 months treatment with a gluten-free diet. Over half (55%) of those coeliacs 
presenting with silent disease were obese or overweight following 12 months 
treatment. 
4.1.3.9.2. Waist circumference and waist: hip circumference 
The mean increase in waist circumference and waist: hip circumference observed 
following 12 months of a gluten-free diet was similar whether coeliacs had presented 
with classic, symptomatic or silent disease (Table 4.45). 
4.1.3.9.3. Blood pressure and hypertension 
There was a significant fall in systolic (mean difference 
-1.9 mmHg; 95%CI -3.5, - 
0.3) and diastolic (mean difference 
-2.3 mmHg; 95%CI -4.7, -0.1) blood pressure 
observed following treatment of coeliacs that had presented with gastrointestinal 
symptoms (Table 4.45). The smaller changes in systolic and diastolic blood pressure 
observed on treating silent and classic coeliac disease with a gluten-free diet did not 
reach statistical significance. 
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4.1.3.9.4. Cholesterol profile 
The mean increase in total cholesterol was observed on treating coeliacs presenting 
with classic disease (mean difference in total cholesterol 0.42 mmol/L; 95%CI 0.03, 
0.80) with no significant change in total cholesterol observed on exposing coeliacs 
with silent or symptomatic disease to a gluten-free diet (Table 4.46). There was a 
small but significant rise in LDL cholesterol associated with treating coeliacs with 
classic disease with a gluten-free diet (mean difference in LDL cholesterol 0.21 
mmol/L; 95%CI 0.02,0.45). The mean increase in HDL cholesterol following 
exposure to a gluten-free diet was similar amongst coeliacs presenting with classic, 
symptomatic or silent disease (Table 4.46). 
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4.1.3.9.5. Haemostasis and thrombosis profile 
There was no significant change in fibrinogen or clotting studies with treatment of 
classic, symptomatic or silent coeliac disease (Table 4.47). The change in platelet 
count alluded to in section 4.1.3.8.5 was observed to only occur in those coeliacs 
presenting with silent coeliac disease (mean difference in platelet count 
-49.5 x 1091L; 
95%CI 
-78.0, -21.1). 
4.1.3.9.6. Inflammatory markers 
Significant rises in ferritin were observed on treatment of symptomatic and silent 
coeliac disease with a gluten-free diet (Table 4.47). Treating coeliac disease that had 
presented with gastrointestinal symptoms was associated with 2g/L fall in CRP (mean 
difference in CRP 
-1.6 g/L; 95%CI -2.9, -0.2). 
4.1.3.9.7. Anaemia 
The greatest improvement in haemoglobin was observed on exposing those coeliacs 
with silent disease with a gluten-free diet (mean difference in haemoglobin 2.5 g/L; 
95%CI 1.7,3.4). 
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4.1.3.10. Vascular disease risk profile in coeliac disease 
The observed vascular risk profile in this study suggests both protective and adverse 
associations of incident coeliac disease (Table 4.48). Exposure to a gluten-free diet 
resulted in an attenuation or indeed reversal of the vascular risk profile in some co- 
variates (Table 4.48). 
277 
00 
N 
as 
y 
. rr 
ri 
.. n 
Q 
C 
u 
b 
.. r 
d 
0 i. 
hi 
00 
H 
A 
ýv, 
E 
.E 
Ü 
u cö 
y U C 
an Z%n 
° 
, -, 
N Ö d. Q., 
ß ý °' ; C 
- 
o 
G 
.7 C 7 Ö 
+ý- 
p Ü '+j 
all 
ö 
cad N 
ß fi 
O /1 p f ßý 
" 
. 
r U lit O "0 
uer, 7 
zi O 
ry .ý ý+ RS ° 
.ý U C'. V " U vý 'ý p : 
--ý U CU U C rl U 
. 
52 y -r- 
0 
O\ Or 4p c u . 
s. ý, + UU 3 . y am'' V >, u 
'ti r- O ci Eä oE EE öA0 
ei c9 N 
0 C> 
ý 
tUa cý ýý, ý Vý N vý 
Rf 
Ü 
o O U .ýU Ü V 4: 
CZ 
ö 
U D 
p p q 4 
U 
Q" ýpq N 
O U 
U cC 
U 
N 
N 
U 
4-1 
... ... U N 
C O a E E- 
V 
... 
r 
.... 
i 
I--ý -, 
,.., 
w O U r.. , cd 
'ý' N 3 "--ý Oý 
o ^. 
3 >% 
^, N ry 3 c Z: Ci _ +M 
2 
rI 
V1 va U 
ie 
u 
U4 2 
.= 
00 
to 
OO b 
1U 2 
vi 
c; v; " 
M 
M 
ö 
. 
"ý 
0) U 
. 
Gn 
N 
co 
-- c 0) 
- 
ö ý o_ 
1 _ -ý.. y - U v U u -d 6". 1 U U 9 > UU 
U vý 
c3 v1 
o 
U 
"", 
cý 
o 
Vl 
M o0 
cd V1 
. 
t. " 
ö U O 
v1 
;ý c. ,o tea, 3''o =(> , ° u`l ° V Ü ýy M VÜ :. ÜÜ N ý+ ZCN 
^. " - O 
4.1 
U Co O 
r. N 
.ýN O U U 
y OP. 
"ý 
In 
. --i . -ý y y U 
U 
po -i 
" 1 o ;2 
0 CJ 
u8 
9'. ö0EEö 
N1 
° 
Up 
ö g81 ä 
, ý, 
CE 
,ý ýn ýt º.. ý an w4 Cl. . ýn anO Z tin it 
a) 
ai 
E 
e4 ° C6 
x '5 . 
' lý r7; U 
ý 
' 
Ü 
10 
rn 
N 
A 
"' N(O 
f2. 
UN 
N 
0 
Uy 
? 
- "- 1-4 
"ci 
> 
äßö 3 ( W 
, -CJ . 
C o °är, ý > > 
"- p o 
pOÜ 
c a ce 
. 
ý. " 
.. ; 0: 
wOQ 
Ö2 7D 2N 
ý 
O Ö 
O 
O Ö 
y d '+~' :- 
y ý - a 
y> 
 = 
O O 
- 
x 
. 
ý c d 
O 
. pN Ü 0 - Ü^' p 
t24 Gn 
cli 
44 ä ' Q_A Ü (U b U oai 9) 10 Ü aoi Ü on Z ýJ. C7 an en 
11 0 0 0 0 
t 
ai 2 
r E 0 4 le 
.2 
2 
00 In . u ms E+ N N q 4 U. E 
0 v 
° 
- 
Z'. Z v ö ö '( 00 
,\ ° 0 ý' 0 
- 
ö V CA °° ö c 
. 
2- Z: U Cd 8 1 L ý ci 
y 
 
-vÜ y rA 
cd U 
6 
E) 
1 
G) 43 W-4 w--4 U0 
c 
U N N 
? cd 
='" QC ) 
U 
U 14 
. 
te b4 cC U 
w ý , N su su >, c c, 
"--ý a 3 u 
, 
N,. y 5 y 
ö 3 U N O y 
V 00 
U 
"d N "d cd 
.= 
M ýG 
U 
b 
_y 
"Li cle = 
.5N 
O ^' cd (U 
-- 
cd E' m OOO 
.. 
of 
2 
U, C 
v, ti, ü i" W 20 u aý w aý öWW `'' u° W 
c c 
) 
,C N 4) , - 
OO 
- 
O pes' 
1 1 
- 
o 
4) 8U 
U 
ý 
-i 
pes' 
U 1 
ä 
oy cu 
im U on 
Z 0 'm A 
le 0 9) 
- 
<0 
'I' O 
C) 
E 
y 
O 
U 
O 
V 
' 
N 
rn 
0) Cam) 0 
yý 
CC rA 2 ä 
m 0 
J., l= 
N2 t 2 
Ö 
_ 
F. 
O ti ~ Ö 
O_ U Uý 
W (1q 4 e A A 
c 
sw Q vi o u 2 0 
G4 
C7 0 40 0 
- 
o ý (U w 0 
0 
ö 
ö 
zi 
bD 'ý Ü O cd r. bA 
., 
ý .., 0 Ei 
0 
b 
b Ä 
Gn 
°Q n äo cn ö n 
9o ýQ) C) 0 0 
-ö Ü Ü= Z Z Z °\ .w Z0 
a - o 
0 O ö n a2i on a i
ou 3 1.. aa) cn ao ý, y o 
O > cd N> O :b V cC 
OO 
.ý 
.., O 
N 
. ty O 
" 
y 
vý 
O 
U 
'N 
gh : ;., 
:ý v 
t°ýý 0 r. CD a-o M 0 3 0 u V, 0o a) E a En - ö 0 
.E 
u 
a 
U le: -=M ýä 
vl 0 
N. "' 
'ý ^t3 0 ^ý O M 
2 
ÖO 
y 0 
eNN tZ OM =N ý 2 Z 4.4 = O 
°+""i O 
N Oi Uý y ý, 
aý an U 
ý'ý, p 
y CO2 
ýý 
A . "ý W 
ý' y 
° 
ÜO 
o 
ý 
ß 
O 
' Co kn 0 CJ ci c , . u2 o 
d 9 u t2 O 
. 
OM2... ý O O 
c 
Q" 
N 
Ö "ý O 
c 
"Ci Oy Cy 
4 cd y 
y , i. 
2p r pb 
OO 
V M 
N Oý "G 
Cý f 
vi 
.Z 
d 
0 
UN 
2 
"... 
cd 
+' 4 O ce 
.ý 
vý N 
jON cý 
.ýW 
.ýV 
yN r-. N 
: 
yO %Z 
vý 
\ tu 
r 
id 
N 
O t. 
d 2 Zu p ý+ O OC U ro . OO 5 U 
Ö 
' Ö ýOr O cd 
O 
b-9 CL i !ýU U bA GL i 1 
. 
C Vi 
ý i"ý u 
90 
0 0 
rA 90 
x° 
0 T3 
. 
ý1 r =+ U on 
U 
GQ y u 4 
, 
', N C) y U N 
0 
O 
4.1.4. Discussion 
4.1.4.1. Principal findings 
The observed vascular risk profile in this study suggests both protective and adverse 
associations of incident coeliac disease with subsequent exposure to a gluten-free diet 
resulting in an attenuation or indeed reversal of the vascular risk profile in some co- 
variates. The lower mean levels of total cholesterol, LDL cholesterol, fibrinogen; the 
higher likelihood of being from more affluent social class; and the small but 
significant rise in HDL cholesterol and reduction in blood pressure amongst coeliacs 
presenting with gastrointestinal symptoms observed following treatment with a 
gluten-free diet are features of a favourable vascular risk profile. However, the higher 
likelihood of having abdominal truncal obesity as reflected by higher raised hip: waist 
circumference ratios amongst incident coeliacs that only worsens following treatment 
with a gluten-free diet together with the higher proportion of measured systolic 
hypertension amongst male coeliacs suggests that there are also potentially adverse 
vascular risk profile features associated with coeliac disease. Having similar 
triglyceride, CRP, glucose and glycated haemoglobin levels to the general population 
as well as coeliacs being as likely to be current smokers, overweight or obese to non- 
coeliacs suggests these exposures are neutral with respect to vascular disease. 
Identifying and treating adults with silent coeliac disease does not appear to cause a 
change in their cholesterol profile but was associated with a fall in platelet count and 
the greatest rise in haemoglobin in comparison to those coeliacs presenting with 
classic disease or with gastrointestinal symptoms. 
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4.1.4.2. Limitations and merits 
This is the first prospective, longitudinal study where there has been systematic and 
routine collection of vascular risk profile in a large, unselected and population-based 
cohort of adults newly diagnosed with coeliac disease and following treatment with a 
gluten-free diet. While we did not identify every patient diagnosed in all three 
hospitals during the period we made extensive efforts to do so with 73% of identified 
incident coeliacs included in our study. We believe it unlikely that the omission of 
the few patients that will have been missed will have led to a substantial bias in the 
observed vascular risk profile and changes with treatment we have reported. 
22% of recruited adults newly diagnosed with coeliac disease did not complete the 
full twelve months of the study with losses to follow-up principally due to non- 
attendance at follow-up appointments made as part of routine NHS care. One could 
argue that these coeliacs that were lost to follow-up differ in their attitudes, 
behaviours and health status compared to those coeliacs who attended routine follow- 
up hospital appointments, introducing selection bias into the study. However, 15 of 
the 33 coeliacs lost to follow-up attended for coeliac review as part of routine clinical 
care at three and six months post-initiation of a gluten-free diet and 6 of the 33 
coeliacs actively sought referral for follow-up at their local hospitals due to change of 
address away from the study centres. 
Data from the Health Survey for England 2006 [347] was used as a general 
population comparator for serum markers of vascular disease and possession of 
vascular disease diagnoses. With 70% of study participants providing a valid blood 
sample for testing and the study having over two-thirds response rate (68% 
households and 88% adults of general population random sample participated) it is 
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regarded as being representative of the whole population at both national and regional 
level and provides an useful comparator for the study with measurements specifically 
taken to assess vascular risk profile in the English general population. However with 
use of medical records in the coeliac study design adding an extra way of ascertaining 
diagnosed vascular disease there are differences in the two study designs that may 
contribute to the differences observed. 
With laboratory measurements commonly subjected to extensive and repeated validity 
checks such as comparing observed measurement with an accepted standard, it is 
likely the serum co-variates in the study reflect the true state of the phenomenon being 
measured. Formal and standardised approaches were taken to maximise the validity of 
other measurements uch as the use of a visual analogue scale to assess compliance to 
the treatment and structured interviews and questionnaires to assess previous 
diagnoses of vascular disease. However non-differential measurement errors are a 
source of bias in the study. For example, the measurement of anthropometric co- 
variates such as height and waist circumference. I tried to minimise measurement 
error in collection of these co-variates through use of standardised protocols; use of 
exactly the same blood pressure machine, scales, stadiometer and inelastic tape 
(sections 4.1.2.6.1. and 4.1.2.6.2. ). All anthropometric measurements were performed 
by the same study investigator though different laboratories with different technicians 
performed the serum measurements. Simultaneous measurements were taken such as 
for blood pressure by the same study investigator who was appropriately trained to 
take blood pressure measurements. Digital scales and a digital blood pressure machine 
were used to minimise observer error. White coat hypertension may also have affected 
the measured values obtained [426]. The change in vascular risk profile observed in 
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the study was associated with exposure with a gluten-free diet / treatment of coeliac 
disease. However the reduction in quantitative vascular risk profile co-variates may 
also be attributable to regression towards the mean [427]. One could have 
incorporated into the study design measures to reduce the effect of regression to the 
mean such as performing duplicate baseline measurements taken on a different 
occasion from the first one drawn. However due to ethical constraints such as 
exposing study participants to a "potentially unpleasant procedure of phlebotomy" as 
raised by the North Staffordshire Research Ethical Committee, as well as to minimise 
inconvenience to study participants to maximise continued participation in the study 
this was not done. At the analysis stage rather than taking differences from the 
baseline value, analysis of covariance could have been performed [428]. 
There were missing serum values amongst some of the incident coeliacs. For 
example, only 86 of the 151 (57%) incident coeliacs had LDL cholesterol measured. 
The principal reason for this is due to local policy of the hospital concerned where 
total cholesterol and HDL cholesterol were routinely measured by the laboratory 
concerned. However there is no reason why the lipoprotein metabolism and lipid 
profile of incident coeliacs at a neighbouring hospital should behave any differently 
and any increase in the number of incident coeliacs tested for LDL cholesterol should 
only act to strengthen the reduction in LDL cholesterol observed. Our study only 
observed what vascular disease had previously been diagnosed prior to the diagnosis 
of coeliac disease and measured any change in the anthropometric and serum markers 
of vascular disease though we did not measure more specific indices of 
atherosclerosis such as intima 
- 
media thickness of extracranial carotid arteries. Such 
measurement of carotid artery intima 
- 
media thickness has not only been shown to be 
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directly related to the risk of coronary artery disease and stroke disease but it is a 
relatively easy, practical procedure that allows observation of subclinical 
atherosclerosis as well as providing a surrogate vascular endpoint requiring shorter 
study periods in comparison to that that may be needed for overt vascular disease 
events such as acute myocardial infarction to develop [429-431]. 
4.1.4.3. Comparison with other studies 
Our observation that people with newly diagnosed coeliac disease have lower total 
cholesterol compared with the general population is consistent with our observations 
in study 3.4. based on historical cohort of coeliacs and is further discussed in the 
discussion 3.4.4.3. Our findings again indicate that blood lipids may be a disease 
marker in coeliac disease with low levels of HDL cholesterol and total cholesterol 
strongly suggestive of untreated coeliac disease. 
Our finding of 40% lower LDL cholesterol in males and 20% lower LDL cholesterol 
in females newly diagnosed with coeliac disease compared with the general 
population is new though it was suggested in the only comparable study where West 
et al found LDL cholesterol levels were 7% lower in endomysial-positive people in 
comparison to endomysial-negative general population controls [170]. It is unclear 
why the reductions in LDL (>1.5 mmol/1) and total cholesterol (>1.5 mmol/L) 
observed in our study are somewhat greater than that observed in West et al [170]. 
This may be a reflection of `active' coeliac disease amongst our study participants 
though the underlying mechanism driving it is not clear. The lack of increase in total 
cholesterol or LDL cholesterol with treatment of coeliac disease together with BMI 
and weight of the coeliacs being comparable between the two studies suggests that 
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any mechanism based on intestinal malabsorption is less likely. Atherosclerosis is an 
inflammatory disease [273] and like other inflammatory and autoimmune conditions 
such as rheumatoid arthritis can be ameliorated and also regress [432-434]. The low 
levels of ferritin due to presumed enteropathy-driven processes such as malabsorption 
together with the absence of raised serum concentrations of CRP which reflect the 
underlying presence of activated, immune-competent cells typical of systemic 
inflammation and atherosclerotic lesions [273] observed in our study may signify that 
we should be measuring other inflammatory factors and cytokines such as TNF-a, IL- 
10 to support a role for systemic inflammation in the dyslipidaemia of coeliac disease 
[435-437]. It is also unclear why such low levels of fibrinogen were observed in our 
study with processes driving elevated levels such as inflammation, smoking, weight 
gain counteracted by some other mechanisms [438,439]. However levels of 
fibrinogen were strongly related to levels of CRP and triglycerides in our study 
suggesting that systemic inflammation and or inflammatory processes have some part 
to play in coeliac disease. Disturbed antioxidant mechanisms in untreated coeliac 
disease [440] may also have a role to play, promoting oxidative modification of LDL 
cholesterol with subsequent ladening of macrophages with lipids becoming the 
characteristic foam cells of the atherosclerotic lesion [441,442]. 
Adults with contemporary coeliac disease presenting with normal BMI or who are 
overweight at diagnosis are increasingly the rule rather than the exception as we have 
observed in our historical cohort studies in section 3 as well as by other authors [443]. 
Failure to recognise this may contribute to failed and delayed diagnosis of coeliac 
disease [219] though of further concern is the potential vascular consequences of the 
abdominal truncal obesity observed in our study with the waist: hip profile worsened 
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with treatment with a gluten-free diet. Incident coeliacs in our study were as likely to 
be overweight or obese as the general population though worryingly were 50% more 
likely to have raised waist: hip circumference. Such abdominal truncal obesity has 
been associated in the general population with a number of atherogenic conditions 
such as elevated systolic and diastolic blood pressure, insulin resistance, glucose 
intolerance, type 2 diabetes, hypertriglyceridaemia, low HDL cholesterol, high serum 
apolipoprotein B, high plasma fibrinogen all through which the risk of vascular 
disease is increased [444-446]. Additional mechanisms through which abdominal 
truncal obesity could also increase the risk of vascular disease include endothelial 
dysfunction [447] and adverse haemodynamic changes such as the increase in heart 
rate, stroke volume [448]. In addition to the adverse metabolic consequences of 
visceral fat, it also has a distinct role as an endocrine organ [449]. Hormones, 
cytokines, and polypeptides are secreted by adipose tissue, and thus adipocytes are 
involved in the regulation of energy homeostasis and neuroendocrine, autonomic and 
immune functions. These secretory products of adipocytes include leptin, TNF-a, 
plasminogen activator inhibitor-1 and angiotensinogen. Such products may in turn 
have an important role in the regulation of vascular risk factors. For example, 
hyperleptinaemia may induce insulin resistance. Increase synthesis of cytokines such 
as TNF-a may contribute to dyslipidaemia, insulin resistance and haemostatic 
disorders. A high plasminogen activator inhibitor-1 level is directly related to a 
prothrombotic state and angiotensinogen to hypertension. There was a mean increase 
in weight by 2.7 kg and waist circumference by 2 cm with 12 months treatment with a 
gluten-free diet which only worsened the abdominal truncal obesity profile; such 
increases were not limited to those coeliacs presenting with villous atrophy or 
malabsorption. Whether such anthropometric changes are reflective of high sugar and 
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fat content of prescribed gluten-free foods or disordered fat storage with gluten 
exclusion [450,451] it is unclear though such changes are associated with three-fold 
increased risk of vascular disease events in the general population [251]. 
Clinically diagnosed coeliac disease is associated with modest though still increased 
risks of malignancy and mortality [262,265,282,283,332-334] though we do not 
know the risk of complications in silent coeliac disease or whether this can be 
modified by a gluten-free diet. This study provides some evidence of benefit in 
identifying those people with silent coeliac disease. The improvement in haemoglobin 
associated with exposure to a gluten-free diet was greatest in those coeliacs presenting 
with silent disease than those with classic disease or those presenting with 
gastrointestinal symptoms. There is no adverse change in total or LDL cholesterol 
associated with exposure of silent disease with 12 months of a gluten-free diet in 
comparison to the significant and adverse rises in total and LDL cholesterol observed 
in classic coeliac disease. The small but significant beneficial rise in HDL cholesterol 
associated with exposure to a gluten-free diet is also seen with silent coeliac disease. 
However 61% of silent coeliacs possessed raised waist: hip ratio at diagnosis of 
coeliac disease which worsened with treatment with a gluten-free diet. With the mean 
2 kilogram mean weight gain associated with exposing silent coeliacs to 12 months of 
a gluten-free diet, 55% silent coeliacs were observed to be overweight or obese at 1 
year post-initiation of treatment. 
288 
4.1.4.4. Summary 
The observed vascular risk profile in this study suggests both protective and adverse 
associations of incident coeliac disease with subsequent exposure to a gluten-free diet 
resulting in an attenuation or indeed reversal of the vascular risk profile in some co- 
variates. The lower mean levels of total cholesterol, LDL cholesterol, fibrinogen; the 
higher likelihood of being from more affluent social class; and the small but 
significant rise in HDL cholesterol and reduction in diastolic blood pressure amongst 
male coeliacs observed following treatment with a gluten-free diet suggests coeliacs 
have favourable vascular risk profile features in comparison to the general population. 
However, the higher likelihood of having abdominal truncal obesity as reflected by 
higher raised hip: waist circumference ratios amongst incident coeliacs that only 
worsens following treatment with a gluten-free diet together with the higher 
proportion of measured systolic hypertension amongst male coeliacs suggests that 
there are also potentially adverse vascular risk profile features associated with coeliac 
disease. Further work is needed to further explore the mechanisms driving the lower 
cholesterol profiles and the abdominal truncal weight changes. 
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4.2. Quality of life at diagnosis of coeliac disease and changes 
following treatment with a gluten-free diet 
4.2.1. Introduction 
By definition of coeliac disease, there is a chronic inflammatory state of the small 
intestinal mucosa that heals when dietary gluten is removed [221]. The beneficial 
effect of a gluten-free diet in people with classic coeliac disease, such as reduction in 
the malabsorptive state, has been observed since at least the times of Dicke [452]. We 
now appreciate that these patients with clinically overt coeliac disease only make up 
the tip of the coeliac iceberg, accounting for the minority of cases of coeliac disease 
[367,453]. The majority of coeliacs have few obvious symptoms despite the presence 
of the enteropathy, have atypical symptoms or have physiological derangements such 
as iron deficiency anaemia or osteoporosis [453]. It is not clear whether such silent 
coeliacs have a reduced quality of life or if quality of life changes following treatment 
with withdrawal of gluten from the diet. Johnson et al (n = 14) observed silent 
coeliacs had no different life quality at diagnosis nor following 1 year of treatment in 
comparison to healthy controls though Nachman et al (n = 8) observed silent coeliacs 
had significantly worse off quality of life in comparison to controls at diagnosis. 
The aim of this longitudinal study is to describe the quality of life at diagnosis of 
coeliac disease in a large contemporary cohort and to observe any change in life 
quality following treatment with a gluten-free diet. 
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4.2.2. Methods 
4.2.2.1. Study design 
Longitudinal observational study. 
4.2.2.2. Study population 
Data was collected on quality of life in adults with incident coeliac disease and 
following their treatment with a gluten-free diet that had attended Nottingham 
University Hospital, Royal Hallamshire Hospital and Derbyshire Royal Infirmary as 
described in section 4.1.2.2. 
4.2.2.2.1. Classification of coeliac disease within study population 
The quality of life between different `glaciers' of the coeliac iceberg as first defined in 
study 4.1 in section 4.1.2.2.1. are given below again for further clarity: 
Classic symptoms 
Those coeliacs presenting with weight loss and diarrhoea. 
Gastrointestinal symptoms 
Those coeliacs presenting with gastrointestinal symptoms including diarrhoea but in 
absence of weight loss (would be included as having ` classic symptoms'), weight loss 
in the absence of diarrhoea (would be included as having `classic symptoms'), 
constipation, IBS syndrome, nausea, bloating, steatorrhoea, acid reflux, heartburn, 
vomiting, abdominal pain. 
Silent coeliac disease 
Those coeliacs presenting with no gastrointestinal symptoms; or physiological 
derangements such as anaemia, osteoporosis, deranged liver chemistries in the 
absence of gastrointestinal symptoms. 
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4.2.2.3. Inclusion criteria 
Adults with incident coeliac disease. 
4.2.2.4. Exclusion criteria 
Significant co-morbidity that would prevent the study participants being well enough 
to take part. 
4.2.2.5. Outcome measures 
" Quality of life in incident coeliac disease presenting with classic symptoms, 
gastrointestinal symptoms and with silent coeliac disease 
" Quality of life at diagnosis of coeliac disease and in comparison to the general 
population (all coeliacs, coeliacs with classic symptoms, coeliacs with 
gastrointestinal symptoms, coeliacs with silent disease) 
9 Change in the quality of life between diagnosis of coeliac disease and 
following 12 months treatment with a gluten-free diet (all coeliacs, coeliacs 
with classic symptoms, coeliacs with gastrointestinal symptoms, coeliacs with 
silent disease) 
" Quality of life in coeliacs following 12 months treatment with a gluten-free 
diet compared to that of the general population 
9 Presence of gastrointestinal symptoms at diagnosis of coeliac disease and 
following 12 months treatment with a gluten-free diet. 
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4.2.2.6. Outcome ascertainment 
4.2.2.6.1. Quality of life 
Quality of life was assessed with the Short-Form (SF-36) questionnaire. SF-36 is a 36 
item questionnaire which measures health functioning on eight scales and is among 
the most widely used, reproducible validated measure of quality of life in studies of 
patients [454,455] and the general population [456] with good internal consistency. 
The questionnaire is self-administered. A copy of the questionnaire may be found in 
Appendix 7.4. 
Figure 4.25 shows the structure of the SF-36. It consists of 36 questions, 35 of which 
are compressed into eight multi-item scales. Physical functioning (PF) is a ten- 
question scale that captures abilities to deal with the physical requirement of life, such 
as attending to personal needs, walking, and flexibility. Role-physical (RP) is a four- 
item scale that evaluates the extent to which physical capabilities limit activity. Bodily 
pain (BP) is a two-item scale that evaluates the perceived amount of pain experienced 
during the previous four weeks and the extent to which that pain interfered with 
normal work activities. General health (GH) is a five-item scale that evaluates general 
health in terms of personal perception. Vitality (VT) is a four-item scale that evaluates 
feelings of pep, energy, and fatigue. Social functioning (SF) is a two-item scale that 
evaluates the extent and amount of time, if any, that physical health or emotional 
problems interfered with family, friends, and other social interactions during the 
previous four weeks. Role-emotional (RE) is a three-item scale that evaluates the 
extent, if any, to which emotional factors interfere with work or other activities. 
Mental health (MH) is a five-item scale that evaluates feelings principally of anxiety 
and depression. Hence, in the SF36 scoring system, the scales are assessed 
quantitatively, each on the basis of answers to two to ten multiple choice questions, 
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and a score between 0 and 100 is then calculated using the summated ratings method 
on the basis of well-defined guidelines, with a higher score indicating a better state of 
health [454]. 
The scales of SF-36 are summarized into two dimensions. The first five scales make 
up the "physical health" dimension, and the last five form the "mental health" 
dimension. The scales vitality and general health are parts of both dimensions. Hence, 
each dimension includes three specific and two overlapping scales [454]. 
The SF-36 also includes a question about self-evaluation of change in health during 
the past year (reported health) that does not belong to any score or dimension or the 
total SF36 score [454]. 
The scores of the two dimensions and the total SF36 score are based on mathematical 
averaging of the scale components. Scores are continuous and are therefore suitable 
for collating into groups and deriving mean scores for comparison between groups at 
a specific time point or within groups over time. The QualityMetric software [454] 
also contains internal validity checks to ensure high quality, reproducible results. 
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Figure 4.25: SF-36 scoring system; scales and dimensions 
Scale 1: Physical functioning 
3. Vigorous activities 
4. Moderate activities 
5. Lift, carry groceries 
6. Climb several flights 
7. Climb one flight 
8. Bend, kneel 
9. Walk one mile 
10. Walk several blocks 
11. Walk one block 
12. Bathe, dress 
Scale 2: Role-Physical 
13. Cut down time 
14. Accomplished less 
15. Limited in kind 
16. Had difficulty 
Scale 3: Bodily Pain 
21. Pain 
- 
magnitude 
22. Pain 
- 
interfere 
Scale 4: General Health 
1. General health rating 
36. Excellent 
34. As healthy as anyone 
33. Sick easier 
35. Health worse 
Scale 5: Vitality 
23. Pep / life 
27. Energy 
29. Worn out 
31. Tired 
Scale 6: Social functioning 
32. Social 
- 
extent 
20. Social 
- 
time 
Scale 7: Role-Emotional 
17. Cut down time 
18. Accomplished less 
19. Not careful 
Scale 8: Mental Health 
24. Nervous 
25. Down in dumps 
26. Peaceful 
28. Blue / sad 
30. Happy 
2. Change in reported health 
Dimension 
A: 
Physical 
Health 
295 
4.2.2.6.2. Presence of gastrointestinal symptoms 
Generic instruments for assessing health-related quality of life do not assess specific 
aspects of a gastroenterological disease such as the presence and or severity of 
gastrointestinal symptoms nor the implications of its treatment (such as perceived 
social and financial restrictions of a gluten-free diet). At the time of designing this 
study, there was no disease-specific health-related quality of life questionnaire for 
people with coeliac disease developed and validated. We systematically collected data 
on the presence or absence of gastrointestinal symptoms including diarrhoea, 
abdominal pain, bloating, constipation, indigestion using questions from the validated 
ROME II questionnaire [457,458]. The questions used of the ROME II questionnaire 
may be found in Appendix 7.5. The data was collected by means of completion of a 
questionnaire. In this questionnaire, we also screened for perceived restrictions of 
both the disease and its management using standard questions (Appendix 7.5). 
4.2.2.7. Assessment of compliance with gluten-free diet 
Compliance with the gluten-free diet was assessed clinically and immunologically as 
described in section 4.1.2.7. 
4.2.2.8. Controls 
Using the norm-based scoring of the SF-36 questionnaire, the quality of life profile of 
people newly diagnosed with coeliac disease was compared with that of the 1998 
American general population. The norm-based scores in the American general 
population have a mean of 50 and a standard deviation of 10. All quality of life scores 
of the coeliac cohort using norm-based methods that are below 50 can be interpreted 
as below the American general population norm; scores above 50 are above the 
American general population norm. Meaningful comparisons across the scale and 
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component scores can thereby be made directly and one can observe which domains 
of health were observed to be most affected by having coeliac disease. 
4.2.2.9. Potential confounders 
Age, sex, socio-economic class. 
Occupational social class and Index of Multiple Deprivation 2007 (IMD07) score 
were used as measures of socio-economic class with data collected using a standard 
questionnaire as described in sections 4.1.2.6.4. and 4.1.2.9. 
4.2.2.10. Statistical analysis 
The mean quality of life SF-36 measures in adults newly diagnosed with coeliac 
disease were compared with the norm-based scores of the general population using 
unpaired t-tests to examine for any difference in the mean values. Paired t-tests were 
used to examine changes in quality of life SF-36 measures from baseline in incident 
coeliacs to following 12 months treatment with a gluten-free diet. 
We considered a p-value of 0.05 to represent statistical significance in all tests. All 
analyses were performed suing STATA SE 9.2 [TexCorp]. 
4.2.2.11. Sample size and power 
Nachman observed a 27 point increase in physical functioning and 35 point increase 
in SF-36 quality of life scores following treatment of 59 incident coeliacs presenting 
with classic symptoms with a gluten-free diet [226]. In contrast there were no 
significant changes in SF-36 quality of life measures in 8 incident coeliacs presenting 
with silent disease following treatment [226]. Our sample size aim was to recruit 150 
297 
study participants in order to have sufficient power to detect any change in quality of 
life SF-36 measures in a contemporary cohort including both classic and silent coeliac 
disease following treatment with a gluten-free diet. 
4.2.2.12. Ethical approval 
North Staffordshire Local Research Ethics Committee gave ethical approval 
(reference 06/Q2604/91) to this study in October 2006. Nottingham University 
Hospital gave research and development approval (reference 06GM012) to this study 
in January 2007. Derby Hospitals NHS Foundation Trust gave research and 
development approval (reference DHRD/2007/005) in April 2007. Royal Hallamshire 
Hospital gave research and development approval (reference STH14597) in March 
2007. 
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4.2.3. Results 
4.2.3.1. Study population 
151 adults newly diagnosed with coeliac disease were recruited to participate in the 
study with the study population described further in section 4.1.3.1. 
4.2.3.2. Demography of cohort 
The demography of the cohort was described as in section 4.1.3.2. 
4.2.3.3. Presenting features of incident coeliac disease 
The presenting features of the 151 incident coeliacs are described in section 4.1.3.3. 
4.2.3.4. Quality of life in adults newly diagnosed with coeliac disease 
The quality of life as reflected by SF36 score and broken down into individual scales 
and dimensions in all incident coeliacs and according to type of coeliac disease is 
shown in the following table. 
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Table 5.49: Quality of life in incident classic, symptomatic and silent coeliac 
disease 
Quality of life All incident Classic Symptomatic Silent 
coeliacs disease disease disease 
n=151 n=22 n=85 n=44 
Mean SF36 score* 59.0 (10.6) 48.7 (19.3) 58.4 (19.2) 65.1 (18.6) 
(SD) 
Mean SF36 (SD) 
scales*: 
Physical functioning 69.5 (26.5) 58.1 (29.4) 70.9 (26.6) 72.3 (24.0) 
Role: physical 58.5 (50.8) 41.7 (37.4) 61.8 (59.8) 60.2 (33.8) 
Bodily pain 57.3 (30.3) 49.8 (27.4) 51.4 (28.6) 72.3 (30.2) 
General health 48.7 (27.7) 44.1 (30.8) 47.6 (27.0) 53.2 (27.7) 
Vitality 34.2 (23.8) 26.9 (24.7) 33.8 (22.2) 38.3 (26.0) 
Social functioning 68.1 (27.4) 47.0 (23.4) 69.2 (26.5) 76.2 (26.1) 
Role: emotional 72.5 (32.5) 55.6 (35.6) 73.8 (30.9) 78.1 (32.1) 
Mental health 62.6 20.8 62.7 23.2 64.1 20.9 69.9 18.9 
Mean SF36 (SD) 
dimensions*: 
Physical health 53.0 (21.5) 44.7 (23.3) 51.8 (20.8) 59.1 (20.5) 
Mental health 57.8(19.7) 1 47.5(18.6) 1 57.6 19.4 63.2 19.3 
*A score between 0 and 100 is given for each of the SF36 scales, for both SF36 
dimensions as well as the overall SF36 score. A higher score indicates a better state of 
health. 
The mean SF36 score was highest in those coeliacs presenting with silent disease and 
lowest in those presenting with classic disease. Silent incident coeliacs had 
significantly better quality of life than those presenting with classic disease (mean 
difference in SF36 scores 
-16.4; 95%CI -26.2, -6.6); p=0.001. Silent incident 
coeliacs had also significantly better quality of life than those coeliacs presenting with 
gastrointestinal symptoms (mean difference in SF36 scores 
-6.7,95%CI -13.7, -0.3); p 
= 0.05. 
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Silent coeliac disease appeared to have better quality of life than those coeliacs with 
classic disease because of. - 
0 better physical functioning (mean difference in scores 
-14.2; 95%CI -27.7, -0.7), 
" 
less bodily pain (mean difference in scores 
-22.5; 95%CI -37.8, -7.2), 
0 better social functioning (mean difference in scores 
-29.2; 95%CI -42.4, -16.0), 
0 better emotional status (mean difference in scores 
-22.5; 95%CI -39.9, -5.1) 
resulting in significantly better physical health (mean difference in scores 
-14.4; 
95%CI 
-25.6, -3.2) and mental health (mean difference in scores -15.7; 95%CI -25.6, - 
5.8). 
Those coeliacs presenting with gastrointestinal symptoms appeared to have better 
quality of life than those presenting with classic disease due to: 
0 better physical functioning (mean difference in scores 
-12.8; 95%CI -25.7, - 
0.1) 
0 better social functioning (mean difference in scores 
-22.2; 95%CI -34.5, -9.9) 
0 better emotional status (mean difference in scores 
-18.2; 95%CI -33.3, -3.1) 
resulting in significantly better mental health (mean difference in scores 
-10.1; 95%CI 
-19.2, -1.0) but not physical health. 
Vitality was the lowest scoring scale of the SF36 profile (mean score in all incident 
coeliacs 34.2 (SD 23.8)) with no difference in vitality scores between coeliacs with 
silent, symptomatic and classic disease. 
The self-reported rating of change of health from when coeliac disease was diagnosed 
to a year prior to diagnosis varied according to mode of presentation of coeliac 
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disease. The majority (61.4%; 95%CI 47.0,75.8) of coeliacs presenting with silent 
disease reported no change in health from diagnosis to a year prior to diagnosis. In 
comparison, those coeliacs presenting with classic disease (76.0%; 95%CI 57.8,94.3) 
and with symptoms (63.5%; 95%CI 53.2,73.7) reported that their health was much 
worse or somewhat worse at diagnosis of coeliac disease compared to a year prior to 
diagnosis. Only 9% of silent coeliacs avoided eating outside the home such as in 
restaurants or at friends which was significantly lower than the 38% of classic 
coeliacs (mean difference in proportion 0.29; 95%CI 0.07,0.51) and 26% of coeliacs 
presenting with gastrointestinal symptoms (mean difference in proportion 0.17; 
95%CI 0.04,0.29). 
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4.2.3.5. Quality of life in adults newly diagnosed with coeliac disease compared to 
the general population 
The quality of life in adults newly diagnosed with coeliac disease was compared to 
that of the general population (Table 4.50). 
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The overall quality of life of incident coeliacs was significantly lower than that of the 
general population regardless of whether they had presented with classic, 
symptomatic or silent disease (Table 4.50). 
Those coeliacs presenting with silent coeliac disease had lower physical (mean 
difference in scores 
-4.9; 95%CI -8.5, -1.3) and mental health dimensions (mean 
difference in scores 
-3.7; 95%CI -7.3, -0.1) than that observed in the general 
population due to: 
" worse physical functioning (mean difference in scores 
-4.7; 95%CI -8.3, -1.1) 
9 worse performance in physical roles (mean difference in scores 
-5.1; 
95%CI 8.6, 
-1.6) 
" worse general health (mean difference in scores 
-8.3; 95%CI -12.2, -4.4) 
9 lower vitality (mean difference in scores 
-9.4; 95%CI -13.2, -5.6) 
though had no difference in social functioning, bodily pain or performance in 
emotional roles. 
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Each of the scales measuring different aspects of quality of life was significantly 
lower in coeliacs presenting with classic symptoms of coeliac disease compared to the 
general population: 
" worse physical functioning (mean difference in scores 
-10.0; 95%CI -14.8, -5.1) 
" worse performance in physical roles (mean difference in scores 
-9.9; 
95%CI 
-14.6, -2.4) 
" worse bodily pain (mean difference in scores 
-9.1; 95%CI -4.2, -2.5) 
" worse general health (mean difference in scores 
-10.6; 95%CI -16.1, -5.1) 
9 lower vitality (mean difference in scores 
-14.7; 95%CI -19.5, -9.9) 
" worse social functioning (mean difference in scores 
-15.2; 95%CI -19.9, -10.5) 
" worse performance in emotional roles (mean difference in scores 
-8.8; 
95%CI 
-13.6, -4.0) 
" worse mental health (mean difference in scores 
-6.0; 95%CI -11.1, -0.9) 
Each and every scale measuring different components of quality of life in coeliacs 
presenting with gastrointestinal symptoms was also significantly lower than that 
observed in the general population (data not shown). 
4.2.3.6. Continued participation in study and adherence to gluten-free diet 
Any losses to follow-up from the study and adherence of the study participants to 
gluten-free diet are further described in section 4.1.3.8. 
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4.2.3.7. Change in quality of life following 12 months treatment of coeliac disease 
with a gluten-free diet 
Following 12 months treatment with a gluten-free diet, there was a significant 
reduction in the prevalence of gastrointestinal symptoms including diarrhoea (mean 
difference in proportion with diarrhoea following treatment to that at diagnosis 
-0.45; 
95% 
-0.56, -0.34), abdominal pain, and heartburn. 
Following exposure to 12 months gluten-free diet, there was a significant 
improvement in the quality of life measured in the coeliacs (mean difference in SF36 
score 18.5; 95%CI 15.4,21.6); p=0.00001 (Table 4.51). 
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Table 4.51: Change in quality of life following 12-months treatment with a 
gluten-free diet 
Quality of life At diagnosis 
of coeliac 
disease (SD) 
Following 12 
months GFD 
(SD) 
Mean 
difference 
95%CI 
Mean SF36 score* (SD) 
All coeliacs (n = 118) 59.1 (19.5) 77.7 (16.5) 18.5 [15.4,21.6] 
Classic disease (n = 17) 48.5 (18.8) 67.1 (25.1) 18.7 [8.4,28.9] 
Symptomatic disease (n = 68) 57.4 (18.5) 77.4 (14.1) 20.0 [15.9,24.1] 
Silent disease (n = 33) 67.6 18.9 83.2 14.3 15.5 [9.9,21.2 
Mean SF36 (SD) scales* 
Physical functioning 
All coeliacs 70.2 (25.9) 82.9 (22.3) 12.7 [9.5,16.0] 
Classic 60.7 (30.5) 72.3 (27.3) 11.7 [-0.6,23.9] 
Symptomatic 70.4 (25.4) 83.4 (21.3) 13.1 [8.7,17.4] 
Silent 74.2 (24.4) 86.8 (20.8) 12.6 [7.3,17.9] 
Role: physical 
All coeliacs 60.0 (53.9) 79.8 (25.6) 19.8 [10.3,29.4] 
Classic 43.3 (35.9) 65.0 (33.8) 21.7 [5.2,38.1] 
Symptomatic 62.7 (64.4) 80.7 (23.6) 18.0 [2.6,33.4] 
Silent 62.1 (33.1) 84.8 (23.3) 22.7 [12.0,33.4] 
Bodily pain 
All coeliacs 57.3 (30.8) 80.8 (22.8) 23.4 [18.5,28.4] 
Classic 51.6 (28.8) 68.3 (30.3) 16.7 [3.9,29.4] 
Symptomatic 50.1 (28.6) 79.4 (22.0) 29.3 [22.8,35.8] 
Silent 74.6 (29.9) 89.3 (17.2) 14.7 [5.4,24.0] 
General health 
All coeliacs 49.5 (27.8) 67.8 (26.2) 18.3 [14.4,22.2] 
Classic 43.1 (28.8) 59.5 (36.0) 16.5 [5.3,27.7] 
Symptomatic 46.5 (27.0) 67.1 (23.7) 20.6 [15.2,25.9] 
Silent 58.5 (27.1) 73.0 (25.5) 14.5 [7.3,21.7] 
Vitality 
All coeliacs 33.4 (25.0) 58.4 (21.0) 25.0 [20.4,29.6] 
Classic 24.3 (23.1) 52.0 (21.1) 27.7 [11.2,44.1] 
Symptomatic 32.5 (23.1) 57.2 (20.7) 24.7 [18.6,30.7] 
Silent 39.2 (28.6) 63.8 (21.1) 24.5 [16.1,32.9] 
Social functioning 
All coeliacs 68.8 (27.2) 85.8 (19.4) 17.0 [12.6,21.4] 
Classic 48.3 (19.5) 70.1 (29.0) 21.7 [10.2,33.3] 
Symptomatic 67.6 (27.3) 87.0 (16.4) 19.5 [13.5,25.5] 
Silent 80.7 (24.2) 90.6 (16.6) 9.8 [2.2,17.5] 
Role: emotional 
All coeliacs 72.5 (31.3) 93.0 (15.1) 20.5 [15.0,25.9] 
Classic 53.4 (35.3) 84.5 (21.3) 31.1 [14.8,47.5] 
Symptomatic 73.2 (29.8) 92.4 (15.4) 19.2 [12.0,26.4] 
Silent 79.9 (29.9) 98.0 (8.0) 18.1 [7.4,28.8] 
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Quality of life At diagnosis 
of coeliac 
disease (SD) 
Following 12 
months GFD 
(SD) 
Mean 
difference 
95%CI 
Mean SF36 (SD) scales* 
Mental health 
All coeliacs 65.0 (21.4) 74.5 (19.4) 9.4 [6.5,12.4] 
Classic 58.4 (25.7) 68.8 (27.0) 10.4 [-0.5,20.9] 
Symptomatic 63.3 (21.1) 73.5 (18.2) 10.1 [6.1,14.2] 
Silent 71.5(17.1) 79.0(17.1) 7.5[2.9,12.1] 
Mean SF36 (SD) dimensions*: 
Physical health 
All coeliacs 53.2 (21.3) 73.8 (18.9) 20.5 [17.1,23.9] 
Classic 45.5 (22.2) 62.9 (27.3) 17.5 [6.1,28.8] 
Symptomatic 50.9 (20.1) 73.4 (16.3) 22.5 [18.1,26.9] 
Silent 61.6 (21.3) 79.4 (17.6) 17.8 [11.7,23.9] 
Mental health 
All coeliacs 57.9 (20.1) 75.7 (16.3) 17.8 [14.5,21.0] 
Classic 45.9 (18.4) 66.9 (24.1) 21.1 [10.4,31.7] 
Symptomatic 56.6 (19.3) 75.1 (14.6) 18.5 [14.0,22.9] 
Silent 66.1 19.4 80.8 13.7 14.8 9.1,20.4 
*A score between 0 and 100 is given for each of the SF36 scales, for both SF36 
dimensions as well as the overall SF36 score. A higher score indicates a better state of 
health. 
The improvement in SF36 score with treatment with a gluten-free diet was similar 
whether the coeliacs had presented with gastrointestinal symptoms, with classic 
disease or with silent disease (mean percentage change in SF36 score in classic 
disease 38.4%, 95%CI 13.8,63.0 versus 23.1%, 95%CI 8.7,37.4). 
There was no difference in the degree of change in physical functioning or 
performance in physical roles with a gluten-free diet whether the initial presentation 
had been with classic, silent or symptomatic coeliac disease. Improvement in social 
functioning and general health appeared to be greater amongst those coeliacs 
presenting with gastrointestinal symptoms than with silent disease. For example, the 
difference in mean % change between symptomatic and silent disease for social 
functioning was 19.6%; 95%CI 0.7,38.5 with p=0.06. However, improvement in 
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performance in emotional roles was significantly greater on treating symptomatic 
disease than that observed on treating silent coeliac disease (difference in mean % 
change symptomatic versus silent disease 35.6%; 95%CI 6.8,64.4). Rather 
unsurprisingly, those coeliacs presenting with gastrointestinal symptoms had much 
higher improvement in pain control with treatment (mean % change in bodily pain 
58.4%; 95%CI 46.6,70.2) than those coeliacs with silent disease (mean % change in 
bodily pain 19.7%; 95%CI 6.1,33.3). 
There was no difference in proportion of silent, classic and symptomatic coeliacs who 
found it difficult to establish whether foods were gluten-free (p > 0.05). However both 
classic and symptomatic coeliacs were more likely to avoid eating outside the home in 
comparison to those coeliacs with silent disease. For example, 75% (95%CI 53.8, 
96.2) of those coeliacs presenting with classic disease avoided eating out in 
comparison to 27% (95%CI 12.1,42.5) of those coeliacs with silent disease. 
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4.2.3.8. Quality of life following 12 months treatment of coeliac disease compared 
to the general population 
The quality of life of the coeliacs following 12 months treatment with a gluten-free 
diet was compared to the quality of life observed in the general population (Table 
4.52). 
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Following 12 months treatment with a gluten-free diet, those coeliacs with classic 
disease had no different reported quality of life to that observed in the general 
population (p > 0.05). Treating coeliacs that presented with gastrointestinal symptoms 
resulted in a significant improvement in their quality of life so that their SF36 scores 
following 12 months exposure to a gluten-free diet was no different to that observed 
in the general population. Furthermore, performance within emotional roles (mean 
difference in norm-based scores 3.0; 95%CI 3.9,5.6) and pain control was even better 
in those with treated symptomatic coeliac disease than that observed in the general 
population. Coeliacs presenting with silent disease had similar or even better reported 
quality of life than that observed in the general population. Treating silent coeliacs 
resulted in better social functioning (mean difference in norm-based scores 4.0; 
95%CI 0.2,8.0), better performance in emotional roles (mean difference in norm- 
based scores 6.0; 95%CI 2.1,9.9) and less pain than that observed in the general 
population. 
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4.2.4. Discussion 
4.2.4.1. Principal findings 
Silent disease was a common mode of presentation of coeliac disease, affecting one- 
third of a contemporary and representative cohort of adults newly diagnosed with 
coeliac disease. Though incident coeliacs with silent disease reported no change in 
their quality of life prior to diagnosis of coeliac disease, silent coeliacs were as likely 
to have villous atrophy and physiological derangement to those coeliacs presenting 
with symptoms or with classic features of coeliac disease. The quality of life reported 
by incident silent coeliacs was worse than that observed in the general population, 
principally due to reductions in physical functioning which may be a reflection of 
underlying malabsorptive and inflammatory processes. Coeliacs presenting with 
classic disease or with gastrointestinal symptoms have significantly lower reported 
quality of life in comparison to those presenting with silent disease, with both 
physical and mental health dimensions affected. The quality of life in coeliacs 
presenting with classic disease or with gastrointestinal symptoms was worse than that 
observed in the general population with the difference more marked than that 
observed in silent coeliac disease. A year's treatment with a gluten-free diet not only 
caused a significant reduction in the prevalence of gastrointestinal symptoms but 
caused a beneficial improvement in the quality of life experienced by the coeliacs. 
Such an improvement with treatment resulted in coeliacs having similar or in some 
components better quality of life than that observed in the general population. The 
rate of change of quality of life was similar amongst those coeliacs with silent, classic 
or symptomatic disease. 
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4.2.4.2. Limitations and merits 
This is the largest, prospective and longitudinal study where there has been systematic 
and routine collection of quality of life measures in an unselected, contemporary and 
population-based cohort of adults newly diagnosed with coeliac disease and following 
treatment with a gluten-free diet. One published study that has assessed a longitudinal 
change in quality of life was based on only 14 screen detected coeliacs and 17 
symptomatic coeliacs [225] whilst the only other published study to evaluate 
longitudinal change from diagnosis had only 8 coeliacs with silent disease whose 
quality of life could only be measured at baseline and at a 3-month visit [226]. While 
we did not identify every patient diagnosed in all three hospitals during the period we 
made extensive efforts to do so with 73% of identified incident coeliacs included in 
our study. We believe it unlikely that the omission of the few patients that have been 
missed will have led to a biased estimate of the quality of life profile and change with 
treatment we have reported. 
22% of recruited adults newly diagnosed with coeliac disease did not complete the 
full twelve months of the study with losses to follow-up principally due to non- 
attendance at follow-up appointments made as part of routine NHS care. One could 
argue that these coeliacs that were lost to follow-up differ in their attitudes, 
behaviours and health status compared to those coeliacs who attended routine follow- 
up hospital appointments, introducing selection bias into the study. However, 15 of 
the 33 coeliacs lost to follow-up attended for coeliac review as part of routine clinical 
care at three and six months post-initiation of a gluten-free diet and 6 of the 33 
coeliacs actively sought referral for follow-up at their local hospitals due to change of 
address away from the study centres. 
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At the time of designing this study, a disease-specific health-related quality of life 
questionnaire for people with coeliac disease had not yet been developed or validated 
according to recognised guidelines [459,460]. Though not able to assess specific 
aspects of a disease such as the potential social and financial restrictions of a gluten- 
free diet, we elected to use the SF36 questionnaire to assess quality of life in our study 
as a generic measure of health status, proven useful in estimating the relative burden 
of a disease, differentiating the health benefits produced by treatment and comparing 
subgroups of different disease modes [461]. The health concepts measured in SF36 
represent the most frequently measured concepts in widely-used health surveys that 
have been shown to be affect by disease and treatment [462]. It also measures 
multiple operational definitions of health, including function and dysfunction, distress 
and well-being, objective reports and subjective ratings and both favourable and 
unfavourable self-evaluations of general health status [462]. The reliability of SF36's 
scales and summary measures, estimated using both internal consistency and test- 
retest methods, is in the order of >0.70 [461]. Validity studies in the literature have 
compared SF36 with some 225 other measures supporting its performance [461]. 
Data from the American general population was used as a general population 
comparator. Norms can be seen to provide anchors to interpret an individual's or a 
group's score in relation to those of others and thus norm-based scores can be seen as 
departures from typical values. Several studies have demonstrated the worth of norm- 
based scoring in assessing the impact of disease in more than 200 different diseases 
including chronic conditions such as emphysema, diabetes, rheumatoid arthritis, 
irritable bowel syndrome [463-466]. However, differences have been observed in 
studies comparing normative data of non-American countries to that of the American 
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general population sample used in SF36 [467-469] and are a limitation to our study. 
Such differences are thought to be due to a combination of cultural differences; 
different age ranges of participants used in the studies (18 
- 
65 years in American 
normative data versus 25 
- 
75 years in Canadian study); and perhaps artefactual 
effects related to translation such as discrepancies in methods and definitions. 
In the absence of a developed and validated questionnaire to assess the disease- 
specific health-related quality of life for people with 'coeliac disease, we 
systematically collected data on the presence or absence of gastrointestinal symptoms 
including diarrhoea, abdominal pain, bloating, constipation, indigestion using 
questions from the validated ROME II questionnaire [457,458] in an attempt to 
assess specific aspects of coeliac disease. We also systematically collected data on the 
presence or absence of social and financial restrictions of a gluten-free diet and 
potential difficulties in following a gluten-free diet using a standard set of questions. 
Such questions were specifically designed to try to include the dimensions of the 
construct we wished to measure to maximise the content validity of the questioning. 
Formal and standardised approaches were also taken to maximise the validity of 
measurements taken such as the use of a visual analogue scale to assess compliance to 
the treatment. The change in quality of life observed in the study was associated with 
exposure with a gluten-free diet / treatment of coeliac disease. However such changes 
in quality of life observed may also be attributable to regression towards the mean 
[427] as discussed in section 4.1.4.2. 
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4.2.4.3. Comparison with other studies 
Our observation that adults with newly diagnosed coeliac disease presenting with 
silent disease (i. e. no gastrointestinal symptoms but have evidence of physiological 
derangements) have worse quality of life compared with the general population is 
different to the observations of the two published studies that have evaluated change 
in SF36 with treatment of silent disease with a gluten-free diet. This may reflect the 
choice of controls in the study by Johnston et al [225] who had volunteered to 
participate in a serological screening survey rather than be representative of the 
general population as a whole. The lack of significant change in SF36 in the 8 silent 
coeliacs in the Nachman study [226] could be due to the short time treated with a 
gluten-free diet (only three months) and or reflective of the low sample number. The 
use of "healthy hospital staff' as controls introducing healthy worker selection bias 
further limited this study. The odds of reported general health as "good or excellent" 
was not statistically different between EMA-positive and EMA-negative general 
population controls though no validated or comprehensive quality of life assessment 
was performed [170]. 
The reduction in quality of life in incident coeliacs with silent disease compared to the 
general population was principally due to reduced physical dimensions such as 
performance in physical roles, physical functioning and vitality. Though silent 
coeliacs were as likely to have villous atrophy and elevated tissue transglutaminase 
titres as those coeliacs presenting with symptomatic disease, silent coeliacs had 
significantly lower haemoglobin values raising the possibility that the lower 
haemoglobin could be implicated in impairing physical performance and functioning 
[470]. Fatigue (overlap of feelings of muscle weakness, tiredness, fatigability [471]) 
has been reported in adults newly diagnosed with coeliac disease raising the 
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possibility by some authors that fatigue could be a gluten-related symptom [472] or 
related to depressive symptoms [473] that ameliorates with gluten exclusion. There 
was no objective evidence of depression in the silent coeliacs in our study. 
Our finding that adults with newly diagnosed coeliac disease presenting with overt 
symptoms have significantly lower quality of life compared with the general 
population and coeliacs presenting with silent disease is consistent with the 
observations by the two other published studies [225,226]. Though symptomatic 
coeliacs were as likely to have villous atrophy and elevated tissue transglutaminase 
titres as those coeliacs presenting with silent disease, one might speculate the reduced 
quality of life observed in symptomatic disease relative to silent disease could be 
reflective of both the disease symptoms, dietary restrictions due to fear of 
exacerbation of disease symptoms, avoidance of social situations due to potential 
exacerbation of the disease symptoms leading to difficulties in daily social and 
emotional functioning, dietary restrictions. Our observations of coeliacs with 
symptomatic disease tending to avoidance of eating outside the home are supportive 
of such speculation. 
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4.2.4.4. Summary 
Silent disease is a common mode of presentation of coeliac disease with similar 
likelihood of having villous atrophy and physiological derangements to those coeliacs 
presenting with gastrointestinal symptoms or with classic features of coeliac disease. 
Though incident coeliacs with silent disease reported no change in their quality of life 
prior to diagnosis of coeliac disease, their quality of life is worse than that observed in 
the general population, principally due to reductions in physical functioning which 
may be a reflection of underlying malabsorptive and inflammatory processes. 
Coeliacs presenting with classic disease or with gastrointestinal symptoms have 
significantly lower reported quality of life in comparison to those presenting with 
silent disease, with both physical and mental health dimensions affected, and much 
lower quality of life than that observed in the general population. A year's treatment 
with a gluten-free diet is associated with a significant reduction in the prevalence of 
gastrointestinal symptoms amongst coeliacs but also with a beneficial improvement in 
their quality of life experienced. Such an improvement with treatment results in 
coeliacs having similar or indeed, in some facets, better quality of life than that 
observed in the general population. The rate of change of quality of life is similar 
amongst those coeliacs with silent, classic or symptomatic disease. 
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Chapter five: Cross-sectional survey of women with 
coeliac disease 
Using the Coeliac UK population-based cohort and the Nottingham, Sheffield and 
Derby historical coeliac disease cohorts a cross-sectional survey was performed with 
the aim to: 
" 
describe the breast cancer risk profile in women with coeliac disease and 
compare to that of the general population 
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5.1. Understanding the reduced risks of breast cancer in 
women with coeliac disease 
5.1.1. Introduction 
Breast cancer is the commonest malignancy in women, comprising 18% of all female 
cancers and having a prevalence of approximately 2% in the British general 
population [288]. Established high-risk demographic factors for female breast cancer 
are: 
" advancing age (relative risk > 10 with each 10 year increase during the 
reproductive years until the menopause) 
" Caucasian race (relative risk >5 to Asians) 
" higher socioeconomic status (relative risk 2 for social classes I and II to other 
classes) [289,291,292]. 
Many of the other established aetiological factors of breast cancer are linked to 
oestrogens with hormonal factors playing a key role as described in section 1.7.6.1. 
and include: 
" early onset of menarche (relative risk 3 for age at menarche before age 11 
years) [294,474] 
" 
later onset of menopause (relative risk 2 for menopause after age 54 years) 
[293,294] 
" 
later age at first birth (two-fold increased risk in women who have their first 
child after the age of 30 years to those who have their first child before the age 
of 20) [295] 
" nulliparity (compared with nulliparous women, women who have had at least 
one full-term pregnancy have on average 25% reduction in breast cancer risk 
[296]) 
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" proliferative breast lesions (with atypia at least four-fold increased risk or 
without atypia has at least two-fold increased risk of breast cancer [297]) 
0 family (a woman's risk of breast cancer is two or more times greater if she 
has a first degree relative who developed the disease before the age of 50 years 
with the younger the relative when she developed breast cancer the greater the 
risk [298]) 
" current use of oral contraceptives (relative risk 1.24) [289,302] 
" use of hormone replacement therapy for more than 10 years (relative risk 1.34) 
[289,302] 
" post-menopausal obesity, increasing adult height, high alcohol intake, high 
intake of saturated fat and folate are also associated with increased breast 
cancer risk (relative risk 1.3 
- 
1.5) [303-309] 
Regular menstrual cycles (relative risk 0.76; 95%CI 0.62,0.94 for <1 year to onset of 
regular menstrual cycles) [300]; breastfeeding (pooled odds ratio 0.84; 95%CI 0.78, 
0.91) [299]; severe caloric restriction caused by anorexia nervosa prior to age 40 years 
(50% lower incidence of breast cancer) [301] have observed to have a protective 
effect upon breast cancer risk. 
Population attributable risk (PAR) estimates suggest that age at first birth at >29 
years, nulliparity, menarche before the age of 14 years, family history of breast cancer 
in 1s` degree relative and history of benign breast disease account for the largest 
fraction of breast cancer cases in published studies (e. g. PAR 29.5% for age at first 
birth > 29 years and nulliparity in white women in United States ; 95%CI 5.6,53.3) 
[292,310]. 
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Several studies have observed that coeliac disease is associated with more than a 50% 
reduced risk of breast cancer [265,282,283,287,318] though the reasons for this 
reduction are unclear. Later age at menarche and earlier onset of menopause has been 
observed in women with coeliac disease in studies using small, selected populations 
[320-323] though a more recent and population-based study observed female coeliacs 
had similar fertility to that of the female general population though female coeliacs 
tended to have their babies at an older age [324]. Short stature, low body mass, caloric 
restriction, fat and folate deficiencies associated with coeliac disease [170,221,325] 
may also be implicated in the apparent reduced risk of breast cancer in women with 
coeliac disease. 
The aim of this chapter is to describe the hormonal, reproductive and anthropometric 
breast cancer risk profile in female incident and prevalent cases of coeliac disease and 
compare with that of the general population using age- and sex-matched controls to 
help understand the reduced risk of breast cancer in coeliac disease. 
5.1.2. Methods 
5.1.2.1. Study design 
Cross-sectional survey. 
5.1.2.2. Study population 
5.1.2.2.1. Historical cohort 
Data was collected on the breast cancer risk profile in incident and prevalent adult 
women that have attended Nottingham University Hospital, Nottingham; Royal 
Hallamshire Hospital, Sheffield; or Derby Hospitals NHS Foundation Trust for 
management of their coeliac disease. The study cohort is further described as in 
sections 2.2.1,2.2.2 and 2.2.3., respectively. Consecutive cases of incident coeliac 
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disease were identified at Nottingham University Hospital using clinical and dietetic 
records as well as pathology databases. Prevalent cases were identified using clinical 
coding and dietetic records. I identified 300 women alive with coeliac disease at 
Nottingham in March 2007. At the Royal Hallamshire Hospital, consecutive cases of 
incident and prevalent coeliac disease were identified using clinical and dietetic 
records as well as pathology and immunology databases. I identified 300 women alive 
with coeliac disease at Sheffield in May 2007. At Derby Hospitals NHS Foundation 
Trust, consecutive cases of incident coeliac disease were identified using clinical and 
dietetic records. Prevalent cases of coeliac disease were identified using a 
computerised coeliac disease database, co-ordinated and maintained by a single 
gastroenterologist since 1978. There are 781 women with coeliac disease that are alive 
in the Derby cohort. Extensive efforts were made to identify all incident and prevalent 
women with coeliac disease at these three centres in order that they could be invited to 
participate in the study. An adult is aged 18 years or over. A childhood diagnosis of 
coeliac disease was coeliac disease diagnosed at age 15 years or younger; all other 
cases were referred to as adulthood-diagnosed coeliac disease. 
5.1.2.2.2. Population-based cohort 
Coeliac UK is the principal national society for people with coeliac disease offering 
invaluable dietary guidelines and represents the largest population-based cohort of 
people with coeliac disease in the United Kingdom. It has over 70,000 registered 
members [personal email communication with Lawrence Munday, Database Manager, 
Coeliac UK] from which we selected all women over the age of 35 years who on their 
membership information had registered a current UK postal address and they had 
reported that they have coeliac disease. This excluded individuals who were members 
of Coeliac UK though did not have coeliac disease such as parents, guardians of 
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affected relatives and also representatives of external organisations such as 
pharmaceutical companies. We also excluded those individuals who had indicated on 
joining Coeliac UK that they did not wish to be contacted for research purposes by a 
third party. We then excluded those women with coeliac disease already included in 
our study by virtue of being NHS patients within the Nottingham, Sheffield and 
Derby historical cohorts described above in Chapter 2. This gave a population of 
29,954 women to select for our study population from which we did by generating a 
simple random sample of 9000 individuals using STATA 9.2 software. 
5.1.2.3. Inclusion criteria 
Females with coeliac disease who are at any stage of their disease. 
5.1.2.4. Exclusion criteria 
Significant co-morbidity that would prevent the study participants being well enough 
to take part. 
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5.1.2.5. Outcome measures 
" age at menarche (mean; proportion of women reaching menarche by age 11, 
12,13,14,15 and 16 years) 
" regularity of menstrual cycles (proportion of women with time from menarche 
to onset of regular menstrual cycles less than one year; and more than one 
year) 
age at menopause (mean; median; proportion of women still menstruating at 
age 45,46,47,48,49,50 years) 
" age at first full-term pregnancy (mean; proportion of women having first full- 
term pregnancy at age 19,21,25,29,33,42 years) 
" nulliparity (proportion) 
" 
breastfeeding (proportion of women never and ever breastfeeding; proportion 
of women with total breastfeeding duration of 12 or more months) 
" family history of breast cancer (proportion of women with one first degree 
relative with breast cancer, one first degree relative with breast cancer 
diagnosed under the age of 40 years, two first or second degree relatives with 
breast cancer diagnosed under the age of 60 years, or three first or second 
degree relatives with breast cancer) 
" previous benign breast disease (proportion of women with atypical epithelial 
hyperplasia, breast fibroadenosis, solitary breast cyst, diffuse cystic 
mastopathy, breast fibrosclerosis, mammary duct ectasia) 
" socioeconomic group (proportion of women in social class I and II) 
" 
body weight (mean; proportion of women weighing 62.0 
- 
67.4,67.5 
- 
74.9, 
>/ 75.0 kilograms; mean weight at age 20 years; mean adult weight change) 
" 
height (mean) 
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" body mass index (proportion of women with normal (18.6 
- 
24.9 kg/m2), 
underweight (\< 18.5 kg/m2), overweight (25.0 
- 
29.9 kg/m2), or obese (>/ 
30.0 kg/m2) body mass index) 
" alcohol intake (proportion of women who are non-drinkers; proportion of 
women consuming > 15 units of alcohol each week) 
" oral contraceptive use (proportions of women never and ever used and 
currently using oral contraceptive pill; proportion of women who start taking 
oral contraceptive pill before the age of 20 years; proportion of women within 
1- 9 years of stopping taking oral contraceptive pill) 
" hormone replacement therapy use (proportion of women ever used hormone 
replacement therapy; proportion of women taking hormone replacement 
therapy for 5,10 or 15 years or more) 
Below are descriptions of how I have defined the outcome measures used within this 
study. 
Definition 46: Age at first full-term birth 
Age in years at birth of their first child. 
Definition 47: Total breastfeeding duration 
Number of months each child was breastfed for added together. 
Definition 48: First degree relative 
Mother, sister or daughter. 
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Definition 49: Second degree relative 
Grandmother, granddaughter, aunt or niece. 
Definition 50: Atypical epithelial hyperplasia 
Refers to fibrocystic change with proliferation of epithelial cells with atypia in the 
ducts and lobules of the breast (ICD-10 code N60). Answer to question 14b in the 
questionnaire "Yes 
- 
had fibrocystic benign breast disease" and or documentation in 
the free text space given "atypical epithelial hyperplasia" "sclerosing adenosis" 
"fibrocystic mastopathy" "ductal hyperplasia" or "lobular hyperplasia". 
Definition 51: Breast fibroadenosis 
Refers to fibrous changes occurring within the lobules (ICD-10 code N60.2). Answer 
to question 14b in the questionnaire "Yes 
- 
had other form of breast disease" and 
documentation in the free text space given "fibrosis in breast" "fibroadenosis" 
"thickening of tissue" "fibrous tissue" "adenosis". 
Definition 52: Solitary breast cyst 
Refers to the presence of fluid-filled spaces that originate from the terminal ductal 
lobular unit or from an obstructed duct (ICD-10 code N60.0). Answer to question 14b 
in the questionnaire "Yes 
- 
had other form of breast disease" and documentation in 
the free text space given "cyst in breast' f. 4cyst" "cyst drained" "benign cyst" "lump in 
breast fluid drained" "non-malignant cyst". 
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Definition 53: Diffuse cystic mastopathy 
Refers to the presence of multiple fluid-filled spaces originating from the terminal 
ductal lobular unit or from an obstructed duct diffusely distributed through the breasts 
(ICD-10 code N60.1). Answer to question 14b in the questionnaire "Yes 
- 
had other 
form of breast disease" and documentation in the free text space given "multiple cysts 
in breast" "cystic change" "cysts throughout breast" "cystitis in all of breast". 
Definition 54: Breast fibrosclerosis 
Refers to cystic mastopathy with epithelial proliferation (ICD-10 code N60.3). 
Answer to question 14b in the questionnaire "Yes 
- 
had other form of breast disease" 
and documentation in the free text space given "fibrosclerosis". 
Definition 55: Mammary duct ectasia 
Refers to the condition in which there is an obstruction to the lactiferous duct (ICD-10 
code N60.4). Answer to question 14b in the questionnaire "Yes 
- 
had other form of 
breast disease" and documentation in the free text space given "duct ectasia" "milk 
duct blockage" "milk duct problem". 
Definition 56: Mean adult weight change 
Difference between reported baseline weight on enrolment to the study and recalled 
weight at 20 years. 
330 
5.1.2.4. Outcome ascertainment 
Female incident and prevalent cases of coeliac disease were invited to complete a 
questionnaire that examined the possession of exposures associated with the 
development of breast cancer. The questionnaire used is found in Appendix 7.6. and is 
the same questionnaire that was used in the European Prospective Investigation into 
Cancer (EPIC) multicentre prospective study [475]. There were a number of reasons 
for using the EPIC questionnaire. It is a standardised and validated questionnaire that 
can be self-completed [476]. The questionnaire collects detailed information on health 
and lifestyle, reproductive and sociodemographic characteristics including the 
participant's reproductive history, oral contraceptive and hormone replacement 
therapy use, an occupational history as well as life history of tobacco smoking and 
alcohol drinking. When this breast cancer risk profile in coeliac disease study was 
being designed, it was thought data from completed questionnaires in the EPIC- 
Norfolk cohort would be used as a general population control [personal 
communication with Professor K-T Khaw]. However in the course of this study we 
have not yet obtained the EPIC-Norfolk data and used alternative data as a control 
comparator as described in section 5.1.2.4. Like in the EPIC study, the questionnaire 
was either mailed to the study participants (both hospital-based and population 
cohorts) or given by hand during attendance at a routine outpatient clinic (hospital- 
based cohort only). The questionnaire was self-completed. Menarche self-reported in 
adulthood has been validated elsewhere [477]. 
As a patient support group, it is likely that there are members of Coeliac UK that have 
coeliac disease. However, family of affected coeliacs (such as mothers of affected 
children, wives of affected husbands) that do not have coeliac disease are also 
members of Coeliac UK. People with functional bowel disturbances whose symptoms 
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are helped with dietary exclusion such as wheat though do not have coeliac disease 
could also be members of Coeliac UK to utilise the dietary support offered by the 
organisation. The membership database has a field where gender is recorded though in 
some members this field may be not completed or completed incorrectly. In addition 
to those questions contained in the original EPIC questionnaire, we included 
screening questions to ensure the study participant was female and they had coeliac 
disease. 
Social class by current or last known occupation of the female coeliac was coded 
according to the Registrar General's classification [422] and grouped into categories: 
professional (social class I), managerial (social class II), non-manual skilled (social 
class IIIN), manual skilled (social class IIIM), manual semi-skilled (social class IV), 
manual unskilled (social class V) [422]. 
5.1.2.5. Controls 
Data from a number of different British birth cohort studies and other cohorts were 
used as a general population comparator. 
5.1.2.5.1. The Office of National Statistics Longitudinal Study 
The Office for National Statistics (ONS) Longitudinal Study has linked the birth 
registration and census records since 1971 for a 1% sample of all women in England 
and Wales [478]. Women born in two `birth cohorts' approximately ten years apart 
are used in the study - women born in 1954 - 1958 ('1950s birth cohort') and 1964 - 
1968 (11960s birth cohort') thus attaining ages 23 
- 
27 years in the Census years 1981 
and 1991 respectively, depending on the woman's exact year of birth within the five- 
year birth cohort. The 1960s birth cohort allow for estimation of the distribution of 
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age at first childbearing for the ages up to 33 years. The 1950s birth cohort however 
allow for estimation of the distribution of age at first childbearing through almost the 
entire range of potential ages of first childbearing and thus was the 1950s birth cohort 
was used as a general population comparator for proportion of women having first 
full-term pregnancy using the age bands used in the ONS Longitudinal study (19,21, 
25,29,33, and 42 years) [479]. When using the ONS Longitudinal Study 1950s 
cohort dataset as a control comparison to coeliac cohort, only those coeliacs born 
between five years before and five years after the age at entry were included in the 
analysis i. e. between 1949 and 1963. 
5.1.2.5.2. Office for National Statistics 
Proportion of female coeliacs that are nulliparous are compared to that of the general 
population using Birth Statistics from the Office for National Statistics [480]. 
Population estimates of women by ethnic group in 2007 in England from the Office 
for National Statistics [481] were used to compare the Caucasian proportion of the 
coeliac cohort to that of the general population. The 2001 Census was used to provide 
general population estimates of socioeconomic status by occupation of women aged 
between 16 
- 
74 years as a comparator to the socioeconomic status by occupation of 
women with coeliac disease of the same age [482]. 
5.1.2.5.3. Medical Research Council National Survey of Health and Development 
The first maternity survey in Great Britain took place in 1946, based on 13,687 of the 
16,695 births that took place between March 3 and 9 of 1946 [483]. Medical officers 
of health in 453 of 458 local authorities in England, Wales and Scotland at that time 
agreed to send health visitors to interview the mother at 8 weeks after the birth. The 
Medical Research Council (MRC) National Survey of Health and Development 
333 
(NSHD) is a birth cohort study consisting of a socially stratified sample of 2547 
women (and 2815 men) of these births [484,485]. There have been twenty-two 
follow-ups of the whole cohort, with the most recent being at age 53 years when 1563 
women provided information representing 61% of the original sample with the 
remainder either living abroad (11% of the original cohort), had withdrawn from the 
study at earlier follow-ups (12%) or had died (9%). The cohort remains nationally 
representative in most respects [486]. Dates of all live births have been collected 
throughout the adult life of the cohort with age at first birth grouped into <20 years, 
20 
- 
29 years and h 30 years [487]. The proportion of female coeliacs having first 
full-term pregnancy using these age bands was compared to that of the MRC NSHD 
data. Proportion of female coeliacs still menstruating was compared to that of the 
MRC NSHD data using the same age categories as in the control dataset (45,46,47, 
48,49, and 50 years) [488,489]. Mean height of female coeliacs was compared to that 
of the MRC NSHD 1946 and 1958 birth cohorts [490]. Proportion of female coeliacs 
of social class I and II was compared to that of the MRC NSHD data [491]. When 
using the MRC NSHD dataset as a control comparison to coeliac cohort, only those 
coeliacs born between five years before and five years after the MRC NSHD age at 
entry were included in the analysis i. e. between 1941 and 1951. 
5.1.2.5.4.1958 British Birth cohort 
This cohort included all children born in England, Scotland and Wales in the week of 
3-9 March 1958 [492] with information obtained on 11,714 (98.2%) births of the 
target population (17,733 births). Major follow-ups of surviving children in this 
longitudinal follow-up study (National Child Development Study (NCDS)) were 
conducted at ages 7,11,16,23 and 33 years [493]. Age at menarche for the female 
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coeliacs was compared to that of the NCDS data using the same age categories as in 
the NCDS control dataset (-11, 
-12, -13, -14, -15 and -16 years) [494]. Data on survey 
performed at 33 years in 1991 when information was collected on 11,405 (n = 5308 
women) members was used for a general population comparison for adult height 
(mean) [495]. When using the NCDS dataset as a control comparison to coeliac 
cohort, only those coeliacs born between five years before and five years after the 
NCDS age at entry were included in the analysis i. e. between 1953 
-1963. 
5.1.2.5.5. EPIC cohort 
The EPIC cohort consists of about 370,000 women (and 150,000 men) recruited 
between 1992 
- 
1998 in ten Western European countries of age range 45 
- 
70 years 
and of mean age 57.5 (SD 9.9) years [476]. As described in section 5.1.2.4. all study 
participants provided extensive standardized questionnaire data as well as 
anthropometric measurements. Mean age at menarche and mean age at menopause in 
the female coeliac cohort were compared to that data from a random sample of the 
EPIC cohort [308]. Age at first full-term pregnancy (<22 years, 22 
- 
24,25 
- 
27,28 
- 
30, and 31+ years) from EPIC-France dataset was also used as a general population 
comparator [496]. Mean recalled weight at 20 years, baseline weight and mean adult 
weight change in the female coeliac cohort were compared to 24,515 UK-EPIC 
control data [497]. Mean weight, height were compared to that of 40,273 EPIC 
control data [309]. When using the EPIC dataset as a control comparison to coeliac 
cohort, only those coeliacs aged between 45 - 70 years were included in the analysis. 
5.1.2.5.6. UK National Case-Control Study Group 
This study included incident cases of breast cancer in 3 discrete time periods (1 
January 1982 
- 
31 December 1985; 1 January 1988 
- 
30 June 1989; 1 July 1990 
- 
30 
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June 1991) identified through regional cancer registries were age-matched to controls 
randomly selected from the list of the case's general practitioner. Data on use of oral 
contraceptives, regularity of menstrual cycles, family history of breast cancer from 
this study was used as a general population comparator to the female coeliac data 
[300]. 
5.1.2.5.7. Infant Feeding Surveys 
The Infant Feeding Survey is the national survey of infant feeding practices [498- 
502]. Surveys have been conducted every five years since 1975 and based on an initial 
national representative sample of babies born in the United Kingdom (in the Infant 
Feeding Survey 2000,9,500 mothers of babies born in the United Kingdom were 
studied). The main aim of the survey is to provide national estimates on the incidence, 
prevalence and duration of breastfeeding and other feeding practices adopted by 
mothers from the birth of their baby up to around nine months. The survey also 
collects information on the smoking and drinking behaviour of mothers before, during 
and after pregnancy. As well as national estimates the survey is also designed to 
provide individual estimates for the four countries of the United Kingdom. The survey 
uses a panel design, with three stages of data collection being carried out over a 9-12 
month period in order to capture feeding practices at different ages. Wave 1 is carried 
out when the babies are approximately 6- 10 weeks old, Wave 2 when they are 
approximately 4-5 months old, and Wave 3 when they are approximately 8-9 
months old. 
The sampling frame in each country consisted of all registrations for births on the 
selected dates that were received by the appropriate registration office within a 
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specified sampling period up to a maximum of eight weeks after the birth [501]. The 
samples in each country were selected from births occurring in a given range of dates 
between August and October of the year of the survey and were designed to be 
representative of all births in these periods. The number of days chosen varied 
between countries, and depended on the estimated number of births in each social 
class group which would be registered within the sampling period and other details of 
the sampling scheme in each country. Typical response rate for the surveys was 
approximately 70%. For example, for the Infant Feeding Survey 1995 72% of the 
original sample of women responded to the first stage questionnaire; response at the 
second stage of the survey was higher than at the first stage, ranging from 86% in 
Scotland to 91% in Northern Ireland (the improvement in response rate was thought 
largely attributable to the interviewer follow-up of non-respondents); and at Stage 3, 
the total response was 88%. 
Data from 1980,1985,1990,1995 and 2000 Infant Feeding Surveys were used as a 
general population comparator to the incidence and prevalence of breastfeeding 
amongst women with coeliac disease. Incidence of breastfeeding was defined in the 
Survey as the proportion of babies who were breastfed initially. This included all 
babies who were put to the breast at all, even if this was on one occasion only. 
Prevalence of breastfeeding was defined as the proportion of all babies who were 
being breastfed at specific ages. When using the Infant Feeding Survey datasets as a 
control comparison to coeliac cohort, only those coeliacs giving birth 2 years before 
or 2 years after or during the year of the Survey were included in the analysis. For 
example, when using the 1980 Infant Feeding Survey as a general population 
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comparator, women who gave birth between 1978 
- 
1982 were included in the 
analysis. 
5.1.2.5.8. Million Women's Study 
The Million Women Study is a population-based cohort study, recruiting women aged 
between 50 
- 
64 years of age. Participating UK National Health Service Breast 
Screening Programme screening centres sent a questionnaire at the time they were 
sent their usual invitation for routine breast screening. The questionnaire is included 
with each woman's invitation for breast screening and returned at the time she was 
screened. It includes questions about lifestyle and sociodemographic factors, 
reproductive history, past use of oral contraceptives, use of HRT, past medical history 
and family history of breast cancer [503]. The proportion of coeliacs with a mother 
and or sister with a history of breast cancer was compared to that in the Million 
Women Study. When using the Million Women Study as a general population 
comparison cohort, only female coeliacs aged between 50 - 64 years of age were 
included in the analysis. 
5.1.2.6. Potential confounders 
Age, socio-economic class. 
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5.1.2.7. Statistical analysis 
Descriptive analyses with calculation of mean and median were performed. 
Comparisons between the female coeliac cohort and the general population controls 
were performed using Chi-squared tests for binary outcomes and between continuous 
data such as mean age at menarche using unpaired t-tests. 
We considered a p-value of 0.05 to represent statistical significance in all tests. All 
analyses were performed using Stata SE 9.2 [TexCorp]. 
5.1.2.8. Ethical approval 
5.1.2.8.1. Hospital-based cohort 
North Staffordshire Local Research Ethics Committee gave ethical approval 
(reference 061Q2604/91) to this study in October 2006. Nottingham University 
Hospital gave research and development approval (reference 06GM012) to this study 
in January 2007. Derby Hospitals NHS Foundation Trust gave research and 
development approval (reference DHRD/2007/005) in April 2007. Royal Hallamshire 
Hospital gave research and development approval (reference STH14597) in March 
2007. 
5.1.2.8.2. Population-based cohort 
Nottingham Medical School Research Ethics Committee gave ethical approval 
(reference J/9/2007) to this study in January 2008. 
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5.1.3. Results 
5.1.3.1. Study population 
907 of the invited 1345 (response rate 67.4%) women of the historical cohort and 
6663 of the invited 9000 (response rate 74.0%) women of the population-based cohort 
completed the study questionnaire. Following excluding 42 participants derived from 
the population-based cohort due to uncertainty re their gender (n = 3) and answering 
that they did not have coeliac disease in the screening questions (n = 39), 7528 
women with coeliac disease were therefore included in our study (Figure 5.26). 
Figure 5.26: Response rate to study 
Historical hospital-based cohort 
1345 women identified as having 
coeliac disease and had attended: 
- 
Derby (n = 781) 
- 
Nottingham (n = 297) 
- 
Sheffield (n = 267) 
hospitals invited to participate in study 
Population-based cohort 
Coeliac UK membership 
9000 female coeliacs invited 
907 (67%) returned questionnaires 6663 (74%) returned questionnaires 
42 study participants excluded: 
- 
uncertainty re gender (n = 3) 
- 
uncertainty re coeliac status (n = 39) 
7528 study participants from 10345 invited coeliacs 
(73% response rate) 
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5.1.3.1. Demography of cohort 
The mean age at entry to the study was 58.6 (SD 12.5) years with the median age 59 
(interquartile range 49 
- 
67) years. The mean age at diagnosis of coeliac disease was 
42.5 (SD 15.7) years with 91.3% (n = 6872) of the coeliacs diagnosed in their 
adulthood years. 97.9% (n = 7370) coeliacs reported they were taking a gluten-free 
diet with the mean duration of consuming a gluten-free diet 28.8 (SD 18.7) years. 
96.9% female coeliacs were Caucasian which was a significantly greater proportion 
than that of the English general population (89.5%); p=0.00001 [424]. The 
proportion of Caucasian coeliacs was similar in the hospital-based and population- 
based cohorts. 
5.1.3.2. Social class 
The proportion of women from social classes I and II based on current or last 
occupation was significantly greater in the coeliac cohort (n = 2243) than in the 2001 
Census general population [482] comparator (48.0%; 95%CI 46.5,49.4 versus 34.2%; 
95%CI 34.2,34.3, respectively); p=0.00001. A similar trend was observed when 
using the MRC NSHD study [491] as a comparator (Table 5.53). The proportion of 
female coeliacs from affluent social classes was similar in the hospital-based and 
population-based cohorts. 
5.1.3.3. Age at menarche 
The mean and median age at menarche was 13.4 (SD 1.7) years and 13 (interquartile 
range 12 
- 
14) years, respectively. On comparison to the EPIC controls, there was no 
difference in mean age at menarche (13.3 (5th 
- 
95th centile: 11.0 
- 
16.0) versus 13.3 
(5th 
- 
95th centile: 11.0 
- 
16.0), respectively); p>0.05 [308]. However a significantly 
greater proportion of coeliac women had started menstruating early in life in 
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comparison to the general population [494] controls (16.8%; 95%C1 15.1,18.4 versus 
2.2%; 95% 1.8,2.6, respectively); p=0.00001 (Table 5.53). 
Table 5.53: Social class, age at menarche and regularity of menstrual cycles in 
coeliac disease and comparison cohorts 
Variable Coeliac disease cohort Comparison cohort p-value 
N % N % 
Social classy 
-I and II 644 26.4 281 20.4 0.00001 
Age at menarcheD 
(years) 
- 
11 328 16.8 97 2.2 0.00001 
- 
12 274 14.0 584 13.2 0.3 
- 
13 452 23.1 1063 24.0 0.5 
- 
14 396 20.3 1492 33.7 0.00001 
- 
15 263 13.5 868 19.6 0.9 
- 
16 133 6.8 221 5.0 0.0036 
- 
Missing data 39 2.0 102 2.3 
Time from 
menarche to onset 
of regular 
menstrual cycles' 
<1 year 1990 67.8 1157 78.1 0.00001 
>/ 1 year 782 26.7 325 21.9 0.00001 
Missing data 163 5.5 
a MRC National Survey of Health and Development 1946 (n = 1373) was used to 
provide general population estimates of socioeconomic status by occupation [491]. 
Only those coeliacs born between 5 years before and 5 years after the MRC study 
age at entry were included in the analysis i. e. between 1941 and 1951 (n = 2441) 
b National Child Development Study (NCDS) 1958 cohort (n = 4427) was used as a 
general population comparator for age at menarche [494]. Only those coeliacs born 
between 5 years before and 5 years after the NCDS study age at entry were included 
in the analysis i. e. between 1953 and 1963 (n = 1927). 
c Data on regularity of menstrual cycles from the UK National Case-Control Study 
Group was used as a general population comparator [300]. 
5.1.3.3. Regularity of menstrual cycles 
69.5% (n = 5235) had regular periods within months from starting menarche. Women 
with coeliac disease took longer to have regular menstrual cycles from the onset of 
menarche in comparison to the general population [300]. A significantly lower 
proportion of women in the coeliac cohort took less than one year from menarche to 
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onset of regular menstrual cycles in comparison to the control cohort (67.8%; 95%CI 
66.1,69.5 versus 78.1%; 95% 76.0,80.2, respectively); p=0.00001 (Table 5.53). 
Conversely, a significantly greater proportion of women with coeliac disease took 
more than one year to onset of regular menstrual cycles from the menarche onset in 
contrast to the control cohort (26.7%; 95%CI 25.1,28.2 versus 21.9; 95%CI 19.8, 
24.0, respectively); p=0.00001. 
5.1.3.4. Age at first full-term birth 
6599 (87.7%) of the coeliac cohort were parous with the mean age at first full-term 
birth 25.7 (SD 4.9) years. A lower proportion of women had their first full-term birth 
aged 30 years or over in the coeliac cohort in comparison to the control [487] cohort 
(25.3%; 95%CI 23.7,26.9 versus 33.3%; 95%CI 32.5,34.1, respectively); p= 
0.00001. Though relative to the comparison cohort [479], coeliac women had a lower 
proportion having their first full-term birth by 19 years, they appeared to `catch up' 
with a higher proportion having their first full-term birth by 30 years (Table 5.54). 
5.1.3.5. Nulliparity 
12.2% (n = 920) of the coeliac cohort were nulliparous. Coeliac women were less 
likely to be nulliparous in comparison to the comparison [480] cohort (proportion 
nulliparous 9.3%; 95%CI 8.1,10.5 versus 12.4%; 95%CI 10.5,14.3); p=0.0042. 
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Table 5.54: Age at first full-term birth, nulliparity and incidence of breastfeeding 
in coeliac disease and comparison cohorts 
Variable Coeliac disease cohort Comparison cohort p-value 
N % N % 
Age at first full- 
term birth (years)' 
- 
19 233 8.4 1638 13.7 0.00001 
- 
21 719 25.8 1280 10.7 0.00001 
- 
25 674 24.2 2774 23.2 0.3 
- 
29 459 16.5 2284 19.1 0.0013 
- 
33 269 9.7 1280 10.7 0.1 
- 
42 3 0.1 801 6.7 0.00001 
Missing data 28 1.0 
Nulliparity 
- 
Nulliparous 227 9.3 145 12.4 0.0042 
Missing data 9 0.1 
Incidence of 
breastfeeding 
- 
1980 287 73.2 2516 67.0 0.0124 
- 
1985 276 76.0 3036 65.0 0.00001 
- 
1990 242 71.2 2965 64.0 0.0075 
- 
1995 180 81.1 3127 68.0 0.00001 
- 
2000 109 80.2 3863 71.0 0.0199 
Missing data 50 
Incidence of 
breastfeeding by 
social class 
1995 
-I 14 93.3 275 91.0 0.8 
- 
II 62 76.5 943 82.0 0.2 
- 
IIIN 40 78.4 255 72.0 0.3 
- 
IIIM 5 71.4 724 65.0 0.7 
- 
IV 31 83.8 280 58.0 0.0021 
-V - - 82 50. - 
2000 
-I 12 80.0 336 91.0 0.2 
- 
II 40 81.6 1153 84.0 0.7 
- 
IIIN 24 75.0 367 79.0 0.6 
- 
HIM 6 100 909 65.0 
- 
- 
IV 11 91.7 359 62.0 0.0355 
-V - - 129 59.0 - 
a ONS Longitudinal Study 1950s cohort (n =11958) used as comparison dataset 
[479]. Only those coeliacs born between 5 years before and 5 years after the ONS 
study age at entry were included in analysis i. e. between 1949 and 1963 (n = 2788). 
b Birth Statistics, Office for National Statistics, provided general population data[480] 
c Data from the 1980,1985,1990,1990,1995 and 2000 Infant Feeding Surveys were 
used as a general population comparator for breastfeeding practices [496-500]. Only 
those coeliacs giving birth 2 years before or 2 years after or during the year of the 
survey were included in the analysis. 
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5.1.3.6. Breastfeeding 
3972 (60.2%) of the 6599 parous women with coeliac disease breastfed. The mean 
total number of months breastfed was 10.9 (SD 10.4) months with 21.0% (n = 1388) 
of the parous coeliacs breastfeeding for a total of 12 months or more. The incidence of 
breastfeeding was significantly greater in the coeliac cohort in comparison to the 
control cohort [496-500] (Table 5.54). For example, the incidence of breastfeeding of 
babies in 1980 in the coeliac cohort was 73.2% (95%CI 68.8,77.6) versus 67.0% 
(95%CI 65.5,68.5). In comparison to the general population cohort, breastfeeding 
incidence did not appear to fall with more deprived socioeconomic status in the 
coeliac cohort (Table 5.54). If anything the converse was observed with higher 
proportions of coeliacs breastfeeding from more deprived social classes than the 
proportions of coeliacs breastfeeding in least deprived social classes (91.7% of 
coeliacs of social class IV (below average class) who gave birth between 1998 - 2002 
breastfed in comparison to 62% of the women in 2000 Infant Feeding Survey used as 
a general population comparator). 
5.1.3.7. Age at menopause 
5540 (73.6%) of the coeliac cohort reported that they had stopped menstruating with 
the mean and median age at menopause for the coeliac cohort for those whom had 
provided information on menopause (n = 5166) was 47.6 (SD 6.4) years and 49 (IQR 
44 
- 
72) years, respectively. Women with coeliac disease had a younger mean age at 
onset of the menopause in comparison to the general population [308] comparison 
cohort (47.8 years; 95%CI 47.5,48.0 versus 49.0 years; 95%CI 48.7,49.3) p= 
0.00001. 
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5.1.3.8. Oral contraceptive and hormone replacement therapy use 
68.7% (n = 5171) coeliacs reported to have ever used the oral contraceptive pill 
(OCP). 39.7% (n = 2041) of OCP users had started to take the OCP before the age of 
20 years. Only 9 coeliacs were current users of the OCP proportion of women with 
201 coeliacs within 1- 9 years of stopping taking the OCP. 
2705 (44.8%) coeliac women of the 5540 that had stopped menstruating had ever used 
hormone replacement therapy (HRT). 1584 (58.6%) of the HRT users in the coeliac 
cohort had taken HRT for 5 or more years. 
5.1.3.9. Benign breast disease 
9% (n = 673) of the cohort reported history of breast disease of which fibrocystic 
change (n = 376) was the most common. 181 of the cohort had been diagnosed with 
breast cancer. 1% (n = 41) of the cohort reported breast fibroadenosis whereas diffuse 
cystic mastopathy was reported by 9 coeliacs. 1% of the cohort reported a history of 
solitary breast cysts. 7 of the cohort had been diagnosed with epithelial hyperplasia 
whereas 6 reported fibrosclerosis and 8 mammary duct ectasia. 
5.1.3.10. Weight, height and body mass index 
The mean height in 7304 coeliacs who had provided data was 162.0 (SD 7.2) 
centimetres (cm). There was no significant difference in observed mean height 
between women with coeliac disease and that of the general [490] population (161.7 
cm; 95%CI 161.4,162.0 versus 161.8 cm; 95%CI 161.5,162.1, respectively) born in 
the 1940s though a small but significant taller height amongst coeliac women born in 
the 1950s '(mean 162.8 cm; 95%CI 162.4,163.1 versus 162.4; 95%CI 162.3,162.5, 
respectively). Using the EPIC-UK cohort [309], coeliac women were shorter than the 
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general population counterparts (mean 162.1 cm; 95%CI 161.9,162.2 versus 163.4 
cm; 95%CI 163.3,163.5, respectively) though 2 kilograms heavier (mean weight 66.0 
kg; 95%CI 65.6,66.3 versus 63.9 kg; 95%CI 63.8,64.0, respectively); p=0.00001. 
The mean BMI of the coeliac cohort was within normal range (24.9 (SD 4.5) kg/m2). 
In keeping with the shorter height but heavier weight, the mean BMI of the coeliac 
women was higher than that of the EPIC-UK comparison cohort (25.1; 95%CI 25.0, 
25.3 versus 24.0; 95%CI 23.9,24.0, respectively); p=0.00001. 
5.1.3.11. Alcohol consumption 
77.1% (n = 5804) drank alcohol with mean intake per week 6.0 (SD 5.6) units. 4.4% 
(n = 330) coeliacs drank 15 or more units of alcohol each week. 
5.1.3.12. Family history of breast cancer 
The prevalence of breast cancer within the coeliac cohort was 2.6% (n = 195). 23.3% 
(n = 1750) of the female coeliacs had a family history of breast cancer. 1098 (14.6%) 
of coeliacs had one or more first degree relative with breast cancer with 79 of these 
coeliacs having one or more first degree relative with breast cancer diagnosed under 
the age of 40 years. 28 coeliacs had two or more second degree relatives with breast 
cancer diagnosed under the age of 60 years. 6 of the coeliac cohort had three first or 
second degree relatives with breast cancer. 
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5.1.3.13. Odds of possessing breast cancer risk exposures 
The breast cancer risk profile of the coeliac cohort compared to the general population 
is summarised in Table 5.55. 
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5.1.4. Discussion 
5.1.4.1. Principal findings 
The breast cancer risk profile suggests both protective and adverse associations of 
coeliac disease. The higher proportion of women being parous, having their first full- 
term pregnancy before 30 years and breastfeeding in addition to the younger mean age 
at menopause suggests women with coeliac disease have favourable breast cancer risk 
profile features in comparison to the general population. However, the higher 
likelihood of being Caucasian and of affluent social class together with higher 
proportion having early menarche and irregular menstrual cycles suggests there are 
also potentially adverse breast cancer risk profile features associated with coeliac 
disease. Having similar height to the general population and BMI within normal range 
suggests anthropometric exposures may not explain the apparent reduced risk of 
breast cancer in women with coeliac disease to the general population. 
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5.1.4.2. Limitations and merits 
This is the first cross-sectional survey where there has been systematic and routine 
collection of breast cancer risk profile in a contemporary and population-based cohort 
of women with coeliac disease. While we cannot be certain that we have identified 
every woman diagnosed or treated with coeliac disease in all three hospitals during 
the study period to generate the historical cohort component of the study, we made 
extensive efforts to do so. Coeliac UK is the principal national society for people with 
coeliac disease and represents the largest assembled and population-based cohort of 
people with coeliac disease in the United Kingdom with over 70,000 registered 
members. One could argue that the use of such members who have voluntarily sought 
help and advice from Coeliac UK may differ in their attitudes, behaviours and health 
status compared to those coeliacs who are non-members, introducing selection bias 
into the study. Nevertheless, at the time the study commenced, membership of Coeliac 
UK was free to join with a freepost paper (also available online) application form 
which was encouraged to be distributed to all those newly diagnosed with coeliac 
disease by anyone involved with managing coeliac disease with the incentive of 
receiving the free and useful food directory. In our study, the reported age at 
diagnosis and breast cancer risk profile in those coeliacs of the Coeliac UK cohort 
was similar to that reported by those coeliacs of the historical cohort suggesting it is 
unlikely the Coeliac UK study participants were unrepresentative of contemporary 
coeliac disease. 
The use of a self-completed questionnaire to ascertain the outcomes of interest was a 
further source of selection bias in the study with responders likely to differ in their 
attitudes, behaviours and health status compared to non-responders. However it is 
difficult to imagine how better ascertainment of outcomes involving such large 
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numbers of population-based female coeliacs could be achieved. The questionnaire 
used is a standardised and validated questionnaire was that used in the EPIC 
prospective study that can be self-completed [475,476]. Equal time and effort was 
spent in inviting each potential study participant to take part in the study with two 
further contacts made to non-responders after a designated lapsed time period using a 
standardised recruitment protocol. Recall of ages at menarche and pregnancy-related 
events is subject to recall error and bias because it was not collected at the time of the 
events. However recall of self-reported menarche and pregnancy-related events in 
adulthood has been validated with correlation coefficients 0.65 
- 
0.75 observed in 
studies comparing recalled measures with prospective measures [477,504-506]. 
Validity has been observed to improve by categorising ages such as age at menarche 
which was used in this study's questionnaire [477]. 
As a patient support group, it is likely members of Coeliac UK have coeliac disease. 
However, family of affected coeliacs (such as mothers of affected children, wives of 
affected husbands) that do not have coeliac disease but are also members of Coeliac 
UK, principally to make use of the dietary guidelines. People with functional bowel 
disturbances whose treatment involves wheat exclusion may also be members of 
Coeliac UK for the dietary advice. With the diagnosis of coeliac disease not 
specifically validated within the Coeliac UK database, we included several different 
screening questions to minimise misclassification bias. In addition to the coding of 
gender in the Coeliac UK electronic database, we included screening questions to 
ensure that the study participant was female. Like with coeliac status, if there was any 
uncertainty re gender status the study participant was excluded from the study. Study 
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participants from the historical cohort were known to have coeliac disease based on 
findings from histopathology, immunological and clinical records. 
British birth cohorts are thought to be national and representative samples of the 
general population and as such were used as a general population comparator. Data 
has been systematically collected from early life to adulthood by trained data 
collectors on infant feeding; occupation, education and training; fertility and physical 
measures with repeated measures. Knowing the time period of when the coeliacs were 
born allowed appropriate control groups to be drawn up from the same period in the 
British birth cohorts. Several different control cohorts were used as the comparator to 
the coeliac cohort for a particular outcome of interest with findings consistent 
irrespective of the control cohort used. Some of the British birth cohort studies were 
somewhat limited by exclusion of births to the unmarried but that was in part dictated 
by the available technology at the time and lack of access to the Adoption Register at 
a time when many births to the unmarried were adopted. 
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5.1.4.3. Comparison with other studies 
Our observation that female coeliacs have earlier onset of menopause is in keeping 
with previous findings [320,321]. It is unclear why female coeliacs have an earlier 
onset of age at natural menopause which has been proposed as a marker of ovarian 
toxicity for environmental and early life factors that may directly or indirectly damage 
the follicular pool [507]. Whether due to more rapid metabolism of oestrogen, lower 
oestrogen levels, interference with oestrogen receptor binding, or accelerated follicle 
ageing by hydrocarbons contained in smoke, cigarette smoking is consistently 
associated with an earlier age of menopause onset [508-510]. However, two-thirds of 
the coeliac cohort had never smoked and were significantly less likely to smoke in 
comparison to age-matched general population controls from 1958 Birth Cohort and 
EPIC-Norfolk [511 ]. In our study, female coeliacs were less likely to be nulliparous 
and had the same parity as general population controls [512] suggesting reproductive 
characteristics [513] are not implicated in causing earlier age at menopause in 
coeliacs. Greater weight [509] and taller height [514] predispose to a later age and 
caloric restriction to an earlier age at menopause [515] though coeliacs having similar 
height and BMI within normal range suggests that anthropometric exposures may not 
explain the earlier onset of menopause in coeliacs. Given that the pool of primordial 
f6llicles is formed during fetal development, the association of lower birthweight, 
lower infant and childhood weight, poorer childhood socioeconomic conditions with 
earlier menopause have suggested early life factors acting in utero or in early 
childhood play a role in determining age at menopause [489,516]. In our related 
study based on the same study population, female coeliacs were more likely to have 
fathers who were from non-manual and more affluent occupational social classes than 
the general population cohort and thus exposed to more affluent childhood 
socioeconomic exposures [511]. 
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Our observation that women with coeliac disease are more likely to have a younger 
age of menarche is in contrast to previous studies [320,321]. However these studies 
were highly selected, hospital-based case series of women with coeliac disease with 
the larger study observing only 130 coeliacs [320]. Age at menarche is an indicator of 
puberty and onset of sexual maturation, controlled by a complex of known and 
unknown genetic and environmental factors. Weight, height and velocity of growth 
are associated with early age at menarche again suggesting favourable early life and 
childhood environmental exposures such as good nutrition are implicated in 
menarcheal age [517,518]. In our related study based on the same study population, 
female coeliacs were more likely to have fathers who were from non-manual and 
more affluent occupational social classes than the general population cohort and thus 
exposed to more affluent childhood socioeconomic exposures [511 ]. Though we do 
not know of any delay in leading to the diagnosis of their coeliac disease, our female 
coeliacs attained similar height to general population comparators with 91% of our 
study participants being diagnosed with coeliac disease in their adulthood years (mean 
age at diagnosis of all coeliacs 42.5 years) suggesting that coeliacs tended to have 
favourable nutritional exposures during early childhood or do not get coeliac disease 
until they are adults. However, the tendency for coeliacs to have irregular menstrual 
cycles during their teenage years observed in our study may suggest enteropathy- 
related nutritional, immunological or some other factors might have come into force. 
Despite female coeliacs possessing a number of high-risk aetiological factors such as 
higher likelihood of being Caucasian (relative risk >5 compared to Asian), of more 
affluent social class (relative risk 2 for social classes I and II to manual classes), of 
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having earlier menarche (relative risk 3 for age at menarche before age 11 years) and 
irregular menstrual cycles (relative risk 1.25 for more than 1 year to onset of regular 
cycles to less than 1 year), published studies have observed coeliac disease is 
associated with a more than 50% reduced risk of breast cancer [265,282,283,287, 
318]. Whether this is in part due to the favourable breast cancer risk profile offered by 
coeliac disease such as higher proportion being parous (25% reduced risk compared to 
nulliparous women), having first-term birth before the age of 30 years (2-fold 
decreased risk in comparison to age at 40 years), earlier age at menopause (relative 
risk 2 for menopause after age 54 years) or that traditional aetiological factors have a 
less of a role to play in coeliac disease in comparison to non-coeliacs it is not clear. 
Further work is required to further explore non-reproductive and non-hormonal 
factors such as immunological mediators or gene loci associated with coeliac disease 
that could be implicated in the reduced risk of breast cancer in coeliac disease. 
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5.1.4.4. Summary 
The breast cancer risk profile suggests both protective and adverse associations of 
coeliac disease. The higher proportion of women being parous, having their first full- 
term pregnancy before 30 years and breastfeeding in addition to the younger mean age 
at menopause suggests women with coeliac disease have favourable breast cancer risk 
profile features in comparison to the general population. However, the higher 
likelihood of being Caucasian and of affluent social class together with higher 
proportion having early menarche and irregular menstrual cycles suggests there are 
also potentially adverse breast cancer risk profile features associated with coeliac 
disease. Having similar height to the general population and BMI within normal range 
suggests anthropometric exposures may not explain the apparent reduced risk of 
breast cancer in women with coeliac disease to the general population. Whether the 
overall effect of these factors is to confer a protective effect or there are as yet 
unknown reasons further work is required to help explain the apparent reduced risk of 
breast cancer in women with coeliac disease. 
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Chapter 6: Thesis conclusions 
6.1. Principal findings 
The principal findings of this thesis are that: 
" Coeliacs with mild enteropathy have few biochemical deficiencies at diagnosis 
of coeliac disease and show no important biochemical improvements 
following treatment with a gluten-free diet in comparison to those with severe 
enteropathy coeliac disease. 
" There is a strong, independent graded association between the incidence rate 
of new diagnoses of coeliac disease and socio-economic status with the rate 
twice as high in adults from affluent areas compared with that in adults living 
in poorer areas. 
" 
Hypertransaminasaemia is uncommon affecting less than 2% of newly 
,, 
diagnosed adults with coeliac disease and in those coeliacs with an abnormal 
test the majority normalised following a year of treatment with a gluten-free 
diet. 
" At diagnosis coeliacs have much lower total cholesterol levels than the general 
population with the observed reduction greater in men (21%) than in women 
(9%) with no increase in total cholesterol observed on treatment with a gluten- 
free diet. 
" 
Coeliac disease has both protective (such as lower mean levels of total 
cholesterol, LDL cholesterol, fibrinogen; the higher likelihood of being from 
more affluent social class; and the small but significant rise in HDL 
cholesterol) and adverse effects (such as higher likelihood of having 
abdominal truncal obesity amongst incident coeliacs that only worsens 
following treatment with a gluten-free diet) on vascular risk profile. 
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" The quality of life reported by coeliacs presenting with silent disease, classic 
disease and with gastrointestinal symptoms is worse than that observed in the 
general population. However a year's treatment with a gluten-free diet results 
in coeliacs having similar or in some components better quality of life than 
that observed in the general population. The rate of change of quality of life 
was similar amongst those coeliacs with silent, classic or symptomatic disease. 
" 
Coeliac disease has both protective (such as higher proportion of women being 
parous, having their first full-term pregnancy before 30 years and 
breastfeeding in addition to the younger mean age at menopause) and adverse 
effects (higher likelihood of being Caucasian and of affluent social class 
together with higher proportion having early menarche and irregular menstrual 
cycles) on breast cancer risk profile 
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6.2. Interpretation 
Clinically diagnosed coeliac disease is associated with morbidity but also benefits to 
health. Although there are clearly some negative health effects such as anaemia and a 
reduction in quality of life whether presenting with silent coeliac disease or with 
gastrointestinal symptoms, physiological derangements normalise and quality of life 
improves with a year's treatment with a gluten-free diet. Coeliacs have much lower 
total cholesterol than the general population with no change on treatment with a 
gluten-free diet. The lower prevalence of hypertransaminasaemia in incident coeliac 
disease and the association of hypertransaminasaemia with clinical and histological 
features of more severe coeliac disease may suggest contemporary coeliac disease has 
a milder disease spectrum in comparison to earlier periods. There is no obvious 
physiological benefit in treating mild enteropathy coeliac disease though the risk of 
morbidity such as malignancy and mortality as well as possible benefits of treatment 
upon symptoms needs further clarification. Adverse anthropometric profiles such as 
tendency to be overweight or obese at diagnosis of coeliac disease with a higher 
likelihood of abdominal truncal obesity highlights the changing face of contemporary 
disease and may help to explain the increased risk of vascular disease events observed 
in some but not all studies. Whether the observed association between incidence rate 
of coeliac disease and affluence is a reflection of the variation in envirpnmental 
exposures to aetiological factors such as breastfeeding or could be accounted for by 
differences in uptake and utilisation of health services it is unclear but further work to 
unravel the contribution of social class to the aetiology and incidence of coeliac 
disease is required. Either the overall effect of factors such as a reduced higher 
proportion of women being parous, having their first full-term pregnancy before 30 
years and breastfeeding in addition to the younger mean age at menopause confers a 
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protective effect or there as yet unknown explanations to the apparent reduced risk of 
breast cancer in women with coeliac disease. 
6.3. Recommendations for future work 
6.3.1. Mild enteropathy coeliac disease 
Further approaches to clarify the impact of mild enteropathy versus severe 
enteropathy are suggested by this work. In the future, a survival analysis and cancer 
registry linkage carried out on this cohort would give information about the mortality 
and malignancy risk in those people with mild enteropathy coeliac disease compared 
to those with severe enteropathy disease. The cohort size may result in such a study 
being dependent on a longer follow-up period before a meaningful analysis could be 
undertaken. Using a similar longitudinal study design to the vascular risk profile study 
in this thesis, the effect of treatment with a gluten-free diet upon quality of life and 
symptoms in coeliacs newly diagnosed with mild versus severe enteropathy disease 
should be performed. 
6.3.2. Screening for silent coeliac disease 
A number of studies have observed that clinically diagnosed coeliac disease still 
confers a 1.3 to 2-fold increased risk of all-cause mortality compared with the general 
population. Recent data suggests people with latent coeliac disease have also an 
increased risk of death. We have observed people with silent coeliac disease have a 
reduction in quality of life in comparison to the general population which improves 
with treatment with a gluten-free diet. However silent coeliacs appear to have the least 
favourable cholesterol and waist: hip circumference profile at diagnosis with the 
degree of abdominal truncal obesity worsening with treatment and cholesterol profile 
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not improving with treatment. It is unclear whether people with silent coeliac disease 
share similar risks of mortality and vascular events to coeliacs with gastrointestinal 
symptoms. In the future, a survival analysis of all-cause and vascular-related deaths 
carried out on this cohort would give information about the mortality risk in those 
people with silent disease and so help contribute to the discussion as to whether 
screening for silent coeliac disease should be performed or not. 
6.3.3. Incidence of coeliac disease and socioeconomic status 
The incidence of coeliac disease by socioeconomic status could be further explored by 
determining the socioeconomic distribution of people who are being screened for 
coeliac disease in both a primary care and hospital setting. Such a study could be 
performed by determining the IMD07 score of each serological test requested by 
source of referral (general practitioner; hospital-based referral) through searching 
immunological databases. Further work is underway using the study cohort of chapter 
5 to compare the childhood socioeconomic status using father's occupational social 
class in women with coeliac disease compared to the general population. 
6.3.4. Fertility of women with coeliac disease 
Data from the study cohort of chapter 5 is being used to examine the fertility 
experience of women with coeliac disease compared to the general population to 
further assess the impact of clinically diagnosed coeliac disease. 
6.3.5. Vascular risk profile in coeliac disease 
We have used anthropometrics such as waist: hip ratio to reflect the presence of 
abdominal truncal obesity though more accurate quantitation of intraabdominal 
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visceral fat mass and distribution at diagnosis of coeliac disease and any change with 
a gluten-free diet could be achieved with the use of dual-energy x-ray absorptiometry 
(DEXA) or computerised tomography measurements. Carotid artery intima and media 
thickness at diagnosis of coeliac disease (classic, those with gastrointestinal 
symptoms, silent disease) and following treatment with a gluten-free diet could be 
non-invasively measured in a longitudinal cohort study, providing a surrogate marker 
for a vascular disease outcome thereby reducing the need for a longer follow-up 
period. The intima and media thickness could also be modelled against predictor 
variables such as presence of villous atrophy, tissue transglutaminase titres using 
logistic regression. 
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Chapter 7: Appendices 
Appendix 7.1. Sheffield geographically defined by super 
output area 
Region Local 
Authority 
Lower Layer 
SOA Code 
Middle Layer 
SOA 
Lower Layer 
SOA 
Yorkshire and The Humber Sheffield E02001611 Sheffield 001 Sheffield 001A 
Yorkshire and The Humber Sheffield E02001611 Sheffield 001 Sheffield 001C 
Yorkshire and The Humber Sheffield E02001611 Sheffield 001 Sheffield 001D 
Yorkshire and The Humber Sheffield E02001611 Sheffield 001 Sheffield 001E 
Yorkshire and The Humber Sheffield E02001611 Sheffield 001 Sheffield 001 B 
Yorkshire and The Humber Sheffield E02001612 Sheffield 002 Sheffield 002D 
Yorkshire and The Humber Sheffield E02001612 Sheffield 002 Sheffield 002C 
Yorkshire and The Humber Sheffield E02001612 Sheffield 002 Sheffield 002A 
Yorkshire and The Humber Sheffield E02001612 Sheffield 002 Sheffield 002B 
Yorkshire and The Humber Sheffield E02001613 Sheffield 003 Sheffield 003B 
Yorkshire and The Humber Sheffield E02001613 Sheffield 003 Sheffield 003A 
Yorkshire and The Humber Sheffield E02001613 Sheffield 003 Sheffield 003C 
Yorkshire and The Humber Sheffield E02001613 Sheffield 003 Sheffield 003D 
Yorkshire and The Humber Sheffield E02001613 Sheffield 003 Sheffield 003E 
Yorkshire and The Humber Sheffield E02001613 Sheffield 003 Sheffield 003F 
Yorkshire and The Humber Sheffield E02001613 Sheffield 003 Sheffield 003G 
Yorkshire and The Humber Sheffield E02001614 Sheffield 004 Sheffield 004A 
Yorkshire and The Humber Sheffield E02001614 Sheffield 004 Sheffield 004E 
Yorkshire and The Humber Sheffield E02001614 Sheffield 004 Sheffield 004C 
Yorkshire and The Humber Sheffield E02001614 Sheffield 004 Sheffield 004D 
Yorkshire and The Humber Sheffield E02001614 Sheffield 004 Sheffield 004B 
Yorkshire and The Humber Sheffield E02001614 Sheffield 004 Sheffield 004G 
Yorkshire and The Humber Sheffield E02001614 Sheffield 004 Sheffield 004F 
Yorkshire and The Humber Sheffield E02001615 Sheffield 005 Sheffield 005A 
Yorkshire and The Humber Sheffield E02001615 Sheffield 005 Sheffield 005C 
Yorkshire and The Humber Sheffield E02001615 Sheffield 005 Sheffield 005D 
Yorkshire and The Humber Sheffield E02001615 Sheffield 005 Sheffield 005E 
Yorkshire and The Humber Sheffield E02001615 Sheffield 005 Sheffield 005B 
Yorkshire and The Humber Sheffield E02001616 Sheffield 006 Sheffield 006A 
Yorkshire and The Humber Sheffield E02001616 Sheffield 006 Sheffield 006B 
Yorkshire and The Humber Sheffield E02001616 Sheffield 006 Sheffield 006D 
Yorkshire and The Humber Sheffield E02001616 Sheffield 006 Sheffield 006E 
Yorkshire and The Humber Sheffield E02001616 Sheffield 006 Sheffield 006C 
Yorkshire and The Humber Sheffield E02001617 Sheffield 007 Sheffield 007C 
Yorkshire and The Humber Sheffield E02001617 Sheffield 007 Sheffield 007B 
Yorkshire and The Humber Sheffield E02001617 Sheffield 007 Sheffield 007A 
Yorkshire and The Humber Sheffield E02001617 Sheffield 007 Sheffield 007D 
Yorkshire and The Humber Sheffield E02001618 Sheffield 008 Sheffield 008C 
Yorkshire and The Humber Sheffield E02001618 Sheffield 008 Sheffield 008B 
Yorkshire and The Humber Sheffield E02001618 Sheffield 008 Sheffield 008D 
Yorkshire and The Humber Sheffield E02001618 Sheffield 008 Sheffield 008E 
Yorkshire and The Humber Sheffield E02001618 Sheffield 008 Sheffield 008A 
Yorkshire and The Humber Sheffield E02001619 Sheffield 009 Sheffield 009A 
Yorkshire and The Humber Sheffield E02001619 Sheffield 009 Sheffield 009G 
Yorkshire and The Humber Sheffield E02001619 Sheffield 009 Sheffield 009F 
Yorkshire and The Humber Sheffield E02001619 Sheffield 009 Sheffield 009E 
Yorkshire and The Humber Sheffield E02001619 Sheffield 009 Sheffield 009D 
Yorkshire and The Humber Sheffield E02001619 Sheffield 009 Sheffield 009C 
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Region Local 
Authority 
Lower Layer 
SOA Code 
Middle Layer 
SOA 
Lower Layer 
SOA 
Yorkshire and The Humber Sheffield E02001619 Sheffield 009 Sheffield 009B 
Yorkshire and The Humber Sheffield E02001620 Sheffield 010 Sheffield 01OA 
Yorkshire and The Humber Sheffield E02001620 Sheffield 010 Sheffield 01OB 
Yorkshire and The Humber Sheffield E02001620 Sheffield 010 Sheffield 01OD 
Yorkshire and The Humber Sheffield E02001620 Sheffield 010 Sheffield 01OC 
Yorkshire and The Humber Sheffield E02001621 Sheffield 011 Sheffield 011D 
Yorkshire and The Humber Sheffield E02001621 Sheffield 011 Sheffield 011 B 
Yorkshire and The Humber Sheffield E02001621 Sheffield 011 Sheffield 011A 
Yorkshire and The Humber Sheffield E02001621 Sheffield 011 Sheffield 011C 
Yorkshire and The Humber Sheffield E02001622 Sheffield 012 Sheffield 012D 
Yorkshire and The Humber Sheffield E02001622 Sheffield 012 Sheffield 012E 
Yorkshire and The Humber Sheffield E02001622 Sheffield 012 Sheffield 012F 
Yorkshire and The Humber Sheffield E02001622 Sheffield 012 Sheffield 012A 
Yorkshire and The Humber Sheffield E02001622 Sheffield 012 Sheffield 012B 
Yorkshire and The Humber Sheffield E02001622 Sheffield 012 Sheffield 012C 
Yorkshire and The Humber Sheffield E02001623 Sheffield 013 Sheffield 013C 
Yorkshire and The Humber Sheffield E02001623 Sheffield 013 Sheffield 013D 
Yorkshire and The Humber Sheffield E02001623 Sheffield 013 Sheffield 013E 
Yorkshire and The Humber Sheffield E02001623 Sheffield 013 Sheffield 013A 
Yorkshire and The Humber Sheffield E02001623 Sheffield 013 Sheffield 013B 
Yorkshire and The Humber Sheffield E02001624 Sheffield 014 Sheffield 014B 
Yorkshire and The Humber Sheffield E02001624 Sheffield 014 Sheffield 014A 
Yorkshire and The Humber Sheffield E02001624 Sheffield 014 Sheffield 014C 
Yorkshire and The Humber Sheffield E02001624 Sheffield 014 Sheffield 014D 
Yorkshire and The Humber Sheffield E02001624 Sheffield 014 Sheffield 014E 
Yorkshire and The Humber Sheffield E02001624 Sheffield 014 Sheffield 014F 
Yorkshire and The Humber Sheffield E02001625 Sheffield 015 Sheffield 015E 
Yorkshire and The Humber Sheffield E02001625 Sheffield 015 Sheffield 015D 
Yorkshire and The Humber Sheffield E02001625 Sheffield 015 Sheffield 015A 
Yorkshire and The Humber Sheffield E02001625 Sheffield 015 Sheffield 015B 
Yorkshire and The Humber Sheffield E02001625 Sheffield 015 Sheffield 015C 
Yorkshire and The Humber Sheffield E02001626 Sheffield 016 Sheffield 016C 
Yorkshire and The Humber Sheffield E02001626 Sheffield 016 Sheffield 016D 
Yorkshire and The Humber Sheffield E02001626 Sheffield 016 Sheffield 016A 
Yorkshire and The Humber Sheffield E02001626 Sheffield 016 Sheffield 016B 
Yorkshire and The Humber Sheffield E02001627 Sheffield 017 Sheffield 017D 
Yorkshire and The Humber Sheffield E02001627 Sheffield 017 Sheffield 017B 
Yorkshire and The Humber Sheffield E02001627 Sheffield 017 Sheffield 017A 
Yorkshire and The Humber Sheffield E02001627 Sheffield 017 Sheffield 017C 
Yorkshire and The Humber Sheffield E02001628 Sheffield 018 Sheffield 018C 
Yorkshire and The Humber Sheffield E02001628 Sheffield 018 Sheffield 018A 
Yorkshire and The Humber Sheffield E02001628 Sheffield 018 Sheffield 018B 
Yorkshire and The Humber Sheffield E02001628 Sheffield 018 Sheffield 018D 
Yorkshire and The Humber Sheffield E02001629 Sheffield 019 Sheffield 019D 
Yorkshire and The Humber Sheffield E02001629 Sheffield 019 Sheffield 019A 
Yorkshire and The Humber Sheffield E02001629 Sheffield 019 Sheffield 019C 
Yorkshire and The Humber Sheffield E02001629 Sheffield 019 Sheffield 019B 
Yorkshire and The Humber Sheffield E02001630 Sheffield 020 Sheffield 020A 
Yorkshire and The Humber Sheffield E02001630 Sheffield 020 Sheffield 020B 
Yorkshire and The Humber Sheffield E02001630 Sheffield 020 Sheffield 020C 
Yorkshire and The Humber Sheffield E02001630 Sheffield 020 Sheffield 020D 
Yorkshire and The Humber Sheffield E02001630 Sheffield 020 Sheffield 020E 
Yorkshire and The Humber Sheffield E02001631 Sheffield 021 Sheffield 021 D 
Yorkshire and The Humber Sheffield E02001631 Sheffield 021 Sheffield 021C 
Yorkshire and The Humber Sheffield E02001631 Sheffield 021 Sheffield 021A 
Yorkshire and The Humber Sheffield E02001631 Sheffield 021 Sheffield 021 E 
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Authority 
Lower Layer 
SOA Code 
Middle Layer 
SOA 
Lower Layer 
SOA 
Yorkshire and The Humber Sheffield E02001631 Sheffield 021 Sheffield 021B 
Yorkshire and The Humber Sheffield E02001632 Sheffield 022 Sheffield 022E 
Yorkshire and The Humber Sheffield E02001632 Sheffield 022 Sheffield 022D 
Yorkshire and The Humber Sheffield E02001632 Sheffield 022 Sheffield 022C 
Yorkshire and The Humber Sheffield E02001632 Sheffield 022 Sheffield 022B 
Yorkshire and The Humber Sheffield E02001632 Sheffield 022 Sheffield 022A 
Yorkshire and The Humber Sheffield E02001632 Sheffield 022 Sheffield 022F 
Yorkshire and The Humber Sheffield E02001633 Sheffield 023 Sheffield 023C 
Yorkshire and The Humber Sheffield E02001633 Sheffield 023 Sheffield 023B 
Yorkshire and The Humber Sheffield E02001633 Sheffield 023 Sheffield 023D 
Yorkshire and The Humber Sheffield E02001633 Sheffield 023 Sheffield 023E 
Yorkshire and The Humber Sheffield E02001633 Sheffield 023 Sheffield 023A 
Yorkshire and The Humber Sheffield E02001634 Sheffield 024 Sheffield 024B 
Yorkshire and The Humber Sheffield E02001634 Sheffield 024 Sheffield 024A 
Yorkshire and The Humber Sheffield E02001634 Sheffield 024 Sheffield 024D 
Yorkshire and The Humber Sheffield E02001634 Sheffield 024 Sheffield 024F 
Yorkshire and The Humber Sheffield E02001634 Sheffield 024 Sheffield 024E 
Yorkshire and The Humber Sheffield E02001634 Sheffield 024 Sheffield 024C 
Yorkshire and The Humber Sheffield E02001635 Sheffield 025 Sheffield 025C 
Yorkshire and The Humber Sheffield E02001635 Sheffield 025 Sheffield 025A 
Yorkshire and The Humber Sheffield E02001635 Sheffield 025 Sheffield 025D 
Yorkshire and The Humber Sheffield E02001635 Sheffield 025 Sheffield 025B 
Yorkshire and The Humber Sheffield E02001636 Sheffield 026 Sheffield 026E 
Yorkshire and The Humber Sheffield E02001636 Sheffield 026 Sheffield 026B 
Yorkshire and The Humber Sheffield E02001636 Sheffield 026 Sheffield 026D 
Yorkshire and The Humber Sheffield E02001636 Sheffield 026 Sheffield 026C 
Yorkshire and The Humber Sheffield E02001636 Sheffield 026 Sheffield 026A 
Yorkshire and The Humber Sheffield E02001637 Sheffield 027 Sheffield 027D 
Yorkshire and The Humber Sheffield E02001637 Sheffield 027 Sheffield 027C 
Yorkshire and The Humber Sheffield E02001637 Sheffield 027 Sheffield 027B 
Yorkshire and The Humber Sheffield E02001637 Sheffield 027 Sheffield 027A 
Yorkshire and The Humber Sheffield E02001638 Sheffield 028 Sheffield 028B 
Yorkshire and The Humber Sheffield E02001638 Sheffield 028 Sheffield 028A 
Yorkshire and The Humber Sheffield E62001638 Sheffield 028 Sheffield 028C 
Yorkshire and The Humber Sheffield E02001638 Sheffield 028 Sheffield 028D 
Yorkshire and The Humber Sheffield E02001639 Sheffield 029 Sheffield 029A 
Yorkshire and The Humber Sheffield E02601639 Sheffield 029 Sheffield 029B 
Yorkshire and The Humber Sheffield E02001639 Sheffield 029 Sheffield 029C 
Yorkshire and The Humber Sheffield E02001639 Sheffield 029 Sheffield 029D 
Yorkshire and The Humber Sheffield E02001640 Sheffield 030 Sheffield 030D 
Yorkshire and The Humber Sheffield E02001640 Sheffield 030 Sheffield 030A 
Yorkshire and The Humber Sheffield E02001640 Sheffield 030 Sheffield 030B 
Yorkshire and The Humber Sheffield E02001640 Sheffield 030 Sheffield 030C 
Yorkshire and The Humber Sheffield E02001640 Sheffield 030 Sheffield 030E 
Yorkshire and The Humber Sheffield E02001641 Sheffield 031 Sheffield 031D 
Yorkshire and The Humber Sheffield E02001641 Sheffield 031 Sheffield 031C 
Yorkshire and The Humber Sheffield E02001641 Sheffield 031 Sheffield 031B 
Yorkshire and The Humber Sheffield E02001641 Sheffield 031 Sheffield 031A 
Yorkshire and The Humber Sheffield E02001642 Sheffield 032 Sheffield 032A 
Yorkshire and The Humber Sheffield E02001642 Sheffield 032 Sheffield 032F 
Yorkshire and The Humber Sheffield E02001642 Sheffield 032 Sheffield 0328 
Yorkshire and The Humber Sheffield E02001642 Sheffield 032 Sheffield 032C 
Yorkshire and The Humber Sheffield E02001642 Sheffield 032 Sheffield 032D 
Yorkshire and The Humber Sheffield E02001642 Sheffield 032 Sheffield 032E 
Yorkshire and The Humber Sheffield E02001643 Sheffield 033 Sheffield 033B 
Yorkshire and The Humber Sheffield E02001643 Sheffield 033 Sheffield 033D 
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Region Local 
Authority 
Lower Layer 
SOA Code 
Middle Layer 
SOA 
Lower Layer 
SOA 
Yorkshire and The Humber Sheffield E02001643 Sheffield 033 Sheffield 033C 
Yorkshire and The Humber Sheffield E02001643 Sheffield 033 Sheffield 033A 
Yorkshire and The Humber Sheffield E02001644 Sheffield 034 Sheffield 034C 
Yorkshire and The Humber Sheffield E02001644 Sheffield 034 Sheffield 034A 
Yorkshire and The Humber Sheffield E02001644 Sheffield 034 Sheffield 034D 
Yorkshire and The Humber Sheffield E02001644 Sheffield 034 Sheffield 034B 
Yorkshire and The Humber Sheffield E02601645 Sheffield 035 Sheffield 035B 
Yorkshire and The Humber Sheffield E02001645 Sheffield 035 Sheffield 035A 
Yorkshire and The Humber Sheffield E02001645 Sheffield 035 Sheffield 035C 
Yorkshire and The Humber Sheffield E02001645 Sheffield 035 Sheffield 035D 
Yorkshire and The Humber Sheffield E02001646 Sheffield 036 Sheffield 036A 
Yorkshire and The Humber Sheffield E02001646 Sheffield 036 Sheffield 036B 
Yorkshire and The Humber Sheffield E02001646 Sheffield 036 Sheffield 036C 
Yorkshire and The Humber Sheffield E02001646 Sheffield 036 Sheffield 036D 
Yorkshire and The Humber Sheffield E02001646 Sheffield 036 Sheffield 036E 
Yorkshire and The Humber Sheffield E02001647 Sheffield 037 Sheffield 037C 
Yorkshire and The Humber Sheffield E02001647 Sheffield 037 Sheffield 037D 
Yorkshire and The Humber Sheffield E02001647 Sheffield 037 Sheffield 037A 
Yorkshire and The Humber Sheffield E02001647 Sheffield 037 Sheffield 037B 
Yorkshire and The Humber Sheffield E02001648 Sheffield 038 Sheffield 038C 
Yorkshire and The Humber Sheffield E02001648 Sheffield 038 Sheffield 038D 
Yorkshire and The Humber Sheffield E02001648 Sheffield 038 Sheffield 038B 
Yorkshire and The Humber Sheffield E02001648 Sheffield 038 Sheffield 038A 
Yorkshire and The Humber Sheffield E02001649 Sheffield 039 Sheffield 039B 
Yorkshire and The Humber Sheffield E02001649 Sheffield 039 Sheffield 039C 
Yorkshire and The Humber Sheffield E02001649 Sheffield 039 Sheffield 039D 
Yorkshire and The Humber Sheffield E02001649 Sheffield 039 Sheffield 039E 
Yorkshire and The Humber Sheffield E02001649 Sheffield 039 Sheffield 039F 
Yorkshire and The Humber Sheffield E02001649 Sheffield 039 Sheffield 039A 
Yorkshire and The Humber Sheffield E02001650 Sheffield 040 Sheffield 040B 
Yorkshire and The Humber Sheffield E02001650 Sheffield 040 Sheffield 040D 
Yorkshire and The Humber Sheffield E02001650 Sheffield 040 Sheffield 040A 
Yorkshire and The Humber Sheffield E02001650 Sheffield 040 Sheffield 040C 
Yorkshire and The Humber Sheffield E02001651 Sheffield 041 Sheffield 041D 
Yorkshire and The Humber Sheffield E02001651 Sheffield 041 Sheffield 041A 
Yorkshire and The Humber Sheffield E02001651 Sheffield 041 Sheffield 041 C 
Yorkshire and The Humber Sheffield E02001651 Sheffield 041 Sheffield 041B 
Yorkshire and The Humber Sheffield E02001651 Sheffield 041 Sheffield 041E 
Yorkshire and The Humber Sheffield E02001652 Sheffield 042 Sheffield 042C 
Yorkshire and The Humber Sheffield E02001652 Sheffield 042 Sheffield 042D 
Yorkshire and The Humber Sheffield E02001652 Sheffield 042 Sheffield 042E 
Yorkshire and The Humber Sheffield E02001652 Sheffield 042 Sheffield 042A 
Yorkshire and The Humber Sheffield E02001652 Sheffield 042 Sheffield 042B 
Yorkshire and The Humber Sheffield E02001653 Sheffield 043 Sheffield 043B 
Yorkshire and The Humber Sheffield E02001653 Sheffield 043 Sheffield 043C 
Yorkshire and The Humber Sheffield E02001653 Sheffield 043 Sheffield 043D 
Yorkshire and The Humber Sheffield E02001653 Sheffield 043 Sheffield 043A 
Yorkshire and The Humber Sheffield E02001654 Sheffield 044 Sheffield 044B 
Yorkshire and The Humber Sheffield E02001654 Sheffield 044 Sheffield 044A 
Yorkshire and The Humber Sheffield E02001654 Sheffield 044 Sheffield 044D 
Yorkshire and The Humber Sheffield E02001654 Sheffield 044 Sheffield 044C 
Yorkshire and The Humber Sheffield E02001655 Sheffield 045 Sheffield 045D 
Yorkshire and The Humber Sheffield E02601655 Sheffield 045 Sheffield 045C 
Yorkshire and The Humber Sheffield E02001655 Sheffield 045 Sheffield 045B 
Yorkshire and The Humber Sheffield E02001655 Sheffield 045 Sheffield 045E 
Yorkshire and The Humber Sheffield E02001655 Sheffield 045 Sheffield 045A 
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Region Local 
Authority 
Lower Layer 
SOA Code 
Middle Layer 
SOA 
Lower Layer 
SOA 
Yorkshire and The Humber Sheffield E02001656 Sheffield 046 Sheffield 046D 
Yorkshire and The Humber Sheffield E02001656 Sheffield 046 Sheffield 046B 
Yorkshire and The Humber Sheffield E02001656 Sheffield 046 Sheffield 046E 
Yorkshire and The Humber Sheffield E02001656 Sheffield 046 Sheffield 046A 
Yorkshire and The Humber Sheffield E02001656 Sheffield 046 Sheffield 046C 
Yorkshire and The Humber Sheffield E02001657 Sheffield 047 Sheffield 047C 
Yorkshire and The Humber Sheffield E02001657 Sheffield 047 Sheffield 047B 
Yorkshire and The Humber Sheffield E02001657 Sheffield 047 Sheffield 047A 
Yorkshire and The Humber Sheffield E02001657 Sheffield 047 Sheffield 047F 
Yorkshire and The Humber Sheffield E02001657 Sheffield 047 Sheffield 047E 
Yorkshire and The Humber Sheffield E02001657 Sheffield 047 Sheffield 047D 
Yorkshire and The Humber Sheffield E02001658 Sheffield 048 Sheffield 048C 
Yorkshire and The Humber Sheffield E02001658 Sheffield 048 Sheffield 048B 
Yorkshire and The Humber Sheffield E02001658 Sheffield 048 Sheffield 048A 
Yorkshire and The Humber Sheffield E02001658 Sheffield 048 Sheffield 048D 
Yorkshire and The Humber Sheffield E02001659 Sheffield 049 Sheffield 049C 
Yorkshire and The Humber Sheffield E02001659 Sheffield 049 Sheffield 049B 
Yorkshire and The Humber Sheffield E02001659 Sheffield 049 Sheffield 049A 
Yorkshire and The Humber Sheffield E02001659 Sheffield 049 Sheffield 049D 
Yorkshire and The Humber Sheffield E02001660 Sheffield 050 Sheffield 050D 
Yorkshire and The Humber Sheffield E02001660 Sheffield 050 Sheffield 050F 
Yorkshire and The Humber Sheffield E02001660 Sheffield 050 Sheffield 050E 
Yorkshire and The Humber Sheffield E02001660 Sheffield 050 Sheffield 050C 
Yorkshire and The Humber Sheffield E02001660 Sheffield 050 Sheffield 050B 
Yorkshire and The Humber Sheffield E02001660 Sheffield 050 Sheffield 050A 
Yorkshire and The Humber Sheffield E02001661 Sheffield 051 Sheffield 051A 
Yorkshire and The Humber Sheffield E02001661 Sheffield 051 Sheffield 051E 
Yorkshire and The Humber Sheffield E02001661 Sheffield 051 Sheffield 051D 
Yorkshire and The Humber Sheffield E02001661 Sheffield 051 Sheffield 051C 
Yorkshire and The Humber Sheffield E02001661 Sheffield 051 Sheffield 051B 
Yorkshire and The Humber Sheffield E02001662 Sheffield 052 Sheffield 052E 
Yorkshire and The Humber Sheffield E02001662 Sheffield 052 Sheffield 052A 
Yorkshire and The Humber Sheffield E02001662 Sheffield 052 Sheffield 052B 
Yorkshire and The Humber Sheffield E02001662 Sheffield 052 Sheffield 052C 
Yorkshire and The Humber Sheffield E02001662 Sheffield 052 Sheffield 052D 
Yorkshire and The Humber Sheffield E02001663 Sheffield 053 Sheffield 053D 
Yorkshire and The Humber Sheffield E02001663 Sheffield 053 Sheffield 053A 
Yorkshire and The Humber Sheffield E02001663 Sheffield 053 Sheffield 053E 
Yorkshire and The Humber Sheffield E02001663 Sheffield 053 Sheffield 053B 
Yorkshire and The Humber Sheffield E02001663 Sheffield 053 Sheffield 053C 
Yorkshire and The Humber Sheffield E02001664 Sheffield 054 Sheffield 054B 
Yorkshire and The Humber Sheffield E02001664 Sheffield 054 Sheffield 054D 
Yorkshire and The Humber Sheffield E02001664 Sheffield 054 Sheffield 054C 
Yorkshire and The Humber Sheffield E02001664 Sheffield 054 Sheffield 054A 
Yorkshire and The Humber Sheffield E02001665 Sheffield 055 Sheffield 055A 
Yorkshire and The Humber Sheffield E02001665 Sheffield 055 Sheffield 055D 
Yorkshire and The Humber Sheffield E02001665 Sheffield 055 Sheffield 055E 
Yorkshire and The Humber Sheffield E02001665 Sheffield 055 Sheffield 055C 
Yorkshire and The Humber Sheffield E02001665 Sheffield 055 Sheffield 055B 
Yorkshire and The Humber Sheffield E02001665 Sheffield 055 Sheffield 055F 
Yorkshire and The Humber Sheffield E02001666 Sheffield 056 Sheffield 056C 
Yorkshire and The Humber Sheffield E02001666 Sheffield 056 Sheffield 056D 
Yorkshire and The Humber Sheffield E02001666 Sheffield 056 Sheffield 056A 
Yorkshire and The Humber Sheffield E02001666 Sheffield 056 Sheffield 056B 
Yorkshire and The Humber Sheffield E02001667 Sheffield 057 Sheffield 057D 
Yorkshire and The Humber Sheffield E02001667 Sheffield 057 Sheffield 057C 
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Region Local 
Authority 
Lower Layer 
SOA Code 
Middle Layer 
SOA 
Lower Layer 
SOA 
Yorkshire and The Humber Sheffield E02001667 Sheffield 057 Sheffield 057B 
Yorkshire and The Humber Sheffield E02001667 Sheffield 057 Sheffield 057A 
Yorkshire and The Humber Sheffield E02001668 Sheffield 058 Sheffield 058B 
Yorkshire and The Humber Sheffield E02001668 Sheffield 058 Sheffield 058D 
Yorkshire and The Humber Sheffield E02001668 Sheffield 058 Sheffield 058C 
Yorkshire and The Humber Sheffield E02001668 Sheffield 058 Sheffield 058A 
Yorkshire and The Humber Sheffield E02001669 Sheffield 059 Sheffield 059C 
Yorkshire and The Humber Sheffield E02001669 Sheffield 059 Sheffield 059A 
Yorkshire and The Humber Sheffield E02001669 Sheffield 059 Sheffield 059D 
Yorkshire and The Humber Sheffield E02001669 Sheffield 059 Sheffield 059B 
Yorkshire and The Humber Sheffield E02001669 Sheffield 059 Sheffield 059E 
Yorkshire and The Humber Sheffield E02001670 Sheffield 060 Sheffield 060A 
Yorkshire and The Humber Sheffield E02001670 Sheffield 060 Sheffield 060D 
Yorkshire and The Humber Sheffield E02001670 Sheffield 060 Sheffield 060C 
Yorkshire and The Humber Sheffield E02001670 Sheffield 060 Sheffield 060B 
Yorkshire and The Humber Sheffield E02001671 Sheffield 061 Sheffield 061D 
Yorkshire and The Humber Sheffield E02001671 Sheffield 061 Sheffield 061C 
Yorkshire and The Humber Sheffield E02001671 Sheffield 061 Sheffield 061A 
Yorkshire and The Humber Sheffield E02001671 Sheffield 061 Sheffield 061B 
Yorkshire and The Humber Sheffield E02001672 Sheffield 062 Sheffield 062A 
Yorkshire and The Humber Sheffield E02001672 Sheffield 062 Sheffield 062B 
Yorkshire and The Humber Sheffield E02001672 Sheffield 062 Sheffield 062C 
Yorkshire and The Humber Sheffield E02001672 Sheffield 062 Sheffield 062D 
Yorkshire and The Humber Sheffield E02001673 Sheffield 063 Sheffield 063D 
Yorkshire and The Humber Sheffield E02001673 Sheffield 063 Sheffield 063B 
Yorkshire and The Humber Sheffield E02001673 Sheffield 063 Sheffield 063C 
Yorkshire and The Humber Sheffield E02001673 Sheffield 063 Sheffield 063A 
Yorkshire and The Humber Sheffield E02001674 Sheffield 064 Sheffield 064A 
Yorkshire and The Humber Sheffield E02001674 Sheffield 064 Sheffield 064C 
Yorkshire and The Humber Sheffield E02001674 Sheffield 064 Sheffield 064E 
Yorkshire and The Humber Sheffield E02001674 Sheffield 064 Sheffield 064F 
Yorkshire and The Humber Sheffield E02001674 Sheffield 064 Sheffield 064B 
Yorkshire and The Humber Sheffield E02001674 Sheffield 064 Sheffield 064D 
Yorkshire and The Humber Sheffield E02001675 Sheffield 065 Sheffield 065F 
Yorkshire and The Humber Sheffield E02001675 Sheffield 065 Sheffield 065C 
Yorkshire and The Humber Sheffield E02001675 Sheffield 065 Sheffield 065E 
Yorkshire and The Humber Sheffield E02001675 Sheffield 065 Sheffield 065D 
Yorkshire and The Humber Sheffield E02001675 Sheffield 065 Sheffield 065A 
Yorkshire and The Humber Sheffield E02001675 Sheffield 065 Sheffield 065B 
Yorkshire and The Humber Sheffield E02001676 Sheffield 066 Sheffield 066A 
Yorkshire and The Humber Sheffield E02001676 Sheffield 066 Sheffield 066B 
Yorkshire and The Humber Sheffield E02001676 Sheffield 066 Sheffield 066C 
Yorkshire and The Humber Sheffield E02001676 Sheffield 066 Sheffield 066D 
Yorkshire and The Humber Sheffield E02001677 Sheffield 067 Sheffield 067E 
Yorkshire and The Humber Sheffield E02001677 Sheffield 067 Sheffield 067D 
Yorkshire and The Humber Sheffield E02001677 Sheffield 067 Sheffield 067B 
Yorkshire and The Humber Sheffield E02001677 Sheffield 067 Sheffield 067C 
Yorkshire and The Humber Sheffield E02001677 Sheffield 067 Sheffield 067A 
Yorkshire and The Humber Sheffield E02001678 Sheffield 068 Sheffield 068A 
Yorkshire and The Humber Sheffield E02001678 Sheffield 068 Sheffield 068E 
Yorkshire and The Humber Sheffield E02001678 Sheffield 068 Sheffield 068F 
Yorkshire and The Humber Sheffield E02001678 Sheffield 068 Sheffield 068C 
Yorkshire and The Humber Sheffield E02001678 Sheffield 068 Sheffield 068D 
Yorkshire and The Humber Sheffield E02001678 Sheffield 068 Sheffield 068B 
Yorkshire and The Humber Sheffield E02001679 Sheffield 069 Sheffield 069D 
Yorkshire and The Humber Sheffield E02001679 Sheffield 069 Sheffield 069A 
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Region Local 
Authority 
Lower Layer 
SOA Code 
Middle Layer 
SOA 
Lower Layer 
SOA 
Yorkshire and The Humber Sheffield E02001679 Sheffield 069 Sheffield 069C 
Yorkshire and The Humber Sheffield E02001679 Sheffield 069 Sheffield 069B 
Yorkshire and The Humber Sheffield E02001680 Sheffield 070 Sheffield 070D 
Yorkshire and The Humber Sheffield E02001680 Sheffield 070 Sheffield 070C 
Yorkshire and The Humber Sheffield E02001680 Sheffield 070 Sheffield 070B 
Yorkshire and The Humber Sheffield E02001680 Sheffield 070 Sheffield 070A 
Yorkshire and The Humber Sheffield E02001681 Sheffield 071 Sheffield 071A 
Yorkshire and The Humber Sheffield E02001681 Sheffield 071 Sheffield 071E 
Yorkshire and The Humber Sheffield E02001681 Sheffield 071 Sheffield 071C 
Yorkshire and The Humber Sheffield E02001681 Sheffield 071 Sheffield 071D 
Yorkshire and The Humber Sheffield E02001681 Sheffield 071 Sheffield 071B 
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Appendix 7.2. Vascular diagnoses possessed by incident 
cases of coeliac disease 
This questionnaire is designed to find out about your medical history. Please try to 
answer every question by writing in the spaces provided or ticking the appropriate 
boxes. 
Question 1 
What is your ethnic group? 
Q Caucasian 
Q Black Caribbean or Black British Caribbean 
Q Black African or Black British African 
Q Other Black background 
Q Asian Indian or Asian British Indian 
Q Asian Pakistani or Asian British Pakistani 
Q Asian Bangladeshi or Asian British Bangladeshi 
Q Chinese or other Ethnic background Chinese 
Q Other Asian background 
Q Mixed 
- 
White and Black Caribbean 
Q Mixed 
- 
White and Black African 
Q Mixed 
- 
White and Asian 
Q Other Mixed background 
Q Other ethnic background 
Question 2 
Do you ever drink alcohol? 
Q No 
Q Yes 
How much alcohol would you typically drink in a week? 
Number of wine glasses per week 
......................... Number of pints of lager, beer or cider per week 
......................... Number of glasses of spirits or liquor per week 
......................... 
Question 3 
Do you smoke? 
O No I have never smoked 
OI don't smoke currently but I have smoked in the past 
How much did you typically smoke in a day? 
Number of cigarettes /cigars /pipes per day 
......................... How many years did you smoke? 
Number of years smoked 
......................... 0I smoke cigarettes / pipe / cigars 
How much would you typically smoke in a day? 
Number of cigarettes / cigars /pipes per day 
......................... How long have you been smoking? 
Number of years smoked 
......................... Question 4 
1. How old were you when you left school? 
................ 
years 
2. What was the highest school / college level which you reached? 
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Q Primary school completed 
O Secondary school completed 
Q Technical or professional secondary school 
O Grammar school or college 
Q University degree 
0 Did not attend school 
Question 5 
Do you own your own home? 
Q No 
Q Yes 
Question 6 
1. What is your occupation? 
................................. 2. What was your father's occupation when you were 10 years old? 
Question 7 
Have you ever been told by a doctor that you have, or had, one or more of the 
following? 
1. Heart attack 
Q No 
Q Yes 
If yes at what age did it first occur? 
................ . 
years 
2. Angina 
Q No 
Q Yes 
If yes at what age did it first occur? 
................ . 
years 
3. Stroke 
Q No 
Q Yes 
If yes at what age did it first occur? 
................ 
years 
4. High blood pressure 
Q No 
Q Yes 
If yes at what age did it first occur? 
................ 
years 
Are you receiving treatment for this? 
Q No 
Q Yes 
........................................ ..... 
name of tablets 
5. High cholesterol 
Q No 
Q Yes 
If yes at what age did it first occur? 
................ 
years 
Are you receiving treatment for this? 
Q No 
Q Yes 
........................................ 
..... 
name of tablets 
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6. Diabetes 
Q No 
Q Yes 
If yes at what age did it first occur? 
................ 
years 
Are you receiving treatment for this? 
Q No 
Q Watching diet 
Q Tablets 
Q Insulin 
7. Circulatory problems in the legs 
Q No 
Q Yes 
If yes at what age did it first occur? 
................ 
years 
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Appendix 7.3. Compliance with a gluten-free diet 
1. How would you describe your compliance to the gluten-free diet? Please place 
a vertical mark on the line below to indicate how you would much you stick to 
the gluten free diet: 
Do not Stick to diet 
stick to diet all the time 
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Appendix 7.4. SF36 questionnaire 
INSTRUCTIONS: This set of questions asks for your views about your health. This information 
will help keep track of how you feel and how well you are able to do your usual activities Answer 
every question by marking the answer as indicated. If you are unsure about how to answer a 
question please give the best answer you can. ''ýa" 
1. In general, would you say your health is: (Please tick one box. ) 
Excellent Q 
Very Good Q 
Good Q 
Fair Q 
Poor Q 
2 Compared to one year ago, how would you rate your health in general now? (Please tick one box. ) 
Much better than one year ago Q 
Somewhat better now than one year ago Q 
About the same as one year ago Q 
Somewhat worse now than one year ago Q 
Much worse now than one year ago Q 
3 The following questions are about activities you might do during a typical day. Does your health 
now limit you in these activities? If so, how much? (Please circle one number on each line. ) 
Yes, Yes, Not 
Limited Limited A Limited Activities A Lot Little At All 
3(a) Vigorous activities, such as running, lifting heavy objects, 1 2 3 
.. 
participating. in strenuous ports 
. ........ ... _...... _......... _ .. __...... »_». »_. ........ .... ». _. _. _.. .... . _........ _ .. _.. 3(b) Moderate activities, such as moving a table, pushing a 1 2 3 
vacuum 
cleaner bowling or, playingolf 
_ .......................... ........ _.. 
3(c) 
3(d) Climbing several fliohts of stairs 1 2 3 
3(e) 
,. 
Climbino one flight of stairs 1 
2 
3 
3(f) 1 2 3 
3(g) Waling-more than a_ mile 2.. 
_ ... 
3 
3(h) Walkino several blocks 2 3 
3(') 
. Wa..... neblock ... _ ................. _............ _ .. _..... _»_. _»»».. _. . ». _ 
1 2 
 
3_. 
30) Bathing or ressing yourself 1 2 3 
4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
Please circle one number on each line. ) Yes No 
4(a) 
Cut 
down on the amount of time yaq spent on work or other activities 1 2 
4(b) 
Accomplished 
less than you would 
4(c) Were limited in the kind of work or other activities 2 
4(d) Had difficulty performing the work or other activities (for example, It took 1 2 
extra effort) 1 
During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (e. g. feeling depressed or anxious)? 
(Please circle one number on each line. ) Yes No 
5(a) 
Cut 
down on the amount of timeyouuspent on work or other activities 1 2 
5(b) 
Accomplished 
less than you would like 
5(c) Didn't do work or other activities as carefully as usual 1 2 
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6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbours, or groups? (Please tick one box. )
Not at all Q 
Slightly 0 
Moderately Q 
Quite a bit Q 
Extremely Q 
7. How much physical pain have you had during the past 4 weeks? (Please tick one box. ) 
None Q 
Very mild Q 
Mild Q 
Moderate 0 
Severe Q 
Very Severe Q 
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work 
outside the home and housework)? (Please tick one box. )
Not at all 0 
A little bit Q 
Moderately Q 
Quite a bit Q 
Extremely Q 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. Please give the one answer that is closest to the way you have been feeling for each item. 
All of Most A Good Some A Little None 
(Please circle one number on each line. ) the of the Bit of of the of the of the Time Time the Time Time Time Time 
9(a) 
.. 
Did You feel 5__, 6 
9(b) 
, 
Have you been a very nervous person 
__ ,_1. 
2 3_» 4 5.. 
_ 
6 
9(c) Have you felt so down in the dumps that 1 2 3 4 5 6 
nothing could cheer You up? 
_ 9(d) Have You felt calm andpeaceful? 
»,,, »,,, _,,,, ý ' . _1 _2,,, 
3,,, 4 
-. 
5,, 6 
9(e) lot of energy? DidYouhave a 1 2 3, 6, 
_ 9(f) Have you felt downhearted, and blue? 
» 
1..... 
, 
2,., 
,,,, _3, ,,,, _ 
4 
,,, -5 .. 
6 
9(g) Did, You feel wom out? 
». »... »». »». ».. ». »...... » . »1.. » .? .» .. »3. ».. ..... .. » _ . 
5... 6. 
9(h) 
. 
Have 
you 
been a happy person? 
_, _ ......... »... 
1 
_....... ...... 
2 
.. »...... ».. 
3 
................ ». 
4 
. ». _.......... 
5 
...... _..... ». 
6 
.... ». »....... 90) Did you feel tired? 1 2 3 4 5 6 
10. During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives etc. ) (Please tick one box. )
All of the time Q 
Most of the time Q 
Some of the time Q 
A little of the time Q 
None of the time 0 
11 How TRUE or FALSE is each of the following statements for you? 
(Please circle one number on each line. ) Definitely Mostly Don't Mostly Definitely 
True True Know False False 
11(a) I seem to get sick a little easier than 1 2 3 4 5 
11(b) 
_I, am, as 
healthy, as»anybody, I, know,,,, 
_,,,, ,_1 
2 3 4 5 
11(c) 
_I, expect my_health, 
to get worse 
__,,, »,,,,, _»_ 
1 2 3 4 
11(d) health is excellent 1 2 3 4 5 
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Appendix 7.5. Assessing presence of gastrointestinal 
symptoms 
1. In the last 3 months, did you often have discomfort or pain in your tummy? 
Please tick one box: 
No or rarely Q 
Yes Q 
Often means that the symptoms were present at least one day in each week 
2. In the last 3 months, did you often have heartburn, a burning pain in your 
chest? Please tick one box: 
No or rarely Q 
Yes Q 
Often means that the symptoms were present at least one day in each week 
3. In the last 3 months, did you have loose, mushy or watery stools during more 
than three-quarters (3/4) of your bowel movements? Please tick one box: 
No or rarely Q 
Yes Q 
4. Do you avoid eating outside the home such as in restaurants or at friends' meal 
invitations? Please tick one box: 
All of the time Q 
Most of the time Q 
Some of the time Q 
Never Q 
377 
Appendix 7.6. Breast cancer risk profile 
This questionnaire is designed to find out about your reproductive history. Please try 
to answer every question by writing in the spaces provided or ticking the appropriate 
boxes, except when there is a specific request to skip a section. 
Question 1 
What is your ethnic group? 
Q Caucasian 
Q Black Caribbean or Black British Caribbean 
Q Black African or Black British African 
Q Other Black background 
Q Asian Indian or Asian British Indian 
Q Asian Pakistani or Asian British Pakistani 
Q Asian Bangladeshi or Asian British Bangladeshi 
Q Chinese or other Ethnic background Chinese 
Q Other Asian background 
Q Mixed 
- 
White and Black Caribbean 
Q Mixed 
- 
White and Black African 
Q Mixed 
- 
White and Asian 
Q Other Mixed background 
Q Other ethnic background 
Question 2 
How old were you when you had your first menstrual period? 
........................................................... 
years of age 
Question 3 
How long was it after your first menstrual period did your periods began to occur at 
regular intervals? 
O Within months 
Q After 1 year 
Q After 2 years 
Q After 3 years 
Q After 4 years 
Q After 5 years 
Q After 5 or more years 
Q Only after 1s` pregnancy 
Q Always irregular in the first 10 years 
Question 4 
Are you still menstruating? 
Q Yes 
Q No 
At what age did you stop having your periods? 
..................... 
years of age 
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Question 5 
Have you ever taken an oral contraceptive ('the pill')? 
Q No 
Q Yes 
If you have ever taken the ` pill', how long in total did you or have you been 
taking it? 
Q1 year or less 
Q1-4 years 
Q5-9 years 
Q 10 
-14 years Q 15 years or more 
How old were you when you started using the pill? 
Q 14 years or less 
Q 15 
- 
20 years 
Q 21- 25 years 
Q 26 
- 
30 years 
Q 31- 35 years 
Q 36 
- 
40 years 
Q 41 years or more 
Question 6 
Have you taken or are you taking hormones for the menopause (`HRT')? 
Q No 
Q Yes 
If yes, how long have you taken menopausal hormones ('HRT')? 
Q Less than 1 year 
Q2-4 years 
Q5-9 years 
Q 10 
-14 years Q 15 years or more 
How old were you when you first started taking HRT? 
Q 40 years or less 
Q 41- 44 years 
Q 45 
- 
50 years 
Q 51 
- 
55 years 
Q 56 
- 
60 years 
Q 60 
- 
65 years 
Q 65-70 years 
Q 71 years or more 
Question 7 
Have you ever been pregnant? 
Q Yes 
Q No 
Please go to question 8 
Please go to question 10 
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Question 8 
Please give details of all previous pregnancies (including miscarriages) in the order of 
occurrence (the earliest pregnancy first): 
Previous Year of Outcome of pregnancy 
pregnancy pregnancy 
1 S` pregnancy Q Live birth 
When baby was born, was he / she born 
early, later or at expected time? 
Q early 
Q late 
Q expected time 
Q Stillbirth 
Q Miscarriage 
Q Ectopic 
Q Abortion 
2nd pregnancy Q Live birth 
When baby was born, was he / she born 
early, later or at expected time? 
Q early 
Q late 
Q expected time 
Q Stillbirth 
Q Miscarriage 
Q Ectopic 
Q Abortion 
3`d pregnancy Q Live birth 
When baby was born, was he / she born 
early, later or at expected time? 
Q early 
Q late 
Q expected time 
Q Stillbirth 
Q Miscarriage 
Q Ectopic 
Q Abortion 
4th pregnancy Q Live birth 
When baby was born, was he / she born 
early, later or at expected time? 
Q early 
Q late 
Q expected time 
Q Stillbirth 
Q Miscarriage 
Q Ectopic 
Q Abortion 
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5`h pregnancy Q Live birth 
When baby was born, was he / she born 
early, later or at expected time? 
Q early 
Q late 
Q expected time 
Q Stillbirth 
Q Miscarriage 
Q Ectopic 
Q Abortion 
0 
6t' pregnancy Q Live birth 
When baby was born, was he / she born 
early, later or at expected time? 
Q early 
Q late 
Q expected time 
Q Stillbirth 
Q Miscarriage 
Q Ectopic 
Q Abortion 
7th pregnancy Q Live birth 
Q Stillbirth 
Q Miscarriage 
Q Ectopic 
Q Abortion 
Question 9 
Did you breast feed? 
Q No 
Q Yes 
If yes for how long did you breast feed? 
Q1 week 
Q 2-3 weeks 
Q 4-5 weeks 
Q 6-7 weeks 
Q 2 months 
Q 3 months 
Q 4-5 months 
Q 6-7 months 
Q 8-9 months 
Q 10-11 months 
Q 12 months or more 
Did you breast feed for a similar length of time with your other children? 
Q Yes 
Q No 
Q Not applicable 
- 
had one child 
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Question 10 
1. Have you had a hysterectomy (womb removed)? 
O No 
O Yes 
If yes at what age did it occur? 
................ 
years of age 
2. Have you ever had an operation to remove one or both of your ovaries? 
O No 
O Yes 
If yes at what age did it occur? 
................ 
years of age 
Question 11 
1. Have you ever been told by a doctor that you have had any breast disease? 
Q No 
Q Yes 
What was condition called? 
O Fibrocystic benign breast disease 
Q Other 
...................................................... 
2. Have you ever been told by a doctor that you have breast cancer? 
Q No 
Q Yes 
If yes, at what age did the breast cancer first occur? 
.................. 
years 
Question 12 
Is there anyone in your family that has / has had breast cancer? 
Q No 
Q Yes 
If yes, which family member had breast cancer? 
Q Mother 
At what age did the breast cancer first occur? 
.................. 
years 
Q Sister 
At what age did the breast cancer first occur? 
.................. 
years 
Q Daughter 
At what age did the breast cancer first occur? 
.................. 
years 
Q Grandmother 
At what age did the breast cancer first occur? 
.................. 
years 
Q Aunt 
At what age did the breast cancer first occur? 
.................. 
years 
Q Niece 
At what age did the breast cancer first occur? 
.................. 
years 
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Question 13 
Do you ever drink alcohol? 
Q No 
Q Yes 
How much alcohol would you typically drink in a week? 
Number of wine glasses per week 
......................... Number of pints of lager, beer or cider per week 
......................... Number of glasses of spirits or liquor per week 
......................... 
Question 14 
1. How old were you when you left school? 
................ 
years 
2. What was the highest school / college level which you reached? 
Q Primary school completed 
Q Secondary school completed 
Q Technical or professional secondary school 
Q Grammar school or college 
Q University degree 
Q Did not attend school 
Question 15 
Do you own your own home? 
D No 
Cl Yes 
Question 16 
3. What is your occupation? 
................................. 
4. What was your father's occupation when you were 10 years old? 
Question 17 
1. What is your height? 
................ 
feet and inches / metres 
2. What is your weight? 
................ 
stones and pounds /kilograms 
3. What was your weight when you were 20 years of age? 
................ 
stones and pounds / kilograms 
4. What was your birth weight? 
................ 
pounds 
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Question 18 
Do you smoke? 
Q No I have never smoked 
QI don't smoke currently but I have smoked in the past 
How much did you typically smoke in a day? 
Number of cigarettes / cigars /pipes per day 
......................... QI smoke cigarettes / pipe / cigars 
How much would you typically smoke in a day? 
Number of cigarettes / cigars l pipes per day 
......................... 
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